WorldWideScience

Sample records for abilify aripiprazole metabolic

  1. Aripiprazole

    Science.gov (United States)

    ... bipolar disorder (manic-depressive disorder; a disease that causes episodes of depression, episodes of mania, and other abnormal moods). Aripiprazole is also used with an antidepressant to treat depression when symptoms cannot ... difficulty communicating and interacting with others). Aripiprazole may ...

  2. Aripiprazole: a review of its use in the management of schizophrenia in adults.

    Science.gov (United States)

    Croxtall, Jamie D

    2012-02-01

    Oral aripiprazole (Abilify®) is an atypical antipsychotic agent that is approved worldwide for use in adult patients with schizophrenia. It is a quinolinone derivative that has a unique receptor binding profile as it exhibits both partial agonist activity at dopamine D(2) receptors and serotonin 5-HT(1A) receptors and antagonist activity at 5-HT(2A) receptors. In several well designed, randomized, clinical trials of 4-6 weeks duration, aripiprazole provided symptomatic control for patients with acute, relapsing schizophrenia or schizoaffective disorder. Furthermore, following 26 weeks' treatment, the time to relapse was significantly longer for patients with chronic, stabilized schizophrenia receiving aripiprazole compared with those receiving placebo. Using a variety of efficacy outcomes, aripiprazole showed a mixed response when evaluated against other antipsychotic agents in randomized clinical trials. Longer-term data showed that improvements in remission rates and response rates favoured aripiprazole over haloperidol, although, the time to failure to maintain a response was not significantly different between the treatment arms. On the other hand, improvements in positive and negative symptom scores mostly favoured olanzapine over aripiprazole, although, the time to all-cause treatment discontinuation was not significantly different between the two treatments. Several open-label, switching trials showed that aripiprazole provided continued control of symptoms in patients with schizophrenia or schizoaffective disorder. Using a variety of efficacy outcomes or quality-of-life scores, longer-term treatment generally favoured patients switched to receive aripiprazole compared with standard-of-care oral antipsychotics. Aripiprazole was generally well tolerated in patients with schizophrenia. In particular, its use seems to be associated with a lower incidence of extrapyramidal symptoms than haloperidol and fewer weight-gain issues than olanzapine. Aripiprazole also

  3. Neurological, Metabolic, and Psychiatric Adverse Events in Children and Adolescents Treated With Aripiprazole

    DEFF Research Database (Denmark)

    Jakobsen, Klaus Damgaard; Bruhn, Christina Hedegaard; Pagsberg, Anne-Katrine

    2016-01-01

    with schizophrenia and psychoses, not otherwise specified; and the non-PS group consisted of fourteen cases including autism spectrum disorders, attention deficit and hyperactivity disorder, obsessive-compulsive disorder, and Tourette syndrome. The main reported adverse effects in the non-PS group were chronic......Aripiprazole is a partial dopamine agonist with only minor neurological and psychiatric adverse effects, making it a potential first-line drug for the treatment of psychiatric disorders. However, the evidence of its use in children and adolescents is rather sparse. The aim of this case study...... [aripiprazole] AND all spontaneous reports since the introduction of aripiprazole in 2003 until December 31, 2015. Nineteen case reports were included in the study and included both patients with psychotic disorders (PS group) and nonpsychotic disorders (non-PS group). The PS group consisted of 5 patients...

  4. Studies of phase transitions in the aripiprazole solid dosage form.

    Science.gov (United States)

    Łaszcz, Marta; Witkowska, Anna

    2016-01-05

    Studies of the phase transitions in an active substance contained in a solid dosage form are very complicated but essential, especially if an active substance is classified as a BCS Class IV drug. The purpose of this work was the development of sensitive methods for the detection of the phase transitions in the aripiprazole tablets containing initially its form III. Aripiprazole exhibits polymorphism and pseudopolymorphism. Powder diffraction, Raman spectroscopy and differential scanning calorimetry methods were developed for the detection of the polymorphic transition between forms III and I as well as the phase transition of form III into aripiprazole monohydrate in tablets. The study involved the initial 10 mg and 30 mg tablets, as well as those stored in Al/Al blisters, a triplex blister pack and HDPE bottles (with and without desiccant) under accelerated and long term conditions. The polymorphic transition was not observed in the initial and stored tablets but it was visible on the DSC curve of the Abilify(®) 10 mg reference tablets. The formation of the monohydrate was observed in the diffractograms and Raman spectra in the tablets stored under accelerated conditions. The monohydrate phase was not detected in the tablets stored in the Al/Al blisters under long term conditions. The results showed that the Al/Al blisters can be recommended as the packaging of the aripiprazole tablets containing form III.

  5. Aripiprazole salts. II. Aripiprazole perchlorate.

    Science.gov (United States)

    Freire, Eleonora; Polla, Griselda; Baggio, Ricardo

    2012-06-01

    The molecular structure of aripiprazole perchlorate (systematic name: 4-(2,3-dichlorophenyl)-1-{4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl}piperazin-1-ium perchlorate), C(23)H(28)Cl(2)N(3)O(2)(+)·ClO(4)(-), does not differ substantially from the recently published structure of aripiprazole nitrate [Freire, Polla & Baggio (2012). Acta Cryst. C68, o170-o173]. Both compounds have almost identical bond distances, bond angles and torsion angles. The two different counter-ions occupy equivalent places in the two structures, giving rise to very similar first-order `packing motifs'. However, these elemental arrangements interact with each other in different ways in the two structures, leading to two-dimensional arrays with quite different organizations.

  6. Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia.

    Science.gov (United States)

    Turncliff, Ryan; Hard, Marjie; Du, Yangchun; Risinger, Robert; Ehrich, Elliot W

    2014-11-01

    Aripiprazole lauroxil is a linker lipid ester of aripiprazole for extended-release intramuscular (IM) injection. This multicenter, randomized, open-label study evaluated the pharmacokinetics (PK), relative bioavailability, and tolerability of a single IM deltoid or gluteal injection of aripiprazole lauroxil in adult subjects with chronic stable schizophrenia or schizoaffective disorder. Forty-six subjects were randomized 1:1 to aripiprazole lauroxil 441 mg IM in the deltoid or gluteal muscle. Samples were collected through 89 days post-dose to measure levels of aripiprazole lauroxil, N-hydroxymethyl aripiprazole, aripiprazole, and dehydro-aripiprazole. Forty-three (93.5%) subjects completed all study assessments; most were CYP2D6 extensive or immediate metabolizers (96%); two (4%) were poor metabolizers. The PK of aripiprazole following aripiprazole lauroxil was characterized by a steady rise in plasma concentrations (Tmax 44-50 days), a broad peak, and prolonged exposure attributable to the dissolution of aripiprazole lauroxil and formation rate-limited elimination of aripiprazole (t1/2=15.4-19.2 days). Deltoid vs. gluteal administration resulted in slightly higher Cmax aripiprazole concentrations [1.31 (1.02, 1.67); GMR 90% CI]; total exposure (AUCinf) was similar between sites of administration [0.84 (0.57, 1.24)]. N-hydroxymethyl-aripiprazole and dehydro-aripiprazole exposures were 10% and 33-36%, respectively, of aripiprazole exposure following aripiprazole lauroxil. The most common adverse events were injection site pain in 20 subjects (43.5%) and headache in 6 subjects (13.0%) of mild intensity occurring at a similar rate with deltoid and gluteal administration. Exposure ranges with deltoid and gluteal administration overlapped, suggesting that these sites may be used interchangeably. Despite a higher incidence of adverse events, deltoid muscle provides a more accessible injection site and could facilitate patient acceptance.

  7. Role of aripiprazole in treatment-resistant schizophrenia

    Directory of Open Access Journals (Sweden)

    Mossaheb N

    2012-05-01

    Full Text Available Nilufar Mossaheb,1 Rainer M Kaufmann21Department of Child and Adolescent Psychiatry, 2Department of Psychiatry and Psychotherapy, Medical University, Vienna, AustriaAbstract: About one third of patients with schizophrenia respond unsatisfactorily to antipsychotic treatment and are termed “treatment-resistant”. Clozapine is still the gold standard in these cases. However, 40%–70% of patients do not improve sufficiently on clozapine either. In the search for more efficacious strategies for treatment-resistant schizophrenia, drugs with different pharmacological profiles seem to raise new hopes, but are they valid? The aim of this review was to evaluate the evidence for aripiprazole as a potential strategy in monotherapy or combination therapy for patients with treatment-resistant schizophrenia. The evidence for aripiprazole monotherapy and for the combination of aripiprazole with psychotropics other than clozapine is scant, and no recommendation can be made on the basis of the currently available data. More effort has been made in describing combinations of aripiprazole and clozapine. Most of the open-label and case studies as well as case reports have shown positive effects of this combination on overall psychopathology and to some extent on negative symptoms. Several reports describe the possibility of dose reduction for clozapine in combination with aripiprazole, a strategy that might help so-called “treatment-intolerant” patients. The findings of four randomized controlled trials with respect to changes in psychopathology seem less conclusive. The most commonly found beneficial effects are better metabolic outcomes and indicators of the possibility of reducing the clozapine dose. However, other side effects, such as akathisia, are repeatedly reported. Further, none of the studies report longer-term outcomes. In the absence of alternatives, polypharmacy is a common strategy in clinical practice. Combining aripiprazole with clozapine in

  8. Aripiprazole-induced priapism

    Directory of Open Access Journals (Sweden)

    Satya K Trivedi

    2016-01-01

    Full Text Available Priapism is a urologic emergency representing a true disorder of penile erection that persists beyond or is unrelated to sexual interest or stimulation. A variety of psychotropic drugs are known to produce priapism, albeit rarely, through their antagonistic action on alpha-1 adrenergic receptors. We report such a case of priapism induced by a single oral dose of 10 mg aripiprazole, a drug with the least affinity to adrenergic receptors among all atypical antipsychotics. Polymorphism of alpha-2A adrenergic receptor gene in schizophrenia patients is known to be associated with sialorrhea while on clozapine treatment. Probably, similar polymorphism of alpha-1 adrenergic receptor gene could contribute to its altered sensitivity and resultant priapism. In future, pharmacogenomics-based approach may help in personalizing the treatment and effectively prevent the emergence of such side effects.

  9. 非水反相高效液相色谱法测定阿立哌唑的含量%Determination of Aripiprazole by Nonaqueous Reversed-Phase High Performance Liquid Chromatography

    Institute of Scientific and Technical Information of China (English)

    刘红菊; 蒋晔; 郝晓花

    2005-01-01

    阿立哌唑(aripiprazole, 7-[4-[4-(2,3-二氯苯基)-1-哌嗪基]丁氧基]-3,4-二氢化喹喏啉酮)是日本Otsuka公司于1988年开发的第二代非典型性抗精神病药,于2002年由美国食品药品管理局(FDA)批准上市,商品名为Abilify,用于精神分裂症的治疗.阿立哌唑的含量测定方法尚未见报道.

  10. Study on metabolic risk of first-episode acute schizophrenia patients treated with aripiprazole%阿立哌唑对首发急性精神分裂症患者代谢风险的探讨

    Institute of Scientific and Technical Information of China (English)

    吴小立; 文飞; 钟智勇; 韩自力

    2011-01-01

    目的:探讨阿立哌唑对首发急性期精神分裂症患者的代谢影响.方法:31例首发急性期精神分裂症患者入选病例组接受阿立哌唑治疗,治疗前后各测量一次体重、腰围、腰臀比、血清TC、TG、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)、载脂蛋白A1(Apo-A1)、载脂蛋白B(Apo B100)、脂蛋白a(LPa)、空腹血糖(FBS)、空腹胰岛素(INS)、C肽(C-P),并分别计算出BMI、胰岛素抵抗指数(HOMA-IR).另设健康对照组44例,同法测量上述指标.将病例组与健康对照组、病例组治疗前后各项指标进行比较分析.结果:病例组INS、C-P及HOMA-IR均高于正常对照组,差异有统计学意义(P<0.05);病例组治疗后体重、BMI、腰围、腰臀比均较治疗前增加,差异有统计学意义(P<0.05);治疗后:病例组TG、INS、C-P、HOMA-IR均高于对照组,差异有统计学意义(P<0.05);且aPOA1低于对照组,差异有统计学意义(P<0.05).结论:精神分裂症患者本身可能存在有代谢异常;非典型抗精神病药物(APS)阿立哌唑对患者血糖、血脂代谢相对影响较小.%AIM: To study the metabolic risk of first-episode acute schizophrenia patients trea ted with aripiprazole.METHODS: 31 first-episode acute patients with schizophrenic were enrolled into case group and 44 healthy subjects were enrolled into controle group, all cases accepted treatment with oral aripiprazole.At the baseline and at the end, all patients were checked or tested for weight, waist circumference, waist-to-hipratio(WHR), TC, TG, high density lipoprotein(HDL), low density lipoprotein(LDL), apolipoprotein A1 ( Apo Al), apolipoprotein B (Apo-B100), lipoprotein a (LPa),fasting blood glucose (FBS), fasting insulin (INS)and c-peptide(C-P),respectively.The BMI and insulin resistance index (HOMA-IR) were calculated.All indexes were compared and analysed between the case group and controle group,pre and post treatment in the case group.RESULTS:The INS, C-P and HOMA

  11. Aripiprazole-induced oculogyric crisis (acute dystonia

    Directory of Open Access Journals (Sweden)

    Jyotik T Bhachech

    2012-01-01

    Full Text Available Aripiprazole is the third generation atypical antipsychotic and a dopamine serotonin system stabilizer (DSS effective against positive and negative symptoms of schizophrenia. It has a low propensity for extrapyramidal side effects, causes minimal weight gain or sedation, produces no elevation in serum prolactin levels, and does not cause prolongation of QTc interval. This case report is of a patient suffering from schizophrenia (paranoid. The patient developed oculogyric crisis (acute dystonia with aripiprazole dose uptitration. Dystonic reaction resolved with promethazine administration. Naranjo′s causality assessment reveals probable association of aripiprazole with oculogyric crisis. A thorough workup and vigilance is required prior to initiation of aripiprazole in the case of schizophrenia.

  12. Worsened hypertension control induced by aripiprazole

    Directory of Open Access Journals (Sweden)

    Yasui-Furukori N

    2013-04-01

    Full Text Available Norio Yasui-Furukori, Akira Fujii Department of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan Abstract: Aripiprazole is widely used in the treatment of schizophrenia and bipolar disorders. Although antipsychotics generally have hypotensive effects, two cases were identified that demonstrated hypertension during the switch from other antipsychotics to aripiprazole. The hypertensive state of these patients recovered after switching back to other antipsychotics, and these cases suggest that aripiprazole may lead to hypertension. Keywords: hypertension, aripiprazole, dopamine antagonist, 5-HT1a

  13. Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole

    Directory of Open Access Journals (Sweden)

    Izchak Kohen

    2010-03-01

    Full Text Available Izchak Kohen1, Paula E Lester2, Sum Lam31Division of Geriatric Psychiatry, Zucker-Hillside Hospital, Glen Oaks, NY, USA; 2Division of Geriatric Medicine, Winthrop University Hospital, Mineola, NY, USA; 3Division of Pharmacy and Geriatrics, St. John’s University College of Pharmacy and Allied Health Professions, Queens, NY, USAAbstract: Delusions, hallucinations and other psychotic symptoms can accompany a number of conditions in late life. As such, elderly patients are commonly prescribed antipsychotic medications for the treatment of psychosis in both acute and chronic conditions. Those conditions include schizophrenia, bipolar disorder, depression and dementia. Elderly patients are at an increased risk of adverse events from antipsychotic medications because of age-related pharmacodynamic and pharmacokinetic changes as well as polypharmacy. Drug selection should be individualized to the patient’s previous history of antipsychotic use, current medical conditions, potential drug interactions, and potential side effects of the antipsychotic. Specifically, metabolic side effects should be closely monitored in this population. This paper provides a review of aripiprazole, a newer second generation antipsychotic agent, for its use in a variety of psychiatric disorders in the elderly including schizophrenia, bipolar disorder, dementia, Parkinson’s disease and depression. We will review the pharmacokinetics and pharmacodynamics of aripiprazole as well as dosing, diagnostic indications, efficacy studies, and tolerability including its metabolic profile. We will also detail patient focused perspectives including quality of life, patient satisfaction and adherence.Keywords: aripiprazole, antipsychotics, elderly, adverse drug reaction

  14. The effects of aripiprazole,risperidone and clozapine administrated for schizophrenia treatment on glucose and lipid metabolism%阿立哌唑、利培酮和氯氮平治疗精神分裂症对糖脂代谢的影响

    Institute of Scientific and Technical Information of China (English)

    马达休; 李永华; 冉庆国; 陈大坤; 周琳钧

    2011-01-01

    Objective To compare the effects of aripiprazole, risperidone and clozapine used for treating schizophrenia on serum glucose and lipids of patients. Methods 270 patients with schizophrenia were divided randomly into 3 groups of 90 patients each; aripiprazole group, risperidone group and clozapine group, and aripiprazole, risperidone and clozapine were administrated for 12 weeks,respectively. Levels of fast blood glucose (FBG) ,total cholesterol (TC) ,triglycericle(TG) and body mass index (BMX) before and after treatment were compared. Results FBG levels of patients in 3 groups after treatment were increased as compared to those before treatment(P0. 05) ,all those in risperidone and clozapine groups increased after treatment as compared with treatment before(P<0. 05) ,and those in clozapine group increased greater than in risperidone group(P<0. 05). Conclusion Aripiprazole,risperidone and clozapine used for schizophrenia treatment can lead to adverse effects of glucose and lipid metabolism which are relatively milder for aripiprazole.%目的 比较阿立哌唑、利培酮和氯氮平治疗精神分裂症对患者血糖、血脂影响.方法 将270例精神分裂症患者随机分为3组:阿立哌唑组、利培酮组及氯氮平组(各90例),分别给予口服阿立哌唑、利培酮及氯氮平治疗12周.比较治疗前后空腹血糖(FBG)、总胆固醇(TC)、三酰甘油(TG),体质量指数(BMI)的变化.结果 3组患者治疗后,FBG较治疗前增高(P<0.05),氯氮平组增高最明显;阿立哌唑组治疗后TC、TG,BMI值较治疗前差异无统计学意义(P>0.05);利培酮及氯氮平组治疗后TC、TG、BMI较治疗前均有升高(P<0.05),且氯氮平组增高大于利培酮组(P<0.05).结论 阿立哌唑、利培酮及氯氮平治疗精神分裂症均可导致糖脂代谢异常的不良反应,阿立哌唑的不良反应相对较小.

  15. Worsened hypertension control induced by aripiprazole

    OpenAIRE

    Yasui-Furukori N; Fujii A

    2013-01-01

    Norio Yasui-Furukori, Akira Fujii Department of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan Abstract: Aripiprazole is widely used in the treatment of schizophrenia and bipolar disorders. Although antipsychotics generally have hypotensive effects, two cases were identified that demonstrated hypertension during the switch from other antipsychotics to aripiprazole. The hypertensive state of these patients recovered after switching back to other antipsychot...

  16. Comparison the effectiveness of aripiprazole and risperidone for the treatment of acute bipolar mania

    Directory of Open Access Journals (Sweden)

    Amir Akhavan Rezayat

    2014-01-01

    Full Text Available Background: Second-generation antipsychotics, approved for the treatment of mania, are associated with adverse effects such as weight gain and metabolic disorders. Aripiprazole, a recently introduced second-generation antipsychotic, are thought to account for its low propensity for weight gain, metabolic disturbances and sedation. The purpose of this study was to investigate the effect of risperidone versus aripiprazole in the treatment of acute mania. Materials and Methods: Fifty patients with acute episodes of mania were enrolled in this study, and they were randomly assigned into a risperidone group of 24 cases and an aripiprazole group of 26 cases. In group A, aripiprazole with a dose of 5-30 mg/day and in group B, risperidone with a dose of 2-8 mg/day was given to patients. The average dose of aripiprazole was 27 mg/day, and the average dose of risperidone was 6 mg/day. The effects of each drug for the treatment of acute mania were assessed on the 1 st day of admission and on days 2, 4, 6, 8 and at weeks 2, 4 and 6 after therapy using the young mania rating scale (YMRS and at the baseline and on weeks 3 and 6 after admission using the clinical global impression (CGI scale. Results: The mean age of the group of risperidone was 34 ± 8.6 years and in a group of aripiprazole it was 34 ± 9.1 years (P = 0.83. Comparison of YMRS scores over the period of 6 weeks revealed a statistically significant difference in both groups (P < 0.0001.There was also a statistically significant difference in YMRS scores between risperidone and aripiprazole at day 8 (P = 0.026 and weeks 2 (P = 0.035 and 4 (P = 0.042. There was also a statistically significant difference in CGI-Severity scale score at weeks 3 (P = 0.003 and 6 (P = 0.000 and in CGI-Improvement scale score at weeks 3 (P = 0.005 and 6 (P = 0.002. The most common side-effect observed in both groups was headache (0%15/4 in aripiprazole vs. %16/7 in risperidone Conclusion: Aripiprazole that is readily

  17. Augmentation of Clozapine with Aripiprazole in Severe Psychotic Bipolar and Schizoaffective Disorders: A Pilot Study

    Science.gov (United States)

    Benedetti, Alessandra; Di Paolo, Antonello; Lastella, Marianna; Casamassima, Francesco; Candiracci, Chiara; Litta, Antonella; Ciofi, Laura; Danesi, Romano; Lattanzi, Lorenzo; Del Tacca, Mario; Cassano, Giovanni Battista

    2010-01-01

    Aim: To evaluate the efficacy and safety of the augmentation of clozapine with aripiprazole in patients with treatment-resistant schizoaffective and psychotic bipolar disorders in a retrospective manner. Pharmacodynamic and pharmacokinetic interactions between the two drugs were also investigated. Patients: Three men and 4 women (median age 36 and 40 years, respectively) who had mean scores at BPRS and CGI-Severity of 59.1±12.0 and 5.4±0.5, respectively, were treated with clozapine (mean dose 292.9±220.7 mg/day). Patients received an adjunctive treatment with aripiprazole (mean dose 6.8 ± 3.7 mg/day). Clozapine, norclozapine and aripiprazole plasma levels were measured by means of a high performance liquid chromatograpy with UV detection. Results: Total scores at BPRS decreased significantly (from 59.1±12.0 to 51.1±15.6, p=0.007) after aripirazole augmentation. In particular, the factors “thought disorder” (from 10.4±4.4 to 9.0±4.5, p=.047) and “anergia” (from 10.0±2.7 to 8.0±2.4, p=.018) significantly improved. Concomitant administration of aripiprazole and clozapine did not result in an increase in side effects over the period of treatment. Dose-normalized plasma levels of both clozapine and norclozapine and the clozapine/norclozapine metabolic ratio in all patients did not vary as well. Conclusion: The augmentation of clozapine with aripirazole was safe and effective in severe psychotic schizoaffective and bipolar disorders which failed to respond to atypical antipsychotics. A possible pharmacokinetic interaction between clozapine and aripiprazole does not account for the improved clinical benefit obtained after aripiprazole augmentation. PMID:20648219

  18. Aripiprazole Can Improve Apraxia of Eyelid Opening in Parkinson's Disease.

    Science.gov (United States)

    Tokisato, Kaori; Fukunaga, Kimiko; Tokunaga, Makoto; Watanabe, Susumu; Nakanishi, Ryoji; Yamanaga, Hiroaki

    2015-01-01

    We herein report three cases of Parkinson's disease associated with difficulty in eyelid opening, referred to as apraxia of eyelid opening (AEO), which improved after aripiprazole treatment. In case 1, aripiprazole was administered as a psychiatric treatment. It proved to be effective in AEO with blepharospasm. In case 2 and case 3, the patients experienced AEO without blepharospasm, and a significant improvement was observed after aripiprazole treatment. In this study, the aripiprazole dosage ranged between 3 and 9 mg/day. This is the first report of aripiprazole as a potentially effective treatment for AEO in Parkinson's disease.

  19. Tardive Dyskinesia and Covert Dyskinesia with Aripiprazole: A Case Series.

    Science.gov (United States)

    Patra, Suravi

    2016-01-01

    Aripiprazole, a dopamine stabilizing atypical antipsychotic is used in treatment of tardive dyskinesia caused by other neuroleptics. Tardive dyskinesia is rarely caused by Aripiprazole and has only been documented in high risk patients i.e., female gender, advanced age, affective illness, coexisting neurological disorders. Here the author describes two atypical cases of tardive dyskinesia associated with Aripiprazole. First case of tardive dyskinesia was observed in a neuroleptic naïve young adult male with paranoid illness after six months of treatment with Aripiprazole upon addition of Fluoxetine and the second case was a middle aged female with affective illness where dyskinetic movements appeared after stopping Aripiprazole. The role of Fluoxetine in causing tardive dyskinesia with Aripiprazole and covert dyskinesia due to Aripiprazole with appropriate management is discussed.

  20. Behandling af Tourettes syndrom med aripiprazol

    DEFF Research Database (Denmark)

    Stenstrøm, Anne Dorte; Sindø, Ingrid

    2008-01-01

    , due to TS. The initial treatment consisted of pimozide and risperidone, both of which had an unsatisfactorily efficacy on tics and side effects in the form of weight gain and sedation. The patient is now treated with aripiprazole and there is a marked reduction of tics and no side effects...

  1. Two Cases of Hypersexuality Probably Associated with Aripiprazole

    OpenAIRE

    Cheon, EunJin; Koo, Bon-Hoon; Seo, Sang Soo; Lee, Jun-Yeob

    2013-01-01

    Sexual dysfunction is a common side effect in patients treated with antipsychotics but significant differences exist across different compounds. We report hypersexuality symptoms in two female patients with schizophrenia who were receiving treatment with aripiprazole. The patients experienced more frequent sexual desire and greater sexual preoccupation after taking aripiprazole. We discuss the potential neuro-chemical mechanisms for this and argue that aripiprazole's unique pharmacological pr...

  2. Effect of lower dose clozapine plus aripiprazole on body weight, glucose and lipid metabolism in patients with schizophrenia%较低剂量氯氮平合并阿立哌唑对精神分裂症患者体质量及糖脂代谢的影响

    Institute of Scientific and Technical Information of China (English)

    王小红; 王艳婷; 周云云; 兰润林; 侯春兰; 侯凌峰; 董继学; 李俊福

    2013-01-01

    目的:探讨较低剂量氯氮平合并阿立哌唑对精神分裂症患者体质量及糖脂代谢的影响.方法:选取2008年3月至2010年3月我院住院精神分裂症患者92例,随机分为研究组和对照组,研究组给予较低剂量氯氮平合并阿立哌唑治疗,对照组给予单纯氯氮平治疗.两组观察疗程24周.两组患者分别在治疗前、治疗12周及24周对其体质量、身高、血糖、餐后2h血糖、三酰甘油及胆固醇进行测定,并做统计分析. 结果:与对照组相比,研究组治疗前后体质量及糖脂代谢变化显著较小(P均<0.01).研究组体质量、血糖及三酰甘油异常率明显低于对照组(P均<0.01). 结论:较低剂量氯氮平合并阿立哌唑治疗与单用较高剂量氯氮平相比,对精神分裂症患者体质量及糖脂代谢影响较小.%Objective: To investigate effect of the lower dose of clozapine plus aripiprazole on body weight,glucose and lipid metabolism in patients with schizophrenia. Method:92 schizophrenic patients from our hospital March,2008 to March,2010 were randomly divided into study group and control group,the study group was given a low dose clozapine combined with aripiprazole and the control group was given clozapine treatment for 24 weeks. The body mass, height, blood glucose, postprandial 2 hour blood glucose, cholesterol and tri-glyceride were measured before treatment, week 12 and 24. Results: Compared with the control group, the study group showed fewer changes on body weight and metabolism of glucose and lipid between before and after the treatment (all P<0.01), and abnormal rates of body mass, glucose and triglyceride (all P<0.01). Conclusion: Lower dose clozapine plus aripiprazole have less impact on the body mass and glucose metabolism than only high doses clozapine in the treatment of schizophrenia.

  3. Comparison of Short-term Metabolic Risk in First-episode Young-adult Schizophrenia Treated with Aripiprazole and Olanzapine%阿立哌唑与奥氮平对首发年轻成人精神分裂症患者短期内代谢风险的比较

    Institute of Scientific and Technical Information of China (English)

    吴小立; 魏钦令; 钟智勇; 张晋碚

    2011-01-01

    摘要:[目的]比较阿立哌唑与奥氮平对首发年轻成人精神分裂症患者短期内的代谢风险.[方法]采用开放对照的临床观察方法,对符合美国精神障碍诊断与统计手册第4版(DSM-Ⅳ)精神分裂症诊断标准的首发住院精神分裂症患者,分别使用阿立哌唑(21例)和奥氮平(42例)治疗,自然观察时间不低于2周,不大于4周,于治疗前后各检测一次体质量、腰围、空腹血脂血糖及胰岛素、C肽.[结果]观察结束时:阿立哌唑组的体质量、体质量指数(BMI)、腰围、腰臀比均有增高(P<0.05),糖脂改变无统计学差异,男女患者间各项代谢指标的变化无统计学差异(P>0.05);奥氮平组的体质量、体质量指数(BMI)、腰围、腰臀比、甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)、载脂蛋白AI和B100及脂蛋白LPa较治疗前增高(P<0.0l),且胰岛素(INS)水平和胰岛素抵抗指数(IR)增高(P<0.05),多元逐步回归分析显示胰岛素抵抗与甘油三脂的增高有关(R2 =0.107,P=0.007);奥氛平组男性患者的空腹胰岛素和C肽、胰岛素抵抗指数均增高(P<0.05),女性患者则没有.[结论]阿立哌唑和奥氮平对首发年轻成人精神分裂症患者短期内的代谢风险即有差异,性别差异可能影响着非典型抗精神病药物的代谢风险.%[Objective] To compare the short-term metabolic risk in the first-episode young-adult schizophrenia treated with Aripiprazole and Olanzapine. [ Methods] The open-lable, natural observed, compared method was designed for this study. All of these cases were diagnosed as first-episode schizophrenia in accordance with the DSM-IV diagnosis criteria and respectively allocated into two groups for either Aripiprazole or Olanzapine treatment. The natural observed period was from two weeks to four weeks. Weight, waist circumference, fasting glucose, and lipid concentration, fasting insulin and C peptide

  4. Postmortem Femoral Blood Reference Concentrations of Aripiprazole, Chlorprothixene, and Quetiapine

    DEFF Research Database (Denmark)

    Skov, Louise; Johansen, Sys Stybe; Linnet, Kristian

    2015-01-01

    Postmortem femoral blood concentrations of the antipsychotic drugs aripiprazole, chlorprothixene and its metabolite, and quetiapine were determined by LC-MS-MS in 25 cases for aripiprazole and 60 cases each for chlorprothixene and quetiapine. For cases where the cause of death was not related to ...

  5. Aripiprazole: the evidence of its therapeutic impact in schizophrenia

    Directory of Open Access Journals (Sweden)

    William Winlow

    2006-06-01

    Full Text Available William Winlow, Louise Profit, Paul ChrispCore Medical Publishing, Knutsford, UKIntroduction: An ideal antipsychotic would rapidly stabilize acute psychotic symptoms and maintain the patient, without relapse, for prolonged periods in the absence of extrapyramidal, endocrine, diabetic, or cardiovascular side effects, and without weight gain. The dopamine partial agonist aripiprazole is compared with this ideal and with conventional antipsychotics, such as haloperidol, and with atypical antipsychotics.Aims: To review the evidence for the clinical impact of aripiprazole in the treatment of patients with schizophrenia.Evidence review: There is clear evidence that aripiprazole is as effective as haloperidol in reducing the positive and negative symptoms of schizophrenia and schizoaffective disorder. In patients with schizophrenia, aripiprazole has been shown to stabilize acute psychotic symptoms, prevent relapse in stabilized patients, and maintain patients with schizophrenia following acute relapse. Furthermore, in common with other atypical antipsychotics, aripiprazole appears to be associated with a lower incidence of side effects than typical antipsychotics and may reduce discontinuation of drug therapy. Evidence also suggests that aripiprazole may be associated with a lower incidence of extrapyramidal symptoms than conventional antipsychotics, but further long-term studies concerning tardive dyskinesia are required. Studies on the cost effectiveness of aripiprazole, as well as the quality of life and general functioning of patients taking the drug are still required, although there is some evidence of improved quality of life. Further evidence comparing aripiprazole with other atypical antipsychotics would be welcome.Clinical value: In conclusion, aripiprazole is an atypical antipsychotic suitable for first-line use in patients with schizophrenia. Its clinical value in relation to other atypical antipsychotics remains to be elucidated.Key words

  6. Two cases of hypersexuality probably associated with aripiprazole.

    Science.gov (United States)

    Cheon, Eunjin; Koo, Bon-Hoon; Seo, Sang Soo; Lee, Jun-Yeob

    2013-06-01

    Sexual dysfunction is a common side effect in patients treated with antipsychotics but significant differences exist across different compounds. We report hypersexuality symptoms in two female patients with schizophrenia who were receiving treatment with aripiprazole. The patients experienced more frequent sexual desire and greater sexual preoccupation after taking aripiprazole. We discuss the potential neuro-chemical mechanisms for this and argue that aripiprazole's unique pharmacological profile, partial agonism with high affinity at dopamine D2-receptor, may have contributed to the development of these symptoms.

  7. Treatment of refractory catatonic schizophrenia with low dose aripiprazole

    Directory of Open Access Journals (Sweden)

    Sasaki Tsuyoshi

    2012-05-01

    Full Text Available Abstract This case is of 54-year-old female with catatonic schizophrenia, characterized by treatment resistance to the pharmacotherapy with olanzapine, risperidone, flunitrazepam, and ECT. Olanzapine and risperidone and flunitrazepam did not improve her catatonic and psychotic symptoms, and induced the extrapyramidal symptoms. The effects of ECT did not continue even for a month. However, the treatment with low-dose aripiprazole dramatically improved the patient’s psychotic symptoms and extrapyramidal symptoms. The mechanisms underlying the effects of low-dose aripiprazole in this case remain unclear, but unlike other antipsychotics, aripiprazole is a dopamine D2 partial agonist. In this regard, our results suggest that aripiprazole has numerous advantages, especially in cases of stuporous catatonia and a defective general status.

  8. Aripiprazole induced non-cardiogenic pulmonary edema: a case report.

    Science.gov (United States)

    Cetin, Mustafa; Celik, Mustafa; Cakıcı, Musa; Polat, Mustafa; Suner, Arif

    2014-01-01

    Aripiprazole is a second-generation antipsychotic drug with partial dopamine agonistic activity. Although the adverse cardiovascular effects of both typical and atypical antipsychotics are well known, similar data on aripiprazole, which was recently introduced, are scarce. Herein we report a 35-year-old female that presented to our emergency department with non-cardiogenic pulmonary edema. Chest X-ray and thoracic CT showed pulmonary edema and bilateral pleural effusion. Anamnesis showed that she had been taking sertraline 200 mg d-1 for obsessive-compulsive disorder for a long time and that aripiprazole10 mg d-1 was added for augmentation 2 months prior to presentation. We think that the CYP 2D6 inhibitor sertraline might have played a role in increasing the plasma concentration and toxicity of aripiprazole in the presented patient.

  9. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia.

    Science.gov (United States)

    Fleischhacker, W Wolfgang; Sanchez, Raymond; Johnson, Brian; Jin, Na; Forbes, Robert A; McQuade, Robert; Baker, Ross A; Carson, William; Kane, John M

    2013-07-01

    The aim of this study was to evaluate the safety and tolerability of aripiprazole once-monthly (ARI-OM) for the maintenance treatment of schizophrenia. This long-term, pivotal study had four phases: oral conversion (phase 1, 4-6 weeks); oral stabilization (phase 2, 4-12 weeks); ARI-OM stabilization with coadministration of oral aripiprazole in the first 2 weeks (phase 3, 12-36 weeks); and a 52-week, randomized [phase 4, ARI-OM vs. placebo (2 : 1)], double-blind, maintenance phase. Safety was assessed across study phases by the time of first onset of adverse events, as were objective measures of extrapyramidal symptoms, fasting metabolic parameters, and body weight. Patient enrollment was phase 1=633; phase 2=710, of whom 210 entered phase 2 directly; phase 3=576; and phase 4=403 (ARI-OM, n=269; placebo, n=134). Adverse events (>5%) in any phase were insomnia, headache, anxiety, akathisia, increase in weight, injection-site pain, and tremor. Headache, somnolence, and nausea had a peak first onset within 4 weeks of treatment initiation. The incidence of extrapyramidal symptoms was similar in all phases. There were no unexpected changes in weight or shifts in fasting metabolic parameters across all study phases. ARI-OM had a safety and tolerability profile comparable with oral aripiprazole in maintenance treatment of schizophrenia.

  10. Salivary and serum biomarkers for the study of side effects of aripiprazole coprescribed with mirtazapine in rats

    Science.gov (United States)

    Bogdan, Maria; Silosi, Isabela; Surlin, Petra; Tica, Andrei Adrian; Tica, Oana Sorina; Balseanu, Tudor-Adrian; Rauten, Anne-Marie; Camen, Adrian

    2015-01-01

    The aim of this study was to investigate whether the co-administration of aripiprazole and mirtazapine could determine weight gain and lipid metabolism disorders in Wistar rats, compared to the same side effects produced by mirtazapine alone, and the risk of hepatotoxicity due to the combination of the two substances. Tumor necrosis factor alpha (TNF-α), liver fatty acid binding protein (L-FABP/FABP1) and repulsive guidance molecule C/hemojuvelin (RGM-C/HJV) levels were determined in serum and in saliva. Also, serum levels for total cholesterol (TC), low and high-density lipoprotein (LDL, HDL), triglycerides (TG), aspartate aminotransferase (ASAT) and alanine amino transferase (ALAT) were assessed. We found positive and statistically significant correlations between serum and salivary levels of TNF-α, L-FABP/FABP1 and RGM-C/HJV. Mirtazapine determined significantly differences of TNF-α and L-FABP serum levels; final body weight; TC and LDL levels, leading to higher concentrations than its association with aripiprazole. Although not statistically significant, mirtazapine group experienced higher values for salivary levels of TNF-α, TG and ASAT, and lower values for HDL, compared to aripiprazole + mirtazapine group. The results suggest that aripiprazole might improve some of the disturbances caused by mirtazapine, and that the two drugs combination cause no additional alterations in liver function. Also, the findings indicate that TNF-α, L-FABP/FABP1 and RGM-C/HJV levels can be helpful as biomarkers for metabolic disturbances and impaired function of hepatocytes, and that their salivary determination can replace serum determination. PMID:26221370

  11. Salivary and serum biomarkers for the study of side effects of aripiprazole coprescribed with mirtazapine in rats.

    Science.gov (United States)

    Bogdan, Maria; Silosi, Isabela; Surlin, Petra; Tica, Andrei Adrian; Tica, Oana Sorina; Balseanu, Tudor-Adrian; Rauten, Anne-Marie; Camen, Adrian

    2015-01-01

    The aim of this study was to investigate whether the co-administration of aripiprazole and mirtazapine could determine weight gain and lipid metabolism disorders in Wistar rats, compared to the same side effects produced by mirtazapine alone, and the risk of hepatotoxicity due to the combination of the two substances. Tumor necrosis factor alpha (TNF-α), liver fatty acid binding protein (L-FABP/FABP1) and repulsive guidance molecule C/hemojuvelin (RGM-C/HJV) levels were determined in serum and in saliva. Also, serum levels for total cholesterol (TC), low and high-density lipoprotein (LDL, HDL), triglycerides (TG), aspartate aminotransferase (ASAT) and alanine amino transferase (ALAT) were assessed. We found positive and statistically significant correlations between serum and salivary levels of TNF-α, L-FABP/FABP1 and RGM-C/HJV. Mirtazapine determined significantly differences of TNF-α and L-FABP serum levels; final body weight; TC and LDL levels, leading to higher concentrations than its association with aripiprazole. Although not statistically significant, mirtazapine group experienced higher values for salivary levels of TNF-α, TG and ASAT, and lower values for HDL, compared to aripiprazole + mirtazapine group. The results suggest that aripiprazole might improve some of the disturbances caused by mirtazapine, and that the two drugs combination cause no additional alterations in liver function. Also, the findings indicate that TNF-α, L-FABP/FABP1 and RGM-C/HJV levels can be helpful as biomarkers for metabolic disturbances and impaired function of hepatocytes, and that their salivary determination can replace serum determination.

  12. The cardiac safety of aripiprazole treatment in patients at high risk for torsade

    DEFF Research Database (Denmark)

    Polcwiartek, Christoffer; Sneider, Benjamin; Graff, Claus;

    2015-01-01

    prolongation risk was lower compared with placebo and active controls. Epidemiological studies linked aripiprazole to weak/moderate torsadogenicity. No studies were found associating aripiprazole with BrS suggesting low affinity for the fast sodium current. CONCLUSIONS: Aripiprazole is a low-risk antipsychotic...

  13. [Hypersexuality associated with aripiprazole: a new case and review of the literature].

    Science.gov (United States)

    Vrignaud, Laura; Aouille, Jerémie; Mallaret, Michel; Durrieu, Geneviève; Jonville-Béra, Annie-Pierre

    2014-01-01

    We report the case of a patient with hypersexuality while he was treated with aripiprazole since 6 months. Clinical manifestations were an increased libido, unusual frequent masturbation and sexual instincts. All have resolved upon discontinuation of aripiprazole, and recurred after it was restarted. The partial dopaminergic agonist effect of aripiprazole could probably explain the occurrence of this compulsive behaviour.

  14. Successful treatment of a prolactinoma with the antipsychotic drug aripiprazole

    Science.gov (United States)

    Bakker, Ilse C A; Schubart, Chris D

    2016-01-01

    Summary In this report, we describe a female patient with both prolactinoma and psychotic disorder who was successfully treated with aripiprazole, a partial dopamine 2 receptor agonist. During the follow-up of more than 10 years, her psychotic symptoms improved considerably, prolactin levels normalised and the size of the prolactinoma decreased. This observation may be of clinical relevance in similar patients who often are difficult to treat with the regular dopaminergic drugs. Learning points Prolactinoma coinciding with psychosis can represent a therapeutic challenge. In contrast to many other antipsychotic drugs, aripiprazole is associated with a decrease in prolactin levels. Aripiprazole can be a valuable pharmaceutical tool to treat both prolactinoma and psychosis. PMID:27284453

  15. Biological conversion of aripiprazole lauroxil − An N-acyloxymethyl aripiprazole prodrug

    Directory of Open Access Journals (Sweden)

    Morten Rohde

    2014-01-01

    Full Text Available N-acyloxyalkylation of NH-acidic compounds can be a prodrug approach for e.g. tertiary or some N-heterocyclic amines and secondary amides and have the potential to modify the properties of the parent drug for specific uses, for example its physicochemical, pharmacokinetic or biopharmaceutical properties. Aripiprazole lauroxil was prepared as a model compound for such prodrugs and its bioconversion was investigated both in vitro and in vivo. Theoretically, N-acyloxyalkyl derivates of NH-acid compounds undergo a two-step bioconversion into the parent NH-acidic drug through an N-hydroxyalkyl intermediate. However, to our knowledge no published studies have investigated the formation of an intermediate in vivo. In the present study, it was demonstrated that the assumed N-hydroxymethyl intermediate was readily observed both in vitro and in vivo. In vivo, the observed plasma concentration of the intermediate was at the same level as the drug (aripiprazole. When prodrug intermediates are formed, it is important to make a proper pharmacological, pharmacokinetic and toxicological evaluation of the intermediates to ensure patient safety; however, several challenges were identified when testing an N-acyloxyalkyl prodrug. These included the development of a suitable bioanalytical method, the accurate prediction of prodrug bioconversion and thereby the related pharmacokinetics in humans and the toxicological potential of the intermediate.

  16. 阿立哌唑联合氯氮平对精神分裂症患者糖脂代谢与睡眠及体重的影响%Effect of aripiprazole combined with clozapine on glucolipid metabolism, sleep and body mass in patients with schizophrenia

    Institute of Scientific and Technical Information of China (English)

    肖鹏; 孙晓花

    2016-01-01

    Objective To investigate the clinical effect of aripiprazole combined with clozapine on glucolipid metabolism , sleep quality and body mass in patients with schizophrenia .Methods Seventy -six pa-tients with schizophrenia were divided into treatment group and control group , each group 38 cases.Control group was given clozapine 400-500 mg・ d -1 .Treatment group was given aripiprazole 30 mg・ d-1 combined clozapine 200-300 mg・ d-1 .The course of treatment was 6 months. The changes of blood glucose and lipid levels , sleep quality , body mass and clinical symptoms were compared in two groups before and after treatment.The clinical efficacy and adverse drug reactions in two groups were observed.Results After treatment, the self-rating scale of sleep ( SRSS ) and pittsburgh sleep quality index ( PSQI ) in treatment group were (15.74 ±3.21), (2.42 ±0.45), significantly lower than (20.45 ±4.67) ,(6.43 ±0.78) in control group(P<0.05).The levels of fasting blood glucose , postprandial 2 h blood glucose, triacylglycerol and cholesterol levels in control group were (5.64 ±0.57), (9.75 ±0.66), (1.57 ±0.18), (5.67 ±0.53) mmol・ L-1, signifi-cantly higher than (4.57 ±0.45), (7.89 ±0.55), (1.03 ±0.13),(4.54 ±0.46) mmol・ L-1 in treatment group ( P <0.05 ) .Body mass and body mass index in control group were ( 68.32 ±4.12 ) kg and ( 26.17 ±4.05 ) kg・ m-2 , significantly higher than (57.56 ±3.63 ) kg and (22.07 ±3.44 ) kg・ m-2 in treatment group ( P<0.05 ) . The total effective rate of treatment group was 92.11%, significantly higher than 76.32%in control group ( P<0.05 ) . The incidence rate of adverse drug reactions in treatment group was 15.79%, obviously lower than 39.47%in control group (P<0.05).Conclusion Aripiprazole combined with clozapine can be beneficial to glucose metabolism and body mass of patients in a stable state in the treatment of patients with schizophrenia , and can improve sleep condition and clinical symptoms of patients , and had

  17. Efficacy of aripiprazole in sulpiride-induced tardive oromandibular dystonia.

    Science.gov (United States)

    Imai, Noboru; Ikawa, Masako

    2011-01-01

    Tardive dystonia is a side effect of dopamine receptor-blocking agents, which are mainly used as antipsychotic drugs. The treatment of tardive dystonia is difficult and often unsuccessful. An 82-year-old woman experienced mandibular deviation to the left due to spasm of the masticatory muscles with involuntary chewing movement and Parkinsonism. She had been treated with sulpiride for motility disorder for 5 years. Parkinsonism almost disappeared after the withdrawal of sulpiride, but tardive oromandibular dystonia showed no improvement. Aripiprazole treatment at 3 mg/day improved tardive oromandibular dystonia without worsening Parkinsonism. Low-dosage aripiprazole may be effective for tardive oromandibular dystonia in patients with no other psychiatric disorder.

  18. Successful treatment of a prolactinoma with the antipsychotic drug aripiprazole

    NARCIS (Netherlands)

    Bakker, Ilse C A; Schubart, Chris D; Zelissen, Pierre M J

    2016-01-01

    In this report, we describe a female patient with both prolactinoma and psychotic disorder who was successfully treated with aripiprazole, a partial dopamine 2 receptor agonist. During the follow-up of more than 10 years, her psychotic symptoms improved considerably, prolactin levels normalised and

  19. Cognitive-enhancing effects of aripiprazole: a case report

    Directory of Open Access Journals (Sweden)

    Galderisi Silvana

    2008-10-01

    Full Text Available Abstract Patients with schizophrenia often present mild to severe cognitive deficits which contribute to their social disability. Second-generation antipsychotics have shown only mild to moderate beneficial effects on cognition. The present case report suggests cognitive enhancing effects of aripiprazole, a dopamine partial agonist, shown to increase dopamine release in prefrontal cortex in animal studies. The patient was in his first-episode of schizophrenia, and had no previous exposure to first-generation antipsychotics. Before schizophrenia onset his cognitive functioning was poor and he could not attend regular courses to reach his high school degree; he started but was not able to attend the University courses for several years. After schizophrenia onset, he was treated, in sequence, with olanzapine, amisulpride and aripiprazole. During treatment with the first two second-generation antipsychotics, positive symptoms markedly improved while cognitive functioning remained poor. During treatment with aripiprazole, clinical remission was obtained and the patient was able to attend university courses and pass several examinations. Social functioning was markedly improved. Aripiprazole demonstrated cognitive enhancing effects in this patient. These effects were long-lasting and paralleled by a positive impact on social functioning.

  20. Effect of aripiprazole on mismatch negativity (MMN in schizophrenia.

    Directory of Open Access Journals (Sweden)

    Zhenhe Zhou

    Full Text Available BACKGROUND: Cognitive deficits are considered core symptoms of the schizophrenia. Cognitive function has been found to be a better predictor of functional outcome than symptom levels. Changed mismatch negativity (MMN reflects abnormalities of early auditory processing in schizophrenia. Up to now, no studies for the effects of aripiprazole on MMN in schizophrenia have been reported. METHODOLOGY/PRINCIPAL FINDINGS: Subjects included 26 patients with schizophrenia, and 26 controls. Psychopathology was rated in patients with the Positive and Negative Syndrome Scale (PANSS at baseline, after 4- and 8-week treatments with aripiprazole. Auditory stimuli for ERP consisted of 100 millisecond/1000 Hz standards, intermixed with 100 millisecond/1500 Hz frequency deviants and 250 millisecond/1000 Hz duration deviants. EEG was recorded at Fz. BESA 5.1.8 was used to perform data analysis. MMN waveforms were obtained by subtracting waveforms elicited by standards from waveforms elicited by frequency- or duration-deviant stimuli. Aripiprazole decreased all PANSS. Patients showed smaller mean amplitudes of frequency and duration MMN at baseline than did controls. A repeated measure ANOVA with sessions (i.e., baseline, 4- and 8-week treatments and MMN type (frequency vs. duration as within-subject factors revealed no significant MMN type or MMN type × session main effect for MMN amplitudes. Session main effect was significant. LSD tests demonstrated significant differences between MMN amplitudes at 8 weeks and those at both baseline and 4 weeks. There was significant negative correlation between changes in amplitudes of frequency and duration MMN and changes in PANSS total scores at baseline and follow-up periods. CONCLUSIONS: Aripiprazole improved the amplitudes of MMN. MMN offers objective evidence that treatment with the aripiprazole may ameliorate preattentive deficits in schizophrenia.

  1. Development and validation of a high-performance liquid chromatography method using diode array detection for the simultaneous quantification of aripiprazole and dehydro-aripiprazole in human plasma.

    Science.gov (United States)

    Lancelin, Frédérique; Djebrani, Kayssa; Tabaouti, Khalid; Kraoul, Linda; Brovedani, Sophie; Paubel, Pascal; Piketty, Marie-Liesse

    2008-05-01

    A high-performance liquid chromatography method with diode array detection (HPLC-DAD) was developed for quantification of aripiprazole and dehydro-aripiprazole, in human plasma. After a simple liquid-liquid extraction, chromatographic separation was carried out on a C18 reversed-phase column, using an ammonium buffer-acetonitrile mobile phase (40:60, v/v). The total run time was only 7 min at a flow-rate of 1.0 ml/min. The precision values were less than 12% and the accuracy values were ranging from 98 to 113% and the lower limit of quantification was 2 ng/ml for both compounds. Calibration curves were linear over a range of 2-1000 ng/ml. The mean trough plasma concentrations in patients treated with aripiprazole were 157 and 29 ng/ml for aripiprazole and dehydro-aripiprazole, respectively.

  2. Use of aripiprazole in clozapine induced enuresis: report of two cases.

    Science.gov (United States)

    Lee, Myung-Ji; Kim, Chul-Eung

    2010-02-01

    This report describes the efficacy of combined use of aripiprazole in the treatment of a patient with clozapine induced enuresis. Aripiprazole acts as a potential dopamine partial agonist and the dopamine blockade in the basal ganglia might be one of the causes of urinary incontinence and enuresis. We speculate that aripiprazole functioned as a D2 agonist in hypodopaminergic state of basal ganglia caused by clozapine and maintained dopamine level that would improve enuresis ultimately.

  3. The prescribing pattern of a new antipsychotic: A descriptive study of aripiprazole for psychiatric in-patients

    DEFF Research Database (Denmark)

    Johansson, M.; Manniche, C.; Andersen, Stig Ejdrup

    2008-01-01

    (range 0-8) psychoactive drugs parallel with aripiprazole. This study demonstrates reality in psychopharmacology and quote aripiprazole as example. In day-to-day practice, aripiprazole is used as part of highly individualized regimens comprising polypharmacy and excessive dosing. Although theoretically......In June 2004, aripiprazole was marketed as a second-generation antipsychotic with an entire new mechanism of action. The objective of this descriptive study is to examine the day-to-day prescriptions of aripiprazole to an unselected population of psychiatric in-patients. From 1 February to 1 May...... 2006, present and former in-patients treated with aripiprazole were identified. Prescriptions of aripiprazole and psychoactive comedication were collected retrospectively from the patient records. Seventy-one patients, mainly schizophrenic, received aripiprazole 2.5 to 55 mg/day for median 350 days...

  4. 阿立哌唑%AbilifyTM

    Institute of Scientific and Technical Information of China (English)

    孙爱风; 吴范宏

    2003-01-01

    @@ [化学名称] [4-[4-(2,3-二氯苯基)-1-哌嗪基]丁氧基]-3,4-二氢-2-(1H)-喹喏啉酮 [药理作用] 本品为非典型抗精神病药,对多巴胺D2,D3,5-HT1A受体和5-HT2A受体的亲和性均很强(Ki值分别为0.34,0.8,1.7和3.4nmol);对多巴胺D4,5-HT1C和5-HT7以及α1-肾上腺受体和组胺H1受体的亲和性中等(Ki值分别为44,15,39,57和61nmol);对胆碱能受体无明显亲和力(IC50>1 000nmol*L-1).

  5. Aripiprazole-induced writer’s cramp: a case report

    Directory of Open Access Journals (Sweden)

    Priyajyoti Chakma

    2016-07-01

    Full Text Available Dystonia is a movement disorder, which causes sustained muscle contractions, twisting movements, and abnormal postures. Writer’s cramp is the most commonly identified tasks-specific focal dystonia of writing, characterised by abnormal muscle spasm of hand and arm. Even in the tenth revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10, writer’s cramp is classified under idiopathic nonfamilial dystonias. Our case was a 20 years, Hindu, unmarried, literate of middle socioeconomic status, from urban part of Tripura. He presented with history of difficulty to write because of a stiffening of his right hand and also he noticed that prolonged period of writing caused cramping pain. He was a diagnosed case of paranoid schizophrenia (F20.0 as per ICD-10 for last three years and was on tablet aripiprazole. Diagnosis of writer’s cramp was made which developed after six months of treatment with aripiprazole 15 mg.

  6. Neurobehavioral and genotoxic parameters of antipsychotic agent aripiprazole in mice

    Institute of Scientific and Technical Information of China (English)

    Jaqueline Nascimento PICADA; Viviane Minuzzo PONTES; Patrícia PEREIRA; Bruna de Jesus Neto DOS SANTOS; Franciele CELSO; Jéssica Dias MONTEIRO; Kelly Morais DA ROSA; Leandro Rosa CAMACHO; Luciana Rodrigues VIEIRA; Taís Madelon FREITAS; Tatiana Grasiela DASILVA

    2011-01-01

    Aim:Aripiprazole is an antipsychotic agent to treat schizophrenia,which acts through dopamine D2 partial agonism,serotonin 5-HT1A partial agonism and 5-HT2A antagonism.This study was designed to evaluate the neurobehavioral effects and genotoxic/mutagenic activities of the agent,as well as its effects on lipoperoxidation.Methods:Open field and inhibitory avoidance tasks were used.Thirty min before performing the behavioral tasks,adult male CF-1 mice were administered aripiprazole (1,3 or 10 mg/kg,ip) once for the acute treatment,or the same doses for 5 d for the subchronic treatment.Genotoxic effects were assessed using comet assay in the blood and brain tissues.Mutagenic effects were evaluated using bone marrow micronucleus test.Lipoperoxidation was assessed with thiobarbituric acid reactive substances (TBARS).Results:Acute and subchronic treatments significantly decreased the number of crossing and rearing in the open field task.Acute treatment significantly increased the step-down latency for both the short- and long-term memory in the inhibitory avoidance task.Subchronic treatments with aripiprazole (3 and 10 mg/kg) caused significant DNA strain-break damage in peripheral blood but not in the brain.Mutagenic effect was not detected in the acute and subchronic treatments.Nor TBARS levels in the liver were affected.Conclusion:Aripiprazole improved memory,but could impair motor activities in mice.The drug increased DNA damage in blood,but did not show mutagenic effects,suggesting that it might affect long-term genomic stability.

  7. Successful treatment of a prolactinoma with the antipsychotic drug aripiprazole

    Directory of Open Access Journals (Sweden)

    Ilse C A Bakker

    2016-06-01

    Full Text Available In this report, we describe a female patient with both prolactinoma and psychotic disorder who was successfully treated with aripiprazole, a partial dopamine 2 receptor agonist. During the follow-up of more than 10 years, her psychotic symptoms improved considerably, prolactin levels normalised and the size of the prolactinoma decreased. This observation may be of clinical relevance in similar patients who often are difficult to treat with the regular dopaminergic drugs.

  8. Augmentation treatment in major depressive disorder: focus on aripiprazole

    Directory of Open Access Journals (Sweden)

    J Craig Nelson

    2008-08-01

    Full Text Available J Craig Nelson1, Andrei Pikalov2, Robert M Berman31University of California San Francisco, San Francisco, California, USA; 2Otsuka Pharmaceutical Inc., Rockville, MD, USA; 3Bristol-Myers Squibb, Wallingford, CT, USAAbstract: Major depressive disorder (MDD is a disabling psychiatric condition for which effective treatment remains an outstanding need. Antidepressants are currently the mainstay of treatment for depression; however, almost two-thirds of patients will fail to achieve remission with initial treatment. As a result, a range of augmentation and combination strategies have been used in order to improve outcomes for patients. Despite the popularity of these approaches, limited data from double-blind, randomized, placebo-controlled studies are available to allow clinicians to determine which are the most effective augmentation options or which patients are most likely to respond to which options. Recently, evidence has shown that adjunctive therapy with atypical antipsychotics has the potential for beneficial antidepressant effects in the absence of psychotic symptoms. In particular, aripiprazole has shown efficacy as an augmentation option with standard antidepressant therapy in two, large, randomized, double-blind studies. Based on these efficacy and safety data, aripiprazole was recently approved by the FDA as adjunctive therapy for MDD. The availability of this new treatment option should allow more patients with MDD to achieve remission and, ultimately, long-term, successful outcomes.Keywords: major depression, antipsychotic, mood disorder, aripiprazole

  9. Aripiprazole for acute mania in an elderly person

    Directory of Open Access Journals (Sweden)

    Balaji Bharadwaj

    2011-01-01

    Full Text Available New-onset bipolar disorder is rare in the elderly. Symptom profile is similar to that in young adults but the elderly are more likely to have neurological co-morbidities. There are no case reports of elderly mania being treated with aripiprazole, an atypical antipsychotic. A 78-year-old gentleman presented to us with symptoms suggestive of mania of 1 month′s duration. He had similar history 3 years ago and a family history of postpartum psychosis in his mother. There were no neurological signs on examination and work-up for an organic etiology was negative except for age-related cerebral atrophy. He improved with aripiprazole and tolerated the medications well. The use of psychotropic medications in the elderly is associated with side-effects of sedation, increased cardiovascular risk, and greater risk of extra-pyramidal side-effects. The use of partial dopaminergic antagonists like aripiprazole may be useful in the balancing of effects and side-effects.

  10. Aripiprazole-associated tic in a schizophrenia patient

    Directory of Open Access Journals (Sweden)

    Guo X

    2015-03-01

    Full Text Available Xieli Guo,1,2,* Dali Lu,3,* Yugang Jiang1 1Department of Neurosurgery, Second Xiangya Hospital of Central South University, Changsha, Hunan, People’s Republic of China; 2Department of Neurosurgery, Jinjiang Hospital of Quanzhou Medical College, Jinjiang, Fujian, People’s Republic of China; 3Department of Psychiatry, Xiamen Xianyue Hospital, Xiamen, Fujian, People’s Republic of China *These authors contributed equally to this work Abstract: Tic disorder, characterized by the presence of both motor and vocal tics is common in adolescents and adults. Antipsychotics including typical antipsychotics and atypical antipsychotics are generally recognized by experts as the most effective pharmacological treatment for tics. However, previous studies suggest that tic-like symptoms might manifest during treatment with atypical antipsychotics such as clo­zapine, quetiapine, but not aripiprazole. We present the first case, to our knowledge, of an adult schizophrenia patient who developed tics during treatment with aripiprazole. Keywords: aripiprazole, antipsychotics, tic, schizophrenia, side effect

  11. Switching to aripiprazole for the treatment of residual mutism resulted in distinct clinical courses in two catatonic schizophrenia cases

    Science.gov (United States)

    Muneoka, Katsumasa; Kanahara, Nobuhisa; Kimura, Shou

    2017-01-01

    Objectives: The efficacy of a partial agonist for the dopamine D2 receptor, aripiprazole, for catatonia in schizophrenia has been reported. Methods: We report distinct clinical courses in challenging aripiprazole to treat residual mutism after severe catatonic symptoms improved. Results: In the first case, mutism was successfully treated when the patient was switched from olanzapine to aripiprazole. In contract, switching to aripiprazole from risperidone aggravated auditory hallucinations in the second case. Conclusions: We will discuss the benefits and risks of using aripiprazole for the treatment of catatonic schizophrenia and the possibility of dopamine supersensitivity psychosis. PMID:28255444

  12. Use of aripiprazole for delirium in the elderly: a short review.

    Science.gov (United States)

    Kirino, Eiji

    2015-03-01

    The effects and tolerability of antipsychotics in delirium treatment remain controversial. Compared to other antipsychotics, aripiprazole differs in pharmacological activity because it exerts its effect as a dopamine D2 partial agonist. The guidelines of the American Psychiatric Association rank aripiprazole highly among antipsychotics with regard to safety, and this drug is likely to be useful for delirium treatment. Here, we reviewed the efficacy and safety of aripiprazole for delirium. The results of our literature review on the efficacy and safety of delirium treatments suggest that aripiprazole is an effective treatment option for delirium in the elderly. Aripiprazole is as effective as other antipsychotics in improving delirium symptoms, and it is safer because it is less likely to cause extrapyramidal symptoms, excessive sedation, and weight gain. However, these findings are based on only a few clinical studies of elderly patients with delirium. Therefore, further investigations are necessary.

  13. Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder

    Directory of Open Access Journals (Sweden)

    Berman R

    2011-05-01

    discontinuation. Mean weight change was 4.4 kg; 36.6% experienced ≥7% increase in weight from baseline (observed case analysis, n = 303. No clinically relevant changes in other metabolic parameters were seen. At the end of open-label treatment, 221 patients (69.7% had a Clinical Global Impression-Severity of Illness score of 1 (not at all ill or 2 (borderline ill.Conclusion: Long-term adjunctive aripiprazole therapy was well tolerated with an acceptable long-term safety and tolerability profile in patients with major depressive disorder who had not responded to treatment with one or more antidepressant therapies. Clinically significant weight gain was observed in about one-third of patients. Overall, the adverse event profile was consistent with that reported in the short-term trials and readily managed clinically.Keywords: adjunctive aripiprazole, antidepressant therapy, major depressive disorder, long-term safety and tolerability

  14. Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials.

    Directory of Open Access Journals (Sweden)

    Xianbin Li

    Full Text Available OBJECTIVE: To compare the safety and efficacy of adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia. METHODS: POPULATION: adult patients presenting with antipsychotic-induced hyperprolactinemia diagnosed by prolactin level with or without prolactin-related symptoms. INTERVENTIONS: adjunctive aripiprazole vs. adjunctive placebo. OUTCOME MEASURES: adverse events and efficacy of treatment. STUDIES: randomized controlled trials. RESULTS: Five randomized controlled trials with a total of 639 patients (326 adjunctive aripiprazole, 313 adjunctive placebo met the inclusion criteria. Adjunctive aripiprazole was associated with a 79.11% (125/158 prolactin level normalization rate. Meta-analysis of insomnia, headache, sedation, psychiatric disorder, extrapyramidal symptom, dry mouth, and fatigue showed no significant differences in the adjunctive aripiprazole treatment group compared with the placebo group (risk difference (Mantel-Haenszel, random or fixed -0.05 to 0.04 (95% confidence interval -0.13 to 0.16; I(2 =0% to 68%, P=0.20 to 0.70. However, sedation, insomnia, and headache were more frequent when the adjunctive aripiprazole dose was higher than 15 mg/day. Meta-analysis of the prolactin level normalization indicated adjunctive aripiprazole was superior to placebo (risk difference (Mantel-Haenszel, random 0.76 (95% confidence interval 0.67 to 0.85; I(2 =43%, P<0.00001. The subgroup analysis confirmed that the subjects who received adjunctive aripiprazole 5 mg/day showed a degree of prolactin normalization similar to that of all participants. No significant differences between groups in discontinuation and improvements of psychiatric symptoms. CONCLUSION: Adjunctive aripiprazole is both safe and effective as a reasonable choice treatment for patients with antipsychotic-induced hyperprolactinemia. The appropriate dose of adjunctive aripiprazole may be 5 mg/day.

  15. Effects of aripiprazole on caffeine-induced hyperlocomotion and neural activation in the striatum.

    Science.gov (United States)

    Batista, Luara A; Viana, Thércia G; Silveira, Vívian T; Aguiar, Daniele C; Moreira, Fabrício A

    2016-01-01

    Aripiprazole is an antipsychotic that acts as a partial agonist at dopamine D2 receptors. In addition to its antipsychotic activity, this compound blocks the effects of some psychostimulant drugs. It has not been verified, however, if aripiprazole interferes with the effects of caffeine. Hence, this study tested the hypothesis that aripiprazole prevents caffeine-induced hyperlocomotion and investigated the effects of these drugs on neural activity in the striatum. Male Swiss mice received injections of vehicle or antipsychotic drugs followed by vehicle or caffeine. Locomotion was analyzed in a circular arena and c-Fos protein expression was quantified in the dorsolateral, dorsomedial, and ventrolateral striatum, and in the core and shell regions of nucleus accumbens. Aripiprazole (0.1, 1, and 10 mg/kg) prevented caffeine (10 mg/kg)-induced hyperlocomotion at doses that do not change basal locomotion. Haloperidol (0.01, 0.03, and 0.1 mg/kg) also decreased caffeine-induced hyperlocomotion at all doses, although at the two higher doses, this compound reduced basal locomotion. Immunohistochemistry analysis showed that aripiprazole increases c-Fos protein expression in all regions studied, whereas caffeine did not alter c-Fos protein expression. Combined treatment of aripiprazole and caffeine resulted in a decrease in the number of c-Fos positive cells as compared to the group receiving aripiprazole alone. In conclusion, aripiprazole prevents caffeine-induced hyperlocomotion and increases neural activation in the striatum. This latter effect is reduced by subsequent administration of caffeine. These results advance our understanding on the pharmacological profile of aripiprazole.

  16. Waterborne aripiprazole blunts the stress response in zebrafish

    Science.gov (United States)

    Barcellos, Heloísa Helena De Alcantara; Kalichak, Fabiana; da Rosa, João Gabriel Santos; Oliveira, Thiago Acosta; Koakoski, Gessi; Idalencio, Renan; de Abreu, Murilo Sander; Giacomini, Ana Cristina Varrone; Fagundes, Michele; Variani, Cristiane; Rossini, Mainara; Piato, Angelo L.; Barcellos, Leonardo José Gil

    2016-11-01

    Here we provide, at least to our knowledge, the first evidence that aripiprazole (APPZ) in the water blunts the stress response of exposed fish in a concentration ten times lower than the concentration detected in the environment. Although the mechanism of APPZ in the neuroendocrine axis is not yet determined, our results highlight that the presence of APPZ residues in the environment may interfere with the stress responses in fish. Since an adequate stress response is crucial to restore fish homeostasis after stressors, fish with impaired stress response may have trouble to cope with natural and/or imposed stressors with consequences to their welfare and survival.

  17. A Case of Aripiprazole-Induced Tardive Dyskinesia with Dramatic Evolution

    Science.gov (United States)

    Heitzmann, Edwige; Weiner, Luisa; Michel, Bruno

    2016-01-01

    Aripiprazole is reported to be a good clinical safety profile antipsychotic. However, recent data suggest that the risk of tardive dyskinesia could be higher than initially thought. We report the case of aripiprazole-induced tardive dyskinesia with dramatic evolution in a patient with several risk factors, including older age and exposure to antipsychotic over a period longer than six months. This case and its dramatic evolution, associated with other cases recently published, suggest reconsidering the real risk of tardive dyskinesia associated with aripiprazole, particularly in the elderly. PMID:27818825

  18. Usefulness of the dopamine system-stabilizer aripiprazole for reducing morphine-induced emesis.

    Science.gov (United States)

    Shiokawa, Mitsuru; Narita, Minoru; Nakamura, Atsushi; Kurokawa, Kazuhiro; Inoue, Tadao; Suzuki, Tsutomu

    2007-09-10

    In the management of pain, nausea and vomiting are some of the most distressing adverse effects induced by opioids. In the present study, we investigated the effect of the dopamine system-stabilizer aripiprazole on morphine-induced emesis. Morphine induced retching and vomiting in a dose-dependent manner in ferrets. The emetic effect of morphine was significantly suppressed by pretreatment with either the dopamine receptor antagonist haloperidol or aripiprazole. These results suggest that the co-administration of aripiprazole may be useful for reducing the severity of morphine-induced emesis.

  19. A Case of Aripiprazole-Induced Tardive Dyskinesia with Dramatic Evolution

    Directory of Open Access Journals (Sweden)

    Edwige Heitzmann

    2016-01-01

    Full Text Available Aripiprazole is reported to be a good clinical safety profile antipsychotic. However, recent data suggest that the risk of tardive dyskinesia could be higher than initially thought. We report the case of aripiprazole-induced tardive dyskinesia with dramatic evolution in a patient with several risk factors, including older age and exposure to antipsychotic over a period longer than six months. This case and its dramatic evolution, associated with other cases recently published, suggest reconsidering the real risk of tardive dyskinesia associated with aripiprazole, particularly in the elderly.

  20. A Case of Aripiprazole-Induced Tardive Dyskinesia with Dramatic Evolution

    OpenAIRE

    Edwige Heitzmann; Hervé Javelot; Luisa Weiner; Bruno Michel

    2016-01-01

    Aripiprazole is reported to be a good clinical safety profile antipsychotic. However, recent data suggest that the risk of tardive dyskinesia could be higher than initially thought. We report the case of aripiprazole-induced tardive dyskinesia with dramatic evolution in a patient with several risk factors, including older age and exposure to antipsychotic over a period longer than six months. This case and its dramatic evolution, associated with other cases recently published, suggest reconsi...

  1. Aripiprazole for treating irritability in children & adolescents with autism: A systematic review

    OpenAIRE

    Ahmad Ghanizadeh; Sylvie Tordjman; Nematollah Jaafari

    2015-01-01

    Background & objectives: No clear therapeutic benefits of antipsychotics have been reported for the treatment of behavioural symptoms in autism. This systematic review provides an assessment of evidence for treating irritability in autism by aripiprazole. Methods: The databases of MEDLINE/PubMed and Google Scholar were searched for relevant articles about the effect of aripiprazole in children with autism. The articles were searched according to the inclusion and exclusion criteria speci...

  2. Aripiprazole: a review of its use in the treatment of irritability associated with autistic disorder patients aged 6-17.

    Science.gov (United States)

    Douglas-Hall, Petrina; Curran, Sarah; Bird, Victoria; Taylor, David

    2011-01-01

    A systematic review and meta-analysis were performed examining the efficacy of aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents. Aripiprazole was found to be more effective in reducing irritability compared with placebo at 8 weeks, SMD -0.64 [-0.90 to -0.39, P autism. Long-term studies are required to determine the efficacy and safety of aripiprazole in autistic disorder in children.

  3. Aripiprazole for treating irritability in children & adolescents with autism: A systematic review

    Directory of Open Access Journals (Sweden)

    Ahmad Ghanizadeh

    2015-01-01

    Full Text Available Background & objectives: No clear therapeutic benefits of antipsychotics have been reported for the treatment of behavioural symptoms in autism. This systematic review provides an assessment of evidence for treating irritability in autism by aripiprazole. Methods: The databases of MEDLINE/PubMed and Google Scholar were searched for relevant articles about the effect of aripiprazole in children with autism. The articles were searched according to the inclusion and exclusion criteria specifed for this review. All the double-blind, controlled, randomized, clinical trials examining the efficacy of aripiprazole for treating children and adolescents with autism were included. Results: From the 93 titles identified, 26 were irrelevant and 58 were evaluated for more details. Only five articles met the inclusive criteria. The evidence from precise randomized double blind clinical trials of aripiprazole for the treatment of autism in children and adolescents was convincing enough to recommend aripiprazole. Adverse effects were not very common and were usually mild. Interpretation & conclusions: Current evidence suggests that aripiprazole is as effective and safe as risperidone for treating irritability in autism. However, further studies with larger sample size and longer duration are required.

  4. Dilemma of prescribing aripiprazole under the Taiwan health insurance program: a descriptive study

    Science.gov (United States)

    Hsu, Yi-Chien; Chou, Yu-Ching; Chang, Hsin-An; Kao, Yu-Chen; Huang, San-Yuan; Tzeng, Nian-Sheng

    2015-01-01

    Objectives Refractory major depressive disorder (MDD) is a serious problem leading to a heavy economic burden. Antipsychotic augmentation treatment with aripiprazole and quetiapine is approved for MDD patients and can achieve a high remission rate. This study aimed to examine how psychiatrists in Taiwan choose medications and how that choice is influenced by health insurance payments and administrative policy. Design Descriptive study. Outcome measures Eight questions about the choice of treatment strategy and atypical antipsychotics, and the reason to choose aripiprazole. Intervention We designed an augmentation strategy questionnaire for psychiatrists whose patients had a poor response to antidepressants, and handed it out during the annual meeting of the Taiwanese Society of Psychiatry in October 2012. It included eight questions addressing the choice of treatment strategy and atypical antipsychotics, and the reason whether or not to choose aripiprazole as the augmentation antipsychotic. Results Choosing antipsychotic augmentation therapy or switching to other antidepressant strategies for MDD patients with an inadequate response to antidepressants was common with a similar probability (76.1% vs 76.4%). The most frequently used antipsychotics were aripiprazole and quetiapine, however a substantial number of psychiatrists chose olanzapine, risperidone, and sulpiride. The major reason for not choosing aripiprazole was cost (52.1%), followed by insurance official policy audit and deletion in the claims review system (30.1%). Conclusion The prescribing behavior of Taiwanese psychiatrists for augmentation antipsy-chotics is affected by health insurance policy. PMID:25657586

  5. Metabolism

    Science.gov (United States)

    ... Are More Common in People With Type 1 Diabetes Metabolic Syndrome Your Child's Weight Healthy Eating Endocrine System Blood Test: Basic Metabolic Panel (BMP) Activity: Endocrine System Growth Disorders Diabetes Center Thyroid Disorders Your Endocrine System Movie: Endocrine ...

  6. Covert dyskinesia associated with aripiprazole: a case report and review of the literature.

    Science.gov (United States)

    Moseley, Carrie N; Simpson-Khanna, Heather A; Catalano, Glenn; Catalano, Maria C

    2013-01-01

    The atypical antipsychotic agents are felt by many to have a lower risk of inducing the development of dyskinetic movements than the conventional antipsychotic agents agents such as haloperidol and fluphenazine. However, that does not mean that treatment with the atypical antipsychotic agents carries no risk of developing dyskinesias. To the contrary, all of the atypical antipsychotic agents, including aripiprazole, have been associated with the induction of dyskinetic movements. We will present the case of a patient who developed a covert dyskinesia that manifested shortly after the discontinuation of aripiprazole. We will review the use of aripiprazole and the adverse effects most commonly associated with its use. We will also discuss the risk factors associated with the development of tardive dyskinesia and review the different clinical variations (withdrawal dyskinesia, covert dyskinesia, tardive diskinesia) of medication-induced dyskinesias.

  7. Aripiprazole in the acute and maintenance phase of bipolar I disorder

    Directory of Open Access Journals (Sweden)

    Zupancic M

    2012-01-01

    Full Text Available Melanie Zupancic1, Misty L Gonzalez2,31Southern Illinois University School of Medicine, 2Division of Medicine Psychiatry, Southern Illinois University School of Medicine, 3Southern Illinois University Edwardsville School of Pharmacy, Southern Illinois University Edwardsville, Springfield, IL, USAAbstract: Bipolar affective disorder is a disabling illness with substantial morbidity and many management challenges. Traditional mood stabilizers such as lithium, valproate, and carbamazepine are often inadequate in controlling symptoms both during the acute and maintenance phase of treatment. Aripiprazole is a second-generation antipsychotic with a unique mechanism of action. Evidence suggests that it is effective in acute manic and mixed states. There are limited data to suggest its efficacy as a maintenance agent. Future studies will be needed to better define the role of aripiprazole relative to other traditional pharmacologic agents.Keywords: aripiprazole, bipolar disorder, acute treatment, maintenance treatment

  8. Low dosage of aripiprazole induced neuroleptic malignant syndrome after interaction with other neuroleptic drugs

    Directory of Open Access Journals (Sweden)

    Albino Petrone

    2013-09-01

    Full Text Available Aripiprazole is a 2nd generation antipsychotic medication, atypical neuroleptic used for treatment of schizophrenia improving symptoms such as hallucinations, delusions, and disorganized thinking. A potentially fatal symptom complex sometimes referred to as neuroleptic malignant syndrome (NMS has been reported in association with administration of antipsychotic drugs, including aripiprazole. Rare cases of NMS occurred during aripiprazole treatment in the worldwide clinical database. The disease is characterized by a distinctive clinical syndrome of mental status change, rigidity, fever, and dysautonomia. We report on a 63-year old woman with depression syndrome who developed neuroleptic malignant syndrome after twelve days of aripripazole 5 mg per day. Our case is added to the small number already described and suggests the need for caution when aripripazole is added to increase the effect of other antipsychotics.

  9. Add-on treatment of aripiprazole in an adult onychophagia patient

    Directory of Open Access Journals (Sweden)

    Mehmet Cemal Kaya

    2012-12-01

    Full Text Available Nail biting (onychophagia is a common disorder whichhas not been investigated yet. There are different opinionsabout to classify onychophagia, but according toDSM-IV-TR it is classified as impulse control disorder nototherwise specified. The knowledge about treatment ofonychophagia is limited. There are a few studies abouttreatment of onychophagia with psychotherapy and astudy with pharmacotherapy. Some studies suggest thatan atypical antipsychotic aripiprazole may have beneficialeffects in the treatment of impulse control disorders. Inthis study we report a case of onychophagia which hassuccessfully treated with aripiprazole add-on to escitalopramtreatment that has never reported before. J Clin ExpInvest 2012; 3(4: 545-547Key words: Onychophagia, aripiprazole, add-on treatment

  10. Metabolism

    Institute of Scientific and Technical Information of China (English)

    2008-01-01

    2008255 Serum adiponectin level declines in the elderly with metabolic syndrome.WU Xiaoyan(吴晓琰),et al.Dept Geriatr,Huashan Hosp,Fudan UnivShanghai200040.Chin J Geriatr2008;27(3):164-167.Objective To investigate the correlation between ser-um adiponectin level and metabolic syndrome in the elderly·Methods Sixty-one subjects with metabolic syndrome and140age matched subjects without metabolic

  11. Aripiprazole versus risperidone for treating children and adolescents with tic disorder: a randomized double blind clinical trial.

    Science.gov (United States)

    Ghanizadeh, Ahmad; Haghighi, Alireza

    2014-10-01

    There are some uncontrolled studies about the efficacy and safety of both aripiprazole and risperidone for treating tic disorder. Moreover, the efficacy of these medications has never been compared. This is the first double blind randomized clinical trial comparing the safety and efficacy of aripiprazole and risperidone for treating patients with tic disorder. Sixty children and adolescents with tic disorder were randomly allocated into one of the two groups to receive either aripiprazole or risperidone for 2 months. The primary outcome measure was the score of Yale Global Tic Severity Scale. In addition, health related quality of life and adverse events were assessed. Both aripiprazole and risperidone decreased the Yale Global Tic Severity Scale score during this trial. Moreover, both medications increased the health related quality of life score. Both aripiprazole and risperidone were tolerated well. Aripiprazole [3.22 (1.9) mg/day] decreased tic score as much as risperidone [0.6 (0.2) mg/day]. Their adverse effects and their effects on health related quality of life were comparable. However, risperidone increased the patients' social functioning more than aripiprazole in short term.

  12. Severe arrhythmia induced by orally disintegrating aripiprazole tablets (Bosiqing®: a case report

    Directory of Open Access Journals (Sweden)

    Shao Q

    2015-12-01

    Full Text Available Qing Shao,1,2,* Wei Quan,1,2,* Xiaoni Jia,1 Jianbo Chen,1 Shanbo Ma,3 Xiaohong Zhang11Xi’an Mental Health Center, Institute of Mental Health, Xi’an Medical University, Xi’an, Shaanxi, People’s Republic of China; 2Institute of Materia Medica, School of Pharmacy, Fourth Military Medical University, Xi’an, Shaanxi, People’s Republic of China; 3Department of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi, People’s Republic of China*These authors contributed equally to this workAbstract: Psychotropic medications have been known to cause cardiac conduction disturbances. Not much is known about the cardiovascular side effects of newer atypical antipsychotics such as aripiprazole. A case of a 13-year-old girl with schizophrenia is presented. An analysis of the presented patient’s clinical history indicates the need for a detailed analysis of the severe arrhythmia induced by aripiprazole. This presented case report contains valuable guidelines that can be of assistance in the treatment of patients with aripiprazole.Keywords: schizophrenia, aripiprazole, arrhythmia, antipsychotics

  13. Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review

    DEFF Research Database (Denmark)

    Ennis, Zandra Nymand; Damkier, Per

    2015-01-01

    To review available data on first-trimester exposure to olanzapine, quetiapine, risperidone and aripiprazole and risk of congenital malformations. We performed a systematic literature search in accordance with PRISMA guidelines identifying studies containing original data on first-trimester expos......To review available data on first-trimester exposure to olanzapine, quetiapine, risperidone and aripiprazole and risk of congenital malformations. We performed a systematic literature search in accordance with PRISMA guidelines identifying studies containing original data on first......-trimester exposure and pregnancy outcome with respect to congenital malformations. Cumulated data for olanzapine were 1090 first-trimester-exposed pregnancies with 38 malformations resulting in a malformation rate of 3.5%. The corresponding numbers for quetiapine, risperidone and aripiprazole were 443/16 (3.6%), 432....../22 (5.1%) and 100/5 (5.0%), respectively. Relative risk estimates and 95% confidence intervals were 1.0 (0.7-1.4) (olanzapine), 1.0 (0.6-1.7) (quetiapine), 1.5 (0.9-2.2) (risperidone) and 1.4 (0.5-3.1) (aripiprazole). First-trimester exposure to olanzapine is not associated with an increased risk...

  14. Aripiprazole blocks acute self-administration of cocaine and is not self-administered in mice

    DEFF Research Database (Denmark)

    Sørensen, Gunnar; Sager, Thomas N; Petersen, Jørgen H

    2008-01-01

    doses (0.03, 0.1, and 0.3 mg/kg/infusion) even caused significant decreases in nose-poking activity, possibly due to extrapyramidal side effects. CONCLUSIONS: These data are consistent with a potential role for aripiprazole in treatment of cocaine addiction without abuse potential per se....

  15. Aripiprazole in the treatment of Huntington’s disease: a case series

    Directory of Open Access Journals (Sweden)

    Andrea Ciammola

    2008-11-01

    Full Text Available Andrea Ciammola1, Jenny Sassone1, Clarissa Colciago1, Niccolò E Mencacci1, Barbara Poletti1, Andrea Ciarmiello2, Ferdinando Squitieri3, Vincenzo Silani11Department of Neurology and Laboratory of Neuroscience, “Dino Ferrari” Centre, University of Milan Medical School – IRCCS Istituto Auxologico Italiano, Milano, Italy; 2Unit of Nuclear Medicine, S. Andrea Hospital, La Spezia, Italy; 3Neurogenetics Unit, IRCCS Neuromed, Pozzilli (IS, ItalyObjectives: The aim of the study was to describe the effects of aripiprazole, a new atypical antipsychotic drug that acts as a partial dopamine agonist on motor, behavioral and cognitive functions in patients with genetically confirmed Huntington’s disease (HD.Methods and results: Three HD patients were evaluated for Unified Huntington Disease Rating Scale part I and II and Beck Depression Inventory at baseline, after two months and one-year treatment. Aripiprazole effectively controlled involuntary movements and psychiatric symptoms, with effects on cognitive functions.Conclusions: Our case reports suggest that aripiprazole is well tolerated, remarkably improving some of the motor and behavioral symptoms in patients affected by HD. Randomized, controlled, long-term studies are warranted.Keywords: Huntington’s disease, aripiprazole, treatment, chorea

  16. Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents

    Directory of Open Access Journals (Sweden)

    Kirino E

    2014-11-01

    Full Text Available Eiji Kirino1–3 1Department of Psychiatry, Juntendo University School of Medicine, 2Department of Psychiatry, Juntendo University Shizuoka Hospital, 3Juntendo Institute of Mental Health, Shizuoka, Japan Abstract: Bipolar disorder is a pernicious illness. Compared with the later-onset form, early onset bipolar disorder is associated with worse psychosocial outcomes, and is characterized by rapid cycling and increased risks of substance abuse and suicide attempts. Controlling mood episodes and preventing relapse in this group of pediatric patients requires careful treatment. Here, we review the effectiveness of aripiprazole for bipolar disorder in children and adolescents, with discussion of this drug's unique pharmacological profile and various clinical study outcomes. Aripiprazole acts as a serotonin 5-HT2A receptor antagonist, as well as a partial agonist of the serotonin 5-HT1A and dopamine D2 receptors. It can be safely used in children and adolescents, as it is highly tolerated and shows lower rates of the side effects typically observed with other antipsychotic drugs, including sedation, weight gain, hyperprolactinemia, and extrapyramidal syndrome. The presently reviewed randomized controlled trials (RCTs and non-RCTs generally reported aripiprazole to be effective and well-tolerated in children and adolescents with bipolar disorder. However, due to the limited number of RCTs, the present conclusions must be evaluated cautiously. Furthermore, aripiprazole cannot yet be considered a preferred treatment for children and adolescents with bipolar disorder, as there is not yet evidence that aripiprazole shows greater efficacy compared to other second-generation antipsychotics. Additional data are needed from future head-to-head comparison studies. Keywords: child, mania, mixed state

  17. Case Reports of Aripiprazole Causing False-Positive Urine Amphetamine Drug Screens in Children.

    Science.gov (United States)

    Kaplan, Justin; Shah, Pooja; Faley, Brian; Siegel, Mark E

    2015-12-01

    Urine drug screens (UDSs) are used to identify the presence of certain medications. One limitation of UDSs is the potential for false-positive results caused by cross-reactivity with other substances. Amphetamines have an extensive list of cross-reacting medications. The literature contains reports of false-positive amphetamine UDSs with multiple antidepressants and antipsychotics. We present 2 cases of presumed false-positive UDSs for amphetamines after ingestion of aripiprazole. Case 1 was a 16-month-old girl who accidently ingested 15 to 45 mg of aripiprazole. She was lethargic and ataxic at home with 1 episode of vomiting containing no identifiable tablets. She remained sluggish with periods of irritability and was admitted for observation. UDS on 2 consecutive days came back positive for amphetamines. Case 2 was of a 20-month-old girl who was brought into the hospital after accidental ingestion of an unknown quantity of her father's medications which included aripiprazole. UDS on the first day of admission came back positive only for amphetamines. Confirmatory testing with gas chromatography-mass spectrometry (GC-MS) on the blood and urine samples were also performed for both patients on presentation to detect amphetamines and were subsequently negative. Both patients returned to baseline and were discharged from the hospital. To our knowledge, these cases represent the first reports of false-positive amphetamine urine drug tests with aripiprazole. In both cases, aripiprazole was the drug with the highest likelihood of causing the positive amphetamine screen. The implications of these false-positives include the possibility of unnecessary treatment and monitoring of patients.

  18. Aripiprazole Improves Depressive Symptoms and Immunological Response to Antiretroviral Therapy in an HIV-Infected Subject with Resistant Depression

    Directory of Open Access Journals (Sweden)

    Chiara Cecchelli

    2010-01-01

    Full Text Available Aripiprazole is the first medication approved by the FDA as an add-on treatment for MDD. The impact of aripiprazole on the response to HIV is unknown. The patient we report on was diagnosed HIV-positive in 1997 and has been treated with antiretroviral therapy since then. In 2008, we diagnosed resistant major depression, hypochondria, and panic disorder. On that occasion, blood tests showed a significantly reduced CD4 count and a positive viral load. We treated this patient with aripiprazole and citalopram. Mood, somatic symptoms, and occupational functioning progressively improved. The last blood examination showed an increase in the CD4 count and a negative viral load. On the basis of the present case study and the review of the literature concerning the effects of psychotropic agents on viral replication, we suggest that the use of aripiprazole in HIV-infected subjects warrants further research.

  19. Metabolism

    Science.gov (United States)

    ... a particular food provides to the body. A chocolate bar has more calories than an apple, so ... acid phenylalanine, needed for normal growth and protein production). Inborn errors of metabolism can sometimes lead to ...

  20. Low-dose aripiprazole resolved complex hallucinations in the left visual field after right occipital infarction (Charles Bonnet syndrome).

    Science.gov (United States)

    Chen, Cheng-Che; Liu, Hsing-Cheng

    2011-06-01

    We reported a patient who suffered from complex visual hallucinations with left homonymous hemianopsia. Brain imaging showed an acute haemorrhage infarct at the right occipital lobe. Charles Bonnet syndrome (CBS) was suspected and aripiprazole was prescribed at 5 mg daily. After 3 weeks, the symptoms of hallucinations and anxiety were relieved. Although some CBS patients might be self-limited without discomfort, low-dose aripiprazole can be considered as a safe medication for significantly anxious patients with CBS.

  1. No difference in frontal cortical activity during an executive functioning task after acute doses of aripiprazole and haloperidol

    Directory of Open Access Journals (Sweden)

    Ingeborg eBolstad

    2015-05-01

    Full Text Available Background: Aripiprazole is an atypical antipsychotic drug that is characterized by partial dopamine D2 receptor agonism. Its pharmacodynamic profile is proposed to be beneficial in the treatment of cognitive impairment, which is prevalent in psychotic disorders. This study compared brain activation characteristics produced by aripiprazole with that of haloperidol, a typical D2 receptor antagonist, during a task targeting executive functioning.Methods: Healthy participants received an acute oral dose of haloperidol, aripiprazole or placebo before performing an executive functioning task while blood-oxygen-level-dependent (BOLD functional magnetic resonance imaging (fMRI was carried out. Results: There was a tendency towards reduced performance in the aripiprazole group compared to the two other groups. The image analysis yielded a strong task-related BOLD-fMRI response within each group. An uncorrected between-group analysis showed that aripiprazole challenge resulted in stronger activation in the frontal and temporal gyri and the putamen compared with haloperidol challenge, but after correcting for multiple testing there was no significant group difference. Conclusion: No significant group differences between aripiprazole and haloperidol in frontal cortical activation were obtained when corrected for multiple comparisons.This study is registered in ClinicalTrials.gov (identifier: 2009-016222-14; https://clinicaltrials.gov/.

  2. TARDIVE DYSKINESIA AND OTHER EXTRAPYRAMIDAL SYMPTOMS ASSOCIATED WITH ARIPIPRAZOLE: A CASE SERIES

    Directory of Open Access Journals (Sweden)

    Nayana Sanjay

    2016-06-01

    Full Text Available BACKGROUND Aripiprazole is a third generation antipsychotic introduced in 2004 for treatment of Schizophrenia and bipolar disorders. It has partial agonist activity at dopamine D2 receptor and D2 antagonist activity under hyperdopaminergic condition. In addition, it is a partial agonist at serotonin 5HT1A receptor and antagonist at 5HT2A receptor. Because its pharmacological profile differs from other atypical antipsychotics, it was initially thought to produce lesser side effects and movement disorders. But over the years, there is a growing body of evidence in the form of case reports and case series of Aripiprazole induced movement disorders like Tardive dyskinesia, Parkinsonism, akathisia and dystonia. Of late it has been advocated for irritability associated with autism and as an augmenter for depressive disorder. It has lower potential for weight gain and sedation, as it has relatively low affinity for H1 [Histamine] receptor compared to clozapine, olanzapine and quetiapine. Based on this unique mechanism, it is claimed to have minimal or non-significant motor side effects like Tardive dyskinesia. We document a case series of 8 patients who developed Tardive dyskinesia, Parkinsonism and akathisia following treatment with Aripiprazole (ARP. METHODS This is both retrospective and observational study. Patients from outpatient and inpatient department of a tertiary psychiatric teaching hospital with an ICD-10 diagnosis of psychiatric disorder, who has experienced movement disorder while on treatment with Aripiprazole are included in this report. All these patients were under the care of authors as treating Psychiatrists. Rating scales like Abnormal Involuntary Movement Scale (AIMS, Naranjo’s Causality Scale, Barnes Akathisia Rating Scale (BARS and Simpson Angus extrapyramidal Scale (SAS were used. RESULTS Total of eight patients presented with various movement disorders associated with Aripiprazole, out of which three patients with tardive

  3. METABOLISM

    Institute of Scientific and Technical Information of China (English)

    1999-01-01

    Objective: To determine the allele frequencies of genetic variants 373 Ala→Pro and 451 Arg→Gln of cholesteryl ester transfer protein (CETP) and to explore their potential impacts on serum lipid metabolism. Methods: The genotypes in CETP codon 373 and 451 in 91 German healthy students and 409 an-

  4. Aripiprazole Improves Associated Comorbid Conditions in Addition to Tics in Adult Patients with Gilles de la Tourette Syndrome.

    Science.gov (United States)

    Gerasch, Sarah; Kanaan, Ahmad Seif; Jakubovski, Ewgeni; Müller-Vahl, Kirsten R

    2016-01-01

    Gilles de la Tourette Syndrome (GTS) is characterized by motor and vocal tics, as well as associated comorbid conditions including obsessive-compulsive disorder (OCD), attention deficit/hyperactivity disorder (ADHD), depression, and anxiety which are present in a substantial number of patients. Although randomized controlled trials including a large number of patients are still missing, aripiprazole is currently considered as a first choice drug for the treatment of tics. The aim of this study was to further investigate efficacy and safety of aripiprazole in a group of drug-free, adult patients. Specifically, we investigated the influence of aripiprazole on tic severity, comorbidities, premonitory urge (PU), and quality of life (QoL). Moreover, we were interested in the factors that influence a patient's decision in electing for-or against- pharmacological treatment. In this prospective uncontrolled open-label study, we included 44 patients and used a number of rating scales to assess tic severity, PU, comorbidities, and QoL at baseline and during treatment with aripiprazole. Eighteen out of fortyfour patients decided for undergoing treatment for their tics with aripiprazole and completed follow-up assessments after 4-6 weeks. Our major findings were (1) aripiprazole resulted in significant reduction of tics, but did not affect PU; (2) aripiprazole significantly improved OCD and showed a trend toward improvement of other comorbidities including depression, anxiety, and ADHD; (3) neither severity of tics, nor PU or QoL influenced patients' decisions for or against treatment of tics with aripiprazole; instead patients with comorbid OCD tended to decide in favor of, while patients with comorbid ADHD tended to decide against tic treatment; (4) most frequently reported adverse effects were sleeping problems; (5) patients' QoL was mostly impaired by comorbid depression. Our results suggest that aripiprazole may improve associated comorbid conditions in addition to tics

  5. A retrospective study of predictive factors for effective aripiprazole augmentation of antidepressant therapy in treatment-resistant depression

    Directory of Open Access Journals (Sweden)

    Sugawara H

    2016-05-01

    Full Text Available Hiroko Sugawara,1,2 Kaoru Sakamoto,1 Tsuyoto Harada,3 Satoru Shimizu,4 Jun Ishigooka1 1Department of Psychiatry, Tokyo Women’s Medical University, 2Support Center for Women Health Care Professionals and Researchers, Tokyo Women’s Medical University, Shinjuku-ku, 3Department of Psychiatry, Tokyo Women’s Medical University Medical Center East, Arakawa-ku, 4Department of Research, Medical Research Institute, Tokyo Women’s Medical University, Shinjuku-ku, Tokyo, Japan Background: Several studies have evaluated the efficacy and tolerability of aripiprazole for augmentation of antidepressant therapy for treatment-resistant depression (TRD. Here, we investigated the efficacy of aripiprazole augmentation for TRD including both major depressive disorder and bipolar disorder and the clinical predictors of treatment efficacy in a Japanese population.  Methods: Eighty-five depressed Japanese patients who underwent aripiprazole augmentation therapy after failing to respond satisfactorily to antidepressant monotherapy were included in the study. Treatment responses were evaluated based on Clinical Global Impression Improvement scores assessed 8 weeks after initiation of aripiprazole administration. We compared demographic and diagnostic variables, psychiatric medication variables, and clinical variables between remission and nonremission groups.  Results: The aripiprazole augmentation remission rate was 36.5%. Multiple logistic regression analysis indicated that aripiprazole augmentation was significantly more effective for bipolar depression than for major depressive disorder, and both absence of comorbid anxiety disorders and current episode duration >3 months were significantly associated with the efficacy of aripiprazole augmentation.  Conclusion: Polarity of depression, comorbidity of anxiety disorders, and current episode duration may predict the efficacy of aripiprazole augmentation for TRD including both major depressive disorder and

  6. 合用与换用阿立哌唑对已绝经女性精神分裂症患者催乳素水平影响的对照研究%Control Study of Combined with Aripiprazole or Switching to Aripiprazole on Prolactin Levels in Postmenopausal Women with Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    倪静; 戴兴海; 朱欣彦; 沈涛; 周颖; 田良辉; 咸晶; 徐颺

    2015-01-01

    Objective: To investigate the role of aripiprazole in prolactin ( PRL ) metabolism through comparing the PRL levels of the postmenopausal women with schizophrenia and hyperprolactinemia .Method:90 women with schizophrenia and hyperprolactinemia were randomly divided into 2 groups:group A with 45 cases, former drugs plus aripiprazole 5mg once a day for 12 weeks) and group B with 45 cases, Aripiprazole 14.78±4.76mg once a day for 12 weeks).Then examined the PRL levels at 5 time points:prior treatment, 2 weeks, 4 weeks, 8 weeks, 12 weeks and accomplished the PANSS scales at the time points stated above as well.Result:According to the result of repeated measures ANOVA , the PRL levels of the 2 groups had no significant differences ( F=3.507,P=0.064) and had interaction between the groups and time points ( P=0. 002), suggesting that PRL was influenced by different treatment of aripiprazole and time .The score of PAN-SS scales had no significant differences (F=0.145,P=0.705).Conclusion:Aripiprazole may down-regulate the expression of the PRL levels of women with schizophrenia and hyperprolactinemia .%目的:探讨已绝经女性精神分裂症合并高催乳素血症患者在合用与换用阿立哌唑时对其催乳素水平影响的对照研究。方法:对90例已绝经女性精神分裂症同时合并高催乳素血症的患者随机分为两组,合用组:45例,为原有药物联合阿立哌唑5mg/d治疗12周,换用组:45例,为原有药物更换为治疗剂量阿立哌唑(14.78±4.76mg/d)12周,治疗前和治疗后2、4、8、12周末分别测定催乳素水平并予以阳性和阴性量表(PANSS)和副反应量表(TESS)评定病情并进行比较。结果:根据重复测量结果,两组间PRL水平尚无统计学差异( F=3.507,P=0.064),但组间检验提示时间、研究组别有交互作用(P=0.002),即PRL的值受到时间和组别的共同影响。 PRL随着时间的推移逐渐下降,且

  7. Successful treatment of catatonic syndrome in bipolar I disorder adding aripiprazole to ECT: A case report

    Directory of Open Access Journals (Sweden)

    Diego Hidalgo, MD

    2012-09-01

    Full Text Available Background and Objectives: Catatonic syndrome is a condition presenting in multiple ways, sharing many of them with the neuroleptic malignant syndrome and other diseases. This diagnostic challenge is the main cause of keep treating catatonic syndromes without neuroleptics. Methods: Review of the literature and a case report. Results: We present the case of a 19 years old bipolar I patient with a severe catatonic syndrome, with a torpid clinical evolution, partial response to benzodiazepines and ECT, which successfully resolved with intramuscular aripiprazole. We found through a systematic review (PubMed 2005-2010 that there are few but significant case reports of catatonic syndromes treated with new second generation antipsychotics for different reasons with good outcomes as ours. The pharmacological profile of aripiprazole and the low incidence of NMS reported make it a suitable option in treating this syndrome. Conclusions: We think that this case report could contribute to add more evidence for aripiprazole to be considered a good third-line option in the treatment of catatonic syndrome. However, this would require randomized controlled trials to confirm its effectiveness and safety.

  8. Effects of amisulpride and aripiprazole on progressive-ratio schedule performance: comparison with clozapine and haloperidol.

    Science.gov (United States)

    den Boon, F S; Body, S; Hampson, C L; Bradshaw, C M; Szabadi, E; de Bruin, N

    2012-09-01

    Clozapine and some other atypical antipsychotics (e.g. quetiapine, olanzapine) have been found to exert a characteristic profile of action on operant behaviour maintained by progressive-ratio schedules, as revealed by Killeen's Mathematical Principles of Reinforcement model of schedule-controlled behaviour. These drugs increase the value of a parameter that expresses the 'incentive value' of the reinforcer (a) and a parameter that is inversely related to the organism's 'motor capacity' (δ). This experiment examined the effects of two further atypical antipsychotics, aripiprazole and amisulpride, on progressive-ratio schedule performance in rats; the effects of clozapine and a conventional antipsychotic, haloperidol, were also examined. In agreement with previous findings, clozapine (4, 8 mg kg⁻¹) increased a and δ, whereas haloperidol (0.05, 0.1 mg kg⁻¹) reduced a and increased δ. Aripiprazole (3,30 mg kg⁻¹) increased δ but did not affect a. Amisulpride (5, 50 mg kg⁻¹) had a delayed and protracted effect: δ was increased 3-6 hours after treatment; a was increased 1.5 hours, and reduced 12-24 hours after treatment. Interpretation based on Killeen's model suggests that aripiprazole does not share clozapine's ability to enhance reinforcer value. Amisulpride produced a short-lived enhancement, followed by a long-lasting reduction, of reinforcer value. Both drugs impaired motor performance.

  9. Aripiprazole once-monthly as treatment for psychosis in Turner syndrome: literature review and case report.

    Science.gov (United States)

    Carlone, Cristiano; Pompili, Enrico; Silvestrini, Cristiana; Nicolò, Giuseppe

    2016-01-01

    Turner syndrome (TS) is a neurogenetic disorder characterized by partial or complete monosomy-X, usually resulting of a sporadic chromosomal nondisjunction. It is one of the most common sex chromosome abnormalities, affecting approximately 1 in 2,000 live born females. There are sporadic few case reports of concomitant TS with schizophrenia worldwide. No defined psychiatric condition has been traditionally related to TS, and it is not mentioned in DSM-IV. Although it is not associated with any psychiatric syndrome, several case reports in the literature describe a similar constellation of symptoms in TS that may represent a biologically-based entity. Aripiprazole once-monthly is a second generation antipsychotic recently developed. Its efficacy and non-inferiority to oral aripiprazole have been demonstrated in preventing relapse in patients with schizophrenia. Experience with oral aripiprazole and the current availability of the long-acting formulation suggest a potential benefit in a variety of clinical scenarios and therefore consideration as a treatment option in the treatment of schizophrenia and psychotic symptoms in several disease like TS.

  10. Blood Biomarkers Predict the Cognitive Effects of Aripiprazole in Patients with Acute Schizophrenia

    Directory of Open Access Journals (Sweden)

    Hikaru Hori

    2017-03-01

    Full Text Available Aripiprazole has been reported to exert variable effects on cognitive function in patients with schizophrenia. Therefore, in the present study, we evaluated biological markers, clinical data, and psychiatric symptoms in order to identify factors that influence cognitive function in patients with schizophrenia undergoing aripiprazole treatment. We evaluated cognitive function in 51 patients with schizophrenia using Brief Assessment of Cognition in Schizophrenia (BACS, as well as background information, psychiatric symptoms, plasma catecholamine metabolites—homovanillic acid (HVA, 3-methoxy-4-hydroxyphenylglycol (MHPG—, and serum brain-derived neurotrophic factor (BDNF. Multivariate analyses were performed in order to identify factors independently associated with cognitive function. Brain-derived neurotrophic factor levels, number of hospitalizations, and MHPG levels were associated with verbal memory and learning. Total hospitalization period and MHPG levels were associated with working memory. Age at first hospitalization and education were associated with motor speed. The number of hospital admissions, Positive and Negative Syndrome Scale negative subscale scores (PANSS-N, MHPG levels, BDNF levels, and Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS scores were associated with verbal fluency. Homovanillic acid and MHPG levels, duration of illness, and PANSS-N scores were associated with attention and processing speed. Brain-derived neurotrophic factor and MHPG levels were associated with executive function. These results suggest that treatment of psychiatric symptoms and cognitive dysfunction may be improved in patients treated with aripiprazole by controlling for these contributing factors.

  11. Aripiprazole improves associated comorbid Conditions in addition to Tics in adult Patients with Gilles de la Tourette Syndrome

    Directory of Open Access Journals (Sweden)

    Sarah Gerasch

    2016-09-01

    Full Text Available Gilles de la Tourette Syndrome (GTS is characterized by motor and vocal tics, as well as associated comorbid conditions including obsessive-compulsive disorder (OCD, attention deficit/hyperactivity disorder (ADHD, depression, and anxiety which are present in a substantial number of patients. Although randomized controlled trials including a large number of patients are still missing, aripiprazole is currently considered as a first choice drug for the treatment of tics. The aim of this study was to further investigate efficacy and safety of aripiprazole in a group of drug-free, adult patients. Specifically, we investigated the influence of aripiprazole on tic severity, comorbidities, premonitory urge (PU, and quality of life (QoL. Moreover we were interested in the factors that influence a patient’s decision in electing for-or against- pharmacological treatment. In this prospective uncontrolled open-label study, we included 44 patients and used a number of rating scales to assess tic severity, PU, comorbidities, and QoL at baseline and during treatment with aripiprazole. 18 out of 44 patients decided for undergoing treatment for their tics with aripiprazole and completed follow-up assessments after 4-6 weeks. Our major findings were (1 aripiprazole resulted in significant reduction of tics, but did not affect PU; (2 aripiprazole significantly improved OCD and showed a trend towards improvement of other comorbidities including depression, anxiety and ADHD; (3 neither severity of tics, nor PU or QoL influenced patients’ decisions for or against treatment of tics with aripiprazole; instead patients with comorbid OCD tended to decide in favor of, while patients with comorbid ADHD tended to decide against tic treatment; (4 most frequently reported adverse effects were sleeping problems; (5 patients’ QoL was mostly impaired by comorbid depression. Our results suggest that aripiprazole may improve associated comorbid conditions in addition to tics

  12. Combination of omega-3 Fatty acids, lithium, and aripiprazole reduces oxidative stress in brain of mice with mania.

    Science.gov (United States)

    Arunagiri, Pandiyan; Rajeshwaran, Krishnamoorthy; Shanthakumar, Janakiraman; Tamilselvan, Thangavel; Balamurugan, Elumalai

    2014-09-01

    Manic episode in bipolar disorder (BD) was evaluated in the present study with supplementation of omega-3 fatty acids in combination with aripiprazole and lithium on methylphenidate (MPD)-induced manic mice model. Administration of MPD 5 mg/kg bw intraperitoneally (i.p.) caused increase in oxidative stress in mice brain. To retract this effect, supplementation of omega-3 fatty acids 1.5 ml/kg (p.o.), aripiprazole 1.5 mg/kg bw (i.p.), and lithium 50 mg/kg bw (p.o) were given to mice. Omega-3 fatty acids alone and in combination with aripiprazole- and lithium-treated groups significantly reduced the levels of superoxide dismutase (SOD), catalase (CAT), and lipid peroxidation products (thiobarbituric acid reactive substances) in the brain. MPD treatment significantly decreased the reduced glutathione (GSH) level and glutathione peroxidase (GPx) activity, and they were restored by supplementation of omega-3 fatty acids with aripiprazole and lithium. There is no remarkable difference in the effect of creatine kinase (CK) activity between MPD-induced manic model and the treatment groups. Therefore, our results demonstrate that oxidative stress imbalance and mild insignificant CK alterations induced by administration of MPD can be restored back to normal physiological levels through omega-3 fatty acids combined with lithium and aripiprazole that attributes to effective prevention against mania in adult male Swiss albino mice.

  13. Aripiprazole Augmentation in the Treatment of Military-Related PTSD with Major Depression: a retrospective chart review

    Directory of Open Access Journals (Sweden)

    Fikretoglu Deniz

    2011-05-01

    Full Text Available Abstract Background In this chart review, we attempted to evaluate the benefits of adding aripiprazole in veterans with military-related PTSD and comorbid depression, who had been minimally or partially responsive to their existing medications. Methods A retrospective chart review of patients who received an open-label, flexible-dose, 12- week course of adjunctive aripiprazole was conducted in 27 military veterans meeting DSM-IV criteria for PTSD and comorbid major depression. Concomitant psychiatric medications continued unchanged, except for other antipsychotics which were discontinued prior to initiating aripiprazole. The primary outcome variable was a change from baseline in the PTSD checklist-military version (PCL-M and the Beck Depression Inventory (BDI-II. Results PTSD severity (Total PCL scores decreased from 56.11 at baseline to 46.85 at 12-weeks (p Conclusions The addition of aripiprazole contributed to a reduction in both PTSD and depression symptomatology in a population that has traditionally demonstrated poor pharmacological response. Further investigations, including double-blind, placebo-controlled studies, are essential to confirm and further demonstrate the benefit of aripiprazole augmentation in the treatment of military related PTSD.

  14. Clinical Usefulness of Aripiprazole and Lamotrigine in Schizoaffective Presentation of Tuberous Sclerosis.

    Science.gov (United States)

    Lee, Seung-Yup; Min, Jung-Ah; Lee, In Goo; Kim, Jung Jin

    2016-08-31

    Tuberous sclerosis is not as rare as once thought and has high psychiatric comorbidities. However, bipolar or psychotic features associated with tuberous sclerosis have been rarely reported. This report first presents a tuberous sclerosis patient, resembling a schizoaffective disorder of bipolar type. A patient with known tuberous sclerosis displayed mood fluctuation and psychotic features. Her symptoms did not remit along with several psychiatric medications. After hospitalization, the patient responded well with lamotrigine and aripiprazole without exacerbation. As demonstrated in this case, tuberous sclerosis may also encompass bipolar affective or psychotic features. We would like to point out the necessity to consider bipolarity in evaluating and treating tuberous sclerosis.

  15. Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone.

    Science.gov (United States)

    Qiao, Ying; Yang, Fuzhong; Li, Chunbo; Guo, Qian; Wen, Hui; Zhu, Suoyu; Ouyang, Qiong; Shen, Weidi; Sheng, Jianhua

    2016-03-30

    This study investigated the effects of a low-dose aripiprazole adjunctive treatment for risperidone- or paliperidone-induced hyperprolactinemia in Han Chinese women with schizophrenia. After 4 weeks of risperidone or paliperidone treatment, 60 out of 66 patients improved significantly and experienced hyperprolactinemia. They were randomly assigned to the treatment group (aripiprazole adjunctive treatment) (n=30) or control group (non-adjunctive treatment) (n=30). The dosage of risperidone and paliperidone were maintained; and aripiprazole was maintained at 5mg/day during the 8-week study period. The prolactin levels at the end of the 8th week were significantly lower in the treatment group than in the control group. The estradiol level correlated negatively with serum prolactin level both in the treatment group and the control group at the end of the 8th week and the 4th week respectively. The Positive and Negative Syndrome Scale score improved significantly during the 8-week study period in both groups. The incidence of treatment-emergent adverse event was similar in two groups. Low-dose aripiprazole adjunctive treatment is effective in relieving risperidone- and paliperidone-induced hyperprolactinemia in female schizophrenic patients without increasing adverse event.

  16. Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole.

    Science.gov (United States)

    De Berardis, Domenico; Fornaro, Michele; Serroni, Nicola; Marini, Stefano; Piersanti, Monica; Cavuto, Marilde; Valchera, Alessandro; Mazza, Monica; Girinelli, Gabriella; Iasevoli, Felice; Perna, Giampaolo; Martinotti, Giovanni; Di Giannantonio, Massimo

    2014-01-01

    Hyperprolactinemia is an unwanted adverse effect present in several typical and atypical antipsychotics. Aripiprazole is a drug with partial agonist activity at the level of dopamine receptors D2, which may be effective for antipsychotic- induced hyperprolactinemia. Therefore, we analyzed the literature concerning the treatment of antipsychoticinduced hyperprolactinemia with aripiprazole by updating a previous paper written on the same topic. More recent studies were reviewed. They showed that there are two options for the treatment of antipsychotic-induced hyperprolactinemia with aripiprazole. The safest strategy may require the addition of aripiprazole to ongoing treatments, in the case patients had previously responded to antipsychotic drugs and then developed hyperprolactinemia. However, it is advisable to monitor the patients in case relapses and/or side effect, although rare, might occur. Switching drugs should be considered when a patient does not appear to be responding to the previous antipsychotic, thus developing hyperprolactinemia. A cross-taper switch should always be considered, but the risk of a relapse in the disorder may occur more frequently and the patients should be closely monitored. However, limitations must be considered and further studies are needed to definitely elucidate this important issue. Some relevant patents are also described in this review.

  17. A Placebo-Controlled, Fixed-Dose Study of Aripiprazole in Children and Adolescents with Irritability Associated with Autistic Disorder

    Science.gov (United States)

    Marcus, Ronald N.; Owen, Randall; Kamen, Lisa; Manos, George; McQuade, Robert D.; Carson, William H.; Aman, Michael G.

    2009-01-01

    Objective: To evaluate the short-term efficacy and safety of aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Method: Two hundred eighteen children and adolescents (aged 6-17 years) with a diagnosis of autistic disorder, and with behaviors such as tantrums, aggression, self-injurious behavior, or a…

  18. Neural correlates of delusional infestation responding to aripiprazole monotherapy: a case report

    Directory of Open Access Journals (Sweden)

    Ponson L

    2015-02-01

    Full Text Available Laura Ponson,1,2 Frédéric Andersson,1 Wissam El-Hage1,2 1Université François-Rabelais de Tours, Inserm, Imagerie et Cerveau UMR U930, Tours, France, 2CHRU de Tours, Clinique Psychiatrique Universitaire, Tours, France Background: The pathophysiology and appropriate pharmacological interventions for delusional infestation remain unknown.Case presentation: Here, we report a case of primary delusional infestation successfully treated with aripiprazole. We performed functional magnetic resonance imaging (fMRI to investigate brain structures and functional modifications. Before antipsychotic treatment, pre- versus post-treatment fMRI images revealed a marked increase in brain activation in the supplementary motor area (SMA.Conclusion: Our results highlight the efficacy and safety of aripiprazole in the treatment of delusional infestation and the possible role of SMA dysfunction in delusional infestation. Indeed, our results suggest that psychiatric improvement of delusional infestation is associated with normalization of brain activity, particularly in the SMA. Keywords: supplementary motor area, antipsychotics, fMRI

  19. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 3: Clinical Trial Data.

    Science.gov (United States)

    Preskorn, Sheldon H; Macaluso, Matthew

    2016-03-01

    This series of columns has 3 main goals: (1) to explain class warnings as used by the United States Food and Drug Administration, (2) to increase awareness of movement disorders that may occur in patients treated with antipsychotic medications, and (3) to understand why clinicians should refrain from immediately assuming a diagnosis of tardive dyskinesia/dystonia (TD) in patients who develop abnormal movements during treatment with antipsychotics. The first column in the series presented a patient who developed abnormal movements while being treated with aripiprazole as an augmentation strategy for major depressive disorder (MDD) and reviewed data concerning the historical background, incidence, prevalence, and risk factors for tardive and spontaneous dyskinesias, the clinical presentations of which closely resemble each other. The second column in the series reviewed the unique mechanism of action of aripiprazole and preclinical studies and an early-phase human translational study that suggest a low, if not absent, risk of TD with aripiprazole. This column reviews clinical trial data to assess whether those data support the conclusion that aripiprazole has a low to absent risk of causing TD when used as an augmentation strategy to treat MDD. To date, no randomized, placebo-controlled trials have established a definitive link between exposure to aripiprazole and TD in patients with MDD. One long-term, open-label, safety trial examined aripiprazole as an augmentation strategy in individuals with MDD and found a rare occurrence (4/987, 0.4%, the confidence interval of which overlaps with zero) of an adverse event termed TD. In all 4 cases, the observed movements resolved within weeks of aripiprazole discontinuation, suggesting that they were either amenable to treatment or represented an acute syndrome rather than TD. No cases of TD were reported in the registration trials for the MDD indication for aripiprazole. These data were presented in a pooled analysis of

  20. Effects of acute and chronic aripiprazole treatment on choice between cocaine self-administration and food under a concurrent schedule of reinforcement in rats

    DEFF Research Database (Denmark)

    Thomsen, Morgane; Fink-Jensen, Anders; Woldbye, David

    2008-01-01

    the hypothesis that aripiprazole, both as acute and as chronic treatment, would preferentially decrease cocaine self-administration while sparing behavior maintained by a natural reinforcer, resulting in a shift in the allocation of behavior from cocaine-taking towards the alternative reinforcer. MATERIALS...... AND METHODS: Rats were trained to self-administer intravenous cocaine in a concurrent choice procedure, with a palatable food as the competing reinforcer, under a fixed ratio (FR) 1 FR 5 chain schedule. Aripiprazole was then administered as continuous infusion by osmotic minipumps for 5 days, during which...... performance in the choice procedure was assessed daily. RESULTS: An intermediate dose of aripiprazole decreased cocaine self-administration and shifted the cocaine choice curve to the right as an acute treatment. However, as a chronic treatment, aripiprazole failed to decrease cocaine self...

  1. A systematic review of quality of life and weight gain-related issues in patients treated for severe and persistent mental disorders: focus on aripiprazole

    Directory of Open Access Journals (Sweden)

    Salvatore Gentile

    2009-02-01

    Full Text Available Salvatore GentileDepartment of Mental Health, ASL Salerno 1, ItalyAbstract: Aripiprazole is a relatively novel second-generation antipsychotic belonging to the chemical class of benzisoxazole derivatives and is characterized by a unique pharmacological profile which suggests that the drug acts as a dopamine-serotonin system stabilizer. Whereas all previously available antipsychotics are antagonists at D2 receptors, aripiprazole is the only available partial agonist at these receptors. Thus, it has been suggested that aripiprazole could be associated with a relatively neutral impact on bodyweight, possibly reducing risks of a detrimental impact on the quality of life that often complicates management for a large number of patients diagnosed with severe and persistent mental disorders (SPMDs treated chronically with antipsychotic medications. However, data from short- and long-term reviewed studies indicate that the prevalence rate of clinically relevant weight gain during therapy with this drug is similar to that occurring during treatments with other antipsychotic agents, either typical or atypical. Moreover, information on the impact of aripiprazole therapy on the quality of life of patients diagnosed with SPMDs is scarce and characterized by conflicting results. Given these results, further, large, well-designed studies are needed before confirming potential advantages of aripiprazole over first-generation antipsychotics and other SGAs.Keywords: aripiprazole, effectiveness, quality of life, safety, weight gain

  2. No negative symptoms in healthy volunteers after single doses of amisulpride, aripiprazole, and haloperidol: a double-blind placebo-controlled trial.

    Science.gov (United States)

    Park, Chul-Hyun; Park, Tae-Won; Yang, Jong-Chul; Lee, Keon-Hak; Huang, Guang-Biao; Tong, Zhao; Park, Myung-Sook; Chung, Young-Chul

    2012-03-01

    Noncompliance and poor outcome in patients with schizophrenia are closely related to the negative symptoms secondary to antipsychotics. No controlled study has evaluated whether amisulpride and aripiprazole induce negative symptoms. The aim of this study was to assess the effects of single doses of amisulpride, aripiprazole, haloperidol, and risperidone in healthy volunteers. Seventy-eight young volunteers took part in this double-blind, randomized, placebo-controlled, parallel study of four antipsychotics: 400 mg amisulpride, 10 mg aripiprazole, 3 mg haloperidol, and 2 mg risperidone. Assessments of negative symptoms were done 4 h after administration using both subjective rating scales (Neuroleptic Induced Deficit Syndrome Scale and Subjective Deficit Syndrome Scale) and an objective rating scale (Scale for the Assessment of Negative Symptoms). Risperidone only produced significant increases on the avolition score of the Neuroleptic Induced Deficit Syndrome Scale and blunted affect and alogia scores of the Scale for the Assessment of Negative Symptoms compared with placebo. The effect on blunted affect persisted after controlling for mental sedation. Amisulpride, aripiprazole, and haloperidol did not induce negative symptoms. Aripiprazole and risperidone induced mild extrapyramidal symptoms. The most common adverse events were somnolence and cognitive slowing. These data indicate that a single risperidone dose induces negative symptoms in normal volunteers, whereas amisulpride, aripiprazole, and haloperidol do not. These characteristics of antipsychotics should be considered when choosing optimal drugs for patients with psychosis.

  3. Safety and efficacy of aripiprazole for the treatment of pediatric Tourette syndrome and other chronic tic disorders

    Directory of Open Access Journals (Sweden)

    Cox JH

    2016-06-01

    Full Text Available Joanna H Cox,1 Stefano Seri,2,3 Andrea E Cavanna,2,4,5 1Heart of England NHS Foundation Trust, 2School of Life and Health Sciences, Aston Brain Centre, Aston University, 3Children’s Epilepsy Surgery Programme, The Birmingham Children’s Hospital NHS Foundation Trust, 4Department of Neuropsychiatry, Birmingham and Solihull Mental Health NHS Foundation Trust, Birmingham, 5Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology and UCL, London, UK Abstract: Tourette syndrome is a childhood-onset chronic tic disorder characterized by multiple motor and vocal tics and often accompanied by specific behavioral symptoms ranging from obsessionality to impulsivity. A considerable proportion of patients report significant impairment in health-related quality of life caused by the severity of their tics and behavioral symptoms and require medical intervention. The most commonly used medications are antidopaminergic agents, which have been consistently shown to be effective for tic control, but are also associated with poor tolerability because of their adverse effects. The newer antipsychotic medication aripiprazole is characterized by a unique mechanism of action (D2 partial agonism, and over the last decade has increasingly been used for the treatment of tics. We conducted a systematic literature review to assess the available evidence on the efficacy and safety of aripiprazole in pediatric patients with Tourette syndrome and other chronic tic disorders (age range: 4–18 years. Our search identified two randomized controlled trials (involving 60 and 61 participants and ten open-label studies (involving between six and 81 participants. The majority of these studies used two validated clinician-rated instruments (Yale Global Tic Severity Scale and Clinical Global Impression scale as primary outcome measures. The combined results from randomized controlled trials and open-label studies showed that aripiprazole is an

  4. Dilemma of prescribing aripiprazole under the Taiwan health insurance program: a descriptive study

    Directory of Open Access Journals (Sweden)

    Hsu YC

    2015-01-01

    Full Text Available Yi-Chien Hsu,1,2 Yu-Ching Chou,3 Hsin-An Chang,1,2,4 Yu-Chen Kao,1,2,5 San-Yuan Huang,1,2 Nian-Sheng Tzeng1,2,4 1Department of Psychiatry, Tri-Service General Hospital, Taipei, Taiwan; 2School of Medicine, 3School of Public Health, 4Student Counseling Center, National Defense Medical Center, Taipei, Taiwan; 5Department of Psychiatry, Tri-Service General Hospital, Song-Shan Branch, Taipei, Taiwan Objectives: Refractory major depressive disorder (MDD is a serious problem leading to a heavy economic burden. Antipsychotic augmentation treatment with aripiprazole and quetiapine is approved for MDD patients and can achieve a high remission rate. This study aimed to examine how psychiatrists in Taiwan choose medications and how that choice is influenced by health insurance payments and administrative policy.Design: Descriptive study.Outcome measures: Eight questions about the choice of treatment strategy and atypical antipsychotics, and the reason to choose aripiprazole.Intervention: We designed an augmentation strategy questionnaire for psychiatrists whose patients had a poor response to antidepressants, and handed it out during the annual meeting of the Taiwanese Society of Psychiatry in October 2012. It included eight questions addressing the choice of treatment strategy and atypical antipsychotics, and the reason whether or not to choose aripiprazole as the augmentation antipsychotic.Results: Choosing antipsychotic augmentation therapy or switching to other antidepressant strategies for MDD patients with an inadequate response to antidepressants was common with a similar probability (76.1% vs 76.4%. The most frequently used antipsychotics were aripiprazole and quetiapine, however a substantial number of psychiatrists chose olanzapine, risperidone, and sulpiride. The major reason for not choosing aripiprazole was cost (52.1%, followed by insurance official policy audit and deletion in the claims review system (30.1%.Conclusion: The prescribing

  5. Enhancement of encapsulation efficiency of nanoemulsion-containing aripiprazole for the treatment of schizophrenia using mixture experimental design

    Directory of Open Access Journals (Sweden)

    Fard Masoumi HR

    2015-10-01

    Full Text Available Hamid Reza Fard Masoumi, Mahiran Basri, Wan Sarah Samiun, Zahra Izadiyan, Chaw Jiang Lim Nanodelivery Group, Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia Abstract: Aripiprazole is considered as a third-generation antipsychotic drug with excellent therapeutic efficacy in controlling schizophrenia symptoms and was the first atypical anti­psychotic agent to be approved by the US Food and Drug Administration. Formulation of nanoemulsion-containing aripiprazole was carried out using high shear and high pressure homo­genizers. Mixture experimental design was selected to optimize the composition of nanoemulsion. A very small droplet size of emulsion can provide an effective encapsulation for delivery system in the body. The effects of palm kernel oil ester (3–6 wt%, lecithin (2–3 wt%, Tween 80 (0.5–1 wt%, glycerol (1.5–3 wt%, and water (87–93 wt% on the droplet size of aripiprazole nanoemulsions were investigated. The mathematical model showed that the optimum formulation for preparation of aripiprazole nanoemulsion having the desirable criteria was 3.00% of palm kernel oil ester, 2.00% of lecithin, 1.00% of Tween 80, 2.25% of glycerol, and 91.75% of water. Under optimum formulation, the corresponding predicted response value for droplet size was 64.24 nm, which showed an excellent agreement with the actual value (62.23 nm with residual standard error <3.2%. Keywords: schizoaffective disorder, antipsychotic drug, bipolar I disorder, D-optimal mixture design, optimization formulation

  6. Switching to Aripiprazole as a Strategy for Weight Reduction: A Meta-Analysis in Patients Suffering from Schizophrenia

    Directory of Open Access Journals (Sweden)

    Yoram Barak

    2011-01-01

    Full Text Available Weight gain is one of the major drawbacks associated with the pharmacological treatment of schizophrenia. Existing strategies for the prevention and treatment of obesity amongst these patients are disappointing. Switching the current antipsychotic to another that may favorably affect weight is not yet fully established in the psychiatric literature. This meta-analysis focused on switching to aripiprazole as it has a pharmacological and clinical profile that may result in an improved weight control. Nine publications from seven countries worldwide were analyzed. These encompassed 784 schizophrenia and schizoaffective patients, 473 (60% men and 311 (40% women, mean age 39.4±7.0 years. The major significant finding was a mean weight reduction by −2.55±1.5 kgs following the switch to aripiprazole (<.001. Switching to an antipsychotic with a lower propensity to induce weight gain needs be explored as a strategy. Our analysis suggests aripiprazole as a candidate for such a treatment strategy.

  7. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 4: Case Report Data.

    Science.gov (United States)

    Macaluso, Matthew; Flynn, Alexandra; Preskorn, Sheldon

    2016-05-01

    This series of columns has 3 main goals: (1) to explain class warnings as used by the United States Food and Drug Administration, (2) to increase awareness of movement disorders that may occur in patients treated with antipsychotic medications, and (3) to understand why clinicians should refrain from immediately assuming a diagnosis of tardive dyskinesia/dystonia (TD) in patients who develop abnormal movements during treatment with antipsychotics. The first column in the series presented a patient who developed abnormal movements while being treated with aripiprazole as an augmentation strategy for major depressive disorder and reviewed data concerning the historical background, incidence, prevalence, and risk factors for tardive and spontaneous dyskinesias, the clinical presentations of which closely resemble each other. The second column in the series reviewed the unique mechanism of action of aripiprazole and reviewed preclinical studies and an early-phase human translational study that suggest a low, if not absent, risk of TD with aripiprazole. The third column in this series reviewed the registration trial data for aripiprazole across all of its indications and found a raw incidence of TD ranging from 0.004 (4 out of 987) in long-term studies of the drug as an augmentation strategy for major depressive disorder to 0.0016 (19 out of 11,897) based on all short-term (ie, weeks to causal relationship between aripiprazole and TD exists.

  8. Effects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-[β-11C]DOPA.

    Directory of Open Access Journals (Sweden)

    Hiroshi Ito

    Full Text Available Dopamine D(2 receptor partial agonist antipsychotic drugs can modulate dopaminergic neurotransmission as functional agonists or functional antagonists. The effects of antipsychotics on presynaptic dopaminergic functions, such as dopamine synthesis capacity, might also be related to their therapeutic efficacy. Positron emission tomography (PET was used to examine the effects of the partial agonist antipsychotic drug aripiprazole on presynaptic dopamine synthesis in relation to dopamine D(2 receptor occupancy and the resulting changes in dopamine synthesis capacity in healthy men. On separate days, PET studies with [(11C]raclopride and L-[β-(11C]DOPA were performed under resting condition and with single doses of aripiprazole given orally. Occupancy of dopamine D(2 receptors corresponded to the doses of aripiprazole, but the changes in dopamine synthesis capacity were not significant, nor was the relation between dopamine D(2 receptor occupancy and these changes. A significant negative correlation was observed between baseline dopamine synthesis capacity and changes in dopamine synthesis capacity by aripiprazole, indicating that this antipsychotic appears to stabilize dopamine synthesis capacity. The therapeutic effects of aripiprazole in schizophrenia might be related to such stabilizing effects on dopaminergic neurotransmission responsivity.

  9. SPE-UPLC-MS/MS method for sensitive and rapid determination of aripiprazole in human plasma to support a bioequivalence study.

    Science.gov (United States)

    Patel, Daxesh P; Sharma, Primal; Sanyal, Mallika; Shrivastav, Pranav S

    2013-04-15

    An improved and rugged UPLC-MS/MS method has been developed and validated for sensitive and rapid determination of aripiprazole in human plasma using aripiprazole-d8 as the internal standard (IS). The analyte and IS were extracted from 100 μL of human plasma by solid-phase extraction using Phenomenex Strata-X (30 mg, 1 cc) cartridges. Chromatography was achieved on an Acquity UPLC BEH C18 (50 mm × 2.1 mm, 1.7 μm) analytical column using methanol: 10mM ammonium formate (85:15, v/v) as the mobile phase with isocratic elution. Quantitation was done using multiple reaction monitoring in the positive ionization mode. The linearity of the method was established in the concentration range 0.05-80 ng/mL. The mean extraction recovery was greater than 96% across QC levels, while intra- and inter batch accuracy and precision (% CV) values ranged from 97.4 to 101.9% and from 1.20 to 3.72% respectively. The relative matrix effect in eight different lots of plasma samples, expressed as % CV for the calculated slopes of calibration curves was 1.08%. The stability of aripiprazole was studied under different storage conditions. The validated method was used to support a bioequivalence study of 10mg aripiprazole formulation in 36 healthy Indian subjects.

  10. Aripiprazole Injection

    Science.gov (United States)

    ... for them, such as increased sexual urges or behaviors, excessive shopping, and binge eating. Call your doctor if you have intense urges to shop, eat, have sex, or gamble, or if you are unable to control your behavior. Tell your family members about this risk so ...

  11. Reduction of Severity of Recurrent Psychotic Episode by Sustained Treatment with Aripiprazole in a Schizophrenic Patient with Dopamine Supersensitivity: A Case Report

    Science.gov (United States)

    Tadokoro, Shigenori; Nonomura, Naho; Kanahara, Nobuhisa; Hashimoto, Kenji; Iyo, Masaomi

    2017-01-01

    Dopamine supersensitivity psychosis (DSP) is a type of acute exacerbation of recurrent psychosis caused by long-term treatment with antipsychotics in schizophrenic patients. Although DSP is exceedingly troublesome for clinicians, effective treatment has not yet been established. Based on clinical research and our animal study, we hypothesize that aripiprazole, an atypical anti-psychotic, may reduce the exacerbation of recurrent psychotic episodes. We report the case of a 46-year-old female who suffered from schizophrenia with DSP. In this case, sustained treatment with a high dose of aripiprazole gradually reduced the severity of her recurrent psychotic episodes. In conclusion, sustained treatment with aripiprazole may reduce the exacerbation of recurrent psychotic episodes in schizophrenic patients with DSP, and may be an effective treatment of DSP. PMID:28138118

  12. Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature.

    Directory of Open Access Journals (Sweden)

    Alexander C Tsai

    2011-05-01

    Full Text Available BACKGROUND: Aripiprazole, a second-generation antipsychotic medication, has been increasingly used in the maintenance treatment of bipolar disorder and received approval from the U.S. Food and Drug Administration for this indication in 2005. Given its widespread use, we sought to critically review the evidence supporting the use of aripiprazole in the maintenance treatment of bipolar disorder and examine how that evidence has been disseminated in the scientific literature. METHODS AND FINDINGS: We systematically searched multiple databases to identify double-blind, randomized controlled trials of aripiprazole for the maintenance treatment of bipolar disorder while excluding other types of studies, such as open-label, acute, and adjunctive studies. We then used a citation search to identify articles that cited these trials and rated the quality of their citations. Our evidence search protocol identified only two publications, both describing the results of a single trial conducted by Keck et al., which met criteria for inclusion in this review. We describe four issues that limit the interpretation of that trial as supporting the use of aripiprazole for bipolar maintenance: (1 insufficient duration to demonstrate maintenance efficacy; (2 limited generalizability due to its enriched sample; (3 possible conflation of iatrogenic adverse effects of abrupt medication discontinuation with beneficial effects of treatment; and (4 a low overall completion rate. Our citation search protocol yielded 80 publications that cited the Keck et al. trial in discussing the use of aripiprazole for bipolar maintenance. Of these, only 24 (30% mentioned adverse events reported and four (5% mentioned study limitations. CONCLUSIONS: A single trial by Keck et al. represents the entirety of the literature on the use of aripiprazole for the maintenance treatment of bipolar disorder. Although careful review identifies four critical limitations to the trial's interpretation

  13. The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063.

    Science.gov (United States)

    Assié, Marie-Bernadette; Carilla-Durand, Elisabeth; Bardin, Laurent; Maraval, Mireille; Aliaga, Monique; Malfètes, Nathalie; Barbara, Michèle; Newman-Tancredi, Adrian

    2008-09-11

    Several novel antipsychotics activate serotonin 5-HT1A receptors as well as antagonising dopamine D2/3 receptors. Such a pharmacological profile is associated with a lowered liability to produce extrapyramidal side effects and enhanced efficacy in treating negative and cognitive symptoms of schizophrenia. However, 5-HT1A receptor agonists increase plasma corticosterone and many antipsychotics disturb the regulation of glucose. Here, we compared the influence on plasma glucose and corticosterone of acute treatments with 'new generation' antipsychotics which target dopamine D2/3 receptors and 5-HT1A receptors, with that of atypical antipsychotics, and with haloperidol. Olanzapine and clozapine, antipsychotics that are known to produce weight gain and diabetes in humans, both at 10 mg/kg p.o., substantially increased plasma glucose (from 0.8 to 1.7 g/l) at 1 h after administration, an effect that returned to control levels after 4 h. In comparison, F15063 (40 mg/kg p.o.) was without effect at any time point. Olanzapine and clozapine dose-dependently increased plasma glucose concentrations as did SLV313 and SSR181507. Haloperidol and risperidone had modest effects whereas aripiprazole, ziprasidone and bifeprunox, antipsychotics that are not associated with metabolic dysfunction in humans, and F15063 had little or no influence on plasma glucose. The same general pattern of response was found for plasma corticosterone levels. The present data provide the first comparative study of conventional, atypical and 'new generation' antipsychotics on glucose and corticosterone levels in rats. A variety of mechanisms likely underlie the hyperglycemia and corticosterone release observed with clozapine and olanzapine, whilst the balance of dopamine D2/3/5-HT1A interaction may contribute to the less favourable impact of SLV313 and SSR181507 compared with that of bifeprunox and F15063.

  14. Aripiprazole loaded poly(caprolactone) nanoparticles: Optimization and in vivo pharmacokinetics.

    Science.gov (United States)

    Sawant, Krutika; Pandey, Abhijeet; Patel, Sneha

    2016-09-01

    In the present investigation, a Quality by Design strategy was applied for formulation and optimization of aripiprazole (APZ) loaded PCL nanoparticles (APNPs) using nanoprecipitation method keeping entrapment efficiency (%EE) and particle size (PS) as critical quality attributes. Establishment of design space was done followed by analysis of its robustness and sensitivity. Characterization of optimized APNPs was done using DSC, FT-IR, PXRD and TEM studies and was evaluated for drug release, hemocompatibility and nasal toxicity. PS, zeta potential and %EE of optimized APNPs were found to be 199.2±5.65nm, -21.4±4.6mV and 69.2±2.34% respectively. In vitro release study showed 90±2.69% drug release after 8h. Nasal toxicity study indicated safety of developed formulation for intranasal administration. APNPs administered via intranasal route facilitated the brain distribution of APZ incorporated with the AUC0→8 in rat brain approximately 2 times higher than that of APNPs administered via intravenous route. Increase in Cmax was observed which might help in dose reduction along with reduction in dose related side effects. The results of the study indicate that intranasally administered APZ loaded PCL NPs can potentially transport APZ via nose to brain and can serve as a non-invasive alternative for the delivery of APZ to brain.

  15. Is aripiprazole the only choice of treatment of the patients who developed anti-psychotic agents-induced leucopenia and neutropenia? A case report.

    Science.gov (United States)

    Yalcin, Demet Ozen; Goka, Erol; Aydemir, M Cigdem; Kisa, Cebrail

    2008-05-01

    Leucopenia and neutropenia could be side effects of anti-psychotic drugs, especially clozapine. However, there is evidence that other anti-psychotics can cause leucopenia and neutropenia. We present the clinical follow-up and treatment process of a patient, who had initially developed quetiapine and amisulpride related neutropenia, but not with aripiprazole.

  16. Aripiprazole loaded poly(caprolactone) nanoparticles: Optimization and in vivo pharmacokinetics

    Energy Technology Data Exchange (ETDEWEB)

    Sawant, Krutika; Pandey, Abhijeet; Patel, Sneha

    2016-09-01

    In the present investigation, a Quality by Design strategy was applied for formulation and optimization of aripiprazole (APZ) loaded PCL nanoparticles (APNPs) using nanoprecipitation method keeping entrapment efficiency (%EE) and particle size (PS) as critical quality attributes. Establishment of design space was done followed by analysis of its robustness and sensitivity. Characterization of optimized APNPs was done using DSC, FT-IR, PXRD and TEM studies and was evaluated for drug release, hemocompatibility and nasal toxicity. PS, zeta potential and %EE of optimized APNPs were found to be 199.2 ± 5.65 nm, − 21.4 ± 4.6 mV and 69.2 ± 2.34% respectively. In vitro release study showed 90 ± 2.69% drug release after 8 h. Nasal toxicity study indicated safety of developed formulation for intranasal administration. APNPs administered via intranasal route facilitated the brain distribution of APZ incorporated with the AUC{sub 0→8} in rat brain approximately 2 times higher than that of APNPs administered via intravenous route. Increase in C{sub max} was observed which might help in dose reduction along with reduction in dose related side effects. The results of the study indicate that intranasally administered APZ loaded PCL NPs can potentially transport APZ via nose to brain and can serve as a non-invasive alternative for the delivery of APZ to brain. - Highlights: • It explores intra-nasal route for treatment of schizophrenia. • Quality by Design strategy has been used for optimization and assessesment of design space robustness. • PCL nanoparticles enhance penetration of drug into brain leading to increased C{sub max} and decrease in T{sub max}. • It can act as potential platform for treatment of schizophrenia with decreased dose related toxicities.

  17. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.

    Science.gov (United States)

    Chen, Jing-Xu; Su, Yun-Ai; Bian, Qing-Tao; Wei, Li-He; Zhang, Rong-Zhen; Liu, Yan-Hong; Correll, Christoph; Soares, Jair C; Yang, Fu-De; Wang, Shao-Li; Zhang, Xiang-Yang

    2015-08-01

    Hyperprolactinemia is an unwanted adverse effect associated with several antipsychotics. The addition of partial dopamine receptor agonist aripiprazole may attenuate antipsychotic-induced hyperprolactinemia effectively. However, the ideal dosing regimen for this purpose is unknown. We aimed to evaluate the dose effects of adjunctive treatment with aripiprazole on prolactin levels and hyperprolactinemia in schizophrenia patients. Stable subjects 18-45 years old with schizophrenia and hyperprolactinemia (i.e., >24 ng/ml for females and >20 ng/ml for males) were randomly assigned to receive 8 weeks of placebo (n=30) or oral aripiprazole 5mg/day (n=30), 10mg/day (n=29), or 20mg/day (n=30) added on to fixed dose risperidone treatment. Serum prolactin levels were measured at baseline and after 2, 4 and 8 weeks; clinical symptoms and side effects were assessed at baseline and week 8 using the Positive and Negative Syndrome Scale, Clinical Global Impressions Severity scale, Barnes Akathisia Scale, Simpson-Angus Scale and UKU Side Effects Rating Scale. Of 119 randomized patients, 107 (89.9%) completed the 8-week study. At study end, all three aripiprazole doses resulted in significantly lower prolactin levels (beginning at week 2), higher response rates (≥30% prolactin reduction) and higher prolactin normalization rates than placebo. Effects were significantly greater in the 10 and 20mg/day groups than the 5mg/day group. No significant changes were observed in any treatment groups regarding psychopathology and adverse effect ratings. Adjunctive aripiprazole treatment was effective and safe for resolving risperidone-induced hyperprolactinemia, producing significant and almost maximal improvements by week 2 without significant effects on psychopathology and side effects.

  18. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR study (NCT00237913

    Directory of Open Access Journals (Sweden)

    Pans Miranda

    2008-12-01

    Full Text Available Abstract Background The aim of this paper is to evaluate the effect of antipsychotics for the treatment of schizophrenia in a community based study on sexual function and prolactin levels comparing the use of aripiprazole and standard of care (SOC, which was a limited choice of three widely used and available antipsychotics (olanzapine, quetiapine or risperidone (The Schizophrenia Trial of Aripiprazole [STAR] study [NCT00237913]. Method This open-label, 26-week, multi-centre, randomised study compared aripiprazole to SOC (olanzapine, quetiapine or risperidone in patients with schizophrenia (DSM-IV-TR criteria. The primary effectiveness variable was the mean total score of the Investigator Assessment Questionnaire (IAQ at Week 26. The outcome research variables included the Arizona Sexual Experience scale (ASEX. This along with the data collected on serum prolactin levels at week 4, 8, 12, 18 and 26 will be the focus of this paper. Results A total of 555 patients were randomised to receive aripiprazole (n = 284 or SOC (n = 271. Both treatment groups experienced improvements in sexual function from baseline ASEX assessments. However at 8 weeks the aripiprazole treatment group reported significantly greater improvement compared with the SOC group (p = 0.007; OC. Although baseline mean serum prolactin levels were similar in the two treatment groups (43.4 mg/dL in the aripiprazole group and 42.3 mg/dL in the SOC group, p = NS at Week 26 OC, mean decreases in serum prolactin were 34.2 mg/dL in the aripiprazole group, compared with 13.3 mg/dL in the SOC group (p Conclusion The study findings suggest that aripiprazole has the potential to reduce sexual dysfunction, which in turn might improve patient compliance.

  19. Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials

    Directory of Open Access Journals (Sweden)

    Oya K

    2015-09-01

    Full Text Available Kazuto Oya, Taro Kishi, Nakao Iwata Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan Objective: We conducted a systematic review and meta-analysis of the efficacy of aripiprazole once monthly (AOM for schizophrenia.Methods: Randomized controlled trials (RCTs on AOM, published until June 25, 2015, were retrieved from PubMed, Cochrane, and PsycINFO databases. Relative risk (RR, standardized mean difference (SMD, 95% confidence intervals (95% CIs, and numbers needed to treat/harm (NNT/NNH were calculated.Results: We identified four relevant RCTs (total n=1,860, two placebo-controlled trials, one noninferiority trial comparing AOM to oral aripiprazole (OA, and one including therapeutic doses of AOM and OA, as well as an AOM dose below therapeutic threshold (control arm. AOM was superior to placebo for decreasing Positive and Negative Syndrome Scale (PANSS total scores (SMD =-0.65, 95% CI =-0.90 to -0.41, n=1,126. However, PANSS total scores did not differ significantly between pooled AOM and OA groups. The pooled AOM group showed significantly lower incidence of all-cause discontinuation (RR =0.54, 95% CI =0.41–0.71, n=1,139, NNH =4 and inefficacy (RR =0.28, 95% CI =0.21–0.38, n=1,139, NNH =5 than placebo, but was not superior to placebo regarding discontinuation due to adverse events (AEs or death. The AOM group exhibited a lower incidence of all-cause discontinuation than OA (RR =0.78, 95% CI =0.64–0.95, n=986, NNH =14, but there were no intergroup differences in discontinuation due to inefficacy, AEs, or death. There were no significant differences in extrapyramidal symptoms scale scores between AOM and placebo or between AOM and OA. AOM resulted in higher weight gain than placebo (SMD =0.41, 95% CI =0.18–0.64, n=734 but lower than OA (SMD =-0.16, 95% CI =-0.29 to -0.02, n=847.Conclusion: AOM has antipsychotic efficacy and low risk of discontinuation due to AEs. Keywords: schizophrenia

  20. A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting

    Directory of Open Access Journals (Sweden)

    Chiu Nan-Ying

    2010-09-01

    Full Text Available Abstract Objective To evaluate the overall long-term effectiveness of aripiprazole in patients with schizophrenia in a general psychiatric practice setting in Taiwan. Methods This was a prospective, open-label, multicenter, post-market surveillance study in Taiwanese patients with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV diagnosis of schizophrenia or schizoaffective disorder requiring a switch in antipsychotic medication because current medication was not well tolerated and/or clinical symptoms were not well controlled. Eligible patients were titrated to aripiprazole (5-30 mg/day over a 12-week switching phase, during which their previous medication was discontinued. Patients could then enter a 52-week, long-term treatment phase. Aripiprazole was flexibly dosed (5-30 mg/day at the discretion of the treating physicians. Efficacy was assessed using the Clinical Global Impression scale Improvement (CGI-I score, the Clinical Global Impression scale Severity (CGI-S score, The Brief Psychiatry Rating Scale (BPRS, and the Quality of Life (QOL scale, as well as Preference of Medicine (POM ratings by patients and caregivers. Safety and tolerability were also assessed. Results A total of 245 patients were enrolled and switched from their prior antipsychotic medications, and 153 patients entered the 52-week extension phase. In all, 79 patients (32.2% completed the study. At week 64, the mean CGI-I score was 3.10 and 64.6% of patients who showed response. Compared to baseline, scores of CGI-S, QOL, and BPRS after 64 weeks of treatment also showed significant improvements. At week 12, 65.4% of subjects and 58.9% of caregivers rated aripiprazole as better than the prestudy medication on the POM. The most frequently reported adverse events (AEs were headache, auditory hallucinations and insomnia. A total of 13 patients (5.3% discontinued treatment due to AEs. No statistically significant changes were noted with respect to

  1. 阿立哌唑与利培酮治疗精神分裂症疗效比较%Aripiprazole and Risperidone in the Treatment of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    赵辉

    2014-01-01

    目的:比较阿立哌唑与利培酮治疗精神分裂症的疗效。方法将我院2012年10月-2013年6月收治的40例精神分裂症患者按随机数字表法随机分为阿立哌唑组和利培酮组各20例,分别使用阿立哌唑和利培酮对两组患者进行治疗,将两组治疗效果按照CCMD-3精神分裂症的诊断标准进行评价,依据副反应量表( TESS )评定副反应,以阳性与阴性症状量表( PANSS)减分率对疗效进行评定。结果阿立哌唑组痊愈9例,7例显著好转,3例好转,1例无效;利培酮组痊愈10例,5例显著好转,3例好转,2例无效。两组间的疗效比较无显著性差异。阿立哌唑组5例出现不良反应,占25%;利培酮组出现不良反应的有12例,占60%,阿立哌唑组不良反应总发生率显著低于利培酮组(χ2=5.013, P<0.05)。结论阿立哌唑与利培酮治疗精神分裂症的疗效显著,在治疗过程中,两种药物各有千秋,但在不良反应发生率方面,阿立哌唑低于利培酮,阿立哌唑的安全性高于利培酮。%Objective To analyze and compare aripiprazole and risperidone in the treatment of schizophrenia treatment .Methods 40 cases of patients with schizophrenia in hospital from October 2012 to June 2013 were randomly divided into aripiprazole group and the risperidone group,respectively,the two groups of patients were evaluated according to CCMD -3 diagnostic criteria,TESS and PANSS. Results In aripiprazole group ,9 cases recure ,7 cases were significantly improved ,3 cases improved ,and one case was invalid .In risper-idone group,10 cases cured,5 cases were significantly improved,3 cases improved,2 cases were ineffective.There was no significant difference in the efficacy between the two groups (P>0.05).Aripiprazole group had 5 cases of adverse reactions (25%),risperidone group had 12 cases of adverse reactions (60%),incidence of adverse reactions in aripiprazole group was

  2. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 2: Preclinical and Early Phase Human Proof of Concept Studies.

    Science.gov (United States)

    Macaluso, Matthew; Flynn, Alexandra; Preskorn, Sheldon

    2016-01-01

    This series of columns has 3 main goals: (1) to explain class warnings as used by the United States Food and Drug Administration, (2) to increase awareness of movement disorders that may occur in patients treated with antipsychotic medications, and (3) to understand why clinicians should refrain from immediately assuming a diagnosis of tardive dyskinesia/dystonia (TD) in patients treated with antipsychotics. The first column in this series began with the case of a 76-year-old man with major depressive disorder who developed orofacial dyskinesias while being treated with aripiprazole as an antidepressant augmentation strategy. It was alleged that a higher than intended dose of aripiprazole (ie, 20 mg/d for 2 wk followed by 10 mg/d for 4 wk instead of the intended dose of 2 mg/d) was the cause of the dyskinetic movements in this man, and the authors were asked to review the case and give their opinion. The principal basis for this theory of causation was the class warning about TD in the package insert for aripiprazole. The rationale for concluding aripiprazole caused TD in the 76-year-old man led to this series of columns about aripiprazole, its potential--if any--to cause TD, and the presence of a class warning about TD in its package insert. The central point is to illustrate why class warnings exist and their implications for practice. The first column in this series focused on the historical background, incidence, prevalence, risk factors, and clinical presentations of tardive and spontaneous dyskinesias and concluded with a discussion of diagnostic considerations explaining why clinicians should avoid making a diagnosis of TD until a thorough differential diagnosis has been considered. This second column in the series reviews the pharmacology of aripiprazole and the preclinical and phase I translational human studies that suggest aripiprazole should have a low to nonexistent risk of causing TD compared with other antipsychotics. The third column in the series

  3. Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: a systematic review and meta-analysis of randomized-controlled trials.

    Science.gov (United States)

    Srisurapanont, Manit; Suttajit, Sirijit; Maneeton, Narong; Maneeton, Benchalak

    2015-03-01

    Limited options are available for clozapine-resistant schizophrenia and intolerable side effects of clozapine. We conducted a systematic review of randomized-controlled trials (RCTs) to determine the efficacy and safety of aripiprazole augmentation of clozapine for schizophrenia. Electronic databases searched included PubMed, Scopus, Cochrane Central Register of Controlled Trials, Cumulative Index to Nursing and Allied Health Literature (CINAHL), and Web of Science. This review synthesized the data of four short-term (8-24 weeks), placebo-controlled trials (N = 347). The overall relative risk (RR, 95% confidence interval) of discontinuation rates was not significantly different between groups (RR = 1.41, 95% CI = 0.78 to 2.56). The pooled standardized mean differences (SMDs, 95% CIs) (Z-test; number of study; I(2)-index) suggested trends of aripiprazole augmentation benefits on overall psychotic [-0.40 (-0.87 to 0.07) (n = 3; Z = 1.68, p = 0.09; I(2) = 68%)], positive [-1.05 (-2.39 to 0.29) (n = 3; Z = 1.54, p = 0.12; I(2) = 94%)], and negative [-0.36 (-0.77 to 0.05) (n = 3; Z = 1.74, p = 0.08; I(2) = 54%)] symptoms. Despite of no benefit on three cardiometabolic indices (i.e., fasting plasma glucose, triglyceride, and high-density lipoprotein), aripiprazole augmentation was superior for weight change with a mean difference (95% CI) of -1.36 kg (-2.35 to -0.36) (n = 3; Z = 2.67, p = 0.008; I(2) = 39%) and LDL-cholesterol with a mean difference of -11.06 mg/dL (-18.25 to -3.87) (n = 3; Z = 3.02, p = 0.003; I(2) = 31%). Aripiprazole augmentation was not correlated with headache and insomnia but significantly associated with agitation/akathesia (RR = 7.59, 95% CI = 1.43 to 40.18) (n = 3; Z = 2.38, p = 0.02; I(2) = 0%) and anxiety (RR = 2.70, 95% CI = 1.02 to 7.15) (n = 1; Z = 2.00, p = 0.05). The limited short-term data suggested that aripiprazole augmentation of clozapine can minimize the cardiometabolic risk, causes agitation/akathesia, and may be effective in

  4. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.

    Science.gov (United States)

    Cosi, Cristina; Carilla-Durand, Elisabeth; Assié, Marie Bernadette; Ormiere, Anne Marie; Maraval, Mireille; Leduc, Nathalie; Newman-Tancredi, Adrian

    2006-03-27

    Dopamine D2 receptor antagonists induce hyperprolactinemia depending on the extent of D2 receptor blockade. We compared the effects of the new antipsychotic agents SSR181507 ((3-exo)-8-benzoyl-N-[[(2 s)7-chloro-2,3-dihydro-1,4-benzodioxin-1-yl]methyl]-8-azabicyclo[3.2.1]octane-3-methanamine monohydrochloride), bifeprunox (DU127090: 1-(2-Oxo-benzoxazolin-7-yl)-4-(3-biphenyl)methylpiperazinemesylate) and SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4-[5-(4-fluorophenyl)-pyridin-3-ylmethyl]-piperazine) with those of aripiprazole (7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]-butyloxy)-3,4-dihydro-2(1 H)-quinolinone), clozapine and haloperidol, on functional measures of dopamine D2 receptor activity in vitro and in vivo: [35S]-GTPgammaS binding to membranes from Sf9 insect cells expressing human dopamine D2 Long (hD2 L) receptors, and serum prolactin levels in the rat. All compounds antagonized apomorphine-induced G protein activation at dopamine hD2 L receptors. Antagonist potencies of aripiprazole, bifeprunox and SLV313 were similar to haloperidol (pK(b) = 9.12), whereas SSR181507 (8.16) and clozapine (7.35) were less potent. Haloperidol, SLV313 and clozapine were silent antagonists but SSR181507, bifeprunox and aripiprazole stimulated [35S]-GTPgammaS binding by 17.5%, 26.3% and 25.6%, respectively, relative to 100 microM apomorphine (Emax = 100%). pEC50s were: SSR181507, 8.08; bifeprunox, 8.97; aripiprazole, 8.56. These effects were antagonized by raclopride. Following oral administration in vivo, the drugs increased prolactin release to different extents. SLV313 and haloperidol potently (ED50 0.12 and 0.22 mg/kg p.o., respectively) stimulated prolactin release up to 86 and 83 ng/ml. Aripiprazole potently (ED50 0.66 mg/kg p.o.) but partially (32 ng/ml) induced prolactin release. SSR181507 (ED50 4.9 mg/kg p.o.) also partially (23 ng/ml) enhanced prolactin release. Bifeprunox only weakly increased prolactin at high doses (13 ng/ml at 40 mg/kg) and clozapine only

  5. Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole

    Directory of Open Access Journals (Sweden)

    Peters-Strickland T

    2016-10-01

    Full Text Available Timothy Peters-Strickland,1 Linda Pestreich,1 Ainslie Hatch,2 Shashank Rohatagi,1 Ross A Baker,1 John P Docherty,2 Lada Markovtsova,1 Praveen Raja,3 Peter J Weiden,4 David P Walling5 1Otsuka Pharmaceutical Development & Commercialization, Inc., 2ODH, Inc., Princeton, NJ, 3Proteus Digital Health, Inc., Redwood City, CA, 4Department of Psychiatry, University of Illinois, Chicago, IL, 5CNS Network, LLC, Long Beach, CA, USA Objective: Digital medicine system (DMS is a novel drug–device combination that objectively measures and reports medication ingestion. The DMS consists of medication embedded with an ingestible sensor (digital medicine, a wearable sensor, and software applications. This study evaluated usability of the DMS in adults with schizophrenia rated by both patients and their health care providers (HCPs during 8-week treatment with prescribed doses of digital aripiprazole.Methods: Six US sites enrolled outpatients into this Phase IIa, open-label study (NCT02219009. The study comprised a screening phase, a training phase (three weekly site visits, and a 5-week independent phase. Patients and HCPs independently rated usability of and satisfaction with the DMS.Results: Sixty-seven patients were enrolled, and 49 (73.1% patients completed the study. The mean age (SD of the patients was 46.6 years (9.7 years; the majority of them were male (74.6%, black (76.1%, and rated mildly ill on the Clinical Global Impression – Severity scale (70.1%. By the end of week 8 or early termination, 82.1% (55/67 of patients had replaced the wearable sensor independently or with minimal assistance, based on HCP rating. The patients used the wearable sensor for a mean (SD of 70.7% (24.7% and a median of 77.8% of their time in the trial. The patients contacted a call center most frequently at week 1. At the last visit, 78% (47/60 of patients were somewhat satisfied/satisfied/extremely satisfied with the DMS.Conclusion: A high proportion of patients with

  6. Antidepressant Effects of Aripiprazole Augmentation for Cilostazol-Treated Mice Exposed to Chronic Mild Stress after Ischemic Stroke

    Science.gov (United States)

    Kim, Yu Ri; Kim, Ha Neui; Hong, Ki Whan; Shin, Hwa Kyoung; Choi, Byung Tae

    2017-01-01

    The aim of this study was to determine the effects and underlying mechanism of aripiprazole (APZ) augmentation for cilostazol (CLS)-treated post-ischemic stroke mice that were exposed to chronic mild stress (CMS). Compared to treatment with either APZ or CLS alone, the combined treatment resulted in a greater reduction in depressive behaviors, including anhedonia, despair-like behaviors, and memory impairments. This treatment also significantly reduced atrophic changes in the striatum, cortex, and midbrain of CMS-treated ischemic mice, and inhibited neuronal cell apoptosis, particularly in the striatum and the dentate gyrus of the hippocampus. Greater proliferation of neuronal progenitor cells was also observed in the ipsilateral striatum of the mice receiving combined treatment compared to mice receiving either drug alone. Phosphorylation of the cyclic adenosine monophosphate response element binding protein (CREB) was increased in the striatum, hippocampus, and midbrain of mice receiving combined treatment compared to treatment with either drug alone, particularly in the neurons of the striatum and hippocampus, and dopaminergic neurons of the midbrain. Our results suggest that APZ may augment the antidepressant effects of CLS via co-regulation of the CREB signaling pathway, resulting in the synergistic enhancement of their neuroprotective effects. PMID:28208711

  7. Influence of aripiprazole, risperidone, and amisulpride on sensory and sensorimotor gating in healthy 'low and high gating' humans and relation to psychometry.

    Science.gov (United States)

    Csomor, Philipp A; Preller, Katrin H; Geyer, Mark A; Studerus, Erich; Huber, Theodor; Vollenweider, Franz X

    2014-09-01

    Despite advances in the treatment of schizophrenia spectrum disorders with atypical antipsychotics (AAPs), there is still need for compounds with improved efficacy/side-effect ratios. Evidence from challenge studies suggests that the assessment of gating functions in humans and rodents with naturally low-gating levels might be a useful model to screen for novel compounds with antipsychotic properties. To further evaluate and extend this translational approach, three AAPs were examined. Compounds without antipsychotic properties served as negative control treatments. In a placebo-controlled, within-subject design, healthy males received either single doses of aripiprazole and risperidone (n=28), amisulpride and lorazepam (n=30), or modafinil and valproate (n=30), and placebo. Prepulse inhibiton (PPI) and P50 suppression were assessed. Clinically associated symptoms were evaluated using the SCL-90-R. Aripiprazole, risperidone, and amisulpride increased P50 suppression in low P50 gaters. Lorazepam, modafinil, and valproate did not influence P50 suppression in low gaters. Furthermore, low P50 gaters scored significantly higher on the SCL-90-R than high P50 gaters. Aripiprazole increased PPI in low PPI gaters, whereas modafinil and lorazepam attenuated PPI in both groups. Risperidone, amisulpride, and valproate did not influence PPI. P50 suppression in low gaters appears to be an antipsychotic-sensitive neurophysiologic marker. This conclusion is supported by the association of low P50 suppression and higher clinically associated scores. Furthermore, PPI might be sensitive for atypical mechanisms of antipsychotic medication. The translational model investigating differential effects of AAPs on gating in healthy subjects with naturally low gating can be beneficial for phase II/III development plans by providing additional information for critical decision making.

  8. Comparison of risperidone and aripiprazole in the treatment of preschool children with disruptive behavior disorder and attention deficit-hyperactivity disorder: A randomized clinical trial

    Directory of Open Access Journals (Sweden)

    Parvin Safavi

    2016-01-01

    Full Text Available Although pharmacotherapy with atypical antipsychotics is common in child psychiatry, there has been little research on this issue. To compare the efficacy and safety of risperidone and aripiprazole in the treatment of preschool children with disruptive behavior disorders comorbid with attention deficit-hyperactivity disorder (ADHD. Randomized clinical trial conducted in a university-affiliated child psychiatry clinic in southwest Iran. Forty 3-6-year-old children, diagnosed with oppositional defiant disorder comorbid with ADHD, were randomized to an 8-week trial of treatment with risperidone or aripiprazole (20 patients in each group. Assessment was performed by Conners′ rating scale-revised and clinical global impressions scale, before treatment, and at weeks 2, 4, and 8 of treatment. The data were analyzed by SPSS version 16. Mean scores between the two groups were compared by analysis of variance and independent and paired t-test. Mean scores of Conners rating scales were not different between two groups in any steps of evaluation. Both groups had significantly reduced scores in week 2 of treatment (P = 0.00, with no significant change in subsequent measurements. Rates of improvement, mean increase in weight (P = 0.894, and mean change in fasting blood sugar (P = 0.671 were not significantly different between two groups. Mean serum prolactin showed a significant increase in risperidone group (P = 0.00. Both risperidone and aripiprazole were equally effective in reducing symptoms of ADHD and oppositional defiant disorder, and relatively safe, but high rates of side effects suggest the cautious use of these drugs in children.

  9. Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: A retrospective cohort study

    Directory of Open Access Journals (Sweden)

    Berger Ariel

    2012-08-01

    Full Text Available Abstract Background Schizophrenia and bipolar disorder are chronic debilitating disorders that are often treated with second-generation antipsychotic agents, such as aripiprazole, quetiapine, and ziprasidone. While patients who are hospitalized for schizophrenia and bipolar disorder often receive these agents at discharge, comparatively little information exists on subsequent patterns of pharmacotherapy. Methods Using a database linking hospital admission records to health insurance claims, we identified all patients hospitalized for schizophrenia (ICD-9-CM diagnosis code 295.XX or bipolar disorder (296.0, 296.1, 296.4-296.89 between January 1, 2001 and September 30, 2008 who received aripiprazole, quetiapine, or ziprasidone at discharge. Patients not continuously enrolled for 6 months before and after hospitalization (“pre-admission” and “follow-up”, respectively were excluded. We examined patterns of use of these agents during follow-up, including adherence with treatment (using medication possession ratios [MPRs] and cumulative medication gaps [CMGs] and therapy switching. Analyses were undertaken separately for patients with schizophrenia and bipolar disorder, respectively. Results We identified a total of 43 patients with schizophrenia, and 84 patients with bipolar disorder. During the 6-month period following hospitalization, patients with schizophrenia received an average of 101 therapy-days with the second-generation antipsychotic agent prescribed at discharge; for patients with bipolar disorder, the corresponding value was 68 therapy-days. Mean MPR at 6 months was 55.1% for schizophrenia patients, and 37.3% for those with bipolar disorder; approximately one-quarter of patients switched to another agent over this period. Conclusions Medication compliance is poor in patients with schizophrenia or bipolar disorder who initiate treatment with aripiprazole, quetiapine, or ziprasidone at hospital discharge.

  10. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder: Part 1.

    Science.gov (United States)

    Preskorn, Sheldon; Flynn, Alexandra; Macaluso, Matthew

    2015-09-01

    This series of columns has 2 main goals: (1) to explain the use of class warnings by the US Food and Drug Administration and (2) to increase clinicians' awareness of movement disorders that may occur in patients being treated with antipsychotic medications and why it is appropriate and good practice to refrain from immediately assuming the diagnosis is tardive dyskinesia/dystonia (TD). This first column in the series will focus on the second goal, which will then serve as a case example for the first goal. Clinicians should refrain from jumping to a diagnosis of TD because a host of other causes need to be ruled out first before inferring iatrogenic causation. The causal relationship between chronic treatment with dopamine antagonists and TD is based on pharmacoepidemiology (ie, the prevalence of such movement disorders is higher in individuals receiving chronic treatment with such agents than in a control group). There is nothing pathognomonic about movement disorders, nor is there any test that can currently prove a drug caused a movement disorder in a specific individual. Another goal of this series is to describe the types of research that would be needed to establish whether a specific agent has a meaningful risk of causing TD. In this first column of the series, we present the case of a patient who developed orofacial dyskinesia while being treated with aripiprazole. In this case, the movement disorder was prematurely called TD, which led to a malpractice lawsuit. This case highlights a number of key questions clinicians are likely to encounter in day-to-day practice. We then review data concerning the historical background, incidence, prevalence, and risk factors for 2 movement disorders, TD and spontaneous dyskinesia. Subsequent columns in this series will review: (1) unique aspects of the psychopharmacology of aripiprazole, (2) the limited and inconsistent data in the literature concerning the causal relationship between aripiprazole and TD, (3) the use of

  11. 利培酮与阿立哌唑治疗精神分裂症的效果比较%Clinical effects and security of aripiprazole and risperidone on the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    李正发

    2010-01-01

    Objective To assess the efficacy and safety of aripiprazole and risperidone on the treatment of schizophrenia. Method 80 patients with schizophrenia were randomly divided into risperidone group ( n = 40) and aripiprazole group( n= 40). According to random, controlled principles, all patients were treated for 8 weeks. The positive and negative syndrome scale ( PANSS ), clinical global impression ( CGI ), treatment emergent symptom scale (TESS) and laboratory examinations were used to assess the effectiveness and the safety of the treatment. Results By the end of the 8 weeks treatment,the scores of PANSS in both groups decreased significantly compared to the baseline ( P 0. 05 ). Total clinical effective rates was 90% in risperidone group and 80% in aripiprazole group, without significant difference between two groups. Digestion adverse reactions in aripiprazole group were significantly more than in risperidone group (P 0.05).治疗后,利培酮组有效率90%,阿立哌唑组有效率80%,两组差异无统计学意义(P>0.05).阿立哌唑组消化道反应发生率明显高于利培酮组(P<0.05).结论 利培酮治疗精神分裂症的疗效较阿立哌唑略好,安全性高.

  12. Clinical effect observation of aripiprazole and risperidone in the treatment of schizophrenia%阿立哌唑与利培酮治疗精神分裂症临床效果观察

    Institute of Scientific and Technical Information of China (English)

    王俊; 孙毅; 卓越; 吕治宇; 严卫国

    2016-01-01

    Objective:To observe the effect of aripiprazole and risperidone in the treatment of schizophrenia.Methods:64 patients with schizophrenia were selected.32 cases treated with aripiprazole were as aripiprazole group.32 cases treated with risperidone were as risperidone group.The treatment effect and adverse reaction between groups were observed.Results:The headache,dry mouth,insomnia incidence in the aripiprazole group were higher than those in risperidone group(P<0.05).In risperidone group, increase the body weight,akathisia,menstrual changes or lactation and tremor of incidence were higher than those in aripiprazole group(P<0.05).Conclusion:The effect of aripiprazole and risperidone in the treatment of schizophrenia are relatively good, but the adverse reaction of aripiprazole is fewer and milder.%目的:观察阿立哌唑与利培酮治疗精神分裂症的效果。方法:收治精神分裂症患者64例,采用阿立哌唑进行治疗的32例患者为阿立哌唑组,应用利培酮进行治疗的32例患者为利培酮组。观察两组的治疗效果和不良反应。结果:阿立哌唑组头痛、口干、失眠的发生率均高于利培酮组(P<0.05),利培酮组体重增加、静坐不能、月经改变或泌乳和震颤的发生率均高于阿立哌唑组(P<0.05)。结论:阿立哌唑与利培酮治疗精神分裂症的效果均比较好,但阿立哌唑产生的不良反应少且轻。

  13. 阿立哌唑与利培酮治疗精神分裂症对比分析%Comparative analysis of aripiprazole and risperidone in the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    李红远; 李义会

    2015-01-01

    Objective:To explore the clinical effect and safety of aripiprazole in the treatment of schizophrenia.Methods:120 patients with schizophrenia were randomly divided into two groups.They were treated with aripiprazole and risperidone respectively.The curative effects and adverse reactions of patients in two groups were compared.Results:The treatment total effective rate of the aripiprazole group and the risperidone group were respectively 83.3% and 81.7% .The incidence rate of adverse reaction(33.3%) in the aripiprazole group was significantly lower than 51.7% of the risperidone group(χ 2=4.126,P<0.01).Conclusion:The curative effects of aripiprazole and risperidone in the treatment of schizophrenia are considerable.The adverse reaction of aripiprazole is low than that of risperidone.The safety of aripiprazole is good.%目的:探讨阿立哌唑治疗精神分裂症的临床效果及安全性。方法:将120例精神分裂症患者随机分为两组,分别给予阿立哌唑和利培酮治疗。对两组患者的疗效及不良反应进行比较。结果:阿立哌唑组和利培酮组的总有效率分别为83.3%和81.7%。阿立哌唑组不良反应发生率33.3%明显低于利培酮组的51.7%(χ2=4.126,P<0.01)。结论:阿立哌唑与利培酮治疗精神分裂症的疗效相当,不良反应比利培酮低,安全性好。

  14. 阿立哌唑治疗抗精神病药所致高催乳素血症的疗效观察%A control study of aripiprazole in the treatment for antipsychotics-induced hyperprolactinemia

    Institute of Scientific and Technical Information of China (English)

    刘诏薄; 曹波; 焦峰; 李多聪; 陈海波; 刘伟

    2011-01-01

    OBJECTIVE To explore the effectiveness and safety of aripiprazole in long term treatment for schizophrenia patients with antipsychotics-induced hyperprolactinemia. METHODS 180 schizophrenia patients with antipsychotics-induced hyperprolactinemia were randomly assigned to aripiprazole group(n = 90) and control group(n = 90),which were observed more than 26 weeks. Aripiprazole group patients were additionally treated with aripiprazole(5 mg·d-1). Clinical global impression scale(CGIS) and the extrapyramidal symptoms rating scale(ESES) were administered, also prolactin(PRL), treatment discontinuation ratio and time to discontinuation(TTD) were recorded at the baseline time and the end of 2,4,12,26 weeks. RESULTS PRL of aripiprazole group showed significant decline at the end of 4 weeks,and arrived a stable state at the end of 8 weeks. PRL of control group there was no change. At the end of 26 weeks, the treatment discontinuation ratio of aripiprazole group was 11.1 %, of control group was 31. 1 %. At the end of 52 weeks, the treatment discontinuation ratio of aripiprazole group was 57. 8%,of control group was 76. 7%. There was significant difference of TTD between aripiprazole group and control group [ (297. 3 ± 92. 6) d vs ( 193. 5 ± 103. 1 )d, t = 6. 86, P = 0. 001]. CONCLUSION Combined a low dose aripiprazole to long term treatment for schizophrenia patient antipsychotics-induced hyperprolactinemia is effective and safe.%目的:验证合并使用小剂量阿立哌唑治疗抗精神病药(APS)所致高催乳素(PRL)血症的长期疗效及安全性.方法:对APS所致高PRL患者随机分为2组,一组继续使用APS治疗,一组在APS基础上合并使用5 mg·d-1阿立哌唑治疗.观察时间至少为26周.在基线及第4,8,12,26周末进行临床总体印象量表--严重程度(CGI-S)、锥体外系症状评定量表(ESRS)、血清PRL水平测定,记录停药率及停药前服药时间(TTD).结果:阿立哌唑组PRL在第4周末即明显下降,到第8

  15. Metabolic acidosis

    Science.gov (United States)

    Acidosis - metabolic ... Metabolic acidosis occurs when the body produces too much acid. It can also occur when the kidneys are not ... the body. There are several types of metabolic acidosis. Diabetic acidosis develops when acidic substances, known as ...

  16. Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial

    DEFF Research Database (Denmark)

    Pagsberg, Anne Katrine; Jeppesen, Pia; Klauber, Dea Gowers

    2014-01-01

    aripiprazole in children and adolescents with psychosis in order to inform rational, effective and safe treatment selections. METHODS/DESIGN: The TEA trial is a Danish investigator-initiated, independently funded, multi-centre, randomised, blinded clinical trial. Based on sample size estimation, 112 patients...... about head-to-head differences in efficacy and tolerability of antipsychotics are scarce in children and adolescents. The TEA trial aims at expanding the evidence base for the use of antipsychotics in early onset psychosis in order to inform more rational treatment decisions in this vulnerable......BACKGROUND: The evidence for choices between antipsychotics for children and adolescents with schizophrenia and other psychotic disorders is limited. The main objective of the Tolerability and Efficacy of Antipsychotics (TEA) trial is to compare the benefits and harms of quetiapine versus...

  17. Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia

    Directory of Open Access Journals (Sweden)

    Piantato Ennio

    2009-05-01

    Full Text Available Abstract Background One third to two thirds of people with schizophrenia have persistent psychotic symptoms despite clozapine treatment. Under real-world circumstances, the need to provide effective therapeutic interventions to patients who do not have an optimal response to clozapine has been cited as the most common reason for simultaneously prescribing a second antipsychotic drug in combination treatment strategies. In a clinical area where the pressing need of providing therapeutic answers has progressively increased the occurrence of antipsychotic polypharmacy, despite the lack of robust evidence of its efficacy, we sought to implement a pre-planned protocol where two alternative therapeutic answers are systematically provided and evaluated within the context of a pragmatic, multicentre, independent randomised study. Methods/Design The principal clinical question to be answered by the present project is the relative efficacy and tolerability of combination treatment with clozapine plus aripiprazole compared with combination treatment with clozapine plus haloperidol in patients with an incomplete response to treatment with clozapine over an appropriate period of time. This project is a prospective, multicentre, randomized, parallel-group, superiority trial that follow patients over a period of 12 months. Withdrawal from allocated treatment within 3 months is the primary outcome. Discussion The implementation of the protocol presented here shows that it is possible to create a network of community psychiatric services that accept the idea of using their everyday clinical practice to produce randomised knowledge. The employed pragmatic attitude allowed to randomly allocate more than 100 individuals, which means that this study is the largest antipsychotic combination trial conducted so far in Western countries. We expect that the current project, by generating evidence on whether it is clinically useful to combine clozapine with aripiprazole

  18. Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia

    Science.gov (United States)

    Nosè, Michela; Accordini, Simone; Artioli, Paola; Barale, Francesco; Barbui, Corrado; Beneduce, Rossella; Berardi, Domenico; Bertolazzi, Gerardo; Biancosino, Bruno; Bisogno, Alfredo; Bivi, Raffaella; Bogetto, Filippo; Boso, Marianna; Bozzani, Alberto; Bucolo, Piera; Casale, Marcello; Cascone, Liliana; Ciammella, Luisa; Cicolini, Alessia; Cipresso, Gabriele; Cipriani, Andrea; Colombo, Paola; Dal Santo, Barbara; De Francesco, Michele; Di Lorenzo, Giorgio; Di Munzio, Walter; Ducci, Giuseppe; Erlicher, Arcadio; Esposito, Eleonora; Ferrannini, Luigi; Ferrato, Farida; Ferro, Antonio; Fragomeno, Nicoletta; Parise, Vincenzo Fricchione; Frova, Maria; Gardellin, Francesco; Garzotto, Nicola; Giambartolomei, Andrea; Giupponi, Giancarlo; Grassi, Luigi; Grazian, Natalia; Grecu, Lorella; Guerrini, Gualtiero; Laddomada, Francesco; Lazzarin, Ermanna; Lintas, Camilla; Malchiodi, Francesca; Malvini, Lara; Marchiaro, Livio; Marsilio, Alessandra; Mauri, Massimo Carlo; Mautone, Antonio; Menchetti, Marco; Migliorini, Giuseppe; Mollica, Marco; Moretti, Daniele; Mulè, Serena; Nicholau, Stylianos; Nosè, Flavio; Occhionero, Guglielmo; Pacilli, Anna Maria; Pecchioli, Stefania; Percudani, Mauro; Piantato, Ennio; Piazza, Carlo; Pontarollo, Francesco; Pycha, Roger; Quartesan, Roberto; Rillosi, Luciana; Risso, Francesco; Rizzo, Raffella; Rocca, Paola; Roma, Stefania; Rossattini, Matteo; Rossi, Giuseppe; Rossi, Giovanni; Sala, Alessandra; Santilli, Claudio; Saraò, Giuseppe; Sarnicola, Antonio; Sartore, Francesca; Scarone, Silvio; Sciarma, Tiziana; Siracusano, Alberto; Strizzolo, Stefania; Tansella, Michele; Targa, Gino; Tasser, Annamarie; Tomasi, Rodolfo; Travaglini, Rossana; Veronese, Antonio; Ziero, Simona

    2009-01-01

    Background One third to two thirds of people with schizophrenia have persistent psychotic symptoms despite clozapine treatment. Under real-world circumstances, the need to provide effective therapeutic interventions to patients who do not have an optimal response to clozapine has been cited as the most common reason for simultaneously prescribing a second antipsychotic drug in combination treatment strategies. In a clinical area where the pressing need of providing therapeutic answers has progressively increased the occurrence of antipsychotic polypharmacy, despite the lack of robust evidence of its efficacy, we sought to implement a pre-planned protocol where two alternative therapeutic answers are systematically provided and evaluated within the context of a pragmatic, multicentre, independent randomised study. Methods/Design The principal clinical question to be answered by the present project is the relative efficacy and tolerability of combination treatment with clozapine plus aripiprazole compared with combination treatment with clozapine plus haloperidol in patients with an incomplete response to treatment with clozapine over an appropriate period of time. This project is a prospective, multicentre, randomized, parallel-group, superiority trial that follow patients over a period of 12 months. Withdrawal from allocated treatment within 3 months is the primary outcome. Discussion The implementation of the protocol presented here shows that it is possible to create a network of community psychiatric services that accept the idea of using their everyday clinical practice to produce randomised knowledge. The employed pragmatic attitude allowed to randomly allocate more than 100 individuals, which means that this study is the largest antipsychotic combination trial conducted so far in Western countries. We expect that the current project, by generating evidence on whether it is clinically useful to combine clozapine with aripiprazole rather than with haloperidol

  19. Interaction of aripiprazole combined with clozapine in treatment of schizophrenia%阿立哌唑与氯氮平联合治疗精神分裂症的交互作用

    Institute of Scientific and Technical Information of China (English)

    陈波; 黄华利; 李玲

    2014-01-01

    Objective To discuss the interaction of aripiprazole combined with clozapine in treatment of schizo-phrenia ,in order to make suitable dose of this combination therapy explicit .Methods A total of 97 cases of schizo-phrenia diagnosed in our hospital between Oct .,2011 and May ,2013 were divided into 4 groups(low dose of aripi-prazole combined with low dose of clozapine ,low dose of aripiprazole combined with high dose of clozapine ,high dose of aripiprazole combined with low dose of clozapine ,high dose of aripiprazole combined with high dose of clozapine ) . The results of efficacy and side effects were all recorded and analyzed .Results In treatment efficacy ,high dose of aripiprazole and clozapine was the best ,when compared with other 3 groups(P<0 .05) ,low dose of aripiprazole and clozapine was the worst (P<0 .05) .On the other hand ,the incidence of side effects was highest in group of high dose of aripiprazole and clozapine ,group of high dose of aripiprazole combined with low dose of clozapine and group of low dose of aripiprazole and clozapine were better than others in safety .Conclusion The efficacy and side effects of aripi-prazole and clozapine are dose dependent ,when using these two medicines to treat schizophrenia ,the doses should be suitable to make good efficacy and avoid side effects .If the side effects are obvious ,the dose of clozapine should be de-creased ,however ,the dose of aripiprazole can be decreased extenuatorily ;If the patients can tolerate the treatment ,the doses of these two medicine can be increased .%目的:探讨阿立哌唑与氯氮平联合治疗精神分裂症的交互作用,以明确两种药物联合治疗精神分裂症时的合适剂量。方法将2011年10月至2013年5月于重庆市黔江中心医院诊治为精神分裂症的97例患者随机分为4组(低剂量阿立哌唑+低剂量氯氮平组、低剂量阿立哌唑+高剂量氯氮平组、高剂量阿立哌唑+低剂量氯氮平组、高剂量阿立

  20. 阿立哌唑的药理作用及治疗精神分裂症的疗效观察%Observation of the Curative Effect of Pharmacological Effects and Treatment of Mental Aripiprazole Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    刘丽红

    2015-01-01

    目的:分析阿立哌唑的药理作用,探究其治疗精神分裂症疗效。方法将67例患者分为治疗组34例和对照组33例,分别经阿立哌唑、利培酮治疗。结果两组治疗效果、PANSS评分对比(P>0.05),治疗组不良反应低于对照组(P<0.05)。结论阿立哌唑可有效治疗精神分裂症。%Objective Pharmacological analysis of aripiprazole, explore the treatment effect of schizophrenia. Methods 67 patients were divided into treatment group 34 cases and control group 33 cases, respectively, by aripiprazole risperidone in the treatment of. Results The effect of PANSS treatment, scores of two groups were compared (P>0.05), adverse reaction in the treatment group than in the control group (P<0.05). Conclusion Aripiprazole is more effective in the treatment of schizophrenia.

  1. 氨磺必利与阿立哌唑治疗首发精神分裂症对照研究%A Comparative Study of Amisulpride and Aripiprazole in the Treatment of First Episode Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    仇红杰

    2014-01-01

    目的:探讨氨磺必利与阿立哌唑治疗首发精神分裂症的临床疗效与安全性。方法:将75例首发精神分裂症患者按照随机数字表法分成两组,氨磺必利组37例,阿立哌唑组38例,治疗8周。采用阳性与阴性症状量表(PANSS)评定疗效,采用治疗中出现的症状量表(TESS)评定不良反应。结果:氨磺必利组的治疗总有效率为89.19%,阿立哌唑组为92.11%,两组比较差异无统计学意义(P>0.05)。治疗第4、6、8周PANSS总分及各因子评分两组比较差异均无统计学意义(P>0.05)。结论:氨磺必利与阿立哌唑治疗首发精神分裂症均有良好效果,不良反应均较少。%Objective:To investigate the efficacy and safety of Amisulpride and Aripiprazole in the treatment of first episode schizophrenia. Method:75 patients of first opisode schizoprenia were randomly divided into two groups(amisulpride 37,aripiprazole 38).Both of the amisulpride and aripiprazole were administered to two groups respectively for 8 weeks. Their symptoms were assessed with PANSS and their side effects were assessed with TESS before and after the treatment. Result:The total cure rates were 89.19%in amisulpride group and 92.11%in aripiprazole group,with no significant difference between the two groups(P>0.05). PANSS score and each factor score in treatment of 4,6,8 weeks between the two groups had no statistical significance(P>0.05). Conclusion:Both of the amisulpride and aripiprazole have notable curative effect with less side-effect in the treatment of first episode schizophrenia.

  2. 阿立哌唑与氯丙嗪治疗精神分裂症的安全性系统评价%Systematic review the safety of aripiprazole versus clorpromazine in the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    杜彪; 李庆平; 母波; 刘福; 周春阳

    2012-01-01

    目的 评价阿立哌唑与氯丙嗪治疗精神分裂症的不良反应的差异.方法 检索国内阿立哌唑与氯丙嗪对照研究治疗精神分裂症的文献,用系统评价方法对10篇文献评估.结果 药物不良反应发生率2组差异有统计学意义(P<0.05).其中,发生头痛、失眠,阿立哌唑组明显比氯丙嗪组多(P<0.05);发生口干、震颤、静坐不能、肌强直、便秘、肝功能异常、心动过速、体重增加、直立性低血压、视物模糊、嗜睡、心电图异常、月经失调、溢乳不良反应,氯丙嗪组明显比阿立哌唑组多(P<0.05).结论 阿立哌唑组发生不良反应的总体风险低于氯丙嗪.%Objective To study the difference in adverse drug reaction ( ADR) between aripiprazole and clorpromazine in the treatment of schizophrenia. Methods A total of 10 paper about control study comparing aripiprazole with clorpromazine in treatment of schizophrenia retrieved were subjected to system evaluation. Results There was significant difference in ADR incidences between the two groups ( P < 0. 05 ). The incidences of ADR ( such as headache insomnia) in aripiprazole group were significantly higher than in clorpromazine group (P < 0. 05 ). The incidences of ADR ( such as dry mouth, tremor, akathisia, rigidity, constipation, abnormal, liver function, tachycardia, weight gain, orthostatic hypotension, blurred vision, drowsiness, menstruation disturbance syndrome) in clorpromazine group were significantly higher than in aripiprazole group ( P < 0. 05 ). Conclusion Aripiprazole has less overall risk of ADR than clorpromazine for the treatment of schizophrenia.

  3. Metabolic Syndrome

    Science.gov (United States)

    Metabolic syndrome is a group of conditions that put you at risk for heart disease and diabetes. These ... doctors agree on the definition or cause of metabolic syndrome. The cause might be insulin resistance. Insulin is ...

  4. Metabolic Panel

    Science.gov (United States)

    ... basic metabolic panel (BMP) and comprehensive metabolic panel (CMP). The BMP checks your blood sugar, calcium, and ... as creatinine to check your kidney function. The CMP includes all of those tests, as well as ...

  5. Metabolic Disorders

    Science.gov (United States)

    ... as your liver, muscles, and body fat. A metabolic disorder occurs when abnormal chemical reactions in your body ... that produce the energy. You can develop a metabolic disorder when some organs, such as your liver or ...

  6. [Metabolic syndrome].

    Science.gov (United States)

    Mitsuishi, Masanori; Miyashita, Kazutoshi; Itoh, Hiroshi

    2009-02-01

    Metabolic syndrome, which is consisted of hypertension, dyslipidemia and impaired glucose tolerance, is one of the most significant lifestyle-related disorders that lead to cardiovascular diseases. Among many upstream factors that are related to metabolic syndrome, obesity, especially visceral obesity, plays an essential role in its pathogenesis. In recent studies, possible mechanisms which connect obesity to metabolic syndrome have been elucidated, such as inflammation, abnormal secretion of adipokines and mitochondrial dysfunction. In this review, we focus on the relationship between obesity and metabolic syndrome; and illustrate how visceral obesity contributes to, and how the treatments for obesity act on metabolic syndrome.

  7. Use of Antipsychotics in Children Is Criticized%阻止精神病药"标签外"用途

    Institute of Scientific and Technical Information of China (English)

    Gardiner Harris; 雪梅

    2008-01-01

    @@ Risperdal (risperidone) 和 Zyprexa (olanzapine)是两种近年来十分常用的精神障碍治疗药.随着近年美国被诊断出患有双相情感障碍的儿童数量突然增加,包括上述两种抗精神病药物在内的一系列药物如Seroquel (quetiapine)、Abilify (aripiprazole)和Geodon(ziprasidone)用于儿童的处方量也迅速上升.

  8. A systematic review and meta-analysis of randomised controlled trials of treatments for clozapine-induced obesity and metabolic syndrome.

    Science.gov (United States)

    Zimbron, Jorge; Khandaker, Golam M; Toschi, Chiara; Jones, Peter B; Fernandez-Egea, Emilio

    2016-09-01

    Metabolic complications are commonly found in people treated with clozapine. Reviews on the management of this problem have generally drawn conclusions by grouping different types of studies involving patients treated with various different antipsychotics. We carried out a systematic review and meta-analysis of pharmacological and non-pharmacological treatments for clozapine-induced obesity or metabolic syndrome. Two researchers independently searched PubMed and Embase for randomised controlled trials (RCTs) of treatments for clozapine-induced obesity or metabolic syndrome. All other types of studies were excluded. We only included RCTs where more than 50% of participants were taking clozapine. We identified 15 RCTs. Effective pharmacological treatments for clozapine-induced obesity and metabolic syndrome include metformin, aripiprazole, and Orlistat (in men only). Meta-analysis of three studies showed a robust effect of metformin in reducing body mass index and waist circumference but no effects on blood glucose, triglyceride levels, or HDL levels. In addition, there is limited evidence for combined calorie restriction and exercise as a non-pharmacological alternative for the treatment of clozapine-induced obesity, but only in an in-patient setting. Rosiglitazone, topiramate, sibutramine, phenylpropanolamine, modafinil, and atomoxetine have not shown to be beneficial, despite reports of efficacy in other populations treated with different antipsychotics. We conclude that randomised-controlled trial data support the use of metformin, aripiprazole, and Orlistat (in men only) for treating clozapine-induced obesity. Calorie restriction in combination with an exercise programme may be effective as a non-pharmacological alternative. Findings from trials in different populations should not be extrapolated to people being treated with clozapine.

  9. Nucleotide Metabolism

    DEFF Research Database (Denmark)

    Martinussen, Jan; Willemoës, M.; Kilstrup, Mogens

    2011-01-01

    Metabolic pathways are connected through their utilization of nucleotides as supplier of energy, allosteric effectors, and their role in activation of intermediates. Therefore, any attempt to exploit a given living organism in a biotechnological process will have an impact on nucleotide metabolism....... The aim of this article is to provide knowledge of nucleotide metabolism and its regulation to facilitate interpretation of data arising from genetics, proteomics, and transcriptomics in connection with biotechnological processes and beyond....

  10. 阿立哌唑治疗利培酮所致精神分裂症女性患者高催乳素血症的研究%Aripiprazole in treatment of female schizophrenics with risperidone induced hyperprolactinemia

    Institute of Scientific and Technical Information of China (English)

    纪菊英; 宋梓祥; 徐乐平; 孙剑; 施建安; 赵汉清; 王焕林

    2008-01-01

    Objective To explore the efficacy and safety of aripiprasole in treatment of female schizophrenics with risperidone induced hyperprolactinemia. Methods All 117 female schizophrenics with hyperprolactinemia after fixed dose risperidone treatment were randomly assigned to aripiprazole group (n=60) and control group (n=57), and received additional aripiprazole 5 nag daily or placebo for 6 weeks respectively. The plasma prolactin (PBL) level was measured at weeks 0 and 6, and the Brief Psychiatric Bating Scale (BPBS) and Treatment Emergent Symptom Scale (TESS) were assessed. Results (1)Plasma prolactin levels were significantly reduced after the study compared with the baseline [(26±6) μg/L vs. (112±40)μg/L] in aripiprazole group (P= 0.000), however there were no significant difference between pre- and post treatment in control group (P =0.180). (2) At weeks 6, the decline rate and the normal ratio of plasma prolactin levels were significantly higher in aripiprazole group [(75±8) % vs. 82%]than in control group [(5±30) % vs. 4%] respectively (beth P = 0.000 ). (3) Compared with the baseline, the BPRS score showed significant reduction in both groups at the end of the study (both P=0.045). The incidence of side effects showed no significant difference between aripiprazole and control group(P =0.553). Conclusion The results indicate that aripiprazole may be effective and safe for the treatment of female schizophrenics with risperidone induced hyperprolactinemis.%目的 探讨阿立哌唑治疗利培酮所致女性患者高催乳素血症的疗效及安全性.方法 117例利培酮所致高催乳素血症的女性患者,随机分为治疗组(60例)和对照组(57例).维持原有利培酮治疗不变,治疗组加用阿立哌唑5 mg,对照组加用安慰剂治疗,疗程均为6周.于治疗第0,6周末检测催乳素,评定简明精神病量表(BPRS)、治疗中需处理的不良反应症状量表(TESS).结果 (1)治疗第6周末,治疗组催乳素[(26±6)

  11. 阿立哌唑与喹硫平治疗精神分裂症的疗效和安全性%Efficacy and safety of aripiprazole and quetiapine in the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    王占敏; 宓为峰; 王晓志; 卢天兰; 付艺; 王雪芹; 郝晓楠; 李玲芝; 张鸿燕

    2012-01-01

    Objective To investigate the clinical efficacy and safety of aripiprazole and quetiapine in the treatment of schizophrenia. Methods A randomized, controlled clinical trial was designed. One hundred and sixty - nine patients with schizophrenia were randomized into aripiprazole group (n = 79, 8 weeks, 10 -30 mg ? D-1) and quetiapine group (n = 90, 8 weeks, 400 - 750 mg ? D -1 ). The positive and negative syndrome scale (PANSS) and response rate were mainly used to evaluate efficacy. The safety was assessed by using the laboratory examination, vital signs and electrocardiogram ( ECG) at the baseline, week 4, 8. Results Compared with the baseline, total scores of PANSS in both groups decreased significantly at week 4 and week 8 ( P < 0. 01 ). At week 8 of treatment the mean reduction scores of PANSS and the clinical response rates were approximate, there were no significant differences between both groups. The incidence of adverse drug reactions related to the drugs 25. 3% (20/79) in aripiprazole and 17. 7% ( 16/90) in quetiapine treatment was approximate in both groups, with lower liability for heart rate in aripiprazole than in quetiapine treatment. The triglyceride(TG) and QRS interval in aripiprazole group showed more significant differences at week 8 than the baseline ( P < 0. 05 ). But the heart rate, body mass, body mass index ( BMI) , hemoglobin ( HGB ) , total cholesterol ( TC ) and low density lipoprotein ( LDL) in quetiapine group different significantly when compared with those at baseline (P < 0. 01). Conclusion Aripiprazole and quetiapine both have good efficacy in the treatment of schizophrenia. They have similar incidence of adverse drug reaction related to the drugs.%目的 评价阿立哌唑与喹硫平治疗精神分裂症的疗效及安全性.方法 169例符合DSM-Ⅳ(第4版)精神分裂症患者,阿立哌唑组79例,剂量10~30mg·d-1;喹硫平组90例,剂量400~ 750 mg·d-1,疗程均8周.治疗前,治疗第4,8周用阳性和阴性症状

  12. A clinical comparative study in first-onset schizophrenia patients treated with Aripiprazole and Quetiapine%阿立哌唑与喹硫平治疗首发精神分裂症的临床对照研究

    Institute of Scientific and Technical Information of China (English)

    刘娜

    2012-01-01

    Objective To study the clinical effects of Aripiprazole and Quetiapine in the treatment of first -onset schizophrenia. Methods 63 adult patients who were diagnosed as schizophreniain accordance with the CCMD-3 diagnosis standard were recruited in this study. All the cases were randomized into two groups and were treated with Aripiprazole and Quetiapine for 8 weeks. The positive and negative syndrome scale (PANSS) and treatment emergent side effect scale (TESS) were used to evaluate efficacy and adverse effects respectively. Results The significant efficacy rates of Aripiprazole was 93.55%, Quetiapine was 90.63%, there was no significant difference (P > 0.05). Before and after treatment between Aripiprazole group and Quetiapine group, the PANSS score had no significant difference (P > 0.05). The level of LEP and TG was elevated which were treated by Aripiprazole, the difference was statistically significant (P < 0.05). The level of LEP, PRL, BG and TG was elevated which were treated by Quetiapine, the difference was statistically significant (P < 0.05). Conclusion The curative effect of first-onset schizophrenia between Aripiprazole and Quetiapine is quite, but the adverse reactions are different, the former is better than the latter.%目的 探讨阿立哌唑与喹硫平治疗首发精神分裂症的临床疗效.方法 63例首发精神分裂症患者,符合CCMD-3精神分裂症诊断标准,随机分成两组,分别使用阿立哌唑和喹硫平治疗,疗程共8周.采用阳性和阴性症状量表(PANSS)和不良反应症状量表(TESS)进行副反应评定.结果 阿立哌唑组总有效率为93.55%,喹硫平组总有效率为90.63%,差异无统计学意义(P>0.05).阿立哌唑组和喹硫平组两组患者治疗前后PANSS量表评分,差异无统计学意义(P>0.05);阿立哌唑组治疗前后相比,瘦素和三酰甘油水平升高,差异有统计学意义(P<0.05),喹硫平组治疗前后瘦素、催乳素、血糖和三酰甘油水平升

  13. 氟西汀合并阿立哌唑对强迫症疗效的对照研究%Fluoxetine combined with Aripiprazole in the treatment of obsessive compulsive disorder

    Institute of Scientific and Technical Information of China (English)

    王道杰

    2013-01-01

    Objective To investigate the efficacy of fluoxetine combined with Aripiprazole in the treatment of obsessive-compulsive disorder(OCD).Method :64 patients with OCD were randomly treated with fluoxetine only and fluoxetine combining with Aripiprazole .The efficacy wad measured with Yale-Brown obsessive compulsive scale(Y-BOCS),Hamilton anxiety scale(HAMA) and Hamilton depression scale(HAMD).Results :There were significant differences between two groups in overall response showed by the reducation rate of Y-BOCS,HAMA and HAMD total scores.Conclusion: It is suggested that fluoxetine combining with Aripiprazole wave a superior effectiveness in the treatment of OCD.%目的探讨氟西汀合并阿立哌唑治疗强迫症的疗效。方法64例强迫症患者随机分为氟西汀组和氟西汀合并阿立哌唑组,疗程8周,采用强迫症量表(Y-BOCS),汉密尔顿焦虑量表(HAMA),汉密尔顿抑郁量表(HAMD),评定疗效。结果治疗结束时两组Y-BOCS,HAMA,HAMD的评分均显著下降,而合并阿立哌唑组更明显。结论氟西汀合并阿立哌唑治疗强迫症可以提高疗效。

  14. Rationale and Baseline Characteristics of PREVENT: A Second-Generation Intervention Trial in Subjects At-Risk (Prodromal) of Developing First-Episode Psychosis Evaluating Cognitive Behavior Therapy, Aripiprazole, and Placebo for the Prevention of Psychosis

    Science.gov (United States)

    Bechdolf, Andreas; Müller, Hendrik; Stützer, Hartmut; Wagner, Michael; Maier, Wolfgang; Lautenschlager, Marion; Heinz, Andreas; de Millas, Walter; Janssen, Birgit; Gaebel, Wolfgang; Michel, Tanja Maria; Schneider, Frank; Lambert, Martin; Naber, Dieter; Brüne, Martin; Krüger-Özgürdal, Seza; Wobrock, Thomas; Riedel, Michael; Klosterkötter, Joachim

    2011-01-01

    Antipsychotics, cognitive behavioral therapy (CBT), and omega-3-fatty acids have been found superior to control conditions as regards prevention of psychosis in people at-risk of first-episode psychosis. However, no large-scale trial evaluating the differential efficacy of CBT and antipsychotics has been performed yet. In PREVENT, we evaluate CBT, aripiprazole, and clinical management (CM) as well as placebo and CM for the prevention of psychosis in a randomized, double-blind, placebo-controlled trial with regard to the antipsychotic intervention and a randomized controlled trial with regard to the CBT intervention with blinded ratings. The hypotheses are first that CBT and aripiprazole and CM are superior to placebo and CM and second that CBT is not inferior to aripiprazole and CM combined. The primary outcome is transition to psychosis. By November 2010, 156 patients were recruited into the trial. The subjects were substantially functionally compromised (Social and Occupational Functioning Assessment Scale mean score 52.5) and 78.3% presented with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition axis I comorbid diagnosis. Prior to randomization, 51.5% of the participants preferred to be randomized into the CBT arm, whereas only 12.9% preferred pharmacological treatment. First, assessments of audiotaped treatment sessions confirmed the application of CBT-specific skills in the CBT condition and the absence of those in CM. The overall quality rating of the CBT techniques applied in the CBT condition was good. When the final results of the trial are available, PREVENT will substantially expand the current limited evidence base for best clinical practice in people at-risk (prodromal) of first-episode psychosis. PMID:21860040

  15. Clinical efficacy comparison of escitalopram treatment combined with aripiprazole on obsessive compulsive disorder%艾司西酞普兰联合阿立哌唑治疗强迫症患者的疗效观察

    Institute of Scientific and Technical Information of China (English)

    姜涛

    2011-01-01

    Objective; To investigate the effectiveness and safety of escitalopram with or without aripi-prazole in the treatment of obsessive-compulsive disorder. Method;60 patients with obsessive compulsive disorder were randomly assigned to receive escitalopram with or without aripiprazole. Effectiveness and adverse effect were assessed by Yale-Brown obsessive compulsive scale (Y-BOCS) and treatment emergent symptom scale ( TESS) , respectively. Results; Patients both received escitalopram and escitalopram with aripiprazole showed significant improvement by Y-BOCS scores after treatment,while the combination group showed a better outcome. There was no significant difference in TESS evaluation between the two groups. Conclusion; Escitalopram could effectively treat obsessive-compulsive disorder, while escitalopram combined with aripiprazole is more effective.%目的:探讨艾司西酞普兰与阿立哌唑联合治疗强迫症的疗效及不良反应.方法:对60例强迫症患者随机分为单用艾司西酞普兰组(单用组)及艾司西酞普兰与阿立哌唑联合用药组(合用组)治疗强迫症患者各30例进行开放、随机、对照研究,通过耶鲁布朗强迫量表(Y-BOCS)评定疗效,治疗中出现的症状量表(TESS)评定不良反应. 结果:艾司西酞普兰治疗后显著改善强迫症状,艾司西酞普兰联合阿立哌唑也能显著改善强迫症状,后者改善效果更好;两组不良反应轻微.结论:艾司西酞普兰联合阿立哌唑较单用艾司西酞普兰的抗强迫效果更好.

  16. Efficacy and adverse reactions of Aripiprazole and Risperidone in treatment of patients with schizophrenia%阿立哌唑与利培酮治疗精神分裂症患者的疗效及不良反应

    Institute of Scientific and Technical Information of China (English)

    臧双九

    2015-01-01

    目的::观察阿立哌唑、利培酮治疗精神分裂症患者的疗效、不良反应及安全性。方法:将60例符合CCMD-3诊断标准的精神分裂症患者随机分为两组,分别给予患者阿立哌唑、利培酮治疗8周,于治疗前以及治疗2、4和8周采用阳性与阴性症状量表( PANSS)评定患者的疗效,不良反应量表( TESS)评定患者的不良反应。结果:两组患者治疗的疗效相当。利培酮组患者的锥体外系反应、内分泌以及体重增加多于阿立哌唑组。结论:阿立哌唑治疗精神分裂症患者的疗效与利培酮相似,但不良反应更少。%Objective: To observe efficacy, adverse reactions and safety of Aripiprazole and Risperidone in treatment of pa-tients with schizophrenia. Methods: 60 cases meeting CCMD3 diagnostic criteria for schizophrenia were randomly divided into 2 groups. They were treated with Aripiprazole and Risperidone for 8 weeks, respectively. Before and 2, 4 and 8 weeks after the treat-ment, PANSS (positive and negative symptom scale) and TESS (treatment emergent symptom scale) were used to evaluate the efficacy and adverse reactions. Results:The two groups had a similar efficacy;however, the extrapyramidal system reactions, endocrine, and weight gain in Risperidone group were more than those of Aripiprazole group. Conclusions:Aripiprazole in the treatment of the patients with schizophrenia has a similar efficacy with Risperidone, but has fewer adverse reactions.

  17. Observation of the clinical efficacy of aripiprazole and risperidone in the treatment of schizophrenia%阿立哌唑与利培酮治疗精神分裂症的临床疗效观察

    Institute of Scientific and Technical Information of China (English)

    刘卫平

    2015-01-01

    目的:探讨阿立哌唑与利培酮治疗精神分裂症的疗效。方法:收治精神分裂症患者60例,随机分为对照组和观察组,对照组采用利培酮治疗,观察组采用阿立哌唑治疗,比较两组治疗效果。结果:对照组总有效率86.7%,观察组总有效率90.0%,P>0.05;对照组出现不良反应18例(60.0%),观察组出现不良反应6例(20.0%),P<0.05。结论:在精神分裂症的治疗中利培酮与阿立哌唑均具有显著的疗效,然而相对于利培酮而言,阿立哌唑具有较低的不良反应发生率,因此其具有较高的安全性。%Objective:To explore the clinical efficacy of aripiprazole and risperidone in the treatment of schizophrenia.Methods:60 patients with schizophrenia were selected.They were randomly divided into the control group and the observation group.The control group was treated with risperidone,and the observation group was treated with aripiprazole.We compared the treatment effect of the two groups.Results:In the control group,the total efficiency was 86.7%;in the observation group,the total efficiency was 90%,P>0.05.In the control group,18 cases(60%) had adverse reactions;in the observation group,6 cases(20%) had adverse reactions,P<0.05.Conclusion:In the treatment of schizophrenia,risperidone and aripiprazole all had significant curative effect,but compared with risperidone,aripiprazole had low adverse reaction rate,so it had a high safety.

  18. Optimization and pharmacokinetics of the sustained release microspheres of aripiprazole%阿立哌唑缓释微球的工艺优化及体内药动学研究

    Institute of Scientific and Technical Information of China (English)

    杨蕾; 彭博; 王明新; 刘津爱; 王毅飞; 王东凯

    2012-01-01

    目的:制备阿立哌唑缓释微球,使用星点设计-效应面法优化工艺,并对其体内血药浓度进行分析.方法:采用乳化溶剂挥发法制备阿立哌唑微球;以油相二氯甲烷体积、水相聚乙烯醇质量分数及乳化转速为自变量,以微球的平均粒径、跨距、载药量、包封率、产率及突释量为因变量,对制备工艺进行优化,并对优化后的工艺进行验证.采用HPLC法测定家兔血浆中药物浓度.结果:最佳工艺为二氯甲烷体积1.62mL,聚乙烯醇质量分数1.91%,乳化转速2161 r·min-1;按优化工艺制备的微球外观圆整、流动性好;平均粒径为41.54μm,跨距为1.01,载药量为18.82%,包封率为75.39%,产率为85.17%,突释为1.68%.自制徽球制剂在家兔体内d1有少量的突释,d5 ~d20维持较稳定的血药浓度,缓慢释放,之后浓度开始下降.结论:所优化的制备工艺重现性好,简单易行;星点设计-效应面法优化微球制备工艺预测性良好,所制备的微球具有较好的体外缓释特性;阿立哌唑缓释微球在家兔体内缓慢释放,该释药行为达到了预期的目的.%Objective: To prepare the sustained release microspheres of aripiprazole, to optimize the formulation by central composite design-response surface methodology, and to evaluate the pharmacokinetics of aripiprazole in rabbits. Methods: Emulsification-solvent evaporation method was used to prepare aripiprazole micro-spheres. The volume of CH2CI2 .polyvinyl alcohol (PVA) concentration and speed of mechanical stirring were listed as three independent variables; the dependent variables were mean diameter, span, durg content, encapsulation efficiency, yield and initial release. The central composite design-response surface methodology was constructed to optimize the formulations, and the optimized formulation was validated. HPLC method was used for the determination of aripiprazole in rabbit plasma. Results: The optimized preparation

  19. Different effects of taking aripiprazole and risperidone on spontaneous brain activity in schizophrenics%阿立哌唑和利培酮对精神分裂症患者自发脑活动的不同影响

    Institute of Scientific and Technical Information of China (English)

    常鑫; 罗程; 侯昌月; 陈琳; 陈曦; 贺辉; 段明君; 蒋宇超; 尧德中

    2015-01-01

    Objective To explore the difference in effects of taking two different kinds of drugs aripiprazole and risperidone on spontaneous brain activity among schizophrenics. Methods Nineteen patients(9 patients taking aripiprazole and 10 patients taking risperidone),who were recruited in the Fourth Peopleˊs Hospital of Chengdu were underwent a resting - state scanning at the Center for Information in Medicine of University of Electronic Science and Technology of China. Two groupsˊfractional amplitude of low - frequency (fALFF)value were calculated and compared using two sample t - test. Results Compared with the aripiprazole group,risperidone group showed significantly decreasing areas of fALFF,including bilateral putamen,olfactory,caudate,orbitofrontal and right palli-dum;left middle temporal gyrus and left supramarginal gyrus where also shown to have increasing areas. Conclusion Indeed,there are different effects of taking aripiprazole and risperidone on spontaneous brain activity in schizophrenics,which is consistent with the pharmacological mechanism of two drugs.%目的:探究临床常用抗精神病药物阿立哌唑和利培酮对精神分裂症患者自发性脑活动的不同影响。方法纳入就诊于成都市第四人民医院的长期服用阿立哌唑进行单药治疗的精神分裂症患者9例,服用利培酮单药治疗的精神分裂症患者10例,进行静息态功能磁共振(fMRI)扫描。分析两组患者 fMRI 信号的分数低频振幅(fALFF)的组间差异。结果与阿立哌唑组比较,利培酮组 fALFF 显著降低的脑区有双侧壳核、嗅皮质、尾状核、眶部额下回和右侧苍白球;fALFF 显著增高脑区有左侧颞中回和左侧缘上回(P <0.05)。结论阿立哌唑和利培酮会对大脑产生不同影响,差异脑区符合两种药物的不同药理机制。

  20. Metabolic acidosis.

    Science.gov (United States)

    Lim, Salim

    2007-01-01

    Acute metabolic acidosis is frequently encountered in critically ill patients. Metabolic acidosis can occur as a result of either the accumulation of endogenous acids that consumes bicarbonate (high anion gap metabolic acidosis) or loss of bicarbonate from the gastrointestinal tract or the kidney (hyperchloremic or normal anion gap metabolic acidosis). The cause of high anion gap metabolic acidosis includes lactic acidosis, ketoacidosis, renal failure and intoxication with ethylene glycol, methanol, salicylate and less commonly with pyroglutamic acid (5-oxoproline), propylene glycole or djenkol bean (gjenkolism). The most common causes of hyperchloremic metabolic acidosis are gastrointestinal bicarbonate loss, renal tubular acidosis, drugs-induced hyperkalemia, early renal failure and administration of acids. The appropriate treatment of acute metabolic acidosis, in particular organic form of acidosis such as lactic acidosis, has been very controversial. The only effective treatment for organic acidosis is cessation of acid production via improvement of tissue oxygenation. Treatment of acute organic acidosis with sodium bicarbonate failed to reduce the morbidity and mortality despite improvement in acid-base parameters. Further studies are required to determine the optimal treatment strategies for acute metabolic acidosis.

  1. Metabolic encephalopathies.

    Science.gov (United States)

    Angel, Michael J; Young, G Bryan

    2011-11-01

    Kinnier Wilson coined the term metabolic encephalopathy to describe a clinical state of global cerebral dysfunction induced by systemic stress that can vary in clinical presentation from mild executive dysfunction to deep coma with decerebrate posturing; the causes are numerous. Some mechanisms by which cerebral dysfunction occurs in metabolic encephalopathies include focal or global cerebral edema, alterations in transmitter function, the accumulation of uncleared toxic metabolites, postcapillary venule vasogenic edema, and energy failure. This article focuses on common causes of metabolic encephalopathy, and reviews common causes, clinical presentations and, where relevant, management.

  2. The comparison of blood prolactin in the female patients with psychosis treated by aripiprazole and Sulpiride%阿立哌唑与舒必利对女性患者血清催乳素影响的对照研究

    Institute of Scientific and Technical Information of China (English)

    祖鑫

    2013-01-01

    目的:探讨阿立哌唑与舒必利对女性患者血清催乳素的影响。方法:将64例精神分裂症女性患者随机分为阿立哌唑组和舒必利组,比较两组治疗前后的血清催乳素变化。结果:阿立哌唑与舒必利对女性患者血清催乳素的影响有显著差异。结论:阿立哌唑对女性患者血清催乳素的影响较舒必利不明显。%Objective:To investigate the change of blood prolactin in female patients with p sychosis treated by aripiprazole and Sulpiride .Methods:64 female patients with schizophrenia or schizophrenia form psychosis were randomized to aripiprazole and Sulpiride .The blood prolactin at the baseline and after treatment were compared.Results:There were significant differences in the blood prolactin after treatment between aripiprazole and Sulpiride groups . Conclusions:The change of blood prolactin in the female patients with psychosis caused by aripiprazole was little then Sulpiride .

  3. Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews

    Directory of Open Access Journals (Sweden)

    Tamara Melnik

    Full Text Available CONTEXT AND OBJECTIVE: According to some cohort studies, the prevalence of refractory schizophrenia (RS is 20-40%. Our aim was to evaluate the effectiveness and safety of aripiprazole, paliperidone, quetiapine and risperidone for treating RS. METHODS: This was a critical appraisal of Cochrane reviews published in the Cochrane Library, supplemented with reference to more recent randomized controlled trials (RCTs on RS. The following databases were searched: Medical Literature Analysis and Retrieval System Online (Medline (1966-2009, Controlled Trials of the Cochrane Collaboration (2009, Issue 2, Embase (Excerpta Medica (1980-2009, Literatura Latino-Americana e do Caribe em Ciências da Saúde (Lilacs (1982-2009. There was no language restriction. Randomized controlled trials, systematic reviews and meta-analyses evaluating atypical antipsychotics for treating RS were included. RESULTS: Seven Cochrane systematic reviews and 10 additional RCTs were included in this review. The data generally showed minor differences between the atypical antipsychotics evaluated and typical antipsychotics, regarding improvement in disease symptoms, despite better adherence to treatment with atypical antipsychotics. Risperidone was specifically evaluated in patients with RS in one of the systematic reviews included, with favorable outcomes, but without definitive superiority compared with other drugs of proven efficacy, like amisulpride, clozapine and olanzapine. CONCLUSIONS: The findings underscore the difficulty in treating these patients, with high dropout rates and treatment patterns of modest improvement in assessments of effectiveness. Atypical antipsychotics have advantages over typical antipsychotics mainly through their better safety profile, which leads to better adherence to treatment. A combination of antipsychotics may also be an option for some refractory patients.

  4. Metabolic neuropathies

    Science.gov (United States)

    ... as porphyria Severe infection throughout the body ( sepsis ) Thyroid disease Vitamin deficiencies (including vitamins B12 , B6 , E , and B1 ) Some metabolic disorders are passed down through families (inherited), while others ...

  5. Metabolic Syndrome

    Science.gov (United States)

    ... hypertension, hypertriglyceridemia, insulin resistance syndrome, low HDL cholesterol, Metabolic Syndrome, overweight, syndrome x, type 2 diabetes Family Health, Kids and Teens, Men, Women January 2005 Copyright © American Academy of Family PhysiciansThis ...

  6. Metabolic syndrome

    Directory of Open Access Journals (Sweden)

    Gogia Atul

    2006-02-01

    Full Text Available The Metabolic syndrome is a widely prevalent and multi-factorial disorder. The syndrome has been given several names, including- the metabolic syndrome, the insulin resistance syndrome, the plurimetabolic syndrome, and the deadly quartet. With the formulation of NCEP/ATP III guidelines, some uniformity and standardization has occurred in the definition of metabolic syndrome and has been very useful for epidemiological purposes. The mechanisms underlying the metabolic syndrome are not fully known; however resistance to insulin stimulated glucose uptake seems to modify biochemical responses in a way that predisposes to metabolic risk factors. The clinical relevance of the metabolic syndrome is related to its role in the development of cardiovascular disease. Management of the metabolic syndrome involves patient-education and intervention at various levels. Weight reduction is one of the main stays of treatment. In this article we comprehensively discuss this syndrome- the epidemiology, pathogenesis, clinical relevance and management. The need to do a comprehensive review of this particular syndrome has arisen in view of the ever increasing incidence of this entitiy. Soon, metabolic syndrome will overtake cigarette smoking as the number one risk factor for heart disease among the US population. Hardly any issue of any primary care medical journal can be opened without encountering an article on type 2 diabetes, dyslipidemia or hypertension. It is rare to see type 2 diabetes, dyslipidemia, obesity or hypertension in isolation. Insulin resistance and resulting hyperinsulinemia have been implicated in the development of glucose intolerance (and progression to type 2 diabetes, hypertriglyceridemia, hypertension, polycystic ovary yndrome, hypercoagulability and vascular inflammation, as well as the eventual development of atherosclerotic cardiovascular disease manifested as myocardial infarction, stroke and myriad end organ diseases. Conversely

  7. Lipid Metabolism

    Institute of Scientific and Technical Information of China (English)

    2008-01-01

    2008393 Effects of angiotensin Ⅱ type 1 receptor blocker on triglyceride metabolism in the liver: experiment with Zucker fatty rats. RAN Jianmin(冉建民), et al. Dept Endocrinol, Guangzhou Red Cross Hosp, 4th Hosp Med Coll, Jinan Univ, Guangzhou 510220. Natl Med J China 2008;88(22):1557-1561. Objective To investigate the effects of angiotensin receptor blocker (ARB) on triglyceride (TG) metabolism and mechanism thereof.

  8. 阿立哌唑与喹硫平治疗精神分裂症的疗效与安全性%Efficacy and safety of aripiprazole and quetiapine in treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    刘永桥; 杜波; 宓为峰; 王晓志; 施莹; 李玲芝; 马文斌; 金超; 杨勇峰; 张鸿燕

    2014-01-01

    Objective To evaluate the efficacy and safety of quetiapine and aripiprazole on patients with schizophrenia.Methods The random-ized, open, multi-center trial recruited 168 patients with schizophrenia , who received a 8-week treatment of aripiprazole (n=79, 10-30 mg· d -1 ) or quetiapine ( n=89 , 400-800 mg · d -1 ).The psychotic syn-dromes were rated with the positive and negative syndrome scale ( PAN-SS)at the baseline, the end of the fourth week and the eighth week.The disease severity was evaluated by the Clinical global impression -severity scale ( CGI-S ) and the Clinical global impression -improvement scale ( CGI-I).The safety was evaluated based on the incidences of adverse events and the comparison of laboratory or electrocardiography examina-tions prior and post the treatment.Results The response rates of aripi-prazole and quetiapine were 71.4%and 72.9%.There was no statistical difference ( P>0.05 ).The incidence rates of adverse events related to aripiprazole and quetiapine were 54.05% and 41.77%.The incidence rate of extrapyramidal symptoms ( EPS ) of the two groups were 36.7%and 4.6%( P<0.001 ).Conclusion Aripiprazole and quetiapine both show similar efficacy in the treatment of schizophrenia.The incidence rates of adverse events are similar but with different profiles.%目的:评价阿立哌唑与喹硫平治疗精神分裂症的疗效和安全性。方法用随机、开放、多中心的研究方法。入选精神分裂症患者168例,随机分入阿立哌唑组79例,剂量10~30 mg· d-1;喹硫平组89例,剂量400~800 mg· d-1,疗程均8周。在基线,4,8周末,用阳性症状与阴性症状量表(PANSS)评价精神病性症状,以临床总体印象量表-严重程度(CGI-S)、疗效总评(CGI-I)评价疾病严重程度;以不良事件、实验室检查、心电图检查等评价安全性。结果阿立哌唑组与喹硫平组有效率分别为71.4%和72.9%,2组差异无统计学意义( P>0.05)。

  9. 阿立哌唑与奥氮平治疗酒精所致精神障碍对照研究%A control study of aripiprazole vs .olanzapine in the treatment of mental disorders due to alcohol

    Institute of Scientific and Technical Information of China (English)

    刘娟; 高营

    2014-01-01

    目的:探讨阿立哌唑与奥氮平治疗酒精所致精神障碍的临床疗效和安全性。方法将66例酒精所致精神障碍患者随机分为两组,分别口服阿立哌唑与奥氮平治疗,观察8周。治疗前后采用阳性与阴性症状量表评定临床疗效,副反应量表评定不良反应。结果治疗8周末阿立哌唑组显效率87.5%,总有效率96.9%,奥氮平组分别为88.2%、97.0%,两组显效率、总有效率比较差异无显著性(χ2=0.19、0.00,P>0.05)。两组不良反应较轻微,阿立哌唑组主要表现为头痛、失眠等;奥氮平组主要表现为嗜睡、体质量增加等。结论阿立哌唑与奥氮平均能快速改善酒精所致精神障碍的精神症状,总体疗效相当,安全性高,但不良反应表现形式有所不同,临床上可根据不同患者选用不同的药物治疗。%Objective To explore the efficacy and safety of aripiprazole vs .olanzapine in the treatment of mental disorders due to alcohol (MDA) .Methods Sixty-six MDA patients were randomly divided into two groups taking orally aripiprazole or olanzapine respectively for 8 weeks .Efficacies were assessed with the Positive and Negative Syndrome Scale (PANSS) before and after treatment and adverse reactions with the Treatment Emergent Syndrome Scale (TESS) .Results At the end of the 8th week ,obvious and total ef-fective rate were respectively 87 .5% and 96 .9% in aripiprazole and 88 .2% and 97 .0% in olanzapine group ,which showed no significant differences (χ2 =0 .19 ,0 .00 ;P>0 .05) .Adverse reactions of both groups were mild ,mainly headache ,insomnia etc .in aripiprazole and hypersomnia and weight gain etc .in olanzapine group .Conclusion Both aripiprazole and olanzapine could improve mental symptoms of MDA quickly ,their total efficacy are equivalent ,both have higher safety ,but manifestations of adverse reactions are somew hat different ,so different pharmacotherapies

  10. Metabolic Syndrome (For Parents)

    Science.gov (United States)

    ... Old Feeding Your 1- to 2-Year-Old Metabolic Syndrome KidsHealth > For Parents > Metabolic Syndrome A A A ... this is a condition called metabolic syndrome . About Metabolic Syndrome Not to be confused with metabolic disease (which ...

  11. Metabolic Syndrome (For Parents)

    Science.gov (United States)

    ... Old Feeding Your 1- to 2-Year-Old Metabolic Syndrome KidsHealth > For Parents > Metabolic Syndrome Print A A ... this is a condition called metabolic syndrome . About Metabolic Syndrome Not to be confused with metabolic disease (which ...

  12. Metabolic Impairments Precede Changes in Hunger and Food Intake Following Short-Term Administration of Second-Generation Antipsychotics.

    Science.gov (United States)

    Teff, Karen L; Rickels, Karl; Alshehabi, Erica; Rickels, Michael R

    2015-10-01

    The second-generation antipsychotics (SGAs) are associated with weight gain and an increased incidence of metabolic diseases. The metabolic impairments are assumed a consequence of increased body adiposity secondary to central nervous system-associated increases in food intake. We have previously reported that, independent of weight gain, 9 days of olanzapine administration to control subjects is associated with insulin resistance and increases in postprandial levels of insulin and glucagon-like peptide 1 to a mixed meal challenge. This current report describes previously unpublished data on the effects of the SGAs olanzapine and aripiprazole compared with placebo on detailed hunger and satiety responses over the 12-day inpatient evaluation as well as postprandial ghrelin and leptin responses prior to and following administration of the 2 SGAs. We found no changes in hunger, fullness, or in the orexigenic hormone ghrelin or satiety hormone leptin, consistent with our previous report indicating no change in weight during this study. The results indicate that the SGAs are associated with metabolic changes prior to changes in hunger, satiety, and food intake, and this temporal separation suggests that there are differential mechanisms mediating SGA-associated changes in metabolism and food intake.

  13. Metabolic syndrome

    Institute of Scientific and Technical Information of China (English)

    Charles Shaeffer

    2004-01-01

    @@ The emergence of cardiac disease as the number one world-wide cause of death justifies efforts to identify individuals at higher risk for preventive therapy. The metabolic syndrome, originally described by Reaven, 1 has been associated with higher cardiovascular disease risk. 2 Type Ⅱ diabetes is also a frequent sequela. 3

  14. 地西泮联合小剂量阿立哌唑治疗酒依赖患者的疗效观察%The clinical effect observation of diazepam combined with aripiprazole in patients with alcohol dependence

    Institute of Scientific and Technical Information of China (English)

    高晓奇; 冯芳; 刘艳江; 石秀华; 李克松; 张国辉

    2014-01-01

    目的:观察地西泮联合小剂量阿立哌唑治疗酒依赖患者的临床效果。方法将144例酒依赖患者随机分为治疗组和对照组各72例。2组均接受常规治疗,治疗组在常规治疗基础上加服阿立哌唑治疗,对比2组治疗前后戒断症状评分。结果2组治疗前戒断症状评分差异无统计学意义(P>0.05)。治疗后2组戒断症状评分均低于治疗前,且观察组低于对照组,差异均有统计学意义(P<0.05)。结论地西泮联合小剂量阿立哌唑治疗酒依赖患者疗效较好,且起效时间短,不良反应轻微,值得推广应用。%Objective To observe the clinical efficacy of diazepam combined with aripiprazole in patients with alcohol dependence .Methods 144 cases patients with alcohol dependence were divided into treatment group and control group ,each of 72 cases.The 2 groups were treated by conventional treatment .Treatment group,on the basis of conventional treatment ,was treated by diazepam combined with aripiprazole .After treatment,compared the withdrawal symptoms score of 2 groups.Results Before treatment,the withdrawal symptoms score of 2 groups was no statistically significant (P>0.05).After treatment,the with-drawal symptoms score of 2 groups were less than that of control group ,and the withdrawal symptoms score of treatment group was less than that of control group ,the difference was statistically significant ( P<0.05) .Conclusion Diazepam combined with arip-iprazole in patients with alcohol dependence has an good efficacy ,less adverse reactions ,and worthy of application .

  15. A control study of duloxetine combined with aripiprazol in the treatment of treatment-resistant depression%度洛西汀联合阿立哌唑治疗难治性抑郁症对照研究

    Institute of Scientific and Technical Information of China (English)

    邓良华; 莫翠英; 吴廷娟; 杨子民

    2014-01-01

    Objective To explore the efficacy and safety of duloxetine combined with aripiprazol in the treatment of treatment-resistant depression (TRD) .Meth-ods Ninety-three TRD patients were randomly divided into two groups ,research group (n=47) was trea-ted with oral duloxetine plus aripiprazol and control group (n=46) with single duloxetine for 8 weeks . Clinical efficacies were assessed with the Hamilton Depression Scale (HAMD) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results At the end of the 8th week ,obvious effective and effective rate were respectively 59 .1% and 77 .3% in research and 31 .1% and 42 .2% in control group , the former was significantly than the latter (χ2 = 7 .04 ,11 .35 ;P0 .05) .Conclusion Duloxetine plus aripiprazol takes effect more rapidly and has an evident effect and higher safety compared with single duloxetine in the treatment of T RD .%目的:探讨度洛西汀联合阿立哌唑治疗难治性抑郁症的临床疗效和安全性。方法将93例难治性抑郁症患者随机分为两组,研究组口服度洛西汀联合阿立哌唑治疗,对照组单用度洛西汀治疗,观察8周。采用汉密顿抑郁量表评定临床疗效,副反应量表评定不良反应。结果治疗8周末研究组显效率59.1%、有效率77.3%,对照组分别为31.1%、42.2%,研究组显效率、有效率均显著高于对照组(χ2=7.04、11.35,P<0.01)。两组不良反应较轻微,发生率比较差异无显著性(P>0.05)。结论度洛西汀联合阿立哌唑治疗难治性抑郁症起效快,疗效显著,安全性高,显著优于单用度洛西汀治疗。

  16. Clinical studies of aripiprazole in child and adolescent tic dis-order%阿立哌唑治疗儿童青少年抽动障碍临床研究

    Institute of Scientific and Technical Information of China (English)

    高蓉; 周渊东; 黄自勇; 金婷婷

    2014-01-01

    目的:探讨阿立哌唑治疗儿童青少年抽动障碍患者的临床疗效和安全性。方法对25例应用其他药物治疗效果不佳或耐受性较差的儿童青少年抽动障碍患者换用阿立哌唑治疗,观察10周。于治疗前后采用耶鲁抽动量表评定临床疗效,副反应量表评定不良反应。结果本组患者治疗10周末耶鲁抽动量表总分及运动抽动、发声抽动、功能损害评分均较基线显著下降(P<0.01);不良反应较轻微,主要表现为失眠、激越、头痛等。结论阿立哌唑治疗儿童青少年抽动障碍疗效显著,安全性高,依从性好。%Objective To explore the efficacy and safety of aripiprazole in child and adolescent tic disorder . Methods Twenty-five tic disorder children and adolescents who had poor treatment effectiveness or toler-ance with other drugs were treated with aripiprazole for 10 weeks .Efficacies with assessed with the Yale Global Tic Severity Scale (YGTSS) before and after treatment and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results At the end of the 10th week total ,motor tic ,vocal tic and functional lesion score of the YGTSS lowered more significantly compared with pretreatment (P<0 .01);adverse reactions were mild and mainly insomnia ,agitation ,headache and so on .Conclusion Aripiprazole has an evident effect ,higher safety and better compliance in child and adolescent tic disorder .

  17. Control study of Wujibaifeng pills and aripiprazole in the treatment of female schizophrenia patients with hyperprolactinemia split caused by risperidone%乌鸡白凤丸与阿立哌唑治疗利培酮所致女性精神分裂症患者高催乳素血症的对照研究

    Institute of Scientific and Technical Information of China (English)

    于丽燕; 丁良; 李玉欣

    2015-01-01

    目的:探讨乌鸡白凤丸与阿立哌唑对女性精神分裂症患者服用利培酮所致高催乳素血症的影响及其安全性。方法将应用利培酮治疗导致高催乳素血症的67例女性精神分裂症患者随机分为乌鸡白凤丸组和阿立哌唑组,疗程4周。结果乌鸡白凤丸组完成28例,阿立哌唑组完成30例,乌鸡白凤丸组血清催乳素明显低于入组前(t=7.624,P=0.000),阿立哌唑组血清催乳素明显低于入组前(t=8.278,P=0.000),两组血清催乳素水平无明显差异(t=1.965,P=0.054)。结论乌鸡白凤丸与阿立哌唑均能降低利培酮所致高催乳素水平,安全性好。%Objective To explore the efifcacy and safety of Wujibaifeng pills and aripiprazole in the treatment of female hyperprolactinemia caused by risperidone.Methods 67 female schizophrenia patients with hyperprolactinemia caused by risperidone and aripiprazole were randomly assigned into Wujibaifeng pills group and aripiprazole group treated for 4 weeks. Results In Wujibaifeng pills group 28 cases were completed the treatment,in aripiprazole group 30 cases completed. In Wujibaifeng pills group, the serum prolactin was significantly lower than before treatment (t=7.624,P=0.000), serum prolactin in aripiprazole group was signiifcantly lower than that before treatment (t=8.278,P=0.000). The serum prolactin levels in the two groups had no significant difference (t=1.965,P=0.054) .Conclusion Wujibaifeng pills and aripiprazole can reduce risperidone induced hyperprolactinemia level with good safety.

  18. Metabolic Syndrome

    Directory of Open Access Journals (Sweden)

    Sevil Ikinci

    2010-10-01

    Full Text Available Metabolic Syndrome is a combination of risk factors including common etiopathogenesis. These risk factors play different roles in occurence of atherosclerotic diseases, type 2 diabetes, and cancers. Although a compromise can not be achieved on differential diagnosis for MS, the existence of any three criterias enable to diagnose MS. These are abdominal obesity, dislipidemia (hypertrigliceridemia, hypercholesterolemia, and reduced high density lipoprotein hypertension, and elevated fasting blood glucose. According to the results of Metabolic Syndrome Research (METSAR, the overall prevalence of MS in Turkey is 34%; in females 40%, and in males it is 28%. As a result of “Western” diet, and increased frequency of obesity, MS is observed in children and in adolescents both in the world and in Turkey. Resulting in chronic diseases, it is thought that the syndrome can be prevented by healthy lifestyle behaviours. [TAF Prev Med Bull 2010; 9(5.000: 535-540

  19. What is Metabolic Syndrome?

    Science.gov (United States)

    ... from the NHLBI on Twitter. What Is Metabolic Syndrome? Metabolic syndrome is the name for a group of ... that may play a role in causing metabolic syndrome. Outlook Metabolic syndrome is becoming more common due to a ...

  20. Efficacy and safety of aripiprazole in treating negative symptoms of schizophrenia%阿立哌唑与利培酮治疗精神分裂症阴性症状的疗效和安全性观察

    Institute of Scientific and Technical Information of China (English)

    贾天成

    2014-01-01

    目的:探讨阿立哌唑治疗精神分裂症阴性症状的疗效和安全性。方法80名精神分裂症患者随机分为研究组(阿立哌唑治疗)和对照组(利培酮治疗),每组40例,在治疗前及治疗的2、4、8周末分别采用潘氏阳性与阴性症状量表(PANSS)、阴性症状评定量表(SANS)评分,并记录治疗期间发生的不良反应。结果两组患者治疗后的 PANSS 量表总分及 SANS 总分均明显降低(P <0.05),但同一时期,两组患者间的 PANSS 量表总分及 SANS 量表评分差异无统计学意义(P >0.05)。在治疗后第4、8周,研究组患者“思维贫乏”及“意志缺乏”的因子分较对照组明显下降(P <0.05),而对照组患者“兴趣/社交缺乏”的评分则明显低于同期的研究组患者(P <0.05)。阿立哌唑不良反应发生率小于利培酮(P <0.05)。结论阿立哌唑与利培酮均能改善精神分裂症患者的阴性症状,且总体疗效相似,但阿立哌唑更善于改善患者的情感与认知症状,而利培酮则对患者的情感与行为症状更有效。阿立哌唑的用药安全性总体上优于利培酮。%Objective To explore the efficacy and safety of aripiprazole in treating negtive symptoms of schizophrenia.Methods Eighty patients with schizophrenia were randomly assigned to the experimental group(treated with aripiprazole)and the control group(treated with risperidone),with 40 cases in each group.Positive and Negative Syndrome Scale(PANSS)and Scale for Assessment of Negative Symptoms(SANS)were used before treatment,and at the weekend of 2nd,4th,8th after treatment respectively.Results The scores of PANSS and SANS in both groups were decreased in comparison with those pretreatment(P 0.05).At the 4th,8th weekends of post-treatment,the scores of“poverty of thought”and“abulia”in experimental group were decreased in comparison with those in the control group(P 0.05).The

  1. Efficacy observation of Aripiprazole and Risperidone in treatment of schizophrenia%阿立哌唑和利培酮治疗精神分裂症的疗效观察

    Institute of Scientific and Technical Information of China (English)

    曲秀颖

    2015-01-01

    目的::探讨阿立哌唑与利培酮治疗精神分裂症的疗效及安全性。方法:选取76例符合CCMD-3精神分裂症诊断标准的患者随机分为阿立哌唑组和利培酮组,每组38例。两组患者分别给予阿立哌唑和利培酮治疗,6周后进行临床疗效评价及不良反应评定。结果:阿立哌唑组患者总有效率为89.47%,利培酮组患者总有效率为86.84%,两组患者总体疗效相当(P>0.05)。两组患者治疗前后PANSS评分比较,差异有统计学意义(P0.05)。治疗6周,阿立哌唑组患者不良反应发生率低于利培酮组(P0. 05). There was a statistical difference in the PANSS score between the two group before and after the treatment (P0. 05). Six weeks after the treatment, the inci-dence rates of adverse reactions of Aripiprazole group were lower than those of Risperidone group (P<0. 05). Conclusions: In the treatment of schizophrenia, Aripiprazole has a similar efficacy with Risperidone, but is superior in influences on extrapyramidal reac-tions, endocrine and weight than Risperidone.

  2. Study on the Efficacy of Aripiprazole in the Treatment of Type II Schizophrenia Spirit%阿立哌唑治疗Ⅱ型精神分裂症疗效研究

    Institute of Scientific and Technical Information of China (English)

    刘林虎; 侯连凤

    2014-01-01

    Objective To investigate the clinical ef ects of aripiprazole in type II schizophrenia therapy. Methods Our hospital in January 2013 ~ January 2014 treated 60 patients with type IIschizophrenic patients as research subjects, using a random list of numbers divided into study group and control group, 30 cases in each. In the control group were treated with risperidone treatment, the study group were treated with aripiprazole treatment, 6 weeks of treatment, both groups of patients with clinical ef icacy and adverse reactions. Results The comparison of the clinical ef icacy of the study group and the control group, the dif erence was not statistical y significant ( >0.05);adverse reactions in the study group extrapyramidal reactions and weight gain was significantly lower than the control group, the dif erence was statistical y significant ( 0.05);研究组不良反应中锥体外系反应和体重增加反应明显低于对照组,差异有统计学意义(P<0.05)。结论通过采用阿立哌唑对Ⅱ型精神分裂症患者进行治疗,可以取得良好的临床疗效,并且锥体外系反应少,患者体重变化少,安全性也比较高,非常值得在临床上进行推广。

  3. To observe the clinical effect of aripiprazole and risperidone in the treatment of female schizophrenia%阿立哌唑与利培酮治疗女性精神分裂症的临床效果探讨

    Institute of Scientific and Technical Information of China (English)

    龚日东; 黄书梅

    2014-01-01

    Objective To investigate the clinical effect of aripiprazole and risperidone in the treatment of female schizophrenia. Methods 100 cases of female spirit admitted in our hospital in 2012 January to 2014 January between the schizophrenia patients for clinical research,The patients were randomly divided into aripiprazole group and risperidone group, compared two groups of patients with clinical curative effect. Results In the two groups before treatment PANSS clinical psychopathology, negative symptoms, positive symptoms and score of contrast was no significant statistical difference (P>0.05), the clinical treatment for 2 weeks, 4 weeks of treatment and 8 weeks after the treatment, PANSS psychopathology, negative symptoms, positive symptoms and total score compared with the statistically significant difference (P0.05),临床治疗2周、治疗4周和治疗8周后PANSS精神病理、阴性症状、阳性症状和总分对比差异具有统计学意义(P<0.05)。两组女性精神分裂症患者临床治疗的总有效率和不良反应发生率对比差异具有统计学意义(P<0.05)。结论该次医学研究结果证实,阿立哌唑用于女性精神分裂症的临床治疗,具有更高的有效率和安全性,因而临床推广和应用价值更高。

  4. Comparison of Efficacy and Prolactin Concentrations between Aripiprazole and Risperidone Treat-ments in Patients with Schizophrenia%阿立哌唑替换利培酮治疗对精神分裂症患者血清催乳素水平的影响

    Institute of Scientific and Technical Information of China (English)

    马筠; 李轶琛; 李毅; 房茂胜; 钟宝亮

    2013-01-01

    Objective: To compare the prolactin concentrations between aripiprazole and risperidone treatment in patients with schizophrenia. Methods: One hundred and twenty-eight schizophrenic patients with hy-perprolactinemia were randomly divided into risperidone group and aripiprazole group. Patients in the risperidone group were treated with risperidone and in the aripiprazole group were treated with aripiprazol instead of risperidone for 8 weeks. The prolactin concentrations were assessed and compared between two groups at weeks 0, 1,2, 4, 6, and 8. The clinical status was assessed by using the positive and negative syndrome scale (PANSS) and the clinical global impressions scale (CGIS) atweeks0 and 8. Results: Fifty-three in the risperidone group and 48 in the aripiprazole group were available for analyzing. Shift risperidone to aripiprazole was effective in reducing serum prolactin levels. The serum prolactin levels in the risperidone group was significantly lower than that in the aripiprazole group at week 8 (P<0.001). No significant changes was found in the PANSS and CGI-S scores between the two groups. Conclusion: Shift risperidone to aripiprazole was effective in reducing serum prolactin levels of schizophrenia patients with hyperprolactinemia.%目的:研究阿立哌唑替换利培酮治疗对精神分裂症患者血清催乳素水平的影响.方法:伴有高催乳素血症的精神分裂症患者128 例,随机分为利培酮组(维持利培酮治疗)和阿立哌唑(阿立哌唑替代利培酮治疗)组,治疗8 周.于第0、1、2、4、6 及8 周测血清催乳素水平及身体质量指数(BMI);在入组时和治疗8 周时采用阳性与阴性症状量表(PANSS)和临床总体印象量表(CGIS)测定疗效.结果:可用于评估的数据101 例,利培酮组53 例,阿立哌唑组48 例.阿立哌唑组替换治疗后第1 周血清催乳素水平即明显下降,第8 周时,显著低于利培酮组(P<0.001);2 组BMI 、PANSS 及CGIS 评分及变化差异无统计

  5. 阿立哌唑与利培酮治疗精神分裂症的疗效与安全性对比分析%Analysis of Efficacy and Safety of Aripiprazole and Risperidone in the Treatment of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    程道猛; 刘靖雯; 黄鹏; 徐世超; 王春江

    2013-01-01

    目的:探讨阿立哌唑与利培酮治疗精神分裂症的收益和风险,优化临床治疗效果与安全性,指导临床合理治疗。方法:将60例符合入组标准的精神分裂症按随机数字表分为阿立哌唑组与利培酮组,各30例,分别给予阿立哌唑与利培酮,8周为1个疗程,治疗前、后观察患者症状,进行阳性症状量表和阴性症状量表(PANSS)评分及不良反应量表(T ESS )评分,评价两组患者的临床疗效与安全性。结果:阿立哌唑组和利培酮组的总有效率均为93.33%,P>0.05;阿立哌唑组和利培酮组的阳性症状量表(PANSS)评分、阴性症状量表(PANSS)评分及量表总评分差异均无统计学意义,均 P>0.05;阿立哌唑组和利培酮组头痛、口干、血压降低、失眠差异无统计学意义,均 P>0.05,但阿立哌唑组锥体外系反应、体质量增加、闭经溢乳的发生率明显低于利培酮,差异具有统计学意义,均 P<0.05。结论:阿立哌唑起效速度、安全性、依从性明显优于利培酮,尤其能明显降低现锥体外系反应、体质量增加、闭经溢乳的副反应,是治疗精神分裂症的首选药物。%Objective :To investigate benefits and risks of aripiprazole and risperidone in the treatment of schizophreni-a ,to optimize clinical efficacy and safety ,guide clinical treatment .Methods :60 schizophrenia patients met the inclusion criteria were randomly divided into aripiprazole group and risperidone group ,30 cases of each group ,each group were given aripiprazole and risperidone ,8 weeks for an effect ,observed symptoms ,made a positive and negative symptom scale symptom scale (PANSS) scores and adverse reactions scale (TESS) scores ,to evaluate the clinical efficacy and safety .Results:The total effective rate of aripiprazole group and risperidone group was 93 .33% ,P>0 .05 ;the positive symptom scale (PANSS) score ,negative

  6. Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics.

    Directory of Open Access Journals (Sweden)

    Joseph McEvoy

    Full Text Available There is a critical need for mapping early metabolic changes in schizophrenia to capture failures in regulation of biochemical pathways and networks. This information could provide valuable insights about disease mechanisms, trajectory of disease progression, and diagnostic biomarkers. We used a lipidomics platform to measure individual lipid species in 20 drug-naïve patients with a first episode of schizophrenia (FE group, 20 patients with chronic schizophrenia that had not adhered to prescribed medications (RE group, and 29 race-matched control subjects without schizophrenia. Lipid metabolic profiles were evaluated and compared between study groups and within groups before and after treatment with atypical antipsychotics, risperidone and aripiprazole. Finally, we mapped lipid profiles to n3 and n6 fatty acid synthesis pathways to elucidate which enzymes might be affected by disease and treatment. Compared to controls, the FE group showed significant down-regulation of several n3 polyunsaturated fatty acids (PUFAs, including 20:5n3, 22:5n3, and 22:6n3 within the phosphatidylcholine and phosphatidylethanolamine lipid classes. Differences between FE and controls were only observed in the n3 class PUFAs; no differences where noted in n6 class PUFAs. The RE group was not significantly different from controls, although some compositional differences within PUFAs were noted. Drug treatment was able to correct the aberrant PUFA levels noted in FE patients, but changes in re patients were not corrective. Treatment caused increases in both n3 and n6 class lipids. These results supported the hypothesis that phospholipid n3 fatty acid deficits are present early in the course of schizophrenia and tend not to persist throughout its course. These changes in lipid metabolism could indicate a metabolic vulnerability in patients with schizophrenia that occurs early in development of the disease.

  7. Endocrine and Metabolic Adverse Effects of Psychotropic Drugs in Children and Adolescents

    Directory of Open Access Journals (Sweden)

    Evrim Aktepe

    2011-12-01

    Full Text Available ABSTRACT Much as an increase in the use of psychotropic drugs is observed in children and adolescents over the last decade, the endocrine and metabolic side effects of these drugs can limit their use. Atypical antipsychotics can cause many side effects, which are not suitable for the developmental periods of children and adolescents, such as those related with thyroid, blood sugar, level of sex hormones, growth rate and bone metabolism. Children are under a more serious risk regarding the weight increasing effects of atypical antipsychotics and weight gain that is not proportionate with age is especially important due to the association between glucose or lipid abnormalities and cardiovascular mortality. Aripiprazole and ziprasidone are the least risky antipsychotic drugs when it comes to metabolic side affects. The antipsychotic drug that is associated with weight increase and diabetes in children and adolescents most is olanzapine. Even though there are no comparative long-term data concerning children, it is suggested by the currently available information that metabolic side effects including dyslipidemia and impaired glucose tolerance are at an alarming level when it comes to long-term treatment with antipsychotics. The most risky agents in terms of hyperglycemia and glucosuria development are olanzapine and clozapine. Use of risperidone and haloperidol should be undertaken with caution since it may bring about the risk of hyperprolactinemia. Among the antidepressants associated with weight loss and suppression of appetite are selective serotonin reuptake inhibitors, bupropion and venlafaxine. Thyroid functions can be affected by lithium, carbamazepine and valproate treatments. It is reported that the side effect most frequently associated with valproate is weight increase. The relationship between valproate treatment and the development of hyperandrogenism and polycystic ovary syndrome in young women should also be kept in mind. [TAF Prev

  8. Carbohydrate Metabolism Disorders

    Science.gov (United States)

    ... you eat. Food is made up of proteins, carbohydrates, and fats. Chemicals in your digestive system (enzymes) ... metabolic disorder, something goes wrong with this process. Carbohydrate metabolism disorders are a group of metabolic disorders. ...

  9. Cost-effectiveness analysis of Risperidone and Aripiprazole in the treat-ment of outpatients with schizophrenia%利培酮、阿立哌唑治疗门诊精神分裂症患者成本-效果分析

    Institute of Scientific and Technical Information of China (English)

    吴宇杰; 李君; 杜鹏; 饶顺曾; 吴彦

    2015-01-01

    Objective To compare therapeutic cost-effects and safety between Risperidone and Aripiprazole in treatment of outpatients with schizophrenia. Methods The schizophrenia patients, who were going on treating with Risperidone or Aripiprazole at discharge, were followed-up 1 year in outpatient. While economic cost-effectiveness and adverse reaction were observed and analyzed. Results Comparing the efficacy between the two groups, it was better in Risperidone group than Aripiprazole group, but there was no statistically significant difference (字2= 0.804, P= 0.84). Drug costs in the Risperidone group was slightly lower than the Aripiprazole group, but there was no statistically significant difference (t = 0.39, P=0.69). The cost-effectiveness of Risperidone was better than Aripiprazole (62.41 v s 64.40). The incidence of high prolactin was up to 26.19% (11/42) in Risperidone group, while in Aripiprazole group had no high prolactin occurring. Conclusion The expenses and efficacy are considerably between Risperidone and Aripiprazole, but the adverse reaction of high prolactin often appears in Risperidone treatment, must be cause caution, for young female patients chosen Risperidone is better.%目的:比较单用利培酮或阿立哌唑治疗门诊精神分裂症患者的经济效果及安全性。方法对出院时使用利培酮治疗方案或阿立哌唑治疗方案的精神分裂症患者门诊随访1年,运用经济学成本-效果分析比较两组优劣,观察治疗不良反应。结果两组在疗效方面比较,利培酮组较阿立哌唑组差,但差异无统计学意义(字2=0.804,P=0.84);利培酮组药物费用略低于阿立哌唑组,但差异无统计学意义(t=0.39,P=0.69);成本-效果方面利培酮组优于阿立哌唑组(62.41比64.40);利培酮组高泌乳素发生率高达26.19%(11/42),而阿立哌唑无高泌乳素发生。结论使用利培酮及阿立哌唑费用及疗效相当,而利培酮引起的高泌乳素副作用发生率较高,

  10. 博思清与氯氮平治疗单纯型精神分裂症疗效与安全性评价%Efficacy and safety evaluation of aripiprazole and clozapine in the treatment of simple type schizophrenia

    Institute of Scientific and Technical Information of China (English)

    毕见好; 高丽静

    2015-01-01

    AIM:To evaluate the efficacy and safety of aripi-prazole and clozapine in the treatment of simple type schizophreni-a.METHODS:100 cases of simple type schizophrenia meeting ICD-10 criteria were analyzed in our hospital from November 2008 to December 2014,and they were divided randomly into two groups.Aripiprazole group was treated with aripiprazol,while clozapine group was treated with clozapine.PANSS reducing rates were used to evaluate the curative effect after 3 months and half a year,and the difference treatment effect and adverse reaction of two groups were analyzed.RESULTS:The total effective rate of two groups was comparative after 3 months (P >0.05);and the total effective rate of aripiprazole group was better than clozapine group after half a year (P <0.05).The incidence of adverse reac-tion of two groups had significant difference,and the incidence of adverse reaction of aripiprazole is lower than clozapine group's (P <0.05).CONCLUSION:The effect is relatively in recent of aripiprazole and clozapine in the treatment of simple type schiz-ophrenia,but aripiprazole has obvious advantages for the long-term efficacy and safety.Its security is greater,and is worthy of promotion.%目的:对博思清与氯氮平治疗单纯型精神分裂症疗效与安全性进行评价.方法:研究对象选取本院2008-11/2014-12收治的100例符合 ICD-10单纯型精神分裂症诊断标准的患者,按随机方法分为两组.博思清组患者采用博思清治疗,氯氮平组患者给予氯氮平治疗.治疗3个月和6个月分别采用 PANSS 量表减分率评价疗效,对比分析两组患者治疗效果和不良反应的差异性.结果:经过3个月治疗后氯氮平组患者总有效率与博思清组相当(P >0.05);而治疗6个月后博思清组治疗总有效率明显优于氯氮平组(P <0.05);两组患者治疗期间不良反应发生率有显著差异,博思清组发生率明显低于氯氮平组(P <0.05)

  11. Clinical Observation on Fluvoxamine and Aripiprazole as Adjunctive Therapy in the Treatment of Obsessive-compulsive Disorders%阿立哌唑辅助氟伏沙明治疗强迫障碍的临床观察

    Institute of Scientific and Technical Information of China (English)

    魏宏强; 康瑞; 李爱玲; 赵秀娟

    2013-01-01

    Objective:To explore the efficacy and safety of fluvoxamine and aripiprazole as adjunctive therapy in the treatment of obsessive-compulsive disorders patients.Method:Total 54 obsessive-compulsive disorders patients were randomly divided into two groups:Fluvoxamine(250-300 mg/d)auxiliaried by aripiprazole(2.5-10 mg/d)group(study group)and fluvoxamine(250-300 mg/d)group(contral group),27 for each. Each group had a 8-week treatment.The efficacy were assessed and analyzed by Yale-Brown Obsessive Compulsive Scale(Y-BOCS) at baseline and at week 2,4,6 and 8. The side effects were assessed by Treatment Emergent Syptom Scale(TESS)during the treatment. Result:Study group and contral group had 1,2 case being off respectively. The obsession and compulsion scores of study group had all statistical difference at baseline and week 2,4 ,6,8 each other(P0.05). At week 4,in both groups,the compulsion scores had statistical difference(P0.05). Conclusion:Fluvoxamine and aripiprazole as adjunctive therapy can effectively continue to improve the compulsive symptoms in the treatment of obsessive-compulsive disorders patients,the rate of side effects is similar to that of simple fluvoxamine therapy.%  目的:探讨阿立哌唑辅助氟伏沙明治疗强迫障碍的临床疗效及安全性.方法:将54例强迫障碍患者随机分为两组(各27例):阿立哌唑(2.5~10 mg/d)辅助氟伏沙明(250~300 mg/d)组(研究组)、氟伏沙明(250~300 mg/d)组(对照组),治疗观察期均为8周.两组患者于基线及治疗2、4、6、8周末分别评定Yale-Brown强迫量表(Y-BOCS),并采用副反应量表(TESS)评定治疗期间的不良反应.结果:研究组、对照组分别脱落1例、2例.研究组的强迫思维和强迫行为评分在基线及2、4、6、8周末时点间比较差异均有统计学意义(P0.05);4周末时,两组间的强迫行为评分比较差异有统计学意义(P0.05).结论:阿立哌唑辅助氟伏沙明可有效、持续地改善强迫障

  12. Effect of aripiprazole combined with clozapine on quality of life in patients with schizophrenia%阿立哌唑合并氯氮平对精神分裂症患者生活质量的影响

    Institute of Scientific and Technical Information of China (English)

    王小红; 周云云; 兰润林; 侯凌峰; 董继雪; 武建斌

    2013-01-01

    Objective:To investigate the effect of aripiprazole combined with clozapine on quality of life in patients with schizophrenia.Method:According to the therapeutic schedule,78 recurrent patients with schizophrenics who were clinical recovery or remarkable progress by the acute treatment were divided into the study group (38 cases) and control group (40 cases).The maintenance treatment was aripiprazole combined with lower dose clozapine in study group and single clozapine in control group.The quality of life was evaluated by scale of general quality of life (GQOL1-74) in the two groups before and after 6,12 months of maintenance treatment,respectively.The results were compared.Results:After 6 and 12 months of maintenance treatment,the scores of GQOL1-74 in in the two groups were significantly increased than before maintenance treatment,and the improvement of score in the study group was more obvious (P <0.01 or P <0.001).The scores of physical function dimension,social function dimension,self-esteem score in psychological functions dimensions in the study group were significantly higher than those in the control group (P < 0.05 or P < 0.01).Conclusion:The quality of life is better in patients with schizophrenia who had the maintenance treatment with aripiprazole combined lower dose clozapine than those with purely clozapine.%目的:探讨阿立哌唑合并氯氮平对精神分裂症患者生活质量的影响. 方法:将78例经急性期治疗达临床痊愈及显著进步的复发性精神分裂症患者按治疗方案分为研究组(38例)和对照组(40例),分别给予阿立哌唑合并低剂量氯氮平及氯氮平单药维持治疗.分别在维持治疗前、6及12个月时采用生活质量综合评定问卷(GQOLl-74)对两组患者生活质量进行评定和比较. 结果:维持治疗6及12个月时,两组GQOLl-74总分较维持治疗前显著提高,且研究组更显著(P<0.01或P<0.001);研究组的躯体功能、社会功能维度评分以及

  13. Aripiprazole combined with clozapine in the treatment of refractory schizophrenia%阿立哌唑合并氯氮平治疗难治性精神分裂症对照研究

    Institute of Scientific and Technical Information of China (English)

    尹永珍

    2015-01-01

    目的:探讨阿立哌唑合并氯氮平治疗难治性精神分裂症的临床疗效及安全性。方法:将68例难治性精神分裂症患者随机分为两组,组34例,研究组口服阿立哌唑联合氯氮平治疗,对照组单用氯氮平治疗,观察8周,于治疗前及治疗第2周,第4周,第8周末采用阳性与阴性症状量表及副反应量表评定临床疗效和不良反应。结果:两组治疗2周末起阳性与阴性症状量表评分均较治疗前有显著下(P<0.05),研究同期两组间比较均无显著性差异(P>0.05),治疗8周末研究组有效率为63.48%,对照组为51.73%,两组无显著性差异(P>0.05),研究组不良反应发生率为31.23%,对照组为57.27%,研究组显著低于对照组(P<0.05),研究组主要表现为静坐不能、震颤、体重增加。对照组主要为流涎、心电图异常、肝功能异常、白细胞减少、嗜睡、头昏、体重增加等。结论:阿立哌唑联合氯氮平治疗难治性精神分裂症疗效显著,安全性高,依从性好。%ObjectiveThe clinical efficacy and safety of aripiprazole combined with clozapine in the treatment of refractory schizophrenia.Methods68 patients with refractory schizophrenia were randomly divided into two groups, each group have 34 cases,the study group use aripiprazole combined with clozapine to treatment, the control group used clozapine treatment, observe 8 weeks, before treatment and second weeks, fourth weeks and eighth weeks using the positive and negative symptoms scale and side effects scale to evaluated the clinical efficacy and adverse reactions.Results The positive and negative symptom scale scores of the two groups after 2 weeks treatment were significantly lower (P 0.05), after 8 weeks the studygroup effective rate was 63.48%, the control group is 51.73%, the two groups was not statistically significant difference (P> 0.05), the incidence of adverse reactions was 31.23% in

  14. Shorterm and mid - term curative effect of Aripiprazole in hyperprolactinemia induced by Risperdai.%阿立哌唑对利培酮所致高催乳素血症的中短期影响

    Institute of Scientific and Technical Information of China (English)

    葛旭峰; 陆燕华; 王佩青; 范慧斌; 刘燕

    2011-01-01

    Objective To study the safety and effectiveness of Aripiprazole in the treatment of hyperprolactinemia induced by Risperdal. Methods Totally 38 female patients with hyperprolactinemia induced by Risperdal received 5mg/d Aripiprazole combination treatment for 24 weeks. The serum prolactin (PRL)level, Risperdal blood concentration and PANSS were measured at baseline and at the end of 4th, 8th, 12th ,24th week respectively. Results After 4 weeks combination treatment, PRL level decreased significantly from 67.58 ± 49. 12ng/ml to 36. 18 ± 35.32ng/ml ( P =0.000). Compared with the baseline, PRL level also decreased significantly at the end of 8th and 12th month(P <0.05 ). The PRL level was stable after 12 weeks treatment. The effective rate was 86.8% and 81.6% respectively at the end of 12th and 24th month. The PRL level of five patients rebounded at the end of 24th month compared with that at the end of 12th month, and two of those five patients' PRL level was higher than normal range. There were no significant differences in PANSS score at each viewpoint compared with the baseline (P > 0. 05 ). Conclusion Aripiprazole is effective and safety in the short - and mid - term treatment of hyperprolactinemia induced by Risperdal, but the long -term effectiveness are not warranted.%目的 探讨利培酮所致高催乳素血症的女性精神分裂症合并应用小剂量阿立哌唑的有效性和安全性.方法 对38例利培酮所致高催乳素血症的女性精神分裂症患者,合并应用阿立哌唑5mg/d,分别于治疗前、治疗第4、8、12、24周末检测血清催乳素水平(PRL)、利培酮血浓度,并评定阳性与阴性症状量表(PANSS).结果 合并治疗4周后PRL显著下降[(67.58+49.12)ng/ml vs(36.18±35.32)ng/ml,P=0.000],在合并治疗的第8周末、第12周末PRL的下降仍存在统计学差异(P0.05).8周末有效率达86.8%,24周末有效率81.6%.全部患者中,有5例在第24周末的PRL浓度较第12

  15. Effect of treatment with Aripiprazole on mismatch negativity potentials in schizophrenia%阿立哌唑对精神分裂症患者失匹配性负波电位的影响

    Institute of Scientific and Technical Information of China (English)

    姚建军; 张紫娟; 周振和

    2012-01-01

    Objective To study the effects of Aripiprazole on mismatch negativity potentials in schizophrenia. Methods 30 patients (age of 18 - 65 years old) met DSM-IV schizophrenia criteria were enrolled as research group and 30 healthy persons were selected as normal control group that performed the frequency and duration deviant MMN task. MMN latency and amplitude at Fz electrodes were obtained. The research group was treated with Quetipine for 8 weeks and assessed with PANSS. MMN amplitudes and latencies of two groups were compared between the groups. Results Aripiprazole decreased all PANSS scales (P < 0. 05). Patients showed smaller mean amplitudes of frequency and duration MMN than that of normal controls (P < 0. 05). A repeated measure ANOVA in MMN type (frequency vs. Duration) and session as between-subject factors revealed no significant MMN type or MMN type X session interaction for MMN amplitudes but significant effects of session. A multiple comparisons by LSD tests demonstrated significant differences in MMN amplitudes at after 8 - week treatment from that at baseline (P < 0. 05) and after 4 - week treatment (P < 0. 05). There was no significant differences in MMN amplitudes between 4- week treatment and baseline (P>0. 05). MMN amplitudes at 8- week treatment were higher than that at 4 -week treatment and at baseline (P < 0. 05). Conclusions It presents cognitive dysfunction in schizophrenia. In neuroelectrophysical aspect,MMN offers objective evidence for Aripiprazole to improves cognitive function in schizophrenia.%目的 探讨阿立哌唑对精神分裂症患者失匹配性负波电位(MMN)的影响.方法 随机选自18~65岁符合DSM-精神分裂症标准患者30例作为研究组,30例健康人作为对照组.研究组于阿立哌唑治疗前、4,8周后予MMN检测,同时予PANSS评定病情严重程度.对照组入组时预MMN检测.观察MMN波幅、潜伏期的变化.结果 研究组在治疗4,8周后PANSS量

  16. A control study of aripiprazole vs .risperidone in type II schiz-ophrenia%阿立哌唑与利培酮治疗Ⅱ型精神分裂症对照研究

    Institute of Scientific and Technical Information of China (English)

    徐烨; 何益群

    2013-01-01

    目的:探讨阿立哌唑与利培酮治疗Ⅱ型精神分裂症患者的临床疗效和安全性。方法将120例Ⅱ型精神分裂症患者随机分为两组,观察组口服阿立哌唑治疗,对照组口服利培酮治疗,观察12周。于治疗前后采用阳性与阴性症状量表评定临床疗效,采用韦氏成人智力量表、韦氏记忆量表及韦斯康星卡片分类测验评定认知功能,副反应量表评定不良反应。结果治疗后两组阳性与阴性症状量表总分及各因子分均较治疗前有显著下降,言语量表、操作量表、全量表和记忆量表评分均较治疗前显著升高( P<0.01);治疗12周末,观察组有效率为85.0%,对照组为88.3%,两组比较差异无显著性( P>0.05)。两组不良反应均轻微,但观察组锥体外系反应、泌乳/闭经、体质量增加、血糖升高发生率显著低于对照组( P<0.05或0.01)。结论阿立哌唑治疗Ⅱ型精神分裂症疗效显著,总体疗效与利培酮相当,但阿立哌唑治疗安全性更高,依从性更好。%Objective To explore the efficacy and safety of aripiprazole vs .risperidone in type II schizo-phrenia .Methods A total of 120 patients with type Ⅱ schizophrenia were randomly divided into two groups ,observation group took orally aripiprazole and control group did risperidone for 12 weeks .Before and after treatment efficacies were assessed with the Positive and Negative Syndrome Scale (PANSS) ,cog-nitive fundions with the WAIS-R ,WMS and WCST and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results After treatment the total and each factor scores of both groups lowered more significantly compared with pre-treatment ,verbal ,performance ,full and memory scale score height-ened (P 0 .05) .Adverse reactions of both groups were mild ,but the incidence of extrapyramidal reaction ,lactation/amenorrhea ,weight gain ,blood glu-cose elevation were

  17. 阿立哌唑辅治酒精所致精神障碍临床观察%Clinical Observation on Aripiprazole to Treat Mental Disorders Due to Alcohol

    Institute of Scientific and Technical Information of China (English)

    马文斌

    2015-01-01

    目的:探讨阿立哌唑辅治酒精所致精神障碍的临床疗效。方法选取2012年5月~2013年6月我院收治的因酒精中毒所致的精神功能障碍患者46例,将其随机平均分为对照组和实验组,两组均采用常规综合治疗方式,实验组采用阿立哌唑辅助治疗,对照组采用传统抗精神病药物氟哌啶醇治疗,观察两组患者的治疗前后的临床疗效、阳性与阴性症状量表评分以及副反应发生情况。结果实验组的治疗总有效率为95.7%(22/23),对照组的治疗总有效率为78.3%(18/23),实验组的治疗总有效率明显高于对照组治疗总有效率,差异有统计学意义(P<0.05);治疗后实验组的阳性与阴性症状量表评分明显低于对照组,差异有统计学意义(P<0.05)。结论阿立哌唑辅治酒精所致精神障碍临床疗效显著,用药安全,副作用少,能够有效促进患者精神功能恢复。%ObjectiveTo explore the effect of Aripiprazole to treat mental disorders due t Alcohol.Methods Selected 46 cases of mental disorders due to alcohol poisoning from May 2012 to June 2013 in our hospital patients, they were randomly divided into control group and experimental group, two groups both used the conventional comprehensive treatment, the experimental group was using the Aripiprazole therapy, the control group was treated with traditional antipsychotic drugs haloperidol treatment, observed the clinical effects of two groups of patients before and after treatment, the positive and negative symptoms rating scale and side effects. Results Treatment group total effective rate was 95.7% (22/23), the treatment of control group total effective rate was 78.3% (18/23), treatment group total effective rate was significantly higher than the control group total effective rate, the difference was statistically signiifcant (P<0.05). The experimental group after treatment of positive and negative symptoms scale score

  18. Escitalopram combined with aripiprazole in the treatment of 46 patients with obsessive compulsive disorder%艾司西酞普兰联合阿立哌唑治疗强迫症46例

    Institute of Scientific and Technical Information of China (English)

    陈红生

    2012-01-01

    目的 探讨艾司西酞普兰与阿立哌唑联合治疗强迫症临床效果及安全性.方法 强迫症患者97例,随机分为两组,其中对照组51例,采用艾司西酞普兰口服治疗,观察组46例,在上述基础上加用阿立哌唑口服治疗;治疗结束后评价临床疗效及不良反应发生情况.结果 观察组患者治疗总有效率为89.1%明显优于对照组68.6%(x2=12.32,P<0.05);观察组患者治疗后Y-BOCS评分(21.82 ±2.88)分亦明显优于对照组患者的(23.68±2.74)分(t=2.64,P<0.05);而两组患者治疗结束后TESS评分及不良反应发生率均差异无统计学意义(t=0.61;x2 =0.03,均P>0.05).结论 艾司西酞普兰联合阿立哌唑治疗强迫症临床效果显著,且不良反应少,具有临床推广使用价值.%Objective To observe and explore the clinical efficacy and safety of escitalopram combined with aripiprazole in the treatment of obsessive-compulsive disorder.Methods 97 patients with obsessive-compulsive disorder were randomly divided into two groups,control group of 51 patients were given oral administration of escitalopram treatment,46 patients in the experimental group received escitalopram and oral aripiprazole treatment.At the end of treatment,the clinical efficacy and adverse events were evaluated.Results In control group and experimental group patients overall effective rate was 68.6%,89.1% ;The experimental group the total effective rate was higher than the control group,the difference between two groups was statistically significant( x2 =12.32,P <0.05 ),The control group and experimental group after treatment Y-BOCS scores were (23.68 ± 2.74 ) points,( 21.82 ± 2.88 ) points ; The experimental group after treatment Y-BOCS score was significantly better than the control group,between the two groups the difference was statistically significant ( t =2.64,P < 0.05 ) ; While after treatment the TESS score and incidence of adverse reactions between the two groups were

  19. A Comparative Study on Aripiprazole and Sulpiride in Treating Schizophrenia Negative Symptoms%阿立哌唑与舒必利治疗精神分裂症阴性症状对照研究

    Institute of Scientific and Technical Information of China (English)

    陈妙扬; 肖垚南; 陈丁玲; 黎艳芳

    2014-01-01

    Objective To evaluate the efficacy and safety of aripiprazole and sulpiride in treatment of schizophrenia negative symptoms. Methods 120 cases of schizophrenia whose predominant clin-ical features were negative symptoms were randomly assigned to treat with either aripiprezole or sulpiride for 3 months each. They were all assessed by SANS and TESS. Results There was a significant difference in efficacy between the groups assessed by SANS. Side effects of aripiprezole were significantly fewer than sulpiride assessed by TESS. Conclusions Aripiprazole has better ef-fect on schizophrenia whose negative symptoms as target symptom and less side effects.%目的:比较阿立哌唑与舒必利治疗精神分裂症阴性症状的疗效和安全性。方法选取120例符合中国精神疾病诊断标准(CCMD3)诊断为精神分裂症且以阴性症状为主的患者,根据随机对照的方法分为研究组(60例)和对照组(60例),研究组应用阿立哌唑治疗,对照组舒必利治疗,疗程均为3个月;用阴性症状评定量表(SANS)、用药物副反应量表(TESS)进行评定。结果两组治疗前后1个月比较有显著性差异(P<0.05),治疗后2、3个月与治疗前比较亦有显著性差异(P<0.05);两组药物副反应比较,阿立哌唑组明显舒必利组少,有显著性差异(P<0.05)。结论阿立哌唑对分裂症阴性症状有较好的治疗效果,药物副反应少,使用安全较高。

  20. Profiling metabolic networks to study cancer metabolism.

    Science.gov (United States)

    Hiller, Karsten; Metallo, Christian M

    2013-02-01

    Cancer is a disease of unregulated cell growth and survival, and tumors reprogram biochemical pathways to aid these processes. New capabilities in the computational and bioanalytical characterization of metabolism have now emerged, facilitating the identification of unique metabolic dependencies that arise in specific cancers. By understanding the metabolic phenotype of cancers as a function of their oncogenic profiles, metabolic engineering may be applied to design synthetically lethal therapies for some tumors. This process begins with accurate measurement of metabolic fluxes. Here we review advanced methods of quantifying pathway activity and highlight specific examples where these approaches have uncovered potential opportunities for therapeutic intervention.

  1. Metabolism disrupting chemicals and metabolic disorders.

    Science.gov (United States)

    Heindel, Jerrold J; Blumberg, Bruce; Cave, Mathew; Machtinger, Ronit; Mantovani, Alberto; Mendez, Michelle A; Nadal, Angel; Palanza, Paola; Panzica, Giancarlo; Sargis, Robert; Vandenberg, Laura N; Vom Saal, Frederick

    2017-03-01

    The recent epidemics of metabolic diseases, obesity, type 2 diabetes(T2D), liver lipid disorders and metabolic syndrome have largely been attributed to genetic background and changes in diet, exercise and aging. However, there is now considerable evidence that other environmental factors may contribute to the rapid increase in the incidence of these metabolic diseases. This review will examine changes to the incidence of obesity, T2D and non-alcoholic fatty liver disease (NAFLD), the contribution of genetics to these disorders and describe the role of the endocrine system in these metabolic disorders. It will then specifically focus on the role of endocrine disrupting chemicals (EDCs) in the etiology of obesity, T2D and NAFLD while finally integrating the information on EDCs on multiple metabolic disorders that could lead to metabolic syndrome. We will specifically examine evidence linking EDC exposures during critical periods of development with metabolic diseases that manifest later in life and across generations.

  2. A Case of Treatment Resistant Depression and Alcohol Abuse in a Person with Mental Retardation: Response to Aripiprazole and Fluvoxamine Therapy upon Consideration of a Bipolar Diathesis after Repetitive Failure to Respond to Multiple Antidepressant Trials.

    Science.gov (United States)

    Fornaro, Michele; Ciampa, Giovanni; Mosti, Nicola; Del Carlo, Alessandra; Ceraudo, Giuseppe; Colicchio, Salvatore

    2010-01-01

    Mental Retardation (MR) is a developmental disability characterized by impairments in adaptive daily life skills and difficulties in social and interpersonal functioning. Since multiple causes may contribute to MR, associated clinical pictures may vary accordingly. Nevertheless, when psychiatric disorders as Treatment Resistant Depression (TRD) and/or alcohol abuse co-exist, their proper detection and management is often troublesome, essentially due to a limited vocabulary MR people could use to describe their symptoms, feelings and concerns, and the lack of reliable screening tools. Furthermore, MR people are among the most medicated subjects, with (over) prescription of antidepressants and/or typical antipsychotics being the rule rather than exception. Thus, treatment resistance or even worsening of depression, constitute frequent occurrences. This report describes the case of a person with MR who failed to respond to repetitive trials of antidepressant monotherapies, finally recovering using aripiprazole to fluvoxamine augmentation upon consideration of a putative bipolar diathesis for "agitated" TRD. Although further controlled investigations are needed to assess a putative bipolar diathesis in some cases of MR associated to TRD, prudence is advised in the long-term prescription of antidepressant monotherapies in such conditions.

  3. Effects of long-term use of aripiprazole and clozapine on myo-cardial enzymes of patients with schizophrenia%长期服用阿立哌唑与氯氮平对精神分裂症患者血清心肌酶的影响

    Institute of Scientific and Technical Information of China (English)

    王冬梅; 李素芝; 王新红

    2016-01-01

    Objective To explore the effects of long‐term use of aripiprazole and clozapine on myocardial enzymes of patients with schizophrenia .Methods Serum myocardial enzymes lev‐els were detected and analyzed in 84 schizophrenics on aripiprazole and 85 ones on clozapine > 3 years ,in‐dexes consisted of creatine kinase (CK) ,creatine kinase isoenzyme MB (CK‐MB) ,lactate dehydrogenase ( LDH) and aspertate aminotransferase (AST ) .Results The CK ,CK‐MB and LDH levels of both groups were all higher than normal value ,but those significantly higher in clizapine than in aripiprazole group (P<0 .05 or 0 .01);AST levels of both groups had no significant difference from normal value . Conclusion Long‐term use of aripiprazole or clozapine could induce the increases of serum myocardial en‐zymes levels in schizophrenics in different degrees ,especially clozapine ,as should be paid attention to .%目的:探讨长期服用阿立哌唑与氯氮平对精神分裂症患者血清心肌酶水平的影响。方法对84例服用阿立哌唑及85例服用氯氮平治疗时间>3 a的精神分裂症患者进行血清心肌酶水平检测分析,指标包括肌酸激酶、肌酸激酶同工酶MB亚型、乳酸脱氢酶和天门冬氨酸氨基转移酶。结果两组肌酸激酶、肌酸激酶同工酶MB亚型、乳酸脱氢酶水平均高于正常值,但氯氮平组显著高于阿立哌唑组( P<0.05或0.01);两组天门冬氨酸氨基转移酶水平与正常值比较均无明显变化。结论精神分裂症患者长期服用阿立哌唑与氯氮平治疗均可导致血清心肌酶水平不同程度的升高,氯氮平升高更为显著,应引起临床医师的关注。

  4. Relationship between serum concentration and clinical efficacy of aripiprazole in the treatment of patients with schizophrenia%阿立派唑治疗精神分裂症的血药浓度与临床效应关系研究

    Institute of Scientific and Technical Information of China (English)

    李建华; 钟华; 沈卫民; 孙菊水; 陈海支; 范振国; 卢桂华

    2011-01-01

    目的:研究阿立哌唑治疗精神分裂症的血药浓度与临床效应之间关系,探索阿立哌唑血药浓度的治疗窗.方法:采用前瞻性研究方法,应用非固定剂量药物治疗8周.以高效液相色谱仪测定阿立哌唑的谷浓度,阳性和阴性症状量表(PANSS),临床总体印象-病情严重程度量表(CGI-SI)评定疗效,治疗时出现的症状量表(TESS)评定不良反应.采用受试者运筹特征曲线(ROC曲线)获得血药浓度的最佳截断值,结合四分位间距法推测阿立哌唑血药浓度的治疗窗.并分析血药浓度与药物剂量、临床疗效、不良反应等之间的相关性.结果:入组80例患者,治疗有效47例、无效29例,另外4例脱落.总的不良反应发生率为32.5%.阿立哌唑血药浓度与药物剂量、PANSS减分率及TESS分值间呈正相关,与CGI-SI分值呈负相关.药物剂量与疗效无相关性.最低有效血药浓度为363 μg/L,发生不良反应的血药浓度阈值为540 μg/L.有效组血药浓度的四分位间距为348~623 μg/L.血药浓度在350~540 μg/L的范围内疗效较好,副反应较轻.结论:阿立哌唑治疗精神分裂症的血药浓度与临床效应之间存在相关性,较适宜的治疗窗是350~540 μg/L.%AIM: To explore the relationship between serum concentration and clinical efficacy of aripiprazole in the treatment of patients with schizophrenia, and the suitable therapeutic window of aripiprazole. METHODS: Prospective study method was adopted. The dosages of aripiprazole were unfixed for eight weeks. The trough serum concentrations were determined by high performance liquid chromatography (HPLC). The clinical efficacy was evaluated with the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression-Severity of Illnes (CGI-SI), side effects were done with the Treatment Emergent Symptom Scale (TESS). The optimized cutoff value of serum concentration was procured by the receiver operator curve (ROC), and the

  5. Mangiferin modulation of metabolism and metabolic syndrome.

    Science.gov (United States)

    Fomenko, Ekaterina Vladimirovna; Chi, Yuling

    2016-09-10

    The recent emergence of a worldwide epidemic of metabolic disorders, such as obesity and diabetes, demands effective strategy to develop nutraceuticals or pharmaceuticals to halt this trend. Natural products have long been and continue to be an attractive source of nutritional and pharmacological therapeutics. One such natural product is mangiferin (MGF), the predominant constituent of extracts of the mango plant Mangifera indica L. Reports on biological and pharmacological effects of MGF increased exponentially in recent years. MGF has documented antioxidant and anti-inflammatory effects. Recent studies indicate that it modulates multiple biological processes involved in metabolism of carbohydrates and lipids. MGF has been shown to improve metabolic abnormalities and disorders in animal models and humans. This review focuses on the recently reported biological and pharmacological effects of MGF on metabolism and metabolic disorders. © 2016 BioFactors, 42(5):492-503, 2016.

  6. Lipid Metabolism Disorders

    Science.gov (United States)

    ... metabolic disorder, something goes wrong with this process. Lipid metabolism disorders, such as Gaucher disease and Tay-Sachs disease, involve lipids. Lipids are fats or fat-like substances. They ...

  7. Disorders of Carbohydrate Metabolism

    Science.gov (United States)

    ... Fundamentals Heart and Blood Vessel Disorders Hormonal and Metabolic Disorders Immune Disorders Infections Injuries and Poisoning Kidney and ... Fundamentals Heart and Blood Vessel Disorders Hormonal and Metabolic Disorders Immune Disorders Infections Injuries and Poisoning Kidney and ...

  8. Cold-induced metabolism

    NARCIS (Netherlands)

    van Marken Lichtenbelt, W.D.; Daanen, A.M.

    2003-01-01

    Cold-induced metabolism. van Marken Lichtenbelt WD, Daanen HA. Department of Human Biology, Maastricht University, Maastricht, The Netherlands. PURPOSE OF REVIEW: Cold response can be insulative (drop in peripheral temperature) or metabolic (increase in energy expenditure). Nonshivering thermogenesi

  9. Inborn errors of metabolism

    Science.gov (United States)

    ... metabolism. A few of them are: Fructose intolerance Galactosemia Maple sugar urine disease (MSUD) Phenylketonuria (PKU) Newborn ... disorder. Alternative Names Metabolism - inborn errors of Images Galactosemia References Bodamer OA. Approach to inborn errors of ...

  10. Mineral metabolism in cats

    OpenAIRE

    Pineda Martos, Carmen María

    2014-01-01

    The present Doctoral Thesis wa metabolism in the feline species. Through a series of studies, the relationship between calcium metabolism and the main hormones involved in it has been determined metabolism during the juvenile stage of growing cats effects linked to feeding calculolytic diets on feline mineral metabolism. The first part of the work was aimed the quantification of intact (I-PTH) and whole PTH) and to characterize the dynamics of PTH secretion, including ...

  11. Metabolic Engineering X Conference

    Energy Technology Data Exchange (ETDEWEB)

    Flach, Evan [American Institute of Chemical Engineers

    2015-05-07

    The International Metabolic Engineering Society (IMES) and the Society for Biological Engineering (SBE), both technological communities of the American Institute of Chemical Engineers (AIChE), hosted the Metabolic Engineering X Conference (ME-X) on June 15-19, 2014 at the Westin Bayshore in Vancouver, British Columbia. It attracted 395 metabolic engineers from academia, industry and government from around the globe.

  12. 氨磺必利与阿立哌唑治疗首发精神分裂症对照研究%A controlled study of amisulpride vs aripiprazole in the first-episode schizophrenia

    Institute of Scientific and Technical Information of China (English)

    陆强

    2015-01-01

    Objective To explore the efficacy and safety of amisulpride and aripi‐prazole in the treatment of first‐episode schizophrenia .Methods Using randomized ,double‐blind ,double‐dummy parallel controlled method 124 first‐episode schizophrenics were assigned to two groups taking o‐rally amisulpride and aripiprazole respectively for 8 weeks .Efficacies were assessed with the Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression (CGI) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results After treatment the PANSS and CGI scores of both groups lowered more significantly compared with pretreatment (P 0 .05) .Ad‐verse reactions were mild ,there were no group significant difference in incidence of adverse reaction (P>0 .05) .Conclusion Both amisulpride and aripiprazole have an equivalent evident effect in first‐episode schizophrenia ,take effect rapidly ,and have higher safety and better compliance .%目的:探讨氨磺必利与阿立哌唑治疗首发精神分裂症的疗效及安全性。方法将124例首发精神分裂症患者按随机数字表分为两组,采用双盲、双模拟平行对照的方法分别口服氨磺必利和阿立哌唑治疗,观察8周。采用阳性与阴性症状量表、临床疗效总评量表评定临床疗效,副反应量表评定不良反应。结果治疗后两组阳性与阴性症状量表和临床疗效总评量表评分均较治疗前显著性下降( P<0.05或0.01);治疗8周末氨磺必利组显效率63.3%、总有效率88.3%,阿立哌唑组分别为64.4%、91.5%,两组比较差异无显著性(χ2=0.01、0.33,P>0.05)。不良反应均较轻微,发生率比较差异无显著性(P>0.05)。结论氨磺必利与阿立哌唑治疗首发精神分裂症疗效显著,总体疗效相当,起效快,安全性高,依从性好。

  13. 阿立哌唑联合利培酮治疗慢性精神分裂症对照研究%A controlled study on aripiprazole combined with risperidone in the treatment of chronic schizophrenia

    Institute of Scientific and Technical Information of China (English)

    杨永秀; 陈斌华; 徐小杰; 陶云海; 施剑飞

    2013-01-01

    目的 评价阿立哌唑联合利培酮治疗慢性精神分裂症的疗效和安全性.方法 212例慢性精神分裂症患者随机分为阿立哌唑联合利培酮组(治疗组,105例)和利培酮组(对照组,107例).分别于治疗前及治疗后第2,4,8周末用阳性症状和阴性症状量表(PANSS)评价疗效,副反应量表(TESS)评价药物不良反应.结果 治疗组完成105例,对照组完成104例.治疗组有效率为92.38%,显著率为77.14%;对照组有效率为85.58%,显著率为66.35%,2组疗效差异无统计学意义(P>0.05).PANSS总分减分及PANSS阴性因子减分在第2,4,8周末治疗组均优于对照组(P <0.05或P<0.01).2组药物不良反应均较轻微,经对症处理大多能缓解,其中在震颤、静坐不能、体重增加及泌乳、月经紊乱等发生率,治疗组明显低于对照组(P<0.05).结论 利培酮联合阿立哌唑治疗慢性精神分裂症疗效良好,不良反应小,患者治疗依从性好.%Objective To evaluate the effectiveness and safety of aripiprazole combined risperidone in the treatment of chronic schizophrenia.Methods A total of 212 patients diagnosed as chronic schizophrenia were randomly divided into aripiprazole combined risperidone group (treatment group,n =105) and risperidone group (control group,n =107).Clinical effectiveness was assessed with the positive and negative syndrome scale(PANSS)and adverse reactions with the treatment emergent symptom scale (TESS) before treatment and at the end of the 2,4,8 week.Results One hundred and five patients of the treatment group and 104 patients of the control group had completed the course.The effective rate and the apparent effect rate in treatment group was 92.38% and 77.14%,whereas that was 85.58% and 66.35% in control group.There was no significant difference between two groups (P > 0.05).Effectiveness of treatment group was superior to control group at the end of the 2,4,8 week by PANSS total scores'subtraction and

  14. Engineering Cellular Metabolism

    DEFF Research Database (Denmark)

    Nielsen, Jens; Keasling, Jay

    2016-01-01

    Metabolic engineering is the science of rewiring the metabolism of cells to enhance production of native metabolites or to endow cells with the ability to produce new products. The potential applications of such efforts are wide ranging, including the generation of fuels, chemicals, foods, feeds...... of metabolic engineering and will discuss how new technologies can enable metabolic engineering to be scaled up to the industrial level, either by cutting off the lines of control for endogenous metabolism or by infiltrating the system with disruptive, heterologous pathways that overcome cellular regulation....

  15. Sustained metabolic scope.

    Science.gov (United States)

    Peterson, C C; Nagy, K A; Diamond, J

    1990-03-01

    Sustained metabolic rates (SusMR) are time-averaged metabolic rates that are measured in free-ranging animals maintaining constant body mass over periods long enough that metabolism is fueled by food intake rather than by transient depletion of energy reserves. Many authors have suggested that SusMR of various wild animal species are only a few times resting (basal or standard) metabolic rates (RMR). We test this conclusion by analyzing all 37 species (humans, 31 other endothermic vertebrates, and 5 ectothermic vertebrates) for which SusMR and RMR had both been measured. For all species, the ratio of SusMR to RMR, which we term sustained metabolic scope, is less than 7; most values fall between 1.5 and 5. Some of these values, such as those for Tour de France cyclists and breeding birds, are surely close to sustainable metabolic ceilings for the species studied. That is, metabolic rates higher than 7 times RMR apparently cannot be sustained indefinitely. These observations pose several questions: whether the proximate physiological causes of metabolic ceilings reside in the digestive tract's ability to process food or in each tissue's metabolic capacity; whether ceiling values are independent of the mode of energy expenditure; whether ceilings are set by single limiting physiological capacities or by coadjusted clusters of capacities (symmorphosis); what the ultimate evolutionary causes of metabolic ceilings are; and how metabolic ceilings may limit animals' reproductive effort, foraging behavior, and geographic distribution.

  16. 阿立哌唑与利培酮治疗女性精神分裂症的临床疗效分析%Effective analysis of aripiprazole and risperidone for patients with first-episode female Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    张加明

    2014-01-01

    目的:对阿立哌唑与利培酮对女性首发精神分裂症的临床疗效以及对患者认知功能的影响进行观察和分析。方法:将我院2010年4月~2013年11月收治的128例女性首发精神分裂患者随机分为阿立哌唑组和利培酮组,每组各64例。2组患者分别于治疗前后采用阳性与阴性症状量表(PANSS)、临床总体印象量表(CGI)以及副反应量表(TESS)对患者的临床疗效和副反应进行评定和比较。结果:2组患者治疗后其阳性症状、阴性症状、一般病理、PANSS总分以及CGI总分均较治疗前显著降低(P<0.01),但组间比较并无明显差异(P>0.05)。治疗后阿立哌唑组和利培酮组的临床显效率和有效率分别为73.44%、96.88%和70.31%、90.62%,差异均不具有统计学意义( P>0.05),而TESS评定结果显示,阿立哌唑组患者评分8.31±4.20分明显低于利培酮组患者评分9.29±4.16分。结论:阿立哌唑和利培酮治疗女性首发精神分裂症上均可有效改善患者的阳性症状、阴性症状、一般病理而起到良好的临床疗效,但相比而言阿立哌唑在治疗过程中副反应更小,因而更加安全有效。%Objective:To explore the efficacy of aripiprazole and risperidone in the treatment of first -episode female schizophrenia . Methods:To select 128 cases of patients with first-episode female schizophrenia who were treated in our hospital from April 2010 to No-vember 2013,and were randomly divided into the saripiprazole group and the risperidone group ,each group was 64 cases.Two groups of patients were take the positive and negative symptoms scale ( PANSS) , the clinical general impression scale (CGI) and the treatment e-mergent symptom scale ( TESS) respectively before and after treatment to evaluated the clinical efficacy and the adverse event .Results:The positive symptoms , negative symptoms , general pathology , PANSS

  17. 阿立哌唑与舒必利治疗以阴性症状为主精神分裂症临床对照观察%Aripiprazole vs Sulpiride in Treatment of Schizophrenia with Negative Symptoms

    Institute of Scientific and Technical Information of China (English)

    董雪刚; 郭丽春; 刘祖松; 曾德志

    2015-01-01

    Objective:To explore the efficacy and safety of aripiprazole in treatment of schizophrenia with negative symptoms .Methods:All 80 patients with negative schizophrenia were randomly assigned to study group and control group ,each 40 cases.The patients were treated with aripiprazole or sulpiride re-spectively for 12 weeks.The Positive and Negative Syndrome Scale ( PANSS) and Treatment Emergent Side effect Scale ( TESS ) were used to evaluate the efficacy and adverse effect respectively .Results:①The scores of PANSS were significantly lower after treatment than those before treatment in the both group .②Contrast comparing:in the 4th,8th,12th weekend after treatment ,the scores of PANSS with negative and general mental pathological symptoms factors in the study group were significantly lower than those in the control group(t=-2.014,-4.359,-6.162,-2.180,-3.042,-6.810;P<0.05).So as the total score of PANSS in the 8th,12th weekend after treatment(t=-3.235,-6.080;P<0.01).But the scores of PANSS with positive factor in the study group were significantly higher than those in the control group in the 8th, 12th weekend after treatment(t=4.630,6.142;P<0.01).③The clinical efficacy in the study group in the 12 th weekend after treatment was significantly better than that in the control group .④The incidence of adverse effect in the study group was significantly lower than that in the control group .Conclusion:Aripiprazole is rather effective and safe in treatment of schizophrenia with negative symptoms .It is much better than sulpiride .%目的:探讨阿立哌唑治疗以阴性症状为主精神分裂症的疗效与安全性。方法:将80例以阴性症状为主精神分裂症患者随机分入研究组和对照组,每组40例,分别使用阿立哌唑和舒必利治疗12周,用阳性与阴性综合征量表( PANSS)和副反应量表( TESS)评定临床疗效和安全性。结果:①两组治疗后PANSS评分均较治疗前下降(P<0.01或0.05

  18. A control study of influence of amisulpride,clozapine and aripiprazole on electrocardiogram and serum levels of myocardial enzymogram in patients with schizophrenia%氨磺必利与氯氮平、阿立哌唑对精神分裂症患者心肌酶和心电图影响的对比研究

    Institute of Scientific and Technical Information of China (English)

    常学润; 张敬悬; 何云鹏

    2015-01-01

    Objective To study the influence of amisulpride,clozapine and aripiprazole on electrocardiogram and serum levels of myocardial enzymogram in patients with schizophrenia.Methods 180 schizophrenic patients were randomly divided into amisulpride group (n =60),clozapine group (n =60)and aripiprazole group (n =60)treated with amisulpride,clozapine and aripiprazole respectively.The electrocardiogram and serum levels of myocardial enzymogram including AST,CK,CK-MB, LDH,α-HBDH were measured at baseline and at the end of the 2nd ,4th ,8th and 12th week of the treatment.Results (1)At the end of the 8th week,serum level of AST in aripiprazole group,as well as serum levels of CK-MB and LDH in amisulpride group were significantly higher than those at baseline (P <0.05 ).Serum levels of CK and α-HBDH in 3 groups were significantly higher at the 4th,8th and 12th week of the treatment than those at baseline (P <0.05).(2)There was significant difference in incidence of abnormal T wave among 3 groups at the 12th week (P <0.05).The incidence of abnormal T wave in clozapine group was significantly higher than that in amisulpride group and aripiprazole group (P <0.05).(3)The incidence rate of abnormal electrocardiogram showed significant difference among 3 groups at the 12th week (P <0.01 ),and was significantly higher in clozapine group than that in amisulpride group and aripiprazole group (P <0.05).Inner-group comparison showed that incidence rates of abnormal electrocardiogram in amisulpride group and aripiprazole group were significantly lower at the end of the 12th week than that at the end of the 2nd week respectively (P <0.05).Conclusion Amisulpride,clozapine and aripiprazole can cause a certain adverse effects on electrocardiogram and myocardial enzymogram in patients with schizophrenia. The influence on electrocardiogram is relatively more obvious in clozapine treated patients and is likely to be more serious with the progress of treatment.%目的:比较氨磺必利与氯

  19. 阿立哌唑与利培酮治疗痴呆精神行为症状的疗效及安全性比较%Comparison of Efifcacy and Safety of Aripiprazole and Risperidone Treating Behavioral and Psychological Symptoms of Dementia

    Institute of Scientific and Technical Information of China (English)

    李洪涛

    2015-01-01

    目的:通过临床试验对阿立哌唑和利培酮对于痴呆精神行为的疗效和安全性进行观察和探讨。方法将本科室近来收治的有痴呆精神行为症状的患者72人进行随机分组,每组36人,并分别用阿立哌唑(A组)和利培酮来(B组)对患者进行为期8 w的治疗,在治疗之前以及治疗的第2、4以及第8周的最后一天对72名患者采用BEHAV-AD对患者的病理行为进行评定,以此来对两种药物的有效性进行对比;同时采用TESS(不良反应检测表)来对药物的安全性进行分析和比较。结果通过阿立哌唑和利培酮进行治疗的两组患者在治疗后BEHAV-AD评分较治疗之前有了明显的降低,A、B两组患者的治疗之前与治疗之后的BEHAV-AD评分相比较具有较为明显的统计学差异(P<0.05)。另外服用阿立哌唑的A组患者的不良反应发生率明显比服用利培酮的B组患者的不良反应发生率低,通过对差异进行分析发现,此差异同样具有统计学意义(P<0.01)。结论阿立哌唑和利培酮对于痴呆精神行为都具有较为明显的疗效,但是利培酮的安全性相比阿立哌唑较差。%Objective Observe and investigate the efficacy and safety of aripiprazole and risperidone for spirit behavior of dementia. Methods 72 patients with behavioral and psychological symptoms of dementia were randomly assigned into two groups, 36 people in each group , they were treated with aripiprazole (A group) and risperidone to (group B) respectively for a period of 8 w, assessed the behavior of the patients by BEHAV-AD at the points of prior to treatment, treatment of 2, 4 and 8 weeks , and the last day, compared the effectiveness of the two drugs, at the same time using the TESS (adverse reaction detection table) to assess the safety of the drugs. Results After the treatment of aripiprazole and risperidone, BEHAV-AD score signiifcantly reduced in two groups, there were

  20. 氨磺必利与阿立哌唑口崩片治疗以阴性症状为主的精神分裂症的临床对照研究%A controlled clinical study of amisulpride and aripiprazole orally disintegrating tablets in treatment of negative schizophrenia

    Institute of Scientific and Technical Information of China (English)

    刘晓

    2014-01-01

    目的:比较氨磺必利和阿立哌唑口崩片治疗以阴性症状为主的精神分裂症的临床疗效和安全性。方法采用随机对照研究,将64例符合《中国精神障碍分类与诊断标准(第3版)》(CCMD-3)诊断标准的以阴性症状为主的精神分裂症患者按照入组先后顺序分为氨磺必利组(研究组)和阿立哌唑口崩片组(对照组)各32例,疗程8周,采用阳性和阴性症状量表( PANSS)评定疗效,采用副反应量表( TESS)评定不良反应。结果治疗8周后,两组PANSS评分均下降(P>0.05),氨磺必利组和阿立哌唑口崩片组有效率分别为90.63%,87.5%,差异无统计学意义(P>0.05)。两组TESS评分分别为(3.98±1.03)分、(4.07±1.89)分,差异无统计学意义(P>0.05)。结论氨磺必利与阿立哌唑口崩片治疗以阴性症状为主的精神分裂症疗效相当,不良反应轻。%Objective To compare the efficacy and safety between amisulpride and aripiprazole in treatment of negative schizo-phrenia. Methods Using randomized controlled trials in this study, 64 patients diagnosed with negative schizophrenia were randomly divided into amisulpride group (study group) and aripiprazole orally disintegrating tablets group (control group). The positive and negative scale ( PANSS) was used to evaluate the efficacy, and treatment emergent side effect scale ( TESS) was used to evaluate the advese reactions. The course of treatment was eight weeks. Results PANSS(P>0. 05) scores of the two groups were both significant-ly decreased after 8 weeks, the efficacy rates of amisulpride group and aripiprazole orally disintegrating tablets group were 90. 63% and 87. 5%, which two groups showed no significant difference fromχ2 test (P>0. 05). The TESS scores of amisulpride group and aripi-prazole group were(3. 98 ± 1. 03)and(4. 07 ± 1. 89), The TESS scores of two groups also showed no significant difference by t-test (P>0. 05). Conclusion Amisulpride are as effective as Aripiprazole orally

  1. 首发精神分裂症患者使用阿立哌唑后血清IL-2、IL-4水平变化的探讨%Explore the level changes of IL-2,IL-4 in the first-episode schizophrenia after the treatment of arip-iprazole

    Institute of Scientific and Technical Information of China (English)

    刘倩倩; 李亚飞; 朱祥路; 蒋天玉

    2014-01-01

    Objective To explore the differences of serum IL-2 ,IL-4 in the first-episode schizo-phrenia and healthy controls were explored ,and to compare the changes of symptoms before and after aripiprazole treatment and the changes of serum IL-2 ,IL-4 .Methods Serum of IL-2 ,IL-4 was exam-ined with Flow Cytometry in 35 healthy volunteers and 35 first episode patients .The symptoms of pa-tients were evaluated with Positive and Negative Syndrome Scale .Results There were no statistical sig-nificantly differents in the serum of IL-2 ,IL-4 in the first-episode schizophrenia than normal .controls (P>0 .05) .The serum levels of IL-4 was lower in patients with first-episode schizophrenia after aripi-prazole treatment (P<0 .01) .IL-2 and IL-4 levels were increased in positive symptoms of schizophre-nia patients before aripiprazole treatment (positive symptoms) than normal controls (P<0 .05) .IL-2 and IL-4 levels were different in positive symptoms of schizophrenia patients before and after aripi-prazole treatment (P<0 .05) .Conclusion The patients with schizophrenia have immune dysfunction ;Aripiprazole of antipsychotics have lowered the level of IL-2 ,IL-4 and positive symptoms also im-proved .Conclusion.%目的:探讨首发精神分裂症患者血清细胞因子IL-2、IL-4与正常人的差异,比较分析首发精神分裂症患者经过阿立哌唑治疗前后症状改变及细胞因子IL-2、IL-4的变化。方法选择35例首发精神分裂症患者作为研究组,35例健康志愿者作为对照组,通过流式细胞学技术测定血清标本中IL-2、IL-4的水平,用PANSS量表评定精神症状。结果(1)首发精神分裂症患者IL-2、IL-4水平与正常对照组相比,差异无统计学意义(P>0.05)。(2)首发精神分裂症患者阿立哌唑治疗后较治疗前IL-4水平降低,差异有统计学意义(P<0.01)。(3)首发精神分裂症阳性症状患者血清IL-2、IL-4水平在治疗前均高于对照组(P<0.05

  2. Metabolic enzymes link morphine withdrawal with metabolic disorder

    Institute of Scientific and Technical Information of China (English)

    Xi Jiang; Jing Li; Lan Ma

    2007-01-01

    @@ Energy metabolism is a fundamental biological process that is vital for the survival of all species. Disorders in the metabolic system result in deficiency or redundancy of certain nutrients, including carbohydrates, lipids, amino acids, etc. Abnormality of the energy metabolism system leads to a number of metabolic diseases, such as the metabolic syndrome. Broadly speaking, the term "metabolic diseases" now tends to be widened to the category that refers to all diseases with metabolism disorder.

  3. Metabolic syndrome and migraine

    Directory of Open Access Journals (Sweden)

    Amit eSachdev

    2012-11-01

    Full Text Available Migraine and metabolic syndrome are highly prevaleirnt and costly conditions.The two conditions coexist, but it is unclear what relationship may exist between the two processes. Metabolic syndrome involves a number of findings, including insulin resistance, systemic hypertension, obesity, a proinflammatory state, and a prothrombotic state. Only one study addresses migraine in metabolic syndrome, finding significant differences in the presentation of metabolic syndrome in migraineurs. However, controversy exists regarding the contribution of each individual risk factor to migraine pathogensis and prevalence. It is unclear what treatment implications, if any, exist as a result of the concomitant diagnosis of migraine and metabolic syndrome. The cornerstone of migraine and metabolic syndrome treatments is prevention, relying heavily on diet modification, sleep hygiene, medication use, and exercise.

  4. Engineering Cellular Metabolism.

    Science.gov (United States)

    Nielsen, Jens; Keasling, Jay D

    2016-03-10

    Metabolic engineering is the science of rewiring the metabolism of cells to enhance production of native metabolites or to endow cells with the ability to produce new products. The potential applications of such efforts are wide ranging, including the generation of fuels, chemicals, foods, feeds, and pharmaceuticals. However, making cells into efficient factories is challenging because cells have evolved robust metabolic networks with hard-wired, tightly regulated lines of communication between molecular pathways that resist efforts to divert resources. Here, we will review the current status and challenges of metabolic engineering and will discuss how new technologies can enable metabolic engineering to be scaled up to the industrial level, either by cutting off the lines of control for endogenous metabolism or by infiltrating the system with disruptive, heterologous pathways that overcome cellular regulation.

  5. Genetic and metabolic engineering

    OpenAIRE

    Yang,Yea-Tyng; Bennett, George N.; San, Ka-yiu

    1998-01-01

    Recent advances in molecular biology techniques, analytical methods and mathematical tools have led to a growing interest in using metabolic engineering to redirect metabolic fluxes for industrial and medical purposes. Metabolic engineering is referred to as the directed improvement of cellular properties through the modification of specific biochemical reactions or the introduction of new ones, with the use of recombinant DNA technology (Stephanopoulos, 1999). This multidisciplinary field dr...

  6. Metabolic disorders in menopause

    OpenAIRE

    Grzegorz Stachowiak; Tomasz Pertyński; Magdalena Pertyńska-Marczewska

    2015-01-01

    Metabolic disorders occurring in menopause, including dyslipidemia, disorders of carbohydrate metabolism (impaired glucose tolerance – IGT, type 2 diabetes mellitus – T2DM) or components of metabolic syndrome, constitute risk factors for cardiovascular disease in women. A key role could be played here by hyperinsulinemia, insulin resistance and visceral obesity, all contributing to dyslipidemia, oxidative stress, inflammation, alter coagulation and atherosclerosis observed during the menopaus...

  7. METABOLISM OF IRON STORES

    OpenAIRE

    Saito, Hiroshi

    2014-01-01

    ABSTRACT Remarkable progress was recently achieved in the studies on molecular regulators of iron metabolism. Among the main regulators, storage iron, iron absorption, erythropoiesis and hepcidin interact in keeping iron homeostasis. Diseases with gene-mutations resulting in iron overload, iron deficiency, and local iron deposition have been introduced in relation to the regulators of storage iron metabolism. On the other hand, the research on storage iron metabolism has not advanced since th...

  8. What is Nutrition & Metabolism?

    Science.gov (United States)

    Feinman, Richard D; Hussain, M Mahmood

    2004-08-17

    A new Open Access journal, Nutrition & Metabolism (N&M) will publish articles that integrate nutrition with biochemistry and molecular biology. The open access process is chosen to provide rapid and accessible dissemination of new results and perspectives in a field that is of great current interest. Manuscripts in all areas of nutritional biochemistry will be considered but three areas of particular interest are lipoprotein metabolism, amino acids as metabolic signals, and the effect of macronutrient composition of diet on health. The need for the journal is identified in the epidemic of obesity, diabetes, dyslipidemias and related diseases, and a sudden increase in popular diets, as well as renewed interest in intermediary metabolism.

  9. Mathematical modelling of metabolism

    DEFF Research Database (Denmark)

    Gombert, Andreas Karoly; Nielsen, Jens

    2000-01-01

    Mathematical models of the cellular metabolism have a special interest within biotechnology. Many different kinds of commercially important products are derived from the cell factory, and metabolic engineering can be applied to improve existing production processes, as well as to make new processes...... availability of genomic information and powerful analytical techniques, mathematical models also serve as a tool for understanding the cellular metabolism and physiology....... available. Both stoichiometric and kinetic models have been used to investigate the metabolism, which has resulted in defining the optimal fermentation conditions, as well as in directing the genetic changes to be introduced in order to obtain a good producer strain or cell line. With the increasing...

  10. Fluoroacetylcarnitine: metabolism and metabolic effects in mitochondria

    Energy Technology Data Exchange (ETDEWEB)

    Bremer, J.; Davis, E.J.

    1973-01-01

    The metabolism and metabolic effects of fluoroacetylcarnitine have been investigated. Carnitineacetyltransferase transfers the fluoro-acetyl group of fluoroacetylcarnitine nearly as rapidly to CoA as the acetyl group of acetylcarnitine. Fluorocitrate is then formed by citrate synthase, but this second reaction is relatively slow. The fluorocitrate formed intramitochondrially inhibits the metabolism of citrate. In heart and skeletal muscle mitochondria the accumulated citrate inhibits citrate synthesis and the ..beta..-oxidation of fatty acids. Free acetate is formed, presumably because accumulated acetyl-CoA is hydrolyzed. In liver mitochondria the accumulation of citrate leads to a relatively increased rate of ketogenesis. Increased ketogenesis is obtained also upon the addition of citrate to the reaction mixture.

  11. Attractor metabolic networks.

    Directory of Open Access Journals (Sweden)

    Ildefonso M De la Fuente

    Full Text Available BACKGROUND: The experimental observations and numerical studies with dissipative metabolic networks have shown that cellular enzymatic activity self-organizes spontaneously leading to the emergence of a Systemic Metabolic Structure in the cell, characterized by a set of different enzymatic reactions always locked into active states (metabolic core while the rest of the catalytic processes are only intermittently active. This global metabolic structure was verified for Escherichia coli, Helicobacter pylori and Saccharomyces cerevisiae, and it seems to be a common key feature to all cellular organisms. In concordance with these observations, the cell can be considered a complex metabolic network which mainly integrates a large ensemble of self-organized multienzymatic complexes interconnected by substrate fluxes and regulatory signals, where multiple autonomous oscillatory and quasi-stationary catalytic patterns simultaneously emerge. The network adjusts the internal metabolic activities to the external change by means of flux plasticity and structural plasticity. METHODOLOGY/PRINCIPAL FINDINGS: In order to research the systemic mechanisms involved in the regulation of the cellular enzymatic activity we have studied different catalytic activities of a dissipative metabolic network under different external stimuli. The emergent biochemical data have been analysed using statistical mechanic tools, studying some macroscopic properties such as the global information and the energy of the system. We have also obtained an equivalent Hopfield network using a Boltzmann machine. Our main result shows that the dissipative metabolic network can behave as an attractor metabolic network. CONCLUSIONS/SIGNIFICANCE: We have found that the systemic enzymatic activities are governed by attractors with capacity to store functional metabolic patterns which can be correctly recovered from specific input stimuli. The network attractors regulate the catalytic patterns

  12. 阿立哌唑与利培酮治疗痴呆精神行为症状的疗效及安全性比较%Comparison of efficacy and safety of aripiprazole and risperidone treating behavioral and psychological symptoms of dementia

    Institute of Scientific and Technical Information of China (English)

    罗克勇; 刘克祥; 王瑞超; 付华斌

    2013-01-01

    目的 观察阿立哌唑和利培酮治疗老年痴呆精神行为症状的疗效及安全性.方法 采用随机对照研究,将具有精神行为症状的痴呆患者68例完全随机分为阿立哌唑组及利培酮组,各34例.阿立哌唑组患者服用阿立哌唑,起始剂量2.5 mg/d,最大剂量不超过15 mg/d;利培酮组患者口服利培酮,起始剂量0.5 mg/d,最大剂量不超过3 mg/d.疗程均为8周.治疗前和治疗第2、4、8周末采用痴呆病理分析评定量表(BEHAVE-AD)评定疗效,用副反应量表(TESS)评定不良反应,并于入组时和治疗第8周末分别检测2组患者空腹血糖、餐后2h血糖、TC、TG、LDL-C、HDL-C及体重.结果 阿立哌唑组和利培酮组患者治疗2、4、8周后BEHAVE-AD评分均明显低于治疗前[阿立哌唑组:(14.8±4.2)、(10.2±3.6)、(6.8±2.8)分比(16.4±4.6)分;利培酮组:(15.2±3.9)、(11.8±3.8)、(7.2±3.0)分比(17.2±5.0)分,P <0.05或P<0.01].2组患者间治疗前及治疗后BEHAVE-AD评分比较,差异均无统计学意义(P>0.05).2组不良反应发生率均为8.8% (3/34),差异无统计学意义(P>0.05).利培酮组治疗8周末体重较治疗前增加明显[(71±6)kg比(66±6) kg,P<0.05],TG及LDL-C升高[分别为(1.62±0.46) mmol/L比(0.96±0.29) mmol/L,(3.82±0.86) mmol/L比(3.08±0.74) mmol/L],而阿立哌唑组则改变不明显(均P>0.05).结论 阿立哌唑治疗老年痴呆精神行为症状总体疗效、安全性与利培酮相当,但阿立哌唑对患者血糖、血脂及体重影响小于利培酮.%Objective To assess the effect and safety of aripiprazole and risperidone in the treatment of behavioral and psychological symptoms of dementia (BPSD).Methods All 68 dementia were randomly divided into aripiprazole group (n =34) and risperidone group (n =34) with a course of 8 weeks.Aripiprazole was administered by patients in aripiprazole group with a starting dose of 2.5 mg/d and less than the maximum dose 15 mg/d,risperidone was administered

  13. Circadian Systems and Metabolism

    NARCIS (Netherlands)

    Roenneberg, Till; Merrow, Martha

    1999-01-01

    Circadian systems direct many metabolic parameters and, at the same time, they appear to be exquisitely shielded from metabolic variations. Although the recent decade of circadian research has brought insights into how circadian periodicity may be generated at the molecular level, little is known ab

  14. Cold-induced metabolism

    NARCIS (Netherlands)

    Lichtenbelt, W. van Marken; Daanen, H.A.M.

    2003-01-01

    Purpose of review Cold response can be insulative (drop in peripheral temperature) or metabolic (increase in energy expenditure). Nonshivering thermogenesis by sympathetic, norepinephrine-induced mitochondrial heat production in brown adipose tissue is a well known component of this metabolic respon

  15. Disorders of fructose metabolism.

    Science.gov (United States)

    Froesch, E R

    1976-11-01

    There are fundamental differences between the metabolic fate of fructose and of glucose. Whereas the metabolism of glucose is controlled by hormones such as insulin, fructose uptake and phosphorylation in the liver occurs independently of hormones and its ultimate metabolic fate is unpredictable. Essential fructosuria, a harmless inherited anomaly of fructose metabolism, is the least harmful of the disorders of fructose metabolism. Hereditary fructose intolerance and fructose-1,6-diphosphatase deficiency are discussed in greater detail with regard to biochemical abnormalities and clinical aspects. HFI is most serious in bottle-fed infants who cannot reject their sucrose-containing diet. Patients with HFI will have no clinical symptoms if kept on a fructose-free diet. In contrast, patients with fructose-1,6-diphosphatase deficiency can tolerate frucose. However, severe infections precipitate attacks of hypoglycaemia and lactic acidosis.

  16. Metabolic Engineering VII Conference

    Energy Technology Data Exchange (ETDEWEB)

    Kevin Korpics

    2012-12-04

    The aims of this Metabolic Engineering conference are to provide a forum for academic and industrial researchers in the field; to bring together the different scientific disciplines that contribute to the design, analysis and optimization of metabolic pathways; and to explore the role of Metabolic Engineering in the areas of health and sustainability. Presentations, both written and oral, panel discussions, and workshops will focus on both applications and techniques used for pathway engineering. Various applications including bioenergy, industrial chemicals and materials, drug targets, health, agriculture, and nutrition will be discussed. Workshops focused on technology development for mathematical and experimental techniques important for metabolic engineering applications will be held for more in depth discussion. This 2008 meeting will celebrate our conference tradition of high quality and relevance to both industrial and academic participants, with topics ranging from the frontiers of fundamental science to the practical aspects of metabolic engineering.

  17. Primary Metabolic Pathways and Metabolic Flux Analysis

    DEFF Research Database (Denmark)

    2015-01-01

    his chapter introduces the metabolic flux analysis (MFA) or stoichiometry-based MFA, and describes the quantitative basis for MFA. It discusses the catabolic pathways in which free energy is produced to drive the cell-building anabolic pathways. An overview of these primary pathways provides...

  18. 阿立哌唑合并氯氮平对难治性精神分裂症疗效和认知功能影响的研究%A self-controlled study of aripiprazole combined with clozapine on efficacy and cognitive function in patients with treatment-resistant schizophrenia

    Institute of Scientific and Technical Information of China (English)

    司桂梅; 王爱波; 秦爱玲

    2012-01-01

    Objective To explore the effects of aripiprazole combined with clozapine on efficacy and cognitive function for patients with treatment-resistant schizophrenia. Methods A total of 45 treatment-resistant schizophrenic patients treated with clozapine were combined with aripiprazole (10-30mg/d) for 12 weeks,at the same time clozapine was lowered to maintenance does within 2 weeks. The efficacy and side effects were assessed with Positive and Negative Symptom Scale (PANSS) and Treatment Emergent Symptoms Scale (TESS) ,the cognitive function were measured with Wisconsion Card Sorting Test (WCST) and Continuous Performance Test (CPT) at baseline and at the 12th weekend of the treatment. Results At the end of the treatment, scores of PANSS and TESS decreased significantly, and each parameters of cognitive function was significantly improved when compared with those at baseline. Conclusion Aripiprazole combined with clozapine can effectively improve the negative symptoms and cognitive functions in patients with treatment-resistant schizophrenia with few side effects.%目的 探讨阿立哌唑合并氯氮平对难治性精神分裂症疗效及认知功能的影响.方法 对45例原服用氯氮平治疗的难治性精神分裂症患者合并阿立哌唑( 10~30) mg/d治疗12周,同时2周内将氯氮平减量至维持剂量后不再变化,并于合并治疗前及治疗后12周末用阳性与阴性症状量表( PA NSS)、副反应量表(TESS)评定疗效和副反应,以威斯康星卡片(WCST)和连续作业测验(CPT)评定患者的认知功能.结果 合并阿立哌唑治疗后12周末PANSS总分和TESS评分较合并前有明显差异(P<0.01,P<0.05),各项认知功能指标均有不同程度改善.结论 阿立哌唑合并氯氮平对难治性精神分裂症阴性症状及认知功能的改善明显,副反应减少.

  19. 阿立哌唑合并康复训练改善精神分裂症患者生活质量的临床研究%Clinical Study of Aripiprazole Combined with Rehabilitation Training to Improve the Quality of Life in Patients with Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    程闯; 张新风

    2013-01-01

    Objective:To explore the effect of aripiprazole combined with rehabilitation training in patients with schizophrenia quality of life of the spirit.Method:Met the Chinese classification and diagnostic criteria of mental disorders Third Edition(CCMD-3)criteria for the diagnosis of 90 patients with schizophrenia were randomly divided into two groups,aripiprazole and clozapine in the treatment of,a total of 8 weeks,two groups were psychiatric rehabilitation training. The positive and negative symptoms scale before and after treatment(PANSS)was introduced in June to assess the efficacy,the side effects scale(TESS)assessment of adverse reactions,the WHO quality of life scale(WHOQOL-100)assessment of quality of life.Result:Aripiprazole group and clozapine group markedly effective rate were 73.3%and 75.6%,with no significant difference between two groups(P>0.05);4,8 weeks after treatment,two groups of PANSS scale scores were decreased than that before treatment(P0.05);治疗后4、8周,两组PANSS量表各项因子分均较治疗前下降(P<0.05),但治疗后8周阿立哌唑组阴性症状及一般精神病理分较氯氮平组差异有统计学意义(P<0.05);阿立哌唑组不良反应发生率显著低于氯氮平组(P<0.05);治疗6个月后两组在(WHOQOL-100)量表各领域均较治疗前有统计学意义(P<0.05),但阿立哌唑组在生理领域、心理领域、社会关系领域、精神支柱、生活质量方面较氯氮平组差异有统计学意义(P<0.05)。结论:阿立哌唑治疗精神分裂症疗效与氯氮平相仿,不良反应少,合并精神康复治疗可显著改善精神分裂症患者的生活质量。

  20. 研究阿立哌唑与奋乃静联合治疗酒精中毒性精神障碍的临床效果%Clinical Study on the Effect of Aripiprazole and Perphenazine Combined Treatment of Alcoholism Mental Disorder

    Institute of Scientific and Technical Information of China (English)

    肖开提; 苏理旦

    2015-01-01

    目的:研究探讨阿立哌唑与奋乃静联合应用治疗酒精中毒性精神障碍的临床效果。方法选取我院2010年9月~2013年5月间就诊的酒精中毒性精神障碍患者60例,随机分为观察组和对照组。对照组单用奋乃静片进行治疗,观察组在对照组的基础上联用阿立哌唑片进行治疗。结果观察组总有效率为93.3%,对照组总有效率为73.3%,两组相比,差异显著;治疗一段时间后,观察组患者不良反应的发生率为20.0%,对照组患者不良反应的发生率为46.7%,两组相比差异显著。结论采用阿立哌唑与奋乃静联合使用对酒精中毒性精神障碍进行治疗,不良反应少,临床疗效较好。%Objective To explore clinical curative effect of aripiprazole and perphenazine combination in the treatment of alcoholism mental disorder. Methods 60 cases of patients with mental disorders were selected in our hospital in 2010 September~2013 May between the treatment of alcoholism, were randomly divided into observation group and control group. The control treatment group with single Perphenazine Tablets, on the basis of the observation group in the control group were treated with AripiprazoleTablets. Results the total effective rate of observation group was 93.3%, the control group the total effective rate was 73.3%, compared to the two groups, significant difference;after a period of treatment, patients in the observation group the incidence rate of adverse reactions of 20%patients in the control group, the incidence rate of adverse reactions was 46.7%, difference between the two groups was significant. Conclusion the use of aripiprazole and perphenazine combined use of treatment for alcoholic psychosis, less adverse reaction, good clinical curative effect.

  1. Metabolic disorders in menopause.

    Science.gov (United States)

    Stachowiak, Grzegorz; Pertyński, Tomasz; Pertyńska-Marczewska, Magdalena

    2015-03-01

    Metabolic disorders occurring in menopause, including dyslipidemia, disorders of carbohydrate metabolism (impaired glucose tolerance - IGT, type 2 diabetes mellitus - T2DM) or components of metabolic syndrome, constitute risk factors for cardiovascular disease in women. A key role could be played here by hyperinsulinemia, insulin resistance and visceral obesity, all contributing to dyslipidemia, oxidative stress, inflammation, alter coagulation and atherosclerosis observed during the menopausal period. Undiagnosed and untreated, metabolic disorders may adversely affect the length and quality of women's life. Prevention and treatment preceded by early diagnosis should be the main goal for the physicians involved in menopausal care. This article represents a short review of the current knowledge concerning metabolic disorders (e.g. obesity, polycystic ovary syndrome or thyroid diseases) in menopause, including the role of a tailored menopausal hormone therapy (HT). According to current data, HT is not recommend as a preventive strategy for metabolic disorders in menopause. Nevertheless, as part of a comprehensive strategy to prevent chronic diseases after menopause, menopausal hormone therapy, particularly estrogen therapy may be considered (after balancing benefits/risks and excluding women with absolute contraindications to this therapy). Life-style modifications, with moderate physical activity and healthy diet at the forefront, should be still the first choice recommendation for all patients with menopausal metabolic abnormalities.

  2. Metabolic disorders in menopause

    Directory of Open Access Journals (Sweden)

    Grzegorz Stachowiak

    2015-04-01

    Full Text Available Metabolic disorders occurring in menopause, including dyslipidemia, disorders of carbohydrate metabolism (impaired glucose tolerance – IGT, type 2 diabetes mellitus – T2DM or components of metabolic syndrome, constitute risk factors for cardiovascular disease in women. A key role could be played here by hyperinsulinemia, insulin resistance and visceral obesity, all contributing to dyslipidemia, oxidative stress, inflammation, alter coagulation and atherosclerosis observed during the menopausal period. Undiagnosed and untreated, metabolic disorders may adversely affect the length and quality of women’s life. Prevention and treatment preceded by early diagnosis should be the main goal for the physicians involved in menopausal care. This article represents a short review of the current knowledge concerning metabolic disorders (e.g. obesity, polycystic ovary syndrome or thyroid diseases in menopause, including the role of a tailored menopausal hormone therapy (HT. According to current data, HT is not recommend as a preventive strategy for metabolic disorders in menopause. Nevertheless, as part of a comprehensive strategy to prevent chronic diseases after menopause, menopausal hormone therapy, particularly estrogen therapy may be considered (after balancing benefits/risks and excluding women with absolute contraindications to this therapy. Life-style modifications, with moderate physical activity and healthy diet at the forefront, should be still the first choice recommendation for all patients with menopausal metabolic abnormalities.

  3. Regulation of lipid metabolism

    Institute of Scientific and Technical Information of China (English)

    Peng LI

    2011-01-01

    @@ Lipids including cholesterol, phospholipids, fatty acids and triacylglycerols are important cellular constituents involved in membrane structure, energy homeostasis and many biological processes such as signal transduction, organelle development and cell differentiation.Recently, the area of lipid metabolism has drawn a great deal of attention due to its emerging role in the development of metabolic disorders such as obesity, diabetes, atherosclerosis and liver steatosis.We decided to organize a special issue of Frontiers in Biology focusing on our current understanding of lipid metabolism.

  4. A Metabolic Switch

    DEFF Research Database (Denmark)

    Hjorth, Poul G.

    Our muscles are metabolically flexible, i.e., they are capable of `switching' between two types of oxidation: (1) when fasting, a predominantly lipid oxidation with high rates of fatty acid uptake, and (2) when fed, suppression of lipid oxidation in favour of increased glucose uptake, oxidation...... and storage, in response to insulin. One of the many manifestations of obesity and Type 2 diabetes is an insulin resistance of the skeletal muscles, which suppresses this metabolic switch. This talk describes recent development of a low-dimensional system of ODEs that model the metabolic switch, displaying...

  5. Sirtuins, Metabolism and Cancer

    Directory of Open Access Journals (Sweden)

    Barbara eMartinez-Pastor

    2012-02-01

    Full Text Available More than a decade ago, sirtuins were discovered as a highly conserved family of NAD+-dependent enzymes that extend lifespan in lower organisms. In mammals, sirtuins are key regulators of stress responses and metabolism, influencing a range of diseases, including diabetes, neurodegeneration and cancer. In recent years, new functions of sirtuins have been characterized, uncovering the underlying mechanisms of their multifaceted role in metabolism. Here, we specifically review recent progress on the role of sirtuins in DNA repair and energy metabolism, further discussing the implication of sirtuins in the biology of cancer.

  6. Efeitos adversos metabólicos de antipsicóticos e estabilizadores de humor Metabolic side effects of antipsychotics and mood stabilizers

    Directory of Open Access Journals (Sweden)

    Paulo José Ribeiro Teixeira

    2006-08-01

    use of lithium and valproic acid once again directed the attention to their metabolic effects. This study aims to review the medical literature with regard to metabolic side effects associated with the use of antipsychotics and mood stabilizers. METHOD: Research was carried out at MEDLINE and LILACS through October 2005. CONCLUSION: Metabolic side effects remain a major concern for psychopharmacology. Clinically relevant weight gain occurs frequently in patients taking antipsychotics and mood stabilizers, particularly clozapine, olanzapine, lithium, and valproic acid. Clozapine and olanzapine are also associated with higher incidence of diabetes mellitus and dyslipidemias, either due to weight gain or because of a direct deleterious action on glucose metabolism. Incidence of obesity and other metabolic disorders is lower with risperidone when compared to olanzapine or clozapine. Carbamazepine is associated with lower weight gain when compared to lithium or valproic acid. Drugs such as haloperidol, ziprasidone, aripiprazole and lamotrigine are not associated with significant weight gain or with higher incidence of diabetes mellitus. They are alternatives for patients more likely to develop these adverse effects.

  7. 阿立哌唑与奥氮平治疗老年期痴呆精神行为症状的效果观察%Effect observation on senile dementia with behavioral and psychological symptoms in the treatment with Aripiprazole and olanzapine

    Institute of Scientific and Technical Information of China (English)

    秦素萍

    2012-01-01

    Objective To Investigate the clinical efficacy on senile dementia with behavioral and psychological symptoms in the treatment with Aripiprazole and Olanzapine. Methods 84 patients with senile dementia associated with behavioral and psychiatric symptoms were selected in the hospital from March 2009 to December 2011, who were divided into two groups randomly. 42 patients who used Olanzapine treatment were as the control group. 42 patients who used Aripiprazole in the treatment were as the observation group. The course of treatment was 8 weeks. After treatment of 1 weeks, 2 weeks, 4 weeks, 8 weeks, AD behavioral pathology In scale (BEHAVE-AD), treatment emergent symptom scale (TESS) of patients were performed. Before the treatment and after treatment of 8 weeks, minimum mental state examination was performed. Results After treatment, AD behavioral pathology in scale total score and each factor scores in the control group and observation group decreased significantly. The incidence rate of adverse drug reactions (19.0%) in the observation group was significantly lower than that In the control group (45.2%), the differences were statistically significant (P < 0.05). Minimum mental state examination scores in the control group and observation group evaluated. Total efficiency of AD behavioral pathology In scale score and minimum mental state examination score In the observation group was slightly higher than those In the control group, while there were no significant differences between them (P > 0.05}. Conclusion Aripiprazole and Olanzapine in the treatment of senile dementia with behavioral and psychological symptoms have equivalent clinical efficacy. But Aripiprazole has better security, which is more suitable for clinical use.%目的 探讨阿立哌唑与奥氮平治疗老年期痴呆的精神行为症状的临床疗效.方法 选取我院2009年3月~2011年12月收治的老年期痴呆伴精神行为症状患者84例,随机分为两

  8. 舒肝解郁胶囊联合阿立哌唑治疗老年精神分裂症阴性症状的临床研究%Clinical research of Shugan Jieyu capsule and aripiprazole in the treatment of senile schizophrenia negative symptoms

    Institute of Scientific and Technical Information of China (English)

    李刚

    2014-01-01

    目的:探讨舒肝解郁胶囊联合阿立哌唑治疗老年精神分裂症阴性症状的临床效果。方法选取本院2011年1月~2013年1月老年精神分裂症阴性症状患者84例,随机分为两组,42例患者采用阿立哌唑治疗为对照组,42例患者采用舒肝解郁胶囊联合阿立哌唑治疗为观察组,治疗前后行阳性与阴性症状量表评定,比较两组患者治疗效果和不良反应情况。结果治疗后,两组患者阳性症状评分、阴性症状评分、一般精神病理症状评分、总分均显著降低。观察组阳性症状评分、阴性症状评分、一般精神病理症状评分、总分均明显低于对照组,观察组治疗总有效率明显高于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率高于对照组,差异无统计学意义(P>0.05)。结论舒肝解郁胶囊联合阿立哌唑可明显改善老年精神分裂症阴性症状,提高治愈率,且安全性较高。%Objective To investigate clinical effect of Shugan Jieyu capsule and aripiprazole in the treatment of senile schizophrenia negative symptoms. Methods 84 elderly patients with schizophrenia negative symptoms were selected in hospital from January 2010 to January 2013, who were randomly divided into two groups.42 patients treated with aripiprazole as control group.42 patients treated with Shugan Jieyu capsule and aripiprazole as observation group. Therapeutic effect and adverse reaction were compared by positive and negative symptom scale before and after treatment between the two groups. Results Positive symptoms score, negative symptoms score, general psychopathology symptoms score, total score in two groups decreased significantly after treatment. Positive symptoms score, negative symptoms score, general psychopathology symptoms score, total score in observation group were significantly lower than control group. Total effective rate in observation group was significantly

  9. Clinical observation of aripiprazole orally disintegrating tablets in the improvement of women's weight,prolactin increase caused by risperidone,sulpiride,olanzapine%阿立哌唑口腔崩解片改善利培酮、舒必利、奥氮平致女性体重、泌乳素增加的临床观察

    Institute of Scientific and Technical Information of China (English)

    卓子禄; 王群英; 熊英; 胡俊英

    2015-01-01

    目的:探讨阿立哌唑口腔崩解片改善利培酮、舒必利、奥氮平等精神类药物所致体重、泌乳素增加的临床效果。方法:收治因服用利培酮、舒必利、奥氮平等精神类药物后引起体重增加及高催乳素血症患者60例,所有患者均维持原抗精神类药物的治疗方案,根据随机数字表将患者分为阿立哌唑口腔崩解片组(观察组)30例和安慰剂组(对照组)30例,两组患者干预12周后测量患者体质指数(BMI)变化及催乳素(PRI)的水平,同时采用不良反应量表(TESS)评定阿立哌唑口腔崩解片治疗的不良反应。结果:与对照组相比,观察组治疗后 BMI 及PRL 显著下降,差异有统计学意义(P<0.01)。观察组总有效率93.33%,对照组总有效率76.67%,两组比较有统计学意义(P<0.05)。TESS 评分观察组(5.12±1.12)分,对照组(4.98±1.08)分,两组比较差异无统计学意义(P>0.05)。结论:阿立哌唑口腔崩解片能有效改善利培酮、舒必利、奥氮平等抗精神病药所致体重、泌乳素增加症状,且安全、可靠,值得临床应用和推广。%Objective:To explore the clinical effect of aripiprazole orally disintegrating tablets in the improvement of women's weight,prolactin increase caused by sulpiride,risperidone,olanzapine.Methods:60 cases of weight gain and hyperprolactinemic patients caused by sulpiride,risperidone,olanzapine were selected.All patients maintained antipsychotic drug treatment scheme of the original.According to the random number table,they were divided into the aripiprazole orally disintegrating tablets group(observation group) with 30 cases and the placebo group(control group) with 30 cases.After 12 weeks of treatment,we measured body mass index patients(BMI) changes and prolactin(PRI) level.At the same time,we evaluated the adverse reactions of aripiprazole orally disintegrating tablets treatment using side effects scale

  10. What is Nutrition & Metabolism?

    Directory of Open Access Journals (Sweden)

    Feinman Richard D

    2004-08-01

    Full Text Available Abstract A new Open Access journal, Nutrition & Metabolism (N&M will publish articles that integrate nutrition with biochemistry and molecular biology. The open access process is chosen to provide rapid and accessible dissemination of new results and perspectives in a field that is of great current interest. Manuscripts in all areas of nutritional biochemistry will be considered but three areas of particular interest are lipoprotein metabolism, amino acids as metabolic signals, and the effect of macronutrient composition of diet on health. The need for the journal is identified in the epidemic of obesity, diabetes, dyslipidemias and related diseases, and a sudden increase in popular diets, as well as renewed interest in intermediary metabolism.

  11. Amino Acid Metabolism Disorders

    Science.gov (United States)

    ... this process. One group of these disorders is amino acid metabolism disorders. They include phenylketonuria (PKU) and maple syrup urine disease. Amino acids are "building blocks" that join together to form ...

  12. Metabolism. Part III: Lipids.

    Science.gov (United States)

    Bodner, George M.

    1986-01-01

    Describes the metabolic processes of complex lipids, including saponification, activation and transport, and the beta-oxidation spiral. Discusses fatty acid degradation in regard to biochemical energy and ketone bodies. (TW)

  13. Epigenetics and Cellular Metabolism

    Science.gov (United States)

    Xu, Wenyi; Wang, Fengzhong; Yu, Zhongsheng; Xin, Fengjiao

    2016-01-01

    Living eukaryotic systems evolve delicate cellular mechanisms for responding to various environmental signals. Among them, epigenetic machinery (DNA methylation, histone modifications, microRNAs, etc.) is the hub in transducing external stimuli into transcriptional response. Emerging evidence reveals the concept that epigenetic signatures are essential for the proper maintenance of cellular metabolism. On the other hand, the metabolite, a main environmental input, can also influence the processing of epigenetic memory. Here, we summarize the recent research progress in the epigenetic regulation of cellular metabolism and discuss how the dysfunction of epigenetic machineries influences the development of metabolic disorders such as diabetes and obesity; then, we focus on discussing the notion that manipulating metabolites, the fuel of cell metabolism, can function as a strategy for interfering epigenetic machinery and its related disease progression as well. PMID:27695375

  14. Endocrine and Metabolic Disorders

    Science.gov (United States)

    ... for disorders of endocrine glands other than the thyroid, compared to 3.1 percent of visits made by women. The rate of visits due to metabolic and immunity disorders was also higher among men than women (2. ...

  15. [Metabolic syndrome and melatonin].

    Science.gov (United States)

    Rapoport, S I; Molchanov, A Iu; Golichenkov, V A; Burlakova, O V; Suprunenko, E S; Savchenko, E S

    2013-01-01

    Metabolic syndrome (MS) is characterized by the following symptoms: obesity, AH, dyslipidemia, insulin resistance. Pathophysiologically, MS is underlain by disorders of many biochemical and physiological processes, such as elevated levels of low density lipoproteins, hyperstimulation of pancreatic b-cells, increased insulin secretion, substitution of lipid metabolism for carbohydrate one, overgrowth of adipose tissue, excess production of adiponectin, leptin and other signal molecules and a rise in their local intravascular concentration, weight gain. Endogenous and exogenous melatonin inhibits these pathophysiological mechanisms, normalizes metabolism, equilibrates insulin secretion, prevents pancreatic hyperfunction, phosphorylates insulin receptors, inactivates active oxygen and nitrogen species including those produced in LDLP metabolism. Melatonin has specific MT1 and MT2 receptors localized in all body cells. Due to this, it exerts combined preventive action in patients with MS. Recently, melatonin has been reported to have therapeutic effect in MS; it may be recommended to treat this condition.

  16. Hypothalamic Hormones and Metabolism

    OpenAIRE

    Thio, Liu Lin

    2012-01-01

    The ketogenic diet is an effective treatment for medically intractable epilepsy and may have antiepileptogenic, neuroprotective, and antitumor properties. While on a ketogenic diet, the body obtains most of its calories from fat rather than carbohydrates. This dramatic change in caloric composition results in a unique metabolic state. In turn, these changes in caloric composition and metabolism alter some of the neurohormones that participate in the complex neuronal network regulating energy ...

  17. 帕罗西汀联合不同剂量阿立哌唑治疗强迫症临床疗效观察%Observation on effect and safety of paroxetine combined with different doses of aripiprazole in treating obsessive-compulsive disorder

    Institute of Scientific and Technical Information of China (English)

    李真; 李雪铮

    2016-01-01

    Objective To investigate the effect and safety of paroxetine combined with different doses of aripiprazole in treating obsessive-compulsive disorder. Methods One hundred and ten patients with obsessive-compulsive disorder admitted in our hospital from May 2013 to May 2015 were randomly divided into 5 groups with 22 cases in each group and respectively given single paroxetine(40 mg/d) and paroxetine(40 mg/d) combined 2.5,5.0,7.5,10.0 mg/d of aripiprazole. The effects and adverse effect oc-currence situation were assessed after 8 weeks. Results After treatment,the total score of the Yale-Brown Obsessive Compulsive Scale (YBOCS) in 5 groups were significantly decreased,the score-reducing rate of Y-BOCS in the 2.5,5.0 mg/d groups was sig nificantly higher than that in the single drug group,the difference was statistically significant(P0.05) and the occurrence rate of adverse reactions in the 7.5 ,10.0mg/d groups was significantly higher than that in the single drug group ,the difference was statistically significant(P0.05),7.5、10.0 mg/d组不良反应发生率明显高于单药组,差异均有统计学意义(P<0.05)。结论帕罗西汀联合阿立哌唑用药剂量为2.5、5.0 mg/d时治疗强迫症的临床疗效优于单用帕罗西汀的临床疗效,而安全性无明显差异。

  18. Tumor cell metabolism

    Science.gov (United States)

    Romero-Garcia, Susana; Lopez-Gonzalez, Jose Sullivan; B´ez-Viveros, José Luis; Aguilar-Cazares, Dolores

    2011-01-01

    Cancer is a genetic disease that is caused by mutations in oncogenes, tumor suppressor genes and stability genes. The fact that the metabolism of tumor cells is altered has been known for many years. However, the mechanisms and consequences of metabolic reprogramming have just begun to be understood. In this review, an integral view of tumor cell metabolism is presented, showing how metabolic pathways are reprogrammed to satisfy tumor cell proliferation and survival requirements. In tumor cells, glycolysis is strongly enhanced to fulfill the high ATP demands of these cells; glucose carbons are the main building blocks in fatty acid and nucleotide biosynthesis. Glutaminolysis is also increased to satisfy NADPH regeneration, whereas glutamine carbons replenish the Krebs cycle, which produces metabolites that are constantly used for macromolecular biosynthesis. A characteristic feature of the tumor microenvironment is acidosis, which results from the local increase in lactic acid production by tumor cells. This phenomenon is attributed to the carbons from glutamine and glucose, which are also used for lactic acid production. Lactic acidosis also directs the metabolic reprogramming of tumor cells and serves as an additional selective pressure. Finally, we also discuss the role of mitochondria in supporting tumor cell metabolism. PMID:22057267

  19. Therapeutic effects of aripiprazole and olanzapine on the patients with first-episode acute schizophrenia and their influence on plasma prolactin level%阿立哌唑与奥氮平对首发精神分裂症 急性期疗效及对催乳素的影响

    Institute of Scientific and Technical Information of China (English)

    吴小立; 王继辉; 钟智勇; 韩自力

    2011-01-01

    AIM:To study the efficacy on first-episode acute schizophrenia treated with aripiprazole and olanzapine and the effect on plasma prolactin level. METHODS: 65 inpatients with first-episode acute schizophrenia were divided into either olanzapine group [n = 42, M21, F21; age(23. 9±6. 6)year] or aripiprazole group[(n=23, M1l, F12; age (23. 7 ± 7. 2) year] for 4 week treatment. The plasma prolactin level, the Positive and Negative Syndrome Scale (PANSS) and clinical global impressionglobal improvement (CGI-I) were measured before and after 4 week treatment. RESULTS: The score of PANSS (59 ± 13) after therapy in olanzapine group was significantly lower than that before therapy (103+15) (P 0.05) in the CGI-I score between the two groups. The difference of negative symptoms and general psychopathological sub-scale scoreschanging from base to end between the two groups was statistically significant (P<0. 01). Compared with the prolactin baseline level (547 ±382) uIu/mL,the plasma prolactin level (418 ±362) ulu/mL in olanzapine group was significantly decreased after treatment, and there was no difference. Compared with the prolactin baseline level (351 ±299) ulu/mL, the plasma prolactin level (123 ±114) ulu/mL in aripiprazole group was significantly decreased after treatment, and there was significant difference ( P < 0.01). CONCLUSION: The therapeutic effects were similar in the aripiprazole and olanzapine group for first-episode acute schizophrenia. Olanzapine is better for the general psychopathological symptoms, and aripiprazole is better for the negative symptoms. Aripiprazole maybe decrease the plasma prolactin level of first-episode acute schizophrenia.%目的:研究奥氮平和阿立哌唑对首发精神分裂症患者急性期疗效及对血中催乳素(PRI)水平的影响.方法:65例首发精神分裂症患者分为奥氮平组42例[男21例,女21例;年龄(23.9±6.6)岁]和阿立哌唑组23例[男11例,女12例;年龄(23.7±7.2)岁].分别给予奥

  20. Evolutionary dynamics of metabolic adaptation

    NARCIS (Netherlands)

    van Hoek, M.J.A.

    2008-01-01

    In this thesis we study how organisms adapt their metabolism to a changing environment. Metabolic adaptation occurs at different timescales. Organisms adapt their metabolism via metabolic regulation, which happens in the order of minutes to hours and via evolution, which takes many generations. Here

  1. Metabolism, temperature, and ventilation.

    Science.gov (United States)

    Mortola, Jacopo P; Maskrey, Michael

    2011-10-01

    In mammals and birds, all oxygen used (VO2) must pass through the lungs; hence, some degree of coupling between VO2 and pulmonary ventilation (VE) is highly predictable. Nevertheless, VE is also involved with CO2 elimination, a task that is often in conflict with the convection of O2. In hot or cold conditions, the relationship between VE and VO2 includes the participation of the respiratory apparatus to the control of body temperature and water balance. Some compromise among these tasks is achieved through changes in breathing pattern, uncoupling changes in alveolar ventilation from VE. This article examines primarily the relationship between VE and VO2 under thermal stimuli. In the process, it considers how the relationship is influenced by hypoxia, hypercapnia or changes in metabolic level. The shuffling of tasks in emergency situations illustrates that the constraints on VE-VO2 for the protection of blood gases have ample room for flexibility. However, when other priorities do not interfere with the primary goal of gas exchange, VE follows metabolic rate quite closely. The fact that arterial CO2 remains stable when metabolism is changed by the most diverse circumstances (moderate exercise, cold, cold and exercise combined, variations in body size, caloric intake, age, time of the day, hormones, drugs, etc.) makes it unlikely that VE and metabolism are controlled in parallel by the condition responsible for the metabolic change. Rather, some observations support the view that the gaseous component of metabolic rate, probably CO2, may provide the link between the metabolic level and VE.

  2. Apelin and energy metabolism

    Directory of Open Access Journals (Sweden)

    Chantal eBertrand

    2015-04-01

    Full Text Available A wide range of adipokines identified over the past years has allowed considering white adipose tissue as a secretory organ closely integrated into overall physiological and metabolic control. Apelin, an ubiquitous peptide was known to exert different physiological effects mainly on the cardiovascular system and the regulation of fluid homeostasis until its identification as an adipokine. This has increased its broad range of action and apelin now appears clearly as a new player in energy metabolism alongside leptin and adiponectin. Apelin has been shown to act on glucose and lipid metabolism but also to modulate insulin secretion. Moreover, different studies in both animals and humans have shown that plasma apelin concentrations are usually increased during obesity and type 2 diabetes. This mini-review will focus on the various systemic apelin effects on energy metabolism by addressing its mechanisms of action. The advances concerning the role of apelin in metabolic diseases in relation with the recent reports on apelin concentrations in obese and/or diabetic subjects will also be discussed.

  3. Nutrition and metabolic syndrome.

    Directory of Open Access Journals (Sweden)

    Albornoz López, Raúl

    2012-12-01

    Full Text Available The metabolic syndrome comprises a cluster of metabolic abnormalities that increase the risk for cardiovascular disease and type 2 diabetes mellitus. The exact etiology is unclear, although it is known thatthere is a complex interaction between genetic, metabolic and environmental factors. Among the environmental factors, dietary habits play an important role in the treatment and prevention of this condition. General classic recommendations include control of obesity, increased physical activity, decreased intake of saturated fat and cholesterol, reduced intake of simple sugars and increased intake of fruits and vegetables. It has been studied the influence of diets low in carbohydrates, diets rich in polyunsaturated and monounsaturated fatty acids, fiber intake, the Mediterranean diet and the glycemic index in relation to metabolic syndrome.Other nutrients recently studied are the micronutrients (magnesium and calcium, soy and other phytochemicals. Evidence suggests that a healthy diet like the Mediterranean protects against metabolic syndrome,caracterized for a low content in saturated and trans fat, high in monounsaturated and polyunsaturated fatty acids, balanced intake of carbohydrates and high in fiber, fruits and vegetables. There is more controversy about the type of diet of choice for the control ofmetabolic syndrome (low-carbohydrate diets or lowfat, needing more studies on the role of soy and other phytochemicals.

  4. Endocannabinoids and Metabolic Disorders.

    Science.gov (United States)

    Gatta-Cherifi, Blandine; Cota, Daniela

    2015-01-01

    The endocannabinoid system (ECS) is known to exert regulatory control on essentially every aspect related to the search for, and the intake, metabolism and storage of calories, and consequently it represents a potential pharmacotherapeutic target for obesity, diabetes and eating disorders. While the clinical use of the first generation of cannabinoid type 1 (CB(1)) receptor blockers has been halted due to the psychiatric side effects that their use occasioned, recent research in animals and humans has provided new knowledge on the mechanisms of actions of the ECS in the regulation of eating behavior, energy balance, and metabolism. In this review, we discuss these recent advances and how they may allow targeting the ECS in a more specific and selective manner for the future development of therapies against obesity, metabolic syndrome, and eating disorders.

  5. Metabolism of phencyclidine

    Energy Technology Data Exchange (ETDEWEB)

    Hoag, M.K.P.

    1987-01-01

    Phencyclidine (PCP) is a drug of abuse which may produce, in some users, a persistent schizophreniform psychosis. The possibility that long term effects of PCP are mediated by metabolic activation of the parent compound to reactive species is consistent with the demonstration of metabolism-dependent covalent binding of radiolabeled PCP in vivo and in vitro to macromolecules in rodent lung, liver, and kidney. Formation of the electrophilic iminium ion metabolite of PCP is believed to be critical for covalent binding since binding was inhibited by cyanide ion at concentrations which did not inhibit metabolism of PCP but did trap the iminium ion to form the corresponding alpha-aminonitrile. The present studies were designed to characterize further the biological fate of PCP by identifying possible macromolecular targets of the reactive metabolite(s).

  6. Metabolism and neurogenesis.

    Science.gov (United States)

    Knobloch, Marlen; Jessberger, Sebastian

    2017-02-01

    The generation of neurons in the developing and adult mammalian brain by neural stem/progenitor cells (NSPCs) depends on a tight control of NSPC activity and neuronal differentiation that is regulated by a plethora of intrinsic and extrinsic molecular cues. Besides well-studied morphogenic signaling pathways and transcriptional codes that govern the distinct developmental steps from the dividing NSPC to a functional neuron, a critical role of cellular metabolism to determine the functional properties of NSPCs and newborn neurons has been recently identified. Here, we review advances in our understanding of how metabolism affects NSPC behavior and subsequent neuronal differentiation and suggest how metabolism may serve as a common signal integrator to ensure life-long addition of new neurons in the mammalian brain.

  7. Circadian physiology of metabolism.

    Science.gov (United States)

    Panda, Satchidananda

    2016-11-25

    A majority of mammalian genes exhibit daily fluctuations in expression levels, making circadian expression rhythms the largest known regulatory network in normal physiology. Cell-autonomous circadian clocks interact with daily light-dark and feeding-fasting cycles to generate approximately 24-hour oscillations in the function of thousands of genes. Circadian expression of secreted molecules and signaling components transmits timing information between cells and tissues. Such intra- and intercellular daily rhythms optimize physiology both by managing energy use and by temporally segregating incompatible processes. Experimental animal models and epidemiological data indicate that chronic circadian rhythm disruption increases the risk of metabolic diseases. Conversely, time-restricted feeding, which imposes daily cycles of feeding and fasting without caloric reduction, sustains robust diurnal rhythms and can alleviate metabolic diseases. These findings highlight an integrative role of circadian rhythms in physiology and offer a new perspective for treating chronic diseases in which metabolic disruption is a hallmark.

  8. Analytics for Metabolic Engineering.

    Science.gov (United States)

    Petzold, Christopher J; Chan, Leanne Jade G; Nhan, Melissa; Adams, Paul D

    2015-01-01

    Realizing the promise of metabolic engineering has been slowed by challenges related to moving beyond proof-of-concept examples to robust and economically viable systems. Key to advancing metabolic engineering beyond trial-and-error research is access to parts with well-defined performance metrics that can be readily applied in vastly different contexts with predictable effects. As the field now stands, research depends greatly on analytical tools that assay target molecules, transcripts, proteins, and metabolites across different hosts and pathways. Screening technologies yield specific information for many thousands of strain variants, while deep omics analysis provides a systems-level view of the cell factory. Efforts focused on a combination of these analyses yield quantitative information of dynamic processes between parts and the host chassis that drive the next engineering steps. Overall, the data generated from these types of assays aid better decision-making at the design and strain construction stages to speed progress in metabolic engineering research.

  9. Nitrile Metabolizing Yeasts

    Science.gov (United States)

    Bhalla, Tek Chand; Sharma, Monica; Sharma, Nitya Nand

    Nitriles and amides are widely distributed in the biotic and abiotic components of our ecosystem. Nitrile form an important group of organic compounds which find their applications in the synthesis of a large number of compounds used as/in pharmaceutical, cosmetics, plastics, dyes, etc>. Nitriles are mainly hydro-lyzed to corresponding amide/acid in organic chemistry. Industrial and agricultural activities have also lead to release of nitriles and amides into the environment and some of them pose threat to human health. Biocatalysis and biotransformations are increasingly replacing chemical routes of synthesis in organic chemistry as a part of ‘green chemistry’. Nitrile metabolizing organisms or enzymes thus has assumed greater significance in all these years to convert nitriles to amides/ acids. The nitrile metabolizing enzymes are widely present in bacteria, fungi and yeasts. Yeasts metabolize nitriles through nitrilase and/or nitrile hydratase and amidase enzymes. Only few yeasts have been reported to possess aldoxime dehydratase. More than sixty nitrile metabolizing yeast strains have been hither to isolated from cyanide treatment bioreactor, fermented foods and soil. Most of the yeasts contain nitrile hydratase-amidase system for metabolizing nitriles. Transformations of nitriles to amides/acids have been carried out with free and immobilized yeast cells. The nitrilases of Torulopsis candida>and Exophiala oligosperma>R1 are enantioselec-tive and regiospecific respectively. Geotrichum>sp. JR1 grows in the presence of 2M acetonitrile and may have potential for application in bioremediation of nitrile contaminated soil/water. The nitrilase of E. oligosperma>R1 being active at low pH (3-6) has shown promise for the hydroxy acids. Immobilized yeast cells hydrolyze some additional nitriles in comparison to free cells. It is expected that more focus in future will be on purification, characterization, cloning, expression and immobilization of nitrile metabolizing

  10. Hypothyroidism in metabolic syndrome

    Directory of Open Access Journals (Sweden)

    Sunil Kumar Kota

    2012-01-01

    Full Text Available Aim: Metabolic syndrome (MetS and hypothyroidism are well established forerunners of atherogenic cardiovascular disease. Considerable overlap occurs in the pathogenic mechanisms of atherosclerotic cardiovascular disease by metabolic syndrome and hypothyroidism. Insulin resistance has been studied as the basic pathogenic mechanism in metabolic syndrome. [1] This cross sectional study intended to assess thyroid function in patients with metabolic syndrome and to investigate the association between hypothyroidism and metabolic syndrome. Materials and Methods: One hundred patients with metabolic syndrome who fulfilled the National Cholesterol Education Program- Adult Treatment Panel (NCEP-ATP III criteria [ 3 out of 5 criteria positive namely blood pressure ≥ 130/85 mm hg or on antihypertensive medications, fasting plasma glucose > 100 mg/dl or on anti-diabetic medications, fasting triglycerides > 150 mg/dl, high density lipoprotein cholesterol (HDL-C 102 cms in men and 88 cms in women] were included in the study group. [2] Fifty patients who had no features of metabolic syndrome (0 out of 5 criteria for metabolic syndrome were included in the control group. Patients with liver disorders, renal disorders, congestive cardiac failure, pregnant women, patients on oral contraceptive pills, statins and other medications that alter thyroid functions and lipid levels and those who are under treatment for any thyroid related disorder were excluded from the study. Acutely ill patients were excluded taking into account sick euthyroid syndrome. Patients were subjected to anthropometry, evaluation of vital parameters, lipid and thyroid profile along with other routine laboratory parameters. Students t-test, Chi square test and linear regression, multiple logistic regression models were used for statistical analysis. P value < 0.05 was considered significant. Results: Of the 100 patients in study group, 55 were females (55% and 45 were males (45%. Of the 50

  11. Toxic and Metabolic Myelopathies.

    Science.gov (United States)

    Ramalho, Joana; Nunes, Renato Hoffmann; da Rocha, Antonio José; Castillo, Mauricio

    2016-10-01

    Myelopathy describes any neurologic deficit related to the spinal cord. It is most commonly caused by its compression by neoplasms, degenerative disc disease, trauma, or infection. Less common causes of myelopathy include spinal cord tumors, infection, inflammatory, neurodegenerative, vascular, toxic, and metabolic disorders. Conditions affecting the spinal cord must be recognized as early as possible to prevent progression that may lead to permanent disability. Biopsy is rarely performed, thus the diagnosis and management rely on patient׳s history, physical examination, laboratory results, and imaging findings. Here we review the clinical presentations, pathophysiological mechanisms, and magnetic resonance imaging findings of myelopathies related to metabolic or toxic etiologies.

  12. Metabolic Factors in Fatigue

    Institute of Scientific and Technical Information of China (English)

    Mark Hargreaves

    2006-01-01

    Increased non-oxidative and oxidative ATP production via metabolic pathways in skeletal muscle is essential for the maintenance of force and power production during exercise. However, substrate depletion and accumulation of metabolic byproducts are potential causes of fatigue. Reduced PCr availability can limit power production during sprint exercise, whereas carbohydrate depletion is a major limitation to endurance performance. During sprint exercise increased Pi and H+ may contribute to fatigue, and during prolonged strenuous exercise, the accumulation of NH3, reactive oxygen species, and heat can limit performance. Appropriate training programs and nutritional interventions are potential strategies to enhance fatigue resistance and exercise performance.

  13. Sleep and Metabolism: An Overview

    Directory of Open Access Journals (Sweden)

    Sunil Sharma

    2010-01-01

    Full Text Available Sleep and its disorders are increasingly becoming important in our sleep deprived society. Sleep is intricately connected to various hormonal and metabolic processes in the body and is important in maintaining metabolic homeostasis. Research shows that sleep deprivation and sleep disorders may have profound metabolic and cardiovascular implications. Sleep deprivation, sleep disordered breathing, and circadian misalignment are believed to cause metabolic dysregulation through myriad pathways involving sympathetic overstimulation, hormonal imbalance, and subclinical inflammation. This paper reviews sleep and metabolism, and how sleep deprivation and sleep disorders may be altering human metabolism.

  14. Metabolism at Evolutionary Optimal States

    Directory of Open Access Journals (Sweden)

    Iraes Rabbers

    2015-06-01

    Full Text Available Metabolism is generally required for cellular maintenance and for the generation of offspring under conditions that support growth. The rates, yields (efficiencies, adaptation time and robustness of metabolism are therefore key determinants of cellular fitness. For biotechnological applications and our understanding of the evolution of metabolism, it is necessary to figure out how the functional system properties of metabolism can be optimized, via adjustments of the kinetics and expression of enzymes, and by rewiring metabolism. The trade-offs that can occur during such optimizations then indicate fundamental limits to evolutionary innovations and bioengineering. In this paper, we review several theoretical and experimental findings about mechanisms for metabolic optimization.

  15. Macrophage Polarization in Metabolism and Metabolic Disease

    Directory of Open Access Journals (Sweden)

    Anna Meiliana

    2013-08-01

    Full Text Available BACKGROUND: Obesity is now recognized as the main cause of the worldwide epidemic of type 2 diabetes. Obesity-associated chronic inflammation is a contributing key factor for type 2 diabetes and cardiovascular disease. Numbers of studies have clearly demonstrated that the immune system and metabolism are highly integrated. CONTENT: Macrophages are an essential component of innate immunity and play a central role in inflammation and host defense. Moreover, these cells have homeostatic functions beyond defense, including tissue remodeling in ontogenesis and orchestration of metabolic functions. Diversity and plasticity are hallmarks of cells of the monocyte-macrophage lineage. In response to interferons (IFNs, toll-like receptor (TLR, or interleukin (IL-4/IL-13 signals, macrophages undergo M1 (classical or M2 (alternative activation. Progress has now been made in defining the signaling pathways, transcriptional networks, and epigenetic mechanisms underlying M1, M2 or M2-like polarized activation. SUMMARY: In response to various signals, macrophages may undergo classical M1 activation (stimulated by TLR ligands and IFN-γ or alternative M2 activation (stimulated by IL-4/IL-13; these states mirror the T helper (Th1–Th2 polarization of T cells. Pathology is frequently associated with dynamic changes in macrophage activation, with classically activated M1 cells implicate in initiating and sustaining inflammation, meanwhile M2 or M2-like activated cells associated with resolution or smoldering chronic inflammation. Identification of the mechanisms and molecules that are associated with macrophage plasticity and polarized activation provides a basis for macrophage centered diagnostic and therapeutic strategies. KEYWORDS: obesity, adipose tissue, inflammation, macrophage polarization.

  16. Methanogenesis: Syntrophic metabolism

    NARCIS (Netherlands)

    Sieber, J.R.; McInerney, M.J.; Plugge, C.M.; Schink, B.; Gunsales, R.P.

    2009-01-01

    "Water is life!" All active cellular systems require water as the medium and solvent of their metabolic activities. Hydrophobic compounds and structures, which tend to exclude water, though providing inter alia excellent sources of energy and a means of biological compartmentalization, present probl

  17. Prebiotic metabolic networks?

    OpenAIRE

    2014-01-01

    A prebiotic origin of metabolism has been proposed as one of several scenarios for the origin of life. In their recent work, Ralser and colleagues (Keller et al, 2014) observe an enzyme‐free, metabolism‐like reaction network under conditions reproducing a possible prebiotic environment.

  18. Ghrelin and Metabolic Surgery

    Directory of Open Access Journals (Sweden)

    Dimitrios J. Pournaras

    2010-01-01

    Full Text Available Metabolic surgery is the most effective treatment for morbid obesity. Ghrelin has been implicated to play a role in the success of these procedures. Furthermore, these operations have been used to study the gut-brain axis. This article explores this interaction, reviewing the available data on changes in ghrelin levels after different surgical procedures.

  19. Sucrose Metabolism in Plastids

    NARCIS (Netherlands)

    Gerrits, N.; Turk, S.C.H.J.; Dun, van K.P.M.; Hulleman, H.D.; Visser, R.G.F.; Weisbeek, P.J.; Smeekens, S.C.M.

    2001-01-01

    The question whether sucrose (Suc) is present inside plastids has been long debated. Low Suc levels were reported to be present inside isolated chloroplasts, but these were argued to be artifacts of the isolation procedures used. We have introduced Suc-metabolizing enzymes in plastids and our experi

  20. Sterol metabolism of insects

    NARCIS (Netherlands)

    Ritter, F.J.; Wientjens, W.H.J.M.

    1967-01-01

    This article surveys the present knowledge of the sterol metabolism of insects. It is emphasized that a high degree of purity of the dietary sterols and the climination of the influence of symbionts are essential to present ambiguity in interpreting results. It is pointed out that a sharp distinctio

  1. Glial metabolism of valine.

    Science.gov (United States)

    Murín, Radovan; Mohammadi, Ghasem; Leibfritz, Dieter; Hamprecht, Bernd

    2009-07-01

    The three essential amino acids, valine, leucine and isoleucine, constitute the group of branched-chain amino acids (BCAAs). BCAAs are rapidly taken up into the brain parenchyma, where they serve several distinct functions including that as fuel material in brain energy metabolism. As one function of astrocytes is considered the production of fuel molecules that support the energy metabolism of adjacent neural cells in brain. Astroglia-rich primary cultures (APC) were shown to rapidly dispose of the BCAAs, including valine, contained in the culture medium. While the metabolisms of leucine and isoleucine by APC have already been studied in detail, some aspects of valine metabolism remained to be determined. Therefore, in the present study an NMR analysis was performed to identify the (13)C-labelled metabolites that are generated by APC during catabolism of [U-(13)C]valine and that are subsequently released into the incubation medium. The results presented show that APC (1) are potently disposing of the valine contained in the incubation medium; (2) are capable of degrading valine to the tricarboxylic acid (TCA) cycle member succinyl-CoA; and (3) release into the extracellular milieu valine catabolites and compounds generated from them such as [U-(13)C]2-oxoisovalerate, [U-(13)C]3-hydroxyisobutyrate, [U-(13)C]2-methylmalonate, [U-(13)C]isobutyrate, and [U-(13)C]propionate as well as several TCA cycle-dependent metabolites including lactate.

  2. ENDOCRINOLOGY AND METABOLISM

    Institute of Scientific and Technical Information of China (English)

    2006-01-01

    2006162 Change of vascular endothelial function in patients with disorders of glucose metabolism. ZHANG Songjing,(张松菁),et al. Dept Endocrinol ,1st Hosp, Fujian Med Univ ,Fuzhou 350005. Chin J Endocrinol Metab 2006;22(1): 11 - 14. Objective: To observe the changes of the endothelium - dependent vasodilation ( EDF) and serum superoxide

  3. Diversified glucosinolate metabolism

    DEFF Research Database (Denmark)

    Frisch, Tina; Motawie, Mohammed Saddik; Olsen, Carl Erik;

    2015-01-01

    were biosynthesized from methionine. The biosynthesis of alliarinoside was shown not to bifurcate from sinigrin biosynthesis at the oxime level in contrast to the general scheme for hydroxynitrile glucoside biosynthesis. Instead, the aglucon of alliarinoside was formed from metabolism of sinigrin...

  4. Hypoxamirs and Mitochondrial Metabolism

    Science.gov (United States)

    Cottrill, Katherine A.; Chan, Stephen Y.

    2014-01-01

    Abstract Significance: Chronic hypoxia can drive maladaptive responses in numerous organ systems, leading to a multitude of chronic mammalian diseases. Oxygen homeostasis is intimately linked with mitochondrial metabolism, and dysfunction in these systems can combine to form the backbone of hypoxic-ischemic injury in multiple tissue beds. Increased appreciation of the crucial roles of hypoxia-associated miRNA (hypoxamirs) in metabolism adds a new dimension to our understanding of the regulation of hypoxia-induced disease. Recent Advances: Myriad factors related to glycolysis (e.g., aldolase A and hexokinase II), tricarboxylic acid cycle function (e.g., glutaminase and iron-sulfur cluster assembly protein 1/2), and apoptosis (e.g., p53) have been recently implicated as targets of hypoxamirs. In addition, several hypoxamirs have been implicated in the regulation of the master transcription factor of hypoxia, hypoxia-inducible factor-1α, clarifying how the cellular program of hypoxia is sustained and resolved. Critical Issues: Central to the discussion of metabolic change in hypoxia is the Warburg effect, a shift toward anaerobic metabolism that persists after normal oxygen levels have been restored. Many newly discovered targets of hypoxia-driven microRNA converge on pathways known to be involved in this pathological phenomenon and the apoptosis-resistant phenotype associated with it. Future Directions: The often synergistic functions of miRNA may make them ideal therapeutic targets. The use of antisense inhibitors is currently being considered in diseases in which hypoxia and metabolic dysregulation predominate. In addition, exploration of pleiotripic miRNA functions will likely continue to offer unique insights into the mechanistic relationships of their downstream target pathways and associated hypoxic phenotypes. Antioxid. Redox Signal. 21, 1189–1201. PMID:24111795

  5. Aripiprazole in the treatment of Alzheimer's disease

    NARCIS (Netherlands)

    De Deyn, P.P.; Drenth, Annemieke F. J.; Kremer, B.P.; Oude Voshaar, R.C.; Van Dam, D.

    2013-01-01

    Introduction: Psychosis is a common and difficult to treat symptom in Alzheimer's disease (AD). It is a cause of diminished quality of life and care-giver distress. Atypical antipsychotics are frequently used for the treatment of dementia-related psychosis, despite FDA warnings because of increased

  6. Aripiprazole in the treatment of Alzheimer's disease

    NARCIS (Netherlands)

    Deyn, P.P. de; Drenth, A.F.; Kremer, B.; Oude Voshaar, R.C.; Dam, D. Van

    2013-01-01

    INTRODUCTION: Psychosis is a common and difficult to treat symptom in Alzheimer's disease (AD). It is a cause of diminished quality of life and caregiver distress. Atypical antipsychotics are frequently used for the treatment of dementia-related psychosis, despite FDA warnings because of increased m

  7. How Is Metabolic Syndrome Treated?

    Science.gov (United States)

    ... page from the NHLBI on Twitter. How Is Metabolic Syndrome Treated? Heart-healthy lifestyle changes are the first line of treatment for metabolic syndrome. If heart-healthy lifestyle changes aren’t enough, ...

  8. SIRT1 and energy metabolism

    Institute of Scientific and Technical Information of China (English)

    Xiaoling Li

    2013-01-01

    Sirtuin 1 (SIRT1) is the most conserved mammalian NAD+-dependent protein deacetylase that has emerged as a key metabolic sensor in various metabolic tissues.In response to different environmental stimuli,SIRT1 directly links the cellular metabolic status to the chromatin structure and the regulation of gene expression,thereby modulating a variety of cellular processes such as energy metabolism and stress response.Recent studies have shown that SIRT1 controls both glucose and lipid metabolism in the liver,promotes fat mobilization and stimulates brown remodeling of the white fat in white adipose tissue,controls insulin secretion in the pancreas,senses nutrient availability in the hypothalamus,influences obesityinduced inflammation in macrophages,and modulates the activity of circadian clock in metabolic tissues.This review focuses on the role of SIRT1 in regulating energy metabolism at different metabolic tissues.

  9. Autophagy research: Lessons from metabolism

    NARCIS (Netherlands)

    A.J. Meijer

    2009-01-01

    Autophagy research continues to expand exponentially. Clearly autophagy and metabolism are intimately connected; however, the rapid expansion of research into this topic inevitably brings the risk that important basic knowledge of metabolism will be overlooked when considering experimental data. Unf

  10. Disorders of Amino Acid Metabolism

    Science.gov (United States)

    ... Fundamentals Heart and Blood Vessel Disorders Hormonal and Metabolic Disorders Immune Disorders Infections Injuries and Poisoning Kidney and ... Fundamentals Heart and Blood Vessel Disorders Hormonal and Metabolic Disorders Immune Disorders Infections Injuries and Poisoning Kidney and ...

  11. Metabolic Syndrome, Androgens, and Hypertension

    OpenAIRE

    Moulana, Mohadetheh; Lima, Roberta; Reckelhoff, Jane F.

    2011-01-01

    Obesity is one of the constellation of factors that make up the definition of the metabolic syndrome. Metabolic syndrome is also associated with insulin resistance, dyslipidemia, hypertriglyceridemia, and type 2 diabetes mellitus. The presence of obesity and metabolic syndrome in men and women is also associated with increased risk of cardiovascular disease and hypertension. In men, obesity and metabolic syndrome are associated with reductions in testosterone levels. In women, obesity and met...

  12. Metabolic syndrome and professional aptitude

    OpenAIRE

    Dorota Rębak; Edyta Suliga; Stanisław Głuszek

    2016-01-01

    The development of civilisation has resulted in a growing problem of metabolic diseases, including metabolic syndrome. Scientific studies show that this disease is an epidemic of the 21st century. Metabolic syndrome is a collection of mutually related metabolic factors, such as obesity, impaired glucose tolerance, lipid disorders, arterial hypertension, and pro-inflammatory and prothrombotic state, increasing the risk of the development of atherosclerosis and type 2 diabetes, and their cardio...

  13. Metabolism of hyperthermophiles.

    Science.gov (United States)

    Schönheit, P; Schäfer, T

    1995-01-01

    Hyperthermophiles are characterized by a temperature optimum for growth between 80 and 110°C. They are considered to represent the most ancient phenotype of living organisms and thus their metabolic design might reflect the situation at an early stage of evolution. Their modes of metabolism are diverse and include chemolithoautotrophic and chemoorganoheterotrophic. No extant phototrophic hyperthermophiles are known. Lithotrophic energy metabolism is mostly anaerobic or microaerophilic and based on the oxidation of H2 or S coupled to the reduction of S, SO inf4 (sup2-) , CO2 and NO inf3 (sup-) but rarely to O2. the substrates are derived from volcanic activities in hyperthermophilic habitats. The lithotrophic energy metabolism of hyperthermophiles appears to be similar to that of mesophiles. Autotrophic CO2 fixation proceeds via the reductive citric acid cycle, considered to be one of the first metabolic cycles, and via the reductive acetyl-CoA/carbon monoxide dehydrogenase pathway. The Calvin cycle has not been found in hyperthermophiles (or any Archaea). Organotrophic metabolism mainly involves peptides and sugars as substrates, which are either oxidized to CO2 by external electron acceptors or fermented to acetate and other products. Sugar catabolism in hyperthermophiles involves non-phosphorylated versions of the Entner-Doudoroff pathway and modified versions of the Embden-Meyerhof pathway. The 'classical' Embden-Meyerhof pathway is present in hyperthermophilic Bacteria (Thermotoga) but not in Archaea. All hyperthermophiles (and Archaea) tested so far utilize pyruvate:ferredoxin oxidoreductase for acetyl-CoA formation from pyruvate. Acetyl-CoA oxidation in anaerobic sulphur-reducing and aerobic hyperthermophiles proceeds via the citric acid cycle; in the hyperthermophilic sulphate-reducer Archaeoglobus an oxidative acetyl-CoA/carbon monoxide dehydrogenase pathway is operative. Acetate formation from acetyl-CoA in Archaea, including hyperthermophiles, is

  14. Role of Dopamine 2 Receptor in Impaired Drug-Cue Extinction in Adolescent Rats.

    Science.gov (United States)

    Zbukvic, Isabel C; Ganella, Despina E; Perry, Christina J; Madsen, Heather B; Bye, Christopher R; Lawrence, Andrew J; Kim, Jee Hyun

    2016-06-01

    Adolescent drug users display resistance to treatment such as cue exposure therapy (CET), as well as increased liability to relapse. The basis of CET is extinction learning, which involves dopamine signaling in the medial prefrontal cortex (mPFC). This system undergoes dramatic alterations during adolescence. Therefore, we investigated extinction of a cocaine-associated cue in adolescent and adult rats. While cocaine self-administration and lever-alone extinction were not different between the two ages, we observed that cue extinction reduced cue-induced reinstatement in adult but not adolescent rats. Infusion of the selective dopamine 2 receptor (D2R)-like agonist quinpirole into the infralimbic cortex (IL) of the mPFC prior to cue extinction significantly reduced cue-induced reinstatement in adolescents. This effect was replicated by acute systemic treatment with the atypical antipsychotic aripiprazole (Abilify), a partial D2R-like agonist. These data suggest that adolescents may be more susceptible to relapse due to a deficit in cue extinction learning, and highlight the significance of D2R signaling in the IL for cue extinction during adolescence. These findings inspire new tactics for improving adolescent CET, with aripiprazole representing an exciting potential pharmacological adjunct for behavioral therapy.

  15. Macrophages and Iron Metabolism.

    Science.gov (United States)

    Soares, Miguel P; Hamza, Iqbal

    2016-03-15

    Iron is a transition metal that due to its inherent ability to exchange electrons with a variety of molecules is essential to support life. In mammals, iron exists mostly in the form of heme, enclosed within an organic protoporphyrin ring and functioning primarily as a prosthetic group in proteins. Paradoxically, free iron also has the potential to become cytotoxic when electron exchange with oxygen is unrestricted and catalyzes the production of reactive oxygen species. These biological properties demand that iron metabolism is tightly regulated such that iron is available for core biological functions while preventing its cytotoxic effects. Macrophages play a central role in establishing this delicate balance. Here, we review the impact of macrophages on heme-iron metabolism and, reciprocally, how heme-iron modulates macrophage function.

  16. 阿立哌唑治疗抗精神病药所致闭经的精神分裂症对照研究%A comparison study of aripiprazole in the treatment of schizophrenic patients with amenorrhea induced by antipsychotics

    Institute of Scientific and Technical Information of China (English)

    黄平; 廖彦浔; 叶慧; 虞晓兰

    2011-01-01

    目的:探讨阿立哌唑对抗精神病药所致闭经的精神分裂症患者的影响.方法:69例抗精神病药引起闭经的女性精神分裂症患者,随机分为A组(单用阿立哌唑治疗)34例和B组(用其他抗精神病药联合中药血府逐瘀汤治疗)35例,观察疗程3个月.于治疗前、治疗后1、2、3个月测定血清催乳素浓度,并评定闭经的疗效.结果:治疗后两组血清催乳素浓度均较治疗前降低;以A组血清催乳素浓度(15.21±6.17)μg/L显著低于B组(85.91±24.86)μg/L(t=-15.870,P=0.000);A组闭经治疗总有效率100%显著高于B组84.85%(χ2=67.00,P=0.000).结论:阿立哌唑治疗因抗精神病药所致闭经的精神分裂症患者安全、有效.%Objective:To study the clinical effect of aripiprazole in the treatment of schizophrenic patients with amenorrhea induced by antipsychotics.Method:69 female schizophrenic patients with amenorrhea induced by antipsychotics were randomly divided into two groups, group A (n =34, treated by aripiprazole) and group B (n = 35, treated by other antipsychotics combined with traditional Chinese medicine Xuefuzhuyu soup) ,for 3 months treatment.The serum level of prolactin was measured before and after 1,2 and 3 months treatment.The efficacy on amenorrhea was evaluated.Results:The serum level of prolactin decreased in both group after treatment, with significant decrease in group A compared with that in group B[(15.21 ± 6.17 ) μg/L vs.( 85.91 ± 24.86) μg/L( t = - 15.870, P = 0.000).The total treatment response rate for amenorrhea was 100% in patients of group A, significanfiy higher than that 84.85% in group B (x2 = 67.00, P=0.000).Conclusion:Aripiprazole can treat amenorrhea induced by antipsychotics in patients with schizophrenia efficaciously and safely.

  17. 阿立哌唑治疗利培酮所致高催乳素血症75例疗效观察%Observation on Effect of Aripiprazole in Treatment of Hyperprolactinemia Caused by Risperidone in Schizophrenic Patients in 75 Cases

    Institute of Scientific and Technical Information of China (English)

    唐萍; 冯婧; 夏南

    2015-01-01

    Objective To study the effectiveness and safety of the combined use of small dose of aripiprazole in the treatment of hyper-prolactinemia caused by risperidone. Methods 150 schizophrenic patients with risperidone caused hyperprolactinemia were randomly as-signed to the research group ( n=75 ) and the control group ( n=75 ) . The two groups maintained the original risperidone treatment. The research group was combined with the use of aripiprazole 5-10 mg/d. Serum prolactin levels at the base line, and the ends of 4, 8 and 12 weeks were measured and the scores of PANSS, CGI-S and UKU at the base line and the end of 12 weeks were as-sessed. Results Serum prolactin level at the end of 12 weeks in the research group was ( 17. 01 0 4. 27 )μg/L, which was significantly reduced compared with ( 95. 73 0 48. 77 )μg/L at the baseline ( P ﹤ 0. 05 ) , the effective rate was 84. 00%. However serum prolactin lev-el in the control group had no statistically significant difference between before and after treatment ( P ﹥ 0. 05 ) . The scores of PANSS and CGI-S and the incidence rate of adverse reactions in the two groups had no statistical differences between before and after treat-ment ( P ﹥ 0. 05 ) . Conclusion Aripiprazole can effectively decrease risperidone caused hyperprolactinemia with few adverse reactions. But the long-term effect needs to be further observed.%目的:探讨利培酮所致高催乳素血症的精神分裂症合并应用小剂量阿立哌唑的有效性和安全性。方法将150例患者随机分为研究组和对照组,各75例。对照组维持原有利培酮治疗不变,研究组在对照组基础上合并用阿立哌唑5~10 mg/d;两组于基线及治疗4,8,12周末检测血清催乳素水平,于基线及治疗12周末评定阳性和阴性综合征量表( PANSS )、临床总体印象量表( CGI-S )、UKU副作用评定量表。结果研究组在第12周末催乳素水平为(17.0104.27)μg/L,较基线(95.73048.77)

  18. Effect of Aripiprazole on Hyperprolactinemia in Patients with Senile Schizophrenia Induced by Antipsychotic Drugs%阿立哌唑对抗精神病药物所致的老年精神分裂症患者高催乳素血症的影响分析

    Institute of Scientific and Technical Information of China (English)

    孙伟; 马世发; 高天飞

    2015-01-01

    目的:探讨阿立哌唑对抗精神病药物所致的老年精神分裂症患者高催乳素血症的影响。方法根据治疗方法对该院于2012年5月-2014年10月收治的患者进行分组,两组患者均继续沿用原有抗精神病药物,在此基础上给予观察组患者阿立哌唑。分别测定两组治疗前、治疗4、8周末血清催乳素水平,同时采用精神病评定量表(BPRS)对精神病症状进行评定,比较两组药物不良反应。结果观察组患者治疗4周、8周末血清催乳素水平显著降低,与对照组比较,差异有统计学意义(P0.05);两组患者药物不良反应发生率差异无统计学意义(P>0.05)。结论阿立哌唑能够有效降低抗精神病药物所致的老年精神分裂症患者高催乳素血症状,且未出现严重药物不良反应,具有有效性和安全性,可作为治疗用药。%Objective To investigate the effect of aripiprazole on hyperprolactinemia in patients with senile schizophrenia induced by antipsychotic drugs. Methods The patients from 2012 May to 2014 October in our hospital were divided according to the meth-ods of treatment. All the patients continued to use original antipsychotic drugs, based on which patients in the observation group were given aripiprazole. Serum prolactin level before the operation, four weeks after operation, 8 weeks after operation of the two groups was detected respectively;and psychiatric symptoms were assessed by Brief Psychiatric Rating Scale (BPRS), and adverse drug reaction of the two groups was compared. Results In the observation group, serum prolactin level after 4 weeks treatment and that after 8 weeks treatment both decreased significantly, and compared with those of the control group, there were significant dif-ferences (P0.05; No obvious sig-nificant difference was found in the rate of adverse drug reactions of the two groups,P>0.05. Conclusion Without serious adverse drug reactions, and with efficacy and

  19. Study on the escitalopram combined with low dose of aripiprazole in the treatment of depression with somatic symptoms%艾司西酞普兰联合小剂量阿立哌唑治疗伴躯体症状抑郁症的研究

    Institute of Scientific and Technical Information of China (English)

    夏金校; 姚华华; 王一冰; 曹世林; 甘建光; 段迪; 吕柏军

    2011-01-01

    AIM: To explore the clinical efficacy of escitalopram combined with low dose of aripiprazole in the treatment of depression with somatic symptoms. METHODS: Eighty patients suffering from depression with somatic symptoms were randomly divided into study group (n = 41) and control group (n = 39), who received either escitalopram combined with low dose of aripiprazole or escitalopram only, respectively. The clinical efficacy and safety were evaluated with Hamilton Depression Rating Scale (HAMD), Self-rating Depression Scale (SDS), Clinical Global Impression (CGD , Treatment E-mergent Symptom Scale (TESS) and Dysfunctional Attitudes Scales (DAS) at the point of baseline and the 1st, 2nd, 4th and 8th weekend. Meanwhile, the medication compliance andsymptom recrudescence rate of two groups were also assessed in 3 months. RESULTS: Scores of HAMD, SDS and CGI decreased in both groups, but more significantly and quickly in study group. There was no difference between two groups in TESS. Patients in study group had better compliance, fewer symptom recrudescence rate and lower scores in DAS in 3 months, compared with control group. CONCLUSION: Escitalopram combined with low dose of aripiprazole works better in the treatment of depression with somatic symptoms than using escitalopram only.%目的:观察艾司西酞普兰联合小剂量阿立哌唑治疗伴躯体症状抑郁症的临床疗效.方法:将80例伴躯体症状抑郁症患者随机分为服用艾司西酞普兰联合小剂量阿立哌唑(简称观察组)41例和单用艾司西酞普兰(简称对照组)39例.从药物起效、症状改善时间,治疗1、2、4及8周末汉密尔顿抑郁量表(HAMD)、抑郁自评量表(SDS)、临床疗效总评量表(CGI)有不良反应量表(TESS)评定,3个月内服药依从性、症状复燃率及DAS评定.结果:治疗后两组HAMD、SDS、CGI分值较治疗前均有显著下降,观察组下降更明显,起效与症状改善上观察组均较对照组快,两组的TESS评分差

  20. 喹硫平、阿立哌唑与氨磺必利治疗精神分裂症的疗效与安全性研究%Efficacy and safety of quetiapine,aripiprazole and amisulpride in the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    张智勇; 谢玲银; 黄伟波

    2015-01-01

    Objective To study the antipsychotic efficacy and safety of three kinds of drugs on patients with schizophrenia. Methods Patients with schizophrenia in our hospital from January to October in 2014 were selected and randomly divided into three groups,quetiapine group (n=98)accepted quetiapine 400 ~800 (512 ± 128)mg/d,aripi-prazole group (n=100) accepted aripiprazole 10~30 (20 ±6) mg/d,amisulpride group (n=102) accepted amisul-pride 400~800(635 ± 147) mg/d respectively for eight weeks. The efficacy and adverse reactions were evaluated by PANSS and TESS,and the social function was evaluated by PSP before and after 4 and 8 weeks of treatment. Results The total effective rate of quetiapine group,aripiprazole group and amisulpride group was 68. 4%,70.0% and 69. 6%respectively,there was no significant difference among the three groups(P>0.05). The score of CGI and PSP of each group increased significantly. Conclusion Quetiapine,aripiprazole and amisulpride have similar efficiency in the treat-ment of schizophrenic patients,but the adverse reactions features are different.%目的 研究喹硫平、阿立哌唑与氨磺必利治疗精神分裂症的疗效与安全性. 方法 选择2014年1-10月在我院精神科住院的300例精神分裂症患者,随机分为喹硫平组、阿立哌唑组、氨磺必利组,分别给予喹硫平[400~800 mg/d,平均(512 ±128)mg/d]、阿立哌唑[10~30 mg/d,平均(20 ±6)mg/d]、氨磺必利[400~800 mg/d,平均(635 ± 147)mg/d]治疗8周. 于分组前及治疗后4、8周用评估阳性和阴性症状量表(PANSS)、不良反应量表( TESS)评定疗效和不良反应,用社会功能量表( PSP)评定患者的社会功能. 结果 喹硫平组总有效率为68. 4%,阿立哌唑组总有效率为70.0%,氨磺必利组总有效率为69. 6%,三组总有效率比较,差异无统计学意义(P>0.05);三组患者CGI评分及PSP评分均显著增加. 结论 喹硫平、阿立哌唑与氨磺必利治疗精神分裂症的疗效相当,但不良反应特点不同.

  1. The Effect of Aripiprazole on Replacement of Risperidone in the Treatment of Serum Prolactin Levels in Female Schizophrenia Patients%研究阿立哌唑替换利培酮治疗对精神分裂症患者血清催乳素水平的影响

    Institute of Scientific and Technical Information of China (English)

    赵晓玲

    2016-01-01

    目的:观察阿立哌唑替换利培酮对精神分裂症患者治疗期血清催乳素水平的影响。方法选取我院2016年1~7月收治的精神分裂症患者100例作为研究对象,按就诊时间先后分为两组,每组各50例患者。观察组使用阿立哌唑治疗,对照组使用利培酮治疗。比较两组患者在治疗期间的血清催乳素变化。结果经5周治疗后,观察组血清催乳素含量为(6.41±1.04)ng/ml,与治疗前比较,下降量为(24.18±2.64)ng/ml;对照组为(38.17±1.67)ng/ml,与治疗前比较,上升量为(6.73±2.46)ng/ml,治疗后两组患者血清催乳素水平对比,差异具有统计学意义(P<0.05)。观察组BMI值为(28.14±1.34) kg/m2,对照组为(27.54±1.84)kg/m2,两组数据对比,差异具有统计学意义(P<0.05)。结论使用阿立哌唑对精神分裂症患者进行治疗,可有效降低体内血清催乳素含量,提升疗效。%Objective To observe the effect of aripiprazole replacement risperidone on serum prolactin levels in patients with schizophrenia treatment.Methods 100 cases of schizophrenia in our hospital from January to July 2016 in our hospital were selected as study subjects. According to the treatment time has been divided into two groups, 50 cases of patients in each group. The observation group was treated with aripiprazole, the control group was treated with risperidone. The change of serum prolactin in two groups were compared.ResultsAfter 5 weeks of treatment, the observation group serum prolactin content (6.41 ± 1.04) ng/ml, compared with before treatment decreased weight (24.18 ± 2.64) ng/ml control group, the average content is (38.17 ± 1.67) ng/ml, compared with before treatment increased weight (6.73 ± 2.46) ng/ml, there were significant differences two groups of patients with serum prolactin levels after treatment with statistical signiifcance,P <0.05. Observation group BMI (28.14 ± 1.34) kg/m2

  2. COMT基因多态性与精神分裂症发病风险及阿立哌唑治疗效应的相关性研究%Association of COMT Gene Polymorphism with Risk of Schizophrenia and Efficacy of Aripiprazole

    Institute of Scientific and Technical Information of China (English)

    李广学; 高树贵; 成佳; 姚文鸣; 郑孝荣; 徐永明

    2014-01-01

    Objective To investigate the association between catechol-O-methyltransferase ( COMT) gene polymorphism and onset risk of schizophrenia , efficacy of aripiprazole.Methods A total of 78 Chinese Han schizophrenic patients and 65 healthy subjects were recruited in this stud-y.All the patients were diagnosed based on the Diagnostic and Statistical Manual of Mental Disorders ( DSM-Ⅳ) .The Positive and Negative Syndrome Scale ( PANSS ) and Clinical Global Impression (CGI) were used to evaluate the clinical efficacy of aripiprazole.Polymerase chain reaction (PCR) and restriction fragment length polymorphism ( RFLP ) were employed to detect COMT geno-types.Results The COMT Val158 Met genotype and allele distributions in schizophrenia patients were significantly different from those in health subjects ( P0.05 ) .Conclusions The polymorphism of COMT gene Val 158/Met is correlated with the onset of schizophrenia , but has no effect on the clinical efficacy of aripiprazole.%目的:探讨儿茶酚氧位甲基转移酶(the catechol-O-methyltransferase, COMT)基因多态性与精神分裂症发病风险及阿立哌唑治疗效应之间的相关性。方法采用病例-对照研究设计,在中国汉族人群中收集78例符合美国精神障碍诊断与统计手册第4版( DSM-Ⅳ)精神分裂症诊断标准的首发精神分裂症患者,并与65例健康志愿者进行对照。用阳性与阴性症状评定量表( PANSS )、临床大体评定量表( CGI )评定阿立哌唑治疗的疗效。运用聚合酶链式反应-限制性片段长度多态分析( PCR-RFLP)方法进行基因分型。结果患者组与正常对照组基因型和等位基因频率分布存在显著性差异( P均<0.05); COMT基因多态性也与精神分裂症患者年龄、病程相关联。经阿立哌唑治疗后,患者精神症状及临床疗效总评分均有明显改善,但其改善程度在3种基因型间比较无明显差异。结论 COMT基因Val158/108 Met

  3. Autophagy, Metabolism, and Cancer.

    Science.gov (United States)

    White, Eileen; Mehnert, Janice M; Chan, Chang S

    2015-11-15

    Macroautophagy (autophagy hereafter) captures intracellular proteins and organelles and degrades them in lysosomes. The degradation breakdown products are released from lysosomes and recycled into metabolic and biosynthetic pathways. Basal autophagy provides protein and organelle quality control by eliminating damaged cellular components. Starvation-induced autophagy recycles intracellular components into metabolic pathways to sustain mitochondrial metabolic function and energy homeostasis. Recycling by autophagy is essential for yeast and mammals to survive starvation through intracellular nutrient scavenging. Autophagy suppresses degenerative diseases and has a context-dependent role in cancer. In some models, cancer initiation is suppressed by autophagy. By preventing the toxic accumulation of damaged protein and organelles, particularly mitochondria, autophagy limits oxidative stress, chronic tissue damage, and oncogenic signaling, which suppresses cancer initiation. This suggests a role for autophagy stimulation in cancer prevention, although the role of autophagy in the suppression of human cancer is unclear. In contrast, some cancers induce autophagy and are dependent on autophagy for survival. Much in the way that autophagy promotes survival in starvation, cancers can use autophagy-mediated recycling to maintain mitochondrial function and energy homeostasis to meet the elevated metabolic demand of growth and proliferation. Thus, autophagy inhibition may be beneficial for cancer therapy. Moreover, tumors are more autophagy-dependent than normal tissues, suggesting that there is a therapeutic window. Despite these insights, many important unanswered questions remain about the exact mechanisms of autophagy-mediated cancer suppression and promotion, how relevant these observations are to humans, and whether the autophagy pathway can be modulated therapeutically in cancer. See all articles in this CCR Focus section, "Cell Death and Cancer Therapy."

  4. Analytics for Metabolic Engineering

    Science.gov (United States)

    Petzold, Christopher J.; Chan, Leanne Jade G.; Nhan, Melissa; Adams, Paul D.

    2015-01-01

    Realizing the promise of metabolic engineering has been slowed by challenges related to moving beyond proof-of-concept examples to robust and economically viable systems. Key to advancing metabolic engineering beyond trial-and-error research is access to parts with well-defined performance metrics that can be readily applied in vastly different contexts with predictable effects. As the field now stands, research depends greatly on analytical tools that assay target molecules, transcripts, proteins, and metabolites across different hosts and pathways. Screening technologies yield specific information for many thousands of strain variants, while deep omics analysis provides a systems-level view of the cell factory. Efforts focused on a combination of these analyses yield quantitative information of dynamic processes between parts and the host chassis that drive the next engineering steps. Overall, the data generated from these types of assays aid better decision-making at the design and strain construction stages to speed progress in metabolic engineering research. PMID:26442249

  5. Analytics for metabolic engineering

    Directory of Open Access Journals (Sweden)

    Christopher J Petzold

    2015-09-01

    Full Text Available Realizing the promise of metabolic engineering has been slowed by challenges related to moving beyond proof-of-concept examples to robust and economically viable systems. Key to advancing metabolic engineering beyond trial-and-error research is access to parts with well-defined performance metrics that can be readily applied in vastly different contexts with predictable effects. As the field now stands, research depends greatly on analytical tools that assay target molecules, transcripts, proteins, and metabolites across different hosts and pathways. Screening technologies yield specific information for many thousands of strain variants while deep omics analysis provide a systems-level view of the cell factory. Efforts focused on a combination of these analyses yield quantitative information of dynamic processes between parts and the host chassis that drive the next engineering steps. Overall, the data generated from these types of assays aid better decision-making at the design and strain construction stages to speed progress in metabolic engineering research.

  6. Genetics of metabolic syndrome.

    Science.gov (United States)

    Stančáková, Alena; Laakso, Markku

    2014-12-01

    Metabolic syndrome (MetS) is a cluster of metabolic traits associated with an increased risk of cardiovascular disease and type 2 diabetes mellitus. Central obesity and insulin resistance are thought to play key roles in the pathogenesis of the MetS. The MetS has a significant genetic component, and therefore linkage analysis, candidate gene approach, and genome-wide association (GWA) studies have been applied in the search of gene variants for the MetS. A few variants have been identified, located mostly in or near genes regulating lipid metabolism. GWA studies for the individual components of the MetS have reported several loci having pleiotropic effects on multiple MetS-related traits. Genetic studies have provided so far only limited evidence for a common genetic background of the MetS. Epigenetic factors (DNA methylation and histone modification) are likely to play important roles in the pathogenesis of the MetS, and they might mediate the effects of environmental exposures on the risk of the MetS. Further research is needed to clarify the role of genetic variation and epigenetic mechanisms in the development of the MetS.

  7. Dysregulated lipid metabolism in cancer

    Institute of Scientific and Technical Information of China (English)

    2012-01-01

    Alteration of lipid metabolism has been increasingly recognized as a hallmark of cancer cells. The changes of expression and activity of lipid metabolizing enzymes are directly regulated by the activity of oncogenic signals. The dependence of tumor cells on the dysregulated lipid metabolism suggests that proteins involved in this process are excellent chemotherapeutic targets for cancer treatment. There are currently several drugs under development or in clinical trials that are based on specifically targeting the altered lipid metabolic pathways in cancer cells. Further understanding of dysregulated lipid metabolism and its associated signaling pathways will help us to better design efficient cancer therapeutic strategy.

  8. Tumor Metabolism of Malignant Gliomas

    Energy Technology Data Exchange (ETDEWEB)

    Ru, Peng; Williams, Terence M.; Chakravarti, Arnab; Guo, Deliang, E-mail: deliang.guo@osumc.edu [Department of Radiation Oncology, Ohio State University Comprehensive Cancer Center & Arthur G James Cancer Hospital, Columbus, OH 43012 (United States)

    2013-11-08

    Constitutively activated oncogenic signaling via genetic mutations such as in the EGFR/PI3K/Akt and Ras/RAF/MEK pathways has been recognized as a major driver for tumorigenesis in most cancers. Recent insights into tumor metabolism have further revealed that oncogenic signaling pathways directly promote metabolic reprogramming to upregulate biosynthesis of lipids, carbohydrates, protein, DNA and RNA, leading to enhanced growth of human tumors. Therefore, targeting cell metabolism has become a novel direction for drug development in oncology. In malignant gliomas, metabolism pathways of glucose, glutamine and lipid are significantly reprogrammed. Moreover, molecular mechanisms causing these metabolic changes are just starting to be unraveled. In this review, we will summarize recent studies revealing critical gene alterations that lead to metabolic changes in malignant gliomas, and also discuss promising therapeutic strategies via targeting the key players in metabolic regulation.

  9. Tumor Metabolism of Malignant Gliomas

    Directory of Open Access Journals (Sweden)

    Deliang Guo

    2013-11-01

    Full Text Available Constitutively activated oncogenic signaling via genetic mutations such as in the EGFR/PI3K/Akt and Ras/RAF/MEK pathways has been recognized as a major driver for tumorigenesis in most cancers. Recent insights into tumor metabolism have further revealed that oncogenic signaling pathways directly promote metabolic reprogramming to upregulate biosynthesis of lipids, carbohydrates, protein, DNA and RNA, leading to enhanced growth of human tumors. Therefore, targeting cell metabolism has become a novel direction for drug development in oncology. In malignant gliomas, metabolism pathways of glucose, glutamine and lipid are significantly reprogrammed. Moreover, molecular mechanisms causing these metabolic changes are just starting to be unraveled. In this review, we will summarize recent studies revealing critical gene alterations that lead to metabolic changes in malignant gliomas, and also discuss promising therapeutic strategies via targeting the key players in metabolic regulation.

  10. 阿立哌唑治疗抗精神病药物所致高催乳素血症疗效及安全性的M eta分析%The efficacy of aripiprazole in the treatment of antipsychotic-induced hyperprolactinemia and safety meta-analysis

    Institute of Scientific and Technical Information of China (English)

    温美玲; 张瑞岭; 崔桂梅

    2016-01-01

    Objective To explore the efficacy and safety of aripiprazole in the treatment of antipsychotic‐induced hyperprolactinemia .Methods Relevant randomized controlled studies prior to June 2015 ,method‐ology quality assessments of included studies performed ,and data extracted for meta‐analysis .Results A total of 16 literatures were recruited ,1 ,304 patients included ,685 ones were in intervention and 619 ones in control group .Meta‐analysis showed that cure rate was significantly higher and serum prolactin levels lowered more significantly in intervention than in control group at the end of the study ,differences were significant (P0 .05) .Conclusion Short‐term aripiprazole adjunctive treatment for other antipsychotic‐induced hyperprolactinemia is safe and effective .%目的:探讨阿立哌唑治疗抗精神病药物所致高催乳素血症的临床疗效及安全性。方法检索2015年6月之前相关的随机对照研究,对纳入研究进行方法学质量评估并提取数据进行M eta分析。结果共纳入16篇文献,总计1304例患者,干预组685例,对照组619例。M eta分析结果显示,在研究终点时,干预组治愈率显著高于对照组且血清催乳素水平显著降低,差异均有显著性(P<0.01);总体不良反应发生率及简明精神病评定量表总分改变两组间比较差异均无显著性(P>0.05)。结论短期内辅加阿立哌唑治疗其他抗精神病药物所致高催乳素血症安全有效。

  11. Uncovering transcriptional regulation of metabolism by using metabolic network topology

    DEFF Research Database (Denmark)

    Patil, Kiran Raosaheb; Nielsen, Jens

    2005-01-01

    therefore developed an algorithm that is based on hypothesis-driven data analysis to uncover the transcriptional regulatory architecture of metabolic networks. By using information on the metabolic network topology from genome-scale metabolic reconstruction, we show that it is possible to reveal patterns...... in the metabolic network that follow a common transcriptional response. Thus, the algorithm enables identification of so-called reporter metabolites (metabolites around which the most significant transcriptional changes occur) and a set of connected genes with significant and coordinated response to genetic...... changes induced by complex regulatory mechanisms coordinating the activity of different metabolic pathways. It is difficult to map such global transcriptional responses by using traditional methods, because many genes in the metabolic network have relatively small changes at their transcription level. We...

  12. Gut microbiome and metabolic syndrome.

    Science.gov (United States)

    Mazidi, Mohsen; Rezaie, Peyman; Kengne, Andre Pascal; Mobarhan, Majid Ghayour; Ferns, Gordon A

    2016-01-01

    The gut microbiome contributes approximately 2kg of the whole body weight, and recent studies suggest that gut microbiota has a profound effect on human metabolism, potentially contributing to several features of the metabolic syndrome. Metabolic syndrome is defined by a clustering of metabolic disorders that include central adiposity with visceral fat accumulation, dyslipidemia, insulin resistance, dysglycemia and non-optimal blood pressure levels. Metabolic syndrome is associated with an increased risk of cardiovascular diseases and type 2 diabetes. It is estimated that around 20-25 percent of the world's adult population has metabolic syndrome. In this manuscript, we have reviewed the existing data linking gut microbiome with metabolic syndrome. Existing evidence from studies both in animals and humans support a link between gut microbiome and various components of metabolic syndrome. Possible pathways include involvement with energy homeostasis and metabolic processes, modulation of inflammatory signaling pathways, interferences with the immune system, and interference with the renin-angiotensin system. Modification of gut microbiota via prebiotics, probiotics or other dietary interventions has provided evidence to support a possible beneficial effect of interventions targeting gut microbiota modulation to treat components or complications of metabolic syndrome.

  13. Metabolic syndrome and pregnancy

    Directory of Open Access Journals (Sweden)

    A V Khromilev

    2014-06-01

    Full Text Available Metabolic syndrome (MS is a major problem of public health and health care system, with rising prevalence in the world. There is evidence that obesity, as the main component of MS, is strongly associated with the presence of gestational complications: fetal growth retardation, fetal macrosomia, gestational diabetes, preeclampsia, preterm delivery, stillbirth and perinatal death. The underlying mechanisms of this association are actively investigated nowadays. The importance of MS in pregnancy is also determined by the increase of the risk of venous trombosis.

  14. Metabolism and Endocrinology

    Institute of Scientific and Technical Information of China (English)

    2009-01-01

    2009039 A survey of glucose and lipid metabolism and concomitant diseases among inpatients in Guangdong province. TANG Kuanxiao(唐宽晓), et al. Dept Endocrinol, 3rd Affili Hosp, Sun Yat-sen Univ, Guangzhou 510630. Chin J Intern Med 2009;48(3):196-200. Objectives To investigate the epidemiological and clinical characteristics of dyslipidemia as well as its treatment and influence on accompanying diseases in impaired glucose status among inpatients. Methods A cross-sectional survey was conducted among the inpatients registered in ten university hospitals of Guangdong, China during the week before the Diabetes Day in 2004.

  15. Metabolic syndrome, diet and exercise.

    Science.gov (United States)

    De Sousa, Sunita M C; Norman, Robert J

    2016-11-01

    Polycystic ovary syndrome (PCOS) is associated with a range of metabolic complications including insulin resistance (IR), obesity, dyslipidaemia, hypertension, obstructive sleep apnoea (OSA) and non-alcoholic fatty liver disease. These compound risks result in a high prevalence of metabolic syndrome and possibly increased cardiovascular (CV) disease. As the cardiometabolic risk of PCOS is shared amongst the different diagnostic systems, all women with PCOS should undergo metabolic surveillance though the precise approach differs between guidelines. Lifestyle interventions consisting of increased physical activity and caloric restriction have been shown to improve both metabolic and reproductive outcomes. Pharmacotherapy and bariatric surgery may be considered in resistant metabolic disease. Issues requiring further research include the natural history of PCOS-associated metabolic disease, absolute CV risk and comparative efficacy of lifestyle interventions.

  16. Metabolic impact of shift work.

    Science.gov (United States)

    Zimberg, Ioná Zalcman; Fernandes Junior, Silvio A; Crispim, Cibele Aparecida; Tufik, Sergio; de Mello, Marco Tulio

    2012-01-01

    In developing countries, shift work represents a considerable contingent workforce. Recently, studies have shown that overweight and obesity are more prevalent in shift workers than day workers. In addition, shift work has been associated with a higher propensity for the development of many metabolic disorders, such as insulin resistance, diabetes, dislipidemias and metabolic syndrome. Recent data have pointed that decrease of the sleep time, desynchronization of circadian rhythm and alteration of environmental aspects are the main factors related to such problems. Shortened or disturbed sleep is among the most common health-related effects of shift work. The plausible physiological and biological mechanisms are related to the activation of the autonomic nervous system, inflammation, changes in lipid and glucose metabolism, and related changes in the risk for atherosclerosis, metabolic syndrome, and type II diabetes. The present review will discuss the impact of shift work on obesity and metabolic disorders and how disruption of sleep and circadian misalignment may contribute to these metabolic dysfunctions.

  17. Metabolic syndrome, androgens, and hypertension.

    Science.gov (United States)

    Moulana, Mohadetheh; Lima, Roberta; Reckelhoff, Jane F

    2011-04-01

    Obesity is one of the constellation of factors that make up the definition of the metabolic syndrome. Metabolic syndrome is also associated with insulin resistance, dyslipidemia, hypertriglyceridemia, and type 2 diabetes mellitus. The presence of obesity and metabolic syndrome in men and women is also associated with increased risk of cardiovascular disease and hypertension. In men, obesity and metabolic syndrome are associated with reductions in testosterone levels. In women, obesity and metabolic syndrome are associated with increases in androgen levels. In men, reductions in androgen levels are associated with inflammation, and androgen supplements reduce inflammation. In women, increases in androgens are associated with increases in inflammatory cytokines, and reducing androgens reduces inflammation. This review discusses the possibility that the effects of androgens on metabolic syndrome and its sequelae may differ between males and females.

  18. Pharmacogenetics of olanzapine metabolism.

    Science.gov (United States)

    Söderberg, Mao Mao; Dahl, Marja-Liisa

    2013-08-01

    The pharmacokinetics of the atypical antipsychotic, olanzapine, display large interindividual variation leading to multiple-fold differences in drug exposure between patients at a given dose. This variation in turn gives rise to the need for individualized dosing in order to avoid concentration-dependent adverse effects or therapeutic failure. Genetically determined differences in olanzapine metabolism represent a less studied source of variability in comparison to environmental and physiological factors. In this review, we summarize available in vitro and in vivo data addressing the influence of polymorphisms in drug-metabolizing enzymes on olanzapine serum exposure. The polymorphic CYP2D6 enzyme appears to have no significant influence on olanzapine steady-state serum concentrations. The formation of the various olanzapine metabolites is influenced by polymorphisms in the genes coding for CYP1A2, CYP1A expression regulator AHR, UGT1A4 and UGT2B10, as well as FMO3. An impact on steady-state olanzapine serum concentrations has been suggested for variants of CYP1A2 and UGT1A4, with somewhat conflicting findings. The potential involvement of FMO1 and CYP3A43 in olanzapine disposition has also been suggested but needs future validation.

  19. Biochemical Hypermedia: Galactose Metabolism.

    Directory of Open Access Journals (Sweden)

    J.K. Sugai

    2013-05-01

    Full Text Available Introduction: Animations of biochemical processes and virtual laboratory environments lead to true molecular simulations. The use of interactive software’s in education can improve cognitive capacity, better learning and, mainly, it makes information acquisition easier. Material and Methods: This work presents the development of a biochemical hypermedia to understanding of the galactose metabolism. It was developed with the help of concept maps, ISIS Draw, ADOBE Photoshop and FLASH MX Program. Results and Discussion: A step by step animation process shows the enzymatic reactions of galactose conversion to glucose-1-phosphate (to glycogen synthesis, glucose-6-phosphate (glycolysis intermediary, UDP-galactose (substrate to mucopolysaccharides synthesis and collagen’s glycosylation. There are navigation guide that allow scrolling the mouse over the names of the components of enzymatic reactions of via the metabolism of galactose. Thus, explanatory text box, chemical structures and animation of the actions of enzymes appear to navigator. Upon completion of the module, the user’s response to the proposed exercise can be checked immediately through text box with interactive content of the answer. Conclusion: This hypermedia was presented for undergraduate students (UFSC who revealed that it was extremely effective in promoting the understanding of the theme.

  20. Metabolic topography of Parkinsonism

    Energy Technology Data Exchange (ETDEWEB)

    Kim, Jae Seung [Asan Medical Center, University of Ulsan College of Medicine, Seoul (Korea, Republic of)

    2007-04-15

    Parkinson's disease is one of the most frequent neurodegenerative diseases, which mainly affects the elderly. Parkinson's disease is often difficult to differentiate from atypical parkinson disorder such as progressive supranuclear palsy, multiple system atrophy, dementia with Lewy body, and corticobasal ganglionic degeneration, based on the clinical findings because of the similarity of phenotypes and lack of diagnostic markers. The accurate diagnosis of Parkinson's disease and atypical Parkinson disorders is not only important for deciding on treatment regimens and providing prognosis, but also it is critical for studies designed to investigate etiology and pathogenesis of parkinsonism and to develop new therapeutic strategies. Although degeneration of the nigrostriatal dopamine system results in marked loss of striatal dopamine content in most of the diseases causing parkinsonism, pathologic studies revealed different topographies of the neuronal cell loss in Parkinsonism. Since the regional cerebral glucose metabolism is a marker of integrated local synaptic activity and as such is sensitive to both direct neuronal/synaptic damage and secondary functional disruption at synapses distant from the primary site of pathology, and assessment of the regional cerebral glucose metabolism with F-18 FDG PET is useful in the differential diagnosis of parkinsonism and evaluating the pathophysiology of Parkinsonism.

  1. Arginine metabolism in wounds

    Energy Technology Data Exchange (ETDEWEB)

    Albina, J.E.; Mills, C.D.; Barbul, A.; Thirkill, C.E.; Henry, W.L. Jr.; Mastrofrancesco, B.; Caldwell, M.D.

    1988-04-01

    Arginine metabolism in wounds was investigated in the rat in 1) lambda-carrageenan-wounded skeletal muscle, 2) Schilling chambers, and 3) subcutaneous polyvinyl alcohol sponges. All showed decreased arginine and elevated ornithine contents and high arginase activity. Arginase could be brought to the wound by macrophages, which were found to contain arginase activity. However, arginase was expressed by macrophages only after cell lysis and no arginase was released by viable macrophages in vitro. Thus the extracellular arginase of wounds may derive from dead macrophages within the injured tissue. Wound and peritoneal macrophages exhibited arginase deiminase activity as demonstrated by the conversion of (guanido-/sup 14/C)arginine to radiolabeled citrulline during culture, the inhibition of this reaction by formamidinium acetate, and the lack of prokaryotic contamination of the cultures. These findings and the known metabolic fates of the products of arginase and arginine deiminase in the cellular populations of the wound suggest the possibility of cooperativity among cells for the production of substrates for collagen synthesis.

  2. Posttransplant Metabolic Syndrome

    Directory of Open Access Journals (Sweden)

    M. Shadab Siddiqui

    2012-01-01

    Full Text Available Metabolic syndrome (MS is a cluster of metabolic derangements associated with insulin resistance and an increased risk of cardiovascular mortality. MS has become a major health concern worldwide and is considered to be the etiology of the current epidemic of diabetes and cardiovascular disease. In addition to cardiovascular disease, the presence of MS is also closely associated with other comorbidities including nonalcoholic fatty liver disease (NAFLD. The prevalence of MS in patients with cirrhosis and end-stage liver disease is not well established and difficult to ascertain. Following liver transplant, the prevalence of MS is estimated to be 44–58%. The main factors associated with posttransplant MS are posttransplant diabetes, obesity, dyslipidemia, and hypertension. In addition to developing NAFLD, posttransplant MS is associated with increased cardiovascular mortality that is 2.5 times that of the age- and sex-matched individuals. Additionally, the presence of posttransplant MS has been associated with rapid progression to fibrosis in individuals transplanted for HCV cirrhosis. There is an urgent need for well-designed prospective studies to fully delineate the natural history and risk factors associated with posttransplant MS. Until then, early recognition, prevention, and treatment of its components are vital in improving outcomes in liver transplant recipients.

  3. Oxidative stress in metabolic syndrome

    OpenAIRE

    Sharma, Praveen; Mishra, Sandhya; Ajmera, Peeyush; Mathur, Sandeep

    2005-01-01

    As antioxidants play a protective role in the pathophysiology of diabetes and cardiovascular diseases, understanding the physiological status of antioxidant concentration among people at high risk for developing these conditions, such as Metabolic Syndrome, is of interest. In present study out of 187 first degree non-diabetic relatives and 192 non-diabetic spouses, 33.1% and 19.7% were found to have metabolic syndrome respectively. Subjects with metabolic syndrome (≥3 risk factors) had poor a...

  4. 帕罗西汀合并不同剂量阿立哌唑治疗强迫症的临床观察%Observing the effect of Paroxetine combined with different doses of ariPiPrazole on obsessive-comPulsive disorder

    Institute of Scientific and Technical Information of China (English)

    朱立毛; 舒菊红; 戴升太

    2014-01-01

    Objective:To investigate the effectiveness and safety of paroxetine combined with different doses of aripiprazole on obsessive-compulsive disorder. Method:One hundred and sixty-four patients with obsessive-compulsive disorder were randomly divided into 2 groups:the paroxetine only group( n = 33),the 2. 2 mg/ d group(n = 32),the 2 mg/ d group(n = 34),the 7. 2mg group(n = 32),the 10 mg/ d group(n = 33). Each group was treated with paroxetine 40 mg/ d combined with corresponding doses of aripiprazole for 8 weeks. Effectiveness and adverse effect were assessed respectively by Yale-Brown obsessive compulsive scale( Y-BOCS)and treatment emergent symptom scale(TESS). Results:After 8 weeks treatment,in the five groups, the scores of Y-BOCS significantly decreased(P ﹤ 0. 02 or P ﹤ 0. 01),the 2. 2 mg/ d group and the 2 mg group were more obvious(all P ﹤ 0. 01). The decreased score rate of Y-BOCS were significantly different between the paroxetine only group and the 2. 2 mg/ d group or the 2 mg group(all P ﹤ 0. 02). After 8 weeks treatment,no significant difference was found in the rates of adverse effect in 2. 2 mg/ d group and 2 mg/ d group compared with paroxetine only group;but in 7. 2 mg/ d group and 10 mg/ d group were sifnificantly higher than paroxetine only group(P ﹤ 0. 02 or P ﹤ 0. 01). Conclusion:The paroxetine combined the 2. 2-2 mg/ d aripiprazole trea-ting patients with obsessive compulsive disorder is more effective than the paroxetine combined the 7. 2-10 mg/d aripiprazole and paroxetine only.%目的:探讨盐酸帕罗西汀联合不同剂量阿立哌唑治疗强迫症的疗效及安全性。方法:164例强迫症患者随机分为帕罗西汀治疗(单药)组及帕罗西汀+阿立哌唑2.2 mg/ d 组、2 mg/ d 组、7.2 mg/d 组及10 mg/ d 组,每组给予帕罗西汀40 mg/ d 及相应剂量的阿立哌唑治疗8周。治疗前后进行耶鲁布朗强迫量表(Y-BOCS)及治疗过程中出现的症状量表

  5. 中药血府逐瘀汤辅助阿立哌唑治疗闭经的精神分裂症对照观察%Controlled observation of traditional Chinese medicine Xuefuzhuyu decoction combined with aripiprazole in treatment of schizophrenic patients with antipsychotic-induced amenorrhea

    Institute of Scientific and Technical Information of China (English)

    黄平; 杨泽云

    2011-01-01

    Objective To study the clinical effects of Xuefuzhuyu decoction (a traditional Chinese medicine) combined with aripiprazole in the treatment of schizophrenic patients with antipsychotic-induced amenorrhea. Methods Sixty-seven schizophrenic patients with antipsychotic-induced amenorrhea were randomly divided into group A (33 patients) treated with Xuefuzhuyu decoction combined with aripiprazole, and group B (34 patients) treated with aripiprazole alone. The treatment course was 3 months. The concentrations of prolactin (PRL) in serum were measured at the beginning of the study and at the end of each month, and the clinical effects on antipsychotic-induced amenorrhea were compared. The clinical effects on schizophrenosis were assessed using Positive and Negative Syndrome Scale (PANSS) at the beginning and the end of the study.Results The differences between PRL concentrations (base line and at the end of the 1st, 2nd, and 3rd months) of group A (113.88 ±40.84 μg/L, 43.59 ±17.35 μg/L, 16.88 ±8.42 μg/L and 15.53 ±6.28 μg/L)and group B (111.94±39.27 μg/L, 42.15 ±17.27 μg/L, 17.59 ±7.22 μg/L and 16.26 ±5.46 μg/L)had no statistical significance (t =0. 196 -0.600, P =0. 845 -0.550). The curative rate of antipsychotic-induced amenorrhea of group A ( 100.00% ) was not significantly different from that of group B (97.06%) (Chi square =0.956, P =0. 328). The total PANSS score of group A (45.69 ± 13.28) was significantly lower than that of group B (54.0318.52) at the end of the 3-month study (t= -2.091, P=0.040). Conclusion In the treatment of schizophrenic patients with antipsychotic-induced amenorrhea, Xuefuzhuyu decoction combined with aripiprazole can help to restore menstruation and improve the curative effect on schizophrenia.%目的 探讨中药血府逐瘀汤辅助阿立哌唑治疗闭经的精神分裂症患者临床疗效.方法 将67例抗精神病药引起闭经的精神分裂症患者按分层随机分为A组(n=33)、B组(n=34),A组中药血

  6. Comparison of efficacy after adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia between different gender%阿立哌唑治疗利培酮所致高催乳素血症效果的性别差异

    Institute of Scientific and Technical Information of China (English)

    陈景旭; 梁雪梅; 卞清涛; 刘可智; 张立刚; 张荣珍; 李伟; 刘艳红

    2015-01-01

    Objective To compare the efficacy and safety of adjunctive treatment with aripiprazole on hyperprolactinemia induced ky risperidone ketween different gender. Methods By using a stratified randomization protocol,116 schizophrenic patients with risperi=done- induced hyperprolactinemia were assigned to research group(28 male and 31 female)and control group(26 male and 31 female), and received 20mg·d-1 aripiprazole or placeko for adjunctive treatment respectively. Serum prolactin levels was measured at kaseline, the end of the 2nd,4th and 8th weed and UKU Side Effects Rating Scale(UKU)were assessed at kaseline and the end of 8th weed. Re-sults Compared with the kaseline,koth male and female in research group showed statistical difference in serum prolactin at the end of the 2nd,4th and 8th weed(P﹤0.001),kut here were no significant difference ketween the 2nd,4th and 8th weed in research group ketween and after treatment in control group(P﹥0. 05). At the end of the 8th weed,there was no statistical deference ketween male and female in research group in the decline rate of serum prolactin levels[(79. 61 ± 17. 81)%(,75. 54 ± 12. 96)%],and the normal ratio of male pa=tients were significantly higher(92. 9%)than that of female patients in research group(58. 1%)(χ2 =9. 39,P﹤0. 001). Conclusion Adjunctive aripiprazole treatment may ke effective for treating risperidone -induced hyperprolactinemia and achieved almost all of its effects after the 2nd weed. The effects on male patients was ketter than female patients with the same e dosage of aripiprazole.%目的探讨阿立哌唑治疗利培酮所致高催乳素血症的效果是否存在性别差异。方法采用分层随机方法将116例利培酮所致高催乳素血症的精神分裂症患者分为研究组(男性28例,女性31例)和对照组(男性26例,女性31例)。维持原有利培酮治疗方案不变,研究组合并用阿立哌唑20mg·d-1,对照组合并安慰剂治

  7. Analysis of the contrast effect of aripiprazole, risperidone and clozapine in patients with schizophrenia%阿立哌唑、利培酮和氯氮平治疗精神分裂症的临床效果分析

    Institute of Scientific and Technical Information of China (English)

    曾荟宇

    2015-01-01

    ObjectiveTo analyze the clinical effect and the damage of cognitive function of aripiprazole, risperidone and clozapine in treatment of patients with schizophrenia.Methods 234 patients with schizophrenia diagnosed and treated in our hospital from September 2011 to October 2013 were randomly divided into three groups A, B and C, 78 cases in each group. Group A received therapy of aripiprazole oral, group B received treatment of risperidone oral, Group C received oral clozapine treatment, after treatment, the clinical efficacy among the three groups were compared, the changes of positive and negative syndrome scale (PANSS) score, the Wechsler adult Intelligence Scale (WAIS-RC) of the total IQ score points and Clinical memory Scale (CMS) score were compared between before and after treatment.ResultsBefore treatment, PANSS, WAIS-RC, CMS scores of A, B, C three groups, the difference was not statistically significant (P>0.05), indicating a good comparability between the three groups. After treatment, A, B, C three groups PANSS, WAIS-RC scores were compared, without statistically significant differences (P>0.05). CMS score of group A after treatment was significantly higher than that of B, C groups, the difference was statistically significant (P0.05). A, B, C three groups after treatment PANSS scores were significantly higher than the scores before treatment (P0.05). Conclusion Aripiprazole compared with risperidone and clozapine, aripiprazole has better clinical efficacy.%目的:分析阿立哌唑、利培酮和氯氮平在精神分裂症患者临床治疗效果及对认知功能的损害情况。方法将我院2011年9月~2013年10月确诊并收治的234例精神分裂症患者随机分为甲、乙、丙三组,每组78例。甲组应用阿立哌唑实施口服治疗,乙组应用利培酮实施口服治疗,丙组应用氯氮平实施口服治疗,治疗结束后比照三组临床疗效,治疗前后的阳性和阴性症状量表(PANSS)评分、韦氏

  8. Gut Microbiota and Metabolic Disorders

    Directory of Open Access Journals (Sweden)

    Kyu Yeon Hur

    2015-06-01

    Full Text Available Gut microbiota plays critical physiological roles in the energy extraction and in the control of local or systemic immunity. Gut microbiota and its disturbance also appear to be involved in the pathogenesis of diverse diseases including metabolic disorders, gastrointestinal diseases, cancer, etc. In the metabolic point of view, gut microbiota can modulate lipid accumulation, lipopolysaccharide content and the production of short-chain fatty acids that affect food intake, inflammatory tone, or insulin signaling. Several strategies have been developed to change gut microbiota such as prebiotics, probiotics, certain antidiabetic drugs or fecal microbiota transplantation, which have diverse effects on body metabolism and on the development of metabolic disorders.

  9. Drug-Induced Metabolic Acidosis.

    Science.gov (United States)

    Pham, Amy Quynh Trang; Xu, Li Hao Richie; Moe, Orson W

    2015-01-01

    Metabolic acidosis could emerge from diseases disrupting acid-base equilibrium or from drugs that induce similar derangements. Occurrences are usually accompanied by comorbid conditions of drug-induced metabolic acidosis, and clinical outcomes may range from mild to fatal. It is imperative that clinicians not only are fully aware of the list of drugs that may lead to metabolic acidosis but also understand the underlying pathogenic mechanisms. In this review, we categorized drug-induced metabolic acidosis in terms of pathophysiological mechanisms, as well as individual drugs' characteristics.

  10. Metabolic Adaptation to Muscle Ischemia

    Science.gov (United States)

    Cabrera, Marco E.; Coon, Jennifer E.; Kalhan, Satish C.; Radhakrishnan, Krishnan; Saidel, Gerald M.; Stanley, William C.

    2000-01-01

    Although all tissues in the body can adapt to varying physiological/pathological conditions, muscle is the most adaptable. To understand the significance of cellular events and their role in controlling metabolic adaptations in complex physiological systems, it is necessary to link cellular and system levels by means of mechanistic computational models. The main objective of this work is to improve understanding of the regulation of energy metabolism during skeletal/cardiac muscle ischemia by combining in vivo experiments and quantitative models of metabolism. Our main focus is to investigate factors affecting lactate metabolism (e.g., NADH/NAD) and the inter-regulation between carbohydrate and fatty acid metabolism during a reduction in regional blood flow. A mechanistic mathematical model of energy metabolism has been developed to link cellular metabolic processes and their control mechanisms to tissue (skeletal muscle) and organ (heart) physiological responses. We applied this model to simulate the relationship between tissue oxygenation, redox state, and lactate metabolism in skeletal muscle. The model was validated using human data from published occlusion studies. Currently, we are investigating the difference in the responses to sudden vs. gradual onset ischemia in swine by combining in vivo experimental studies with computational models of myocardial energy metabolism during normal and ischemic conditions.

  11. Metabolic interrelationships software application: Interactive learning tool for intermediary metabolism

    NARCIS (Netherlands)

    A.J.M. Verhoeven (Adrie); M. Doets (Mathijs); J.M.J. Lamers (Jos); J.F. Koster (Johan)

    2005-01-01

    textabstractWe developed and implemented the software application titled Metabolic Interrelationships as a self-learning and -teaching tool for intermediary metabolism. It is used by undergraduate medical students in an integrated organ systems-based and disease-oriented core curriculum, which start

  12. Regulation of Terpene Metabolism

    Energy Technology Data Exchange (ETDEWEB)

    Rodney Croteau

    2004-03-14

    OAK-B135 Research over the last four years has progressed fairly closely along the lines initially proposed, with progress-driven expansion of Objectives 1, 2 and 3. Recent advances have developed from three research thrusts: 1. Random sequencing of an enriched peppermint oil gland cDNA library has given access to a large number of potential pathway and regulatory genes for test of function; 2. The availability of new DNA probes and antibodies has permitted investigation of developmental regulation and organization of terpenoid metabolism; and 3. The development of a transformation system for peppermint by colleagues at Purdue University has allowed direct transgenic testing of gene function and added a biotechnological component to the project. The current status of each of the original research objectives is outlined below.

  13. Metabolism during hypodynamia

    Science.gov (United States)

    Federov, I. V.

    1980-01-01

    Physical immobilization, inaction due to space travel, a sedentary occupation, or bed confinement due to a chronic illness elicit similar alternations in the metabolism of man and animals (rat, rabbit, dog, mouse). After a preliminary period of weight loss, there is eventually weight gain due to increased lipid storage. Protein catabolism is enhanced and anabolism depressed, with elevated urinary excretion of amino acids, creatine, and ammonia. Glycogen stores are depleted and glyconeogenesis is accelerated. Polyuria develops with subsequent redistribution of body fluids in which the blood volume of the systemic circulation is decreased and that of pulmonary circulation increased. This results in depressed production of vasopressin by the posterior pituitary which further enhances urinary water and salt loss.

  14. [Regulation of terpene metabolism

    Energy Technology Data Exchange (ETDEWEB)

    Croteau, R.

    1989-11-09

    Terpenoid oils, resins, and waxes from plants are important renewable resources. The objective of this project is to understand the regulation of terpenoid metabolism using the monoterpenes (C[sub 10]) as a model. The pathways of monoterpene biosynthesis and catabolism have been established, and the relevant enzymes characterized. Developmental studies relating enzyme levels to terpene accumulation within the oil gland sites of synthesis, and work with bioregulators, indicate that monoterpene production is controlled by terpene cyclases, the enzymes catalyzing the first step of the monoterpene pathway. As the leaf oil glands mature, cyclase levels decline and monoterpene biosynthesis ceases. Yield then decreases as the monoterpenes undergo catabolism by a process involving conversion to a glycoside and transport from the leaf glands to the root. At this site, the terpenoid is oxidatively degraded to acetate that is recycled into other lipid metabolites. During the transition from terpene biosynthesis to catabolism, the oil glands undergo dramatic ultrastructural modification. Degradation of the producing cells results in mixing of previously compartmentized monoterpenes with the catabolic enzymes, ultimately leading to yield decline. This regulatory model is being applied to the formation of other terpenoid classes (C[sub 15] C[sub 20], C[sub 30], C[sub 40]) within the oil glands. Preliminary investigations on the formation of sesquiterpenes (C[sub 15]) suggest that the corresponding cyclases may play a lesser role in determining yield of these products, but that compartmentation effects are important. From these studies, a comprehensive scheme for the regulation of terpene metabolism is being constructed. Results from this project wail have important consequences for the yield and composition of terpenoid natural products that can be made available for industrial exploitation.

  15. Renal metabolism of calcitonin

    Energy Technology Data Exchange (ETDEWEB)

    Simmons, R.E.; Hjelle, J.T.; Mahoney, C.; Deftos, L.J.; Lisker, W.; Kato, P.; Rabkin, R.

    1988-04-01

    The kidneys account for approximately two-thirds of the metabolism of calcitonin, but relatively little is known regarding the details thereof. To further characterize this process, we examined the renal handling and metabolism of human calcitonin (hCT) by the isolated perfused rat kidney. We also studied the degradation of radiolabeled salmon calcitonin (sCT) by subcellular fractions prepared from isolated rabbit proximal tubules. The total renal (organ) clearance of immunoreactive hCT by the isolated kidney was 1.96 +/- 0.18 ml/min. This was independent of the perfusate total calcium concentration from 5.5 to 10.2 mg/dl. Total renal clearance exceeded the glomerular filtration rate (GFR, 0.68 +/- 0.05 ml/min), indicating filtration-independent removal. Urinary calcitonin clearance as a fraction of GFR averaged 2.6%. Gel filtration chromatography of medium from isolated kidneys perfused with /sup 125/I-labeled sCT showed the principal degradation products to be low molecular weight forms eluting with monoiodotyrosine. Intermediate size products were not detected. In the subcellular fractionation experiments, when carried out at pH 5.0, calcitonin hydrolysis exclusively followed the activities of the lysosomal enzyme N-acetyl-beta-glucosaminidase. Typically, at pH 7.5, 42% of total degradation occurred in the region of the brush-border enzyme alanyl aminopeptidase and 29% occurred in the region of the cytosolic enzyme phosphoglucomutase. Although 9% of the calcitonin-degrading activity was associated with basolateral membrane fractions, most of this activity could be accounted for by the presence of brush-border membranes.

  16. Metabolic syndrome and oxidative stress.

    Science.gov (United States)

    Ando, Katsuyuki; Fujita, Toshiro

    2009-08-01

    Metabolic syndrome is an obesity-associated collection of disorders, each of which contributes to cardiovascular risk. Metabolic syndrome is also associated with overproduction of reactive oxygen species (ROS). ROS contribute to the interrelationship between metabolic syndrome and salt-sensitive hypertension, which are both caused by obesity and excess salt consumption and are major threats to health in developed countries. ROS can induce insulin resistance, which is indispensable for the progression of metabolic syndrome, and salt-sensitive hypertension stimulates ROS production, thereby promoting the development of metabolic syndrome. Moreover, ROS activate mineralocorticoid receptors (MRs) and the sympathetic nervous system, which can contribute to the development of metabolic syndrome and salt-sensitive hypertension. Salt-induced progression of cardiovascular disease (CVD) is also accelerated in animal models with metabolic syndrome, probably owing to further stimulation of ROS overproduction and subsequent ROS-induced MR activation and sympathetic excitation. Therefore, ROS contribute to the progression of the metabolic syndrome itself and to the CVD accompanying it, particularly in conjunction with excessive salt consumption.

  17. Metabolic alterations in dialysis patients

    NARCIS (Netherlands)

    Drechsler, Christiane

    2010-01-01

    Assessing metabolic risk in dialysis patients, three main aspects are important: a) the pathophysiologic effects of metabolic disturbances as known from the general population are unlikely to completely reverse once patients reach dialysis. b) Specific additional problems related to chronic kidney d

  18. Selected Metabolic Responses to Skateboarding

    Science.gov (United States)

    Hetzler, Ronald K.; Hunt, Ian; Stickley, Christopher D.; Kimura, Iris F.

    2011-01-01

    Despite the popularity of skateboarding worldwide, the authors believe that no previous studies have investigated the metabolic demands associated with recreational participation in the sport. Although metabolic equivalents (METs) for skateboarding were published in textbooks, the source of these values is unclear. Therefore, the rise in…

  19. Lysophosphatidylinositol Signalling and Metabolic Diseases

    Directory of Open Access Journals (Sweden)

    Syamsul A. Arifin

    2016-01-01

    Full Text Available Metabolism is a chemical process used by cells to transform food-derived nutrients, such as proteins, carbohydrates and fats, into chemical and thermal energy. Whenever an alteration of this process occurs, the chemical balance within the cells is impaired and this can affect their growth and response to the environment, leading to the development of a metabolic disease. Metabolic syndrome, a cluster of several metabolic risk factors such as abdominal obesity, insulin resistance, high cholesterol and high blood pressure, and atherogenic dyslipidaemia, is increasingly common in modern society. Metabolic syndrome, as well as other diseases, such as diabetes, obesity, hyperlipidaemia and hypertension, are associated with abnormal lipid metabolism. Cellular lipids are the major component of cell membranes; they represent also a valuable source of energy and therefore play a crucial role for both cellular and physiological energy homeostasis. In this review, we will focus on the physiological and pathophysiological roles of the lysophospholipid mediator lysophosphatidylinositol (LPI and its receptor G-protein coupled receptor 55 (GPR55 in metabolic diseases. LPI is a bioactive lipid generated by phospholipase A (PLA family of lipases which is believed to play an important role in several diseases. Indeed LPI can affect various functions such as cell growth, differentiation and motility in a number of cell-types. Recently published data suggest that LPI plays an important role in different physiological and pathological contexts, including a role in metabolism and glucose homeostasis.

  20. [Hypertension and the metabolic syndrome.

    DEFF Research Database (Denmark)

    Olsen, Michael; Jeppesen, Jørgen; Larsen, Mogens

    2009-01-01

    The metabolic syndrome is a relatively prevalent condition characterized by co-existence of several metabolic and cardiovascular risk factors including hypertension. Patients with hypertension have an increased risk of developing the metabolic syndrome which, in turn, increases the cardiovascular...... risk associated with increased blood pressure. As the definition of the metabolic syndrome is based on dichotomization of cardiovascular risk factors with a continuously increasing risk, it cannot match risk stratification tools like the HeartScore for calculation of prognosis. However, the metabolic...... syndrome is of clinical importance as it makes the treating physician test for other elements of the syndrome in patients with one of the elements, e.g. hypertension. Udgivelsesdato: 2009-Jun-15...

  1. Vasomotor symptoms and metabolic syndrome.

    Science.gov (United States)

    Tuomikoski, Pauliina; Savolainen-Peltonen, Hanna

    2017-03-01

    A vast majority of menopausal women suffer from vasomotor symptoms, such as hot flushes and night sweats, the mean duration of which may be up to 7-10 years. In addition to a decreased quality of life, vasomotor symptoms may have an impact on overall health. Vasomotor symptoms are associated with overactivity of the sympathetic nervous system, and sympathetic overdrive in turn is associated with metabolic syndrome, which is a known risk factor for cardiovascular disease. Menopausal hot flushes have a complex relationship to different features of the metabolic syndrome and not all data point towards an association between vasomotor symptoms and metabolic syndrome. Thus, it is still unclear whether vasomotor symptoms are an independent risk factor for metabolic syndrome. Research in this area is constantly evolving and we present here the most recent data on the possible association between menopausal vasomotor symptoms and the metabolic syndrome.

  2. CIDE proteins and lipid metabolism.

    Science.gov (United States)

    Xu, Li; Zhou, Linkang; Li, Peng

    2012-05-01

    Lipid homeostasis is maintained through the coordination of lipid metabolism in various tissues, including adipose tissue and the liver. The disruption of lipid homeostasis often results in the development of metabolic disorders such as obesity, diabetes mellitus, liver steatosis, and cardiovascular diseases. Cell death-inducing DNA fragmentation factor 45-like effector family proteins, including Cidea, Cideb, and Fsp27 (Cidec), are emerging as important regulators of various lipid metabolic pathways and play pivotal roles in the development of metabolic disorders. This review summarizes the latest cell death-inducing DNA fragmentation factor 45-like effector protein discoveries related to the control of lipid metabolism, with emphasis on the role of these proteins in lipid droplet growth in adipocytes and in the regulation of very low-density lipoprotein lipidation and maturation in hepatocytes.

  3. Metabolic regulation of circadian clocks.

    Science.gov (United States)

    Haydon, Michael J; Hearn, Timothy J; Bell, Laura J; Hannah, Matthew A; Webb, Alex A R

    2013-05-01

    Circadian clocks are 24-h timekeeping mechanisms, which have evolved in plants, animals, fungi and bacteria to anticipate changes in light and temperature associated with the rotation of the Earth. The current paradigm to explain how biological clocks provide timing information is based on multiple interlocking transcription-translation negative feedback loops (TTFL), which drive rhythmic gene expression and circadian behaviour of growth and physiology. Metabolism is an important circadian output, which in plants includes photosynthesis, starch metabolism, nutrient assimilation and redox homeostasis. There is increasing evidence in a range of organisms that these metabolic outputs can also contribute to circadian timing and might also comprise independent circadian oscillators. In this review, we summarise the mechanisms of circadian regulation of metabolism by TTFL and consider increasing evidence that rhythmic metabolism contributes to the circadian network. We highlight how this might be relevant to plant circadian clock function.

  4. Retinoid Metabolism and Diabetes Mellitus

    Directory of Open Access Journals (Sweden)

    Eun-Jung Rhee

    2012-06-01

    Full Text Available Retinoid acid is a metabolite of vitamin A and functions as an important factor in cell survival, differentiation and death. Most previous studies on retinoid metabolism have focused on its association with cancer, hematologic and dermatologic disorders. Given the special concern over the recent increase in the prevalence of diabetes worldwide, the role of retinoid metabolism on glucose metabolism and insulin resistance in the human body is of marked importance. Therefore, in this issue, we review the literature on the association of retinoid metabolism with glucose tolerance, with regard to insulin secretion, pancreatic autoimmunity, insulin sensitivity and lipid metabolism. Further, we tried to assess the possibility of using retinoids as a novel therapeutic strategy for diabetes.

  5. [Hypovitaminosis D and metabolic syndrome].

    Science.gov (United States)

    Miñambres, Inka; de Leiva, Alberto; Pérez, Antonio

    2014-12-23

    Metabolic syndrome and hypovitaminosis D are 2 diseases with high prevalence that share several risk factors, while epidemiological evidence shows they are associated. Although the mechanisms involved in this association are not well established, hypovitaminosis D is associated with insulin resistance, decreased insulin secretion and activation of the renin-angiotensin system, mechanisms involved in the pathophysiology of metabolic syndrome. However, the apparent ineffectiveness of vitamin D supplementation on metabolic syndrome components, as well as the limited information about the effect of improving metabolic syndrome components on vitamin D concentrations, does not clarify the direction and the mechanisms involved in the causal relationship between these 2 pathologies. Overall, because of the high prevalence and the epidemiological association between both diseases, hypovitaminosis D could be considered a component of the metabolic syndrome.

  6. 六种非经典抗精神病药对首发精神分裂症患者代谢的影响%Influences of six atypical antipsychotics on metabolism in the treatment for patients with first-episode schizophrenia

    Institute of Scientific and Technical Information of China (English)

    亓高超

    2012-01-01

    Objective To explore the influences of 6 atypical antipsychotics on blood triglyceride (TG), high density lipoproteins (HDL), glucose, glycohemoglobin (HbAlC) and body weight in the treatment for patients with frist-episode schizophrenia. Methods A total of 210 patients with frist-episode schizophrenia were divided into clozapine group ( 38 cases) , olanzapine group (34 cases) , quetiapine group ( 32 cases ) , risperidone group ( 37 cases ) , amisulpride group (33 cases) and aripiprazole group (36 cases) for 8 weeks treatment. The blood TG, HDL, glucose, HbA1C and body weight were measured at baseline and at the end of the treatment. Results Compared with the baseline, there were no significant differences in blood level of TG, HDL, glucose, HbAlC and body weight of patients in aripiprazole group after the 8-week treatment. All the indexes mentioned above in clozapine group and olanzapine group increased significantly after the treatment (P <0. 05 or P <0. 01). Body weight increased significantly after the treatment in patients in quetiapine group, risperidone group and amisulpride group (P<0.01), however, no significant differences were found on TG, HDL, glucose and HbA1C in the 3 groups after the treatment compared with the baseline. Conclusion Aripiprazole has no effect on metabolic markers in patients with schizophrenia, but clozapine and olanzapine can heighten the blood TG, HDL, glucose, HbAlC and body weight. Quetiapine, risperidone, amisulpride only result in body weight gain in schizophrenic patients.%目的 探讨非经典抗精神病药对精神分裂症患者血甘油三酯(TG)、高密度脂蛋白(HDL)、血糖、糖化血红蛋白(HbA1C)和体质量的影响.方法 将210例精神分裂症患者分为氯氮平组38例、奥氮平组34例、喹硫平组32例、利培酮组37例、氨磺必利组33例、阿立哌唑组36例,治疗8周.于治疗前和治疗8周测量空腹血TG、HDL、血糖、HbA1C和体质量.结果 治疗前后

  7. Xenobiotic Metabolism and Gut Microbiomes

    Science.gov (United States)

    Das, Anubhav; Srinivasan, Meenakshi; Ghosh, Tarini Shankar; Mande, Sharmila S.

    2016-01-01

    Humans are exposed to numerous xenobiotics, a majority of which are in the form of pharmaceuticals. Apart from human enzymes, recent studies have indicated the role of the gut bacterial community (microbiome) in metabolizing xenobiotics. However, little is known about the contribution of the plethora of gut microbiome in xenobiotic metabolism. The present study reports the results of analyses on xenobiotic metabolizing enzymes in various human gut microbiomes. A total of 397 available gut metagenomes from individuals of varying age groups from 8 nationalities were analyzed. Based on the diversities and abundances of the xenobiotic metabolizing enzymes, various bacterial taxa were classified into three groups, namely, least versatile, intermediately versatile and highly versatile xenobiotic metabolizers. Most interestingly, specific relationships were observed between the overall drug consumption profile and the abundance and diversity of the xenobiotic metabolizing repertoire in various geographies. The obtained differential abundance patterns of xenobiotic metabolizing enzymes and bacterial genera harboring them, suggest their links to pharmacokinetic variations among individuals. Additional analyses of a few well studied classes of drug modifying enzymes (DMEs) also indicate geographic as well as age specific trends. PMID:27695034

  8. Metabolic syndrome and eye diseases.

    Science.gov (United States)

    Poh, Stanley; Mohamed Abdul, Riswana Banu Binte; Lamoureux, Ecosse L; Wong, Tien Y; Sabanayagam, Charumathi

    2016-03-01

    Metabolic syndrome is becoming a worldwide medical and public health challenge as it has been seen increasing in prevalence over the years. Age-related eye diseases, the leading cause of blindness globally and visual impairment in developed countries, are also on the rise due to aging of the population. Many of the individual components of the metabolic syndrome have been shown to be associated with these eye diseases. However, the association of metabolic syndrome with eye diseases is not clear. In this review, we reviewed the evidence for associations between metabolic syndrome and certain ocular diseases in populations. We also reviewed the association of individual metabolic syndrome components with ocular diseases due to a paucity of research in this area. Besides, we also summarised the current understanding of etiological mechanisms of how metabolic syndrome or the individual components lead to these ocular diseases. With increasing evidence of such associations, it may be important to identify patients who are at risk of developing metabolic syndrome as prompt treatment and intervention may potentially decrease the risk of developing certain ocular diseases.

  9. Martial Arts and Metabolic Diseases

    Directory of Open Access Journals (Sweden)

    Hidetaka Hamasaki

    2016-05-01

    Full Text Available Different forms of martial arts are practiced worldwide, each with various intensities of physical activity. These disciplines are potentially an effective exercise therapy for metabolic diseases. Tai chi is the most well-studied style of martial arts and has shown evidence of its effect on metabolic diseases; however, little evidence is available regarding the association between other styles of martial arts and metabolic health. To summarize and evaluate the effects of martial arts on metabolic diseases, eligible articles were searched by using Pubmed. To date, systematic reviews provide no definite conclusion on the effectiveness of tai chi for treating metabolic diseases because of a small numbers of subjects, short durations of clinical trials, and some biases involved in testing. However, there are several clinical studies on subjects with metabolic diseases, which show that tai chi improves obesity, glycemic control, blood pressure control, and lipid profiles. Currently, some limited evidence suggests that other martial arts, such as kung fu and karate, may be beneficial for body composition, glycemic control, and arterial stiffness. To clarify the effectiveness of martial arts for treating metabolic diseases, well-designed prospective studies, preferably with a larger number of subjects and of longer duration, are warranted.

  10. [Regulation of terpene metabolism

    Energy Technology Data Exchange (ETDEWEB)

    Croteau, R.

    1991-01-01

    During the last grant period, we have completed studies on the key pathways of monoterpene biosynthesis and catabolism in sage and peppermint, and have, by several lines of evidence, deciphered the rate-limiting step of each pathway. We have at least partially purified and characterized the relevant enzymes of each pathway. We have made a strong case, based on analytical, in vivo, and in vitro studies, that terpene accumulation depends upon the balance between biosynthesis and catabolism, and provided supporting evidence that these processes are developmentally-regulated and very closely associated with senescence of the oil glands. Oil gland ontogeny has been characterized at the ultrastructural level. We have exploited foliar-applied bioregulators to delay gland senescence, and have developed tissue explant and cell culture systems to study several elusive aspects of catabolism. We have isolated pure gland cell clusters and localized monoterpene biosynthesis and catabolism within these structures, and have used these preparations as starting materials for the purification to homogeneity of target regulatory'' enzymes. We have thus developed the necessary background knowledge, based on a firm understanding of enzymology, as well as the necessary experimental tools for studying the regulation of monoterpene metabolism at the molecular level. Furthermore, we are now in a position to extend our systematic approach to other terpenoid classes (C[sub 15]-C[sub 30]) produced by oil glands.

  11. Physics of metabolic organization.

    Science.gov (United States)

    Jusup, Marko; Sousa, Tânia; Domingos, Tiago; Labinac, Velimir; Marn, Nina; Wang, Zhen; Klanjšček, Tin

    2016-09-09

    We review the most comprehensive metabolic theory of life existing to date. A special focus is given to the thermodynamic roots of this theory and to implications that the laws of physics-such as the conservation of mass and energy-have on all life. Both the theoretical foundations and biological applications are covered. Hitherto, the foundations were more accessible to physicists or mathematicians, and the applications to biologists, causing a dichotomy in what always should have been a single body of work. To bridge the gap between the two aspects of the same theory, we (i) adhere to the theoretical formalism, (ii) try to minimize the amount of information that a reader needs to process, but also (iii) invoke examples from biology to motivate the introduction of new concepts and to justify the assumptions made, and (iv) show how the careful formalism of the general theory enables modular, self-consistent extensions that capture important features of the species and the problem in question. Perhaps the most difficult among the introduced concepts, the utilization (or mobilization) energy flow, is given particular attention in the form of an original and considerably simplified derivation. Specific examples illustrate a range of possible applications-from energy budgets of individual organisms, to population dynamics, to ecotoxicology.

  12. Physics of metabolic organization

    Science.gov (United States)

    Jusup, Marko; Sousa, Tânia; Domingos, Tiago; Labinac, Velimir; Marn, Nina; Wang, Zhen; Klanjšček, Tin

    2017-03-01

    We review the most comprehensive metabolic theory of life existing to date. A special focus is given to the thermodynamic roots of this theory and to implications that the laws of physics-such as the conservation of mass and energy-have on all life. Both the theoretical foundations and biological applications are covered. Hitherto, the foundations were more accessible to physicists or mathematicians, and the applications to biologists, causing a dichotomy in what always should have been a single body of work. To bridge the gap between the two aspects of the same theory, we (i) adhere to the theoretical formalism, (ii) try to minimize the amount of information that a reader needs to process, but also (iii) invoke examples from biology to motivate the introduction of new concepts and to justify the assumptions made, and (iv) show how the careful formalism of the general theory enables modular, self-consistent extensions that capture important features of the species and the problem in question. Perhaps the most difficult among the introduced concepts, the utilization (or mobilization) energy flow, is given particular attention in the form of an original and considerably simplified derivation. Specific examples illustrate a range of possible applications-from energy budgets of individual organisms, to population dynamics, to ecotoxicology.

  13. Brain Regulation of Energy Metabolism.

    Science.gov (United States)

    Roh, Eun; Kim, Min Seon

    2016-12-01

    In healthy individuals, energy intake is in balance with energy expenditure, which helps to maintain a normal body weight. The brain's inability to control energy homeostasis underlies the pathology of hyperphagia and obesity. The brain detects body energy excess and deficit by sensing the levels of circulating metabolic hormones and nutrients and by receiving metabolic information from the periphery via the autonomic nervous system. A specialized neuronal network coordinates energy intake behavior and the metabolic processes affecting energy expenditure. Here, we briefly review neuronal mechanisms by which our body maintains energy balance.

  14. Citrate Metabolism by Pediococcus halophilus

    OpenAIRE

    Kanbe, Chiyuki; Uchida, Kinji

    1987-01-01

    Several strains of non-citrate-metabolizing Pediococcus halophilus have previously been isolated from soy sauce mash or moromi. The factors controlling the metabolism of citrate in soy pediococci were studied. All the soy pediococcal strains tested which failed to decompose citrate did not possess citrate lyase [citrate (pro-3S)-lyase; EC 4.1.3.6] activity. In P. halophilus, citrate lyase was an inducible enzyme, and the optimum pH for activity was 7.0. The metabolism of citrate in P. halophi...

  15. Human metabolic atlas: an online resource for human metabolism.

    Science.gov (United States)

    Pornputtapong, Natapol; Nookaew, Intawat; Nielsen, Jens

    2015-01-01

    Human tissue-specific genome-scale metabolic models (GEMs) provide comprehensive understanding of human metabolism, which is of great value to the biomedical research community. To make this kind of data easily accessible to the public, we have designed and deployed the human metabolic atlas (HMA) website (http://www.metabolicatlas.org). This online resource provides comprehensive information about human metabolism, including the results of metabolic network analyses. We hope that it can also serve as an information exchange interface for human metabolism knowledge within the research community. The HMA consists of three major components: Repository, Hreed (Human REaction Entities Database) and Atlas. Repository is a collection of GEMs for specific human cell types and human-related microorganisms in SBML (System Biology Markup Language) format. The current release consists of several types of GEMs: a generic human GEM, 82 GEMs for normal cell types, 16 GEMs for different cancer cell types, 2 curated GEMs and 5 GEMs for human gut bacteria. Hreed contains detailed information about biochemical reactions. A web interface for Hreed facilitates an access to the Hreed reaction data, which can be easily retrieved by using specific keywords or names of related genes, proteins, compounds and cross-references. Atlas web interface can be used for visualization of the GEMs collection overlaid on KEGG metabolic pathway maps with a zoom/pan user interface. The HMA is a unique tool for studying human metabolism, ranging in scope from an individual cell, to a specific organ, to the overall human body. This resource is freely available under a Creative Commons Attribution-NonCommercial 4.0 International License.

  16. Redesigned Human Metabolic Simulator

    Science.gov (United States)

    Duffield, Bruce; Jeng, Frank; Lange, Kevin

    2008-01-01

    A design has been formulated for a proposed improved version of an apparatus that simulates atmospheric effects of human respiration by introducing controlled amounts of carbon dioxide, water vapor, and heat into the air. Denoted a human metabolic simulator (HMS), the apparatus is used for testing life-support equipment when human test subjects are not available. The prior version of the HMS, to be replaced, was designed to simulate the respiratory effects of as many as four persons. It exploits the catalytic combustion of methyl acetate, for which the respiratory quotient (the molar ratio of carbon dioxide produced to oxygen consumed) is very close to the human respiratory quotient of about 0.86. The design of the improved HMS provides for simulation of the respiratory effects of as many as eight persons at various levels of activity. The design would also increase safety by eliminating the use of combustion. The improved HMS (see figure) would include a computer that would exert overall control. The computer would calculate the required amounts of oxygen removal, carbon dioxide addition, water addition, and heat addition by use of empirical equations for metabolic profiles of respiration and heat. A blower would circulate air between the HMS and a chamber containing a life-support system to be tested. With the help of feedback from a mass flowmeter, the blower speed would be adjusted to regulate the rate of flow according to the number of persons to be simulated and to a temperature-regulation requirement (the air temperature would indirectly depend on the rate of flow, among other parameters). Oxygen would be removed from the circulating air by means of a commercially available molecular sieve configured as an oxygen concentrator. Oxygen, argon, and trace amounts of nitrogen would pass through a bed in the molecular sieve while carbon dioxide, the majority of nitrogen, and other trace gases would be trapped by the bed and subsequently returned to the chamber. If

  17. Testosterone and metabolic syndrome.

    Science.gov (United States)

    Cunningham, Glenn R

    2015-01-01

    Controversies surround the usefulness of identifying patients with the metabolic syndrome (MetS). Many of the components are accepted risk factors for cardiovascular disease (CVD). Although the MetS as defined includes many men with insulin resistance, insulin resistance is not universal. The low total testosterone (TT) and sex hormone binding globulin (SHBG) levels in these men are best explained by the hyperinsulinism and increased inflammatory cytokines that accompany obesity and increased waist circumference. It is informative that low SHBG levels predict future development of the MetS. Evidence is strong relating low TT levels to CVD in men with and without the MetS; however, the relationship may not be causal. The recommendations of the International Diabetes Federation for managing the MetS include cardiovascular risk assessment, lifestyle changes in diet, exercise, weight reduction and treatment of individual components of the MetS. Unfortunately, it is uncommon to see patients with the MetS lose and maintain a 10% weight loss. Recent reports showing testosterone treatment induced dramatic changes in weight, waist circumference, insulin sensitivity, hemoglobin A1c levels and improvements in each of the components of the MetS are intriguing. While some observational studies have reported that testosterone replacement therapy increases cardiovascular events, the Food and Drug Administration in the United States has reviewed these reports and found them to be seriously flawed. Large, randomized, placebo-controlled trials are needed to provide more definitive data regarding the efficacy and safety of this treatment in middle and older men with the MetS and low TT levels.

  18. Testosterone and metabolic syndrome

    Directory of Open Access Journals (Sweden)

    Glenn R Cunningham

    2015-04-01

    Full Text Available Controversies surround the usefulness of identifying patients with the metabolic syndrome (MetS. Many of the components are accepted risk factors for cardiovascular disease (CVD. Although the MetS as defined includes many men with insulin resistance, insulin resistance is not universal. The low total testosterone (TT and sex hormone binding globulin (SHBG levels in these men are best explained by the hyperinsulinism and increased inflammatory cytokines that accompany obesity and increased waist circumference. It is informative that low SHBG levels predict future development of the MetS. Evidence is strong relating low TT levels to CVD in men with and without the MetS; however, the relationship may not be causal. The recommendations of the International Diabetes Federation for managing the MetS include cardiovascular risk assessment, lifestyle changes in diet, exercise, weight reduction and treatment of individual components of the MetS. Unfortunately, it is uncommon to see patients with the MetS lose and maintain a 10% weight loss. Recent reports showing testosterone treatment induced dramatic changes in weight, waist circumference, insulin sensitivity, hemoglobin A1c levels and improvements in each of the components of the MetS are intriguing. While some observational studies have reported that testosterone replacement therapy increases cardiovascular events, the Food and Drug Administration in the United States has reviewed these reports and found them to be seriously flawed. Large, randomized, placebo-controlled trials are needed to provide more definitive data regarding the efficacy and safety of this treatment in middle and older men with the MetS and low TT levels.

  19. Metabolic Syndrome in Nurses

    Directory of Open Access Journals (Sweden)

    María Escasany

    2014-01-01

    Full Text Available Objectives: To estimate the prevalence of metabolic syndrome (MS in female nurses in the Hospital Juan A. Fernandez (HJAF, Buenos Aires, Argentina, and to determine whether work, rest, diet, and health, are predictive of it.Materials and methods: For the first objective, a descriptive, observational and cross-sectional study was conducted, and for the second, a multivariate cross-sectional observational multivariate analysis was made comparing independent samples. A total of 192 nurses were studied between October 2008 and March 2009. They completed a questionnaire that include indicators that could be predictors of MS. Anthropometric measurements, including blood pressure were taken, was well as a blood sample to analyze fasting glucose, HDL-C and plasma triglycerides.Results: It was found that 35% and 41% of nurses were overweight and obese, respectively. A total of 92% had centro-abdominal obesity. The prevalence of MS found was 33.3% (95%CI, 26.7 to 40.5. Those who had this disease were between 53±9 years. Statistically significant differences were found in the bivariate analysis between MS and the variables, age, length of service, time worked during night shift, and academic studies.Conclusions: The prevalence of MS was 64/192 in HJAF nurses (33.3% I 95%CI, 26.7-40.5. There were no statistically significant differences with the indicators of, age, “time worked during night shift”, and “studies”. These results suggest that age is the most important variable in predicting the onset of MS in the population of nurses.

  20. Novel genes in LDL metabolism

    DEFF Research Database (Denmark)

    Christoffersen, Mette; Tybjærg-Hansen, Anne

    2015-01-01

    of these findings still require independent replications and/or functional studies to confirm the exact role in LDL metabolism and the clinical implications for human health. SUMMARY: GWAS, exome sequencing studies, and recently 'exome chip' studies have suggested several novel genes with effects on LDL cholesterol....... Novel genes in LDL metabolism will improve our understanding of mechanisms in LDL metabolism, and may lead to the identification of new drug targets to reduce LDL cholesterol levels.......PURPOSE OF REVIEW: To summarize recent findings from genome-wide association studies (GWAS), whole-exome sequencing of patients with familial hypercholesterolemia and 'exome chip' studies pointing to novel genes in LDL metabolism. RECENT FINDINGS: The genetic loci for ATP-binding cassette...

  1. Context-dependent metabolic networks

    CERN Document Server

    Beguerisse-Díaz, Mariano; Oyarzún, Diego; Picó, Jesús; Barahona, Mauricio

    2016-01-01

    Cells adapt their metabolism to survive changes in their environment. We present a framework for the construction and analysis of metabolic reaction networks that can be tailored to reflect different environmental conditions. Using context-dependent flux distributions from Flux Balance Analysis (FBA), we produce directed networks with weighted links representing the amount of metabolite flowing from a source reaction to a target reaction per unit time. Such networks are analyzed with tools from network theory to reveal salient features of metabolite flows in each biological context. We illustrate our approach with the directed network of the central carbon metabolism of Escherichia coli, and study its properties in four relevant biological scenarios. Our results show that both flow and network structure depend drastically on the environment: networks produced from the same metabolic model in different contexts have different edges, components, and flow communities, capturing the biological re-routing of metab...

  2. Adipose Tissue Metabolism During Hypobaria

    Directory of Open Access Journals (Sweden)

    D. P. Chattopadhyay

    1974-10-01

    Full Text Available Possible factors affecting the metabolism of adipose tissue under hypobaric conditions have been reviewed. The hormonal changes brought into play under hypoxic stress generally stress generally increase the adipose tissue lipolysis.

  3. Metabolism and biochemistry in hypogravity

    Science.gov (United States)

    Leach, Carolyn S.

    The headward shift of body fluid and increase in stress-related hormones that occur in hypogravity bring about a number of changes in metabolism and biochemistry of the human body. Such alterations may have important effects on health during flight and during a recovery period after return to Earth. Body fluid and electrolytes are lost, and blood levels of several hormones that control metabolism are altered during space flight. Increased serum calcium may lead to an increased risk of renal stone formation during flight, and altered drug metabolism could influence the efficacy of therapeutic agents. Orthostatic intolerance and an increased risk of fracturing weakened bones are concerns at landing. It is important to understand biochemistry and metabolism in hypogravity so that clinically important developments can be anticipated and prevented or ameliorated.

  4. Metabolism and biochemistry in hypogravity

    Science.gov (United States)

    Leach, Carolyn S.

    1991-01-01

    The headward shift of body fluid and increase in stress-related hormones that occur in hypogravity bring about a number of changes in metabolism and biochemistry of the human body. Such alterations may have important effects on health during flight and during a recovery period after return to earth. Body fluid and electrolytes are lost, and blood levels of several hormones that control metabolism are altered during space flight. Increased serum calcium may lead to an increased risk of renal stone formation during flight, and altered drug metabolism could influence the efficacy of therapeutic agents. Orthostatic intolerance and an increased risk of fracturing weakened bones are concerns at landing. It is important to understand biochemistry and metabolism in hypogravity so that clinically important developments can be anticipated and prevented or ameliorated.

  5. Metabolic Resistance in Bed Bugs

    Directory of Open Access Journals (Sweden)

    Omprakash Mittapalli

    2011-03-01

    Full Text Available Blood-feeding insects have evolved resistance to various insecticides (organochlorines, pyrethroids, carbamates, etc. through gene mutations and increased metabolism. Bed bugs (Cimex lectularius are hematophagous ectoparasites that are poised to become one of the major pests in households throughout the United States. Currently, C. lectularius has attained a high global impact status due to its sudden and rampant resurgence. Resistance to pesticides is one factor implicated in this phenomenon. Although much emphasis has been placed on target sensitivity, little to no knowledge is available on the role of key metabolic players (e.g., cytochrome P450s and glutathione S-transferases towards pesticide resistance in C. lectularius. In this review, we discuss different modes of resistance (target sensitivity, penetration resistance, behavioral resistance, and metabolic resistance with more emphasis on metabolic resistance.

  6. Exercise training in metabolic myopathies

    DEFF Research Database (Denmark)

    Vissing, J

    2016-01-01

    , patients with FAODs typically develop symptoms later in exercise than patients with GSDs. Due to the exercise-related symptoms in metabolic myopathies, patients generally have been advised to shun physical training. However, immobility is associated with multiple health issues, and may even cause unwanted...... metabolic adaptations, such as increased dependence on glycogen use and a reduced capacity for fatty acid oxidation, which is detrimental in GSDs. Training has not been studied systematically in any FAODs and in just a few GSDs. However, studies on single bouts of exercise in most metabolic myopathies show...... that particularly moderate intensity aerobic exercise is well tolerated in these conditions. Even low-intensity resistance training of short duration is tolerated in McArdle disease. Training in patients with FAOD potentially can also expand the metabolic bottleneck by increasing expression of the defective...

  7. Gait Dynamics and Locomotor Metabolism

    Science.gov (United States)

    2009-05-01

    field settings from simple technologies such as gps monitors and pedometers. 15. SUBJECT TERMS Locomotion, gait, metabolism, body size, load...a reduction in exercise intensity. REFERENCES: 1. Alexander, RM. Sprinting and endurance for runners and cyclists . American Journal of

  8. Multidimensional optimality of microbial metabolism.

    Science.gov (United States)

    Schuetz, Robert; Zamboni, Nicola; Zampieri, Mattia; Heinemann, Matthias; Sauer, Uwe

    2012-05-04

    Although the network topology of metabolism is well known, understanding the principles that govern the distribution of fluxes through metabolism lags behind. Experimentally, these fluxes can be measured by (13)C-flux analysis, and there has been a long-standing interest in understanding this functional network operation from an evolutionary perspective. On the basis of (13)C-determined fluxes from nine bacteria and multi-objective optimization theory, we show that metabolism operates close to the Pareto-optimal surface of a three-dimensional space defined by competing objectives. Consistent with flux data from evolved Escherichia coli, we propose that flux states evolve under the trade-off between two principles: optimality under one given condition and minimal adjustment between conditions. These principles form the forces by which evolution shapes metabolic fluxes in microorganisms' environmental context.

  9. Metabolic control of renin secretion.

    Science.gov (United States)

    Peti-Peterdi, János; Gevorgyan, Haykanush; Lam, Lisa; Riquier-Brison, Anne

    2013-01-01

    One emerging topic in renin-angiotensin system (RAS) research is the direct local control of renin synthesis and release by endogenous metabolic intermediates. During the past few years, our laboratory has characterized the localization and signaling of the novel metabolic receptor GPR91 in the normal and diabetic kidney and established GPR91 as a new, direct link between high glucose and RAS activation in diabetes. GPR91 (also called SUCNR1) binds tricarboxylic acid (TCA) cycle intermediate succinate which can rapidly accumulate in the local tissue environment when energy supply and demand are out of balance. In a variety of physiological and pathological conditions associated with metabolic stress, succinate signaling via GPR91 appears to be an important mediator or modulator of renin secretion. This review summarizes our current knowledge on the control of renin release by molecules of endogenous metabolic pathways with the main focus on succinate/GPR91.

  10. Tailoring the metabolism against mutations

    Science.gov (United States)

    Gulbahce, Natali; Motter, Adilson E.; Almaas, Eivind; Barabasi, Albert Laszlo

    2008-03-01

    In the post-genomic era, organisms can be modelled at the whole-cell level in silico via steady state methods to describe their metabolic capabilities. We use two such methods, Flux Balance Analysis and Minimization of Metabolic Adjustment to explore the behavior of cells (of E. coli and S. cerevisiae) after severe mutations. We propose experimentally feasible ways of modifying the underlying biochemical reaction network of a mutant cell such that cell functionality, in particular growth rate, is significantly improved.

  11. Evolution of metabolic network organization

    Directory of Open Access Journals (Sweden)

    Bonchev Danail

    2010-05-01

    Full Text Available Abstract Background Comparison of metabolic networks across species is a key to understanding how evolutionary pressures shape these networks. By selecting taxa representative of different lineages or lifestyles and using a comprehensive set of descriptors of the structure and complexity of their metabolic networks, one can highlight both qualitative and quantitative differences in the metabolic organization of species subject to distinct evolutionary paths or environmental constraints. Results We used a novel representation of metabolic networks, termed network of interacting pathways or NIP, to focus on the modular, high-level organization of the metabolic capabilities of the cell. Using machine learning techniques we identified the most relevant aspects of cellular organization that change under evolutionary pressures. We considered the transitions from prokarya to eukarya (with a focus on the transitions among the archaea, bacteria and eukarya, from unicellular to multicellular eukarya, from free living to host-associated bacteria, from anaerobic to aerobic, as well as the acquisition of cell motility or growth in an environment of various levels of salinity or temperature. Intuitively, we expect organisms with more complex lifestyles to have more complex and robust metabolic networks. Here we demonstrate for the first time that such organisms are not only characterized by larger, denser networks of metabolic pathways but also have more efficiently organized cross communications, as revealed by subtle changes in network topology. These changes are unevenly distributed among metabolic pathways, with specific categories of pathways being promoted to more central locations as an answer to environmental constraints. Conclusions Combining methods from graph theory and machine learning, we have shown here that evolutionary pressures not only affects gene and protein sequences, but also specific details of the complex wiring of functional modules

  12. Gut Microbiota and Metabolic Disorders

    OpenAIRE

    Kyu Yeon Hur; Myung-Shik Lee

    2015-01-01

    Gut microbiota plays critical physiological roles in the energy extraction and in the control of local or systemic immunity. Gut microbiota and its disturbance also appear to be involved in the pathogenesis of diverse diseases including metabolic disorders, gastrointestinal diseases, cancer, etc. In the metabolic point of view, gut microbiota can modulate lipid accumulation, lipopolysaccharide content and the production of short-chain fatty acids that affect food intake, inflammatory tone, or...

  13. Carbohydrate Metabolism in Submariner Personnel

    Science.gov (United States)

    1983-06-01

    metabolism the Wilkerson Point System, for glucose values, used in conjunction with patterns of insulin response described by Kraft(4) serves as the means...amount of exercise and carbohydrate metabolism characteristics occurred in both submariners and non-submariners. An inverse relationship also seems to...individuals(7). In the present study a significant negative correlation was also found between exercise vs one and two hour postprandial glucose and two hour

  14. Metabolic syndrome and cardiovascular risk

    Directory of Open Access Journals (Sweden)

    Abdullah M Alshehri

    2010-11-01

    Full Text Available The constellation of dyslipidemia (hypertriglyceridemia and low levels of high-density lipoprotein cholesterol, elevated blood pressure, impaired glucose tolerance, and central obesity is now classified as metabolic syndrome, also called syndrome X. In the past few years, several expert groups have attempted to set forth simple diagnostic criteria for use in clinical practice to identify patients who manifest the multiple components of the metabolic syndrome. These criteria have varied somewhat in specific elements, but in general, they include a combination of multiple and metabolic risk factors. The most widely recognized of the metabolic risk factors are atherogenic dyslipidemia, elevated blood pressure, and elevated plasma glucose. Individuals with these characteristics, commonly manifest a prothrombotic state as well as and a proinflammatory state. Atherogenic dyslipidemia consists of an aggregation of lipoprotein abnormalities including elevated serum triglyceride and apolipoprotein B (apoB, increased small LDL particles, and a reduced level of HDL cholesterol (HDL-C. The metabolic syndrome is often referred to as if it were a discrete entity with a single cause. Available data suggest that it truly is a syndrome, ie, a grouping of atherosclerotic cardiovascular disease (ASCVD risk factors, that probably has more than one cause. Regardless of cause, the syndrome identifies individuals at an elevated risk for ASCVD. The magnitude of the increased risk can vary according to the components of the syndrome present as well as the other, non-metabolic syndrome risk factors in a particular person.

  15. Inherited or acquired metabolic disorders.

    Science.gov (United States)

    Eichler, Florian; Ratai, Eva; Carroll, Jason J; Masdeu, Joseph C

    2016-01-01

    This chapter starts with a description of imaging of inherited metabolic disorders, followed by a discussion on imaging of acquired toxic-metabolic disorders of the adult brain. Neuroimaging is crucial for the diagnosis and management of a number of inherited metabolic disorders. Among these, inherited white-matter disorders commonly affect both the nervous system and endocrine organs. Magnetic resonance imaging (MRI) has enabled new classifications of these disorders that have greatly enhanced both our diagnostic ability and our understanding of these complex disorders. Beyond the classic leukodystrophies, we are increasingly recognizing new hereditary leukoencephalopathies such as the hypomyelinating disorders. Conventional imaging can be unrevealing in some metabolic disorders, but proton magnetic resonance spectroscopy (MRS) may be able to directly visualize the metabolic abnormality in certain disorders. Hence, neuroimaging can enhance our understanding of pathogenesis, even in the absence of a pathologic specimen. This review aims to present pathognomonic brain MRI lesion patterns, the diagnostic capacity of proton MRS, and information from clinical and laboratory testing that can aid diagnosis. We demonstrate that applying an advanced neuroimaging approach enhances current diagnostics and management. Additional information on inherited and metabolic disorders of the brain can be found in Chapter 63 in the second volume of this series.

  16. Metabolic management of brain cancer.

    Science.gov (United States)

    Seyfried, Thomas N; Kiebish, Michael A; Marsh, Jeremy; Shelton, Laura M; Huysentruyt, Leanne C; Mukherjee, Purna

    2011-06-01

    Malignant brain tumors are a significant health problem in children and adults. Conventional therapeutic approaches have been largely unsuccessful in providing long-term management. As primarily a metabolic disease, malignant brain cancer can be managed through changes in metabolic environment. In contrast to normal neurons and glia, which readily transition to ketone bodies (β-hydroxybutyrate) for energy under reduced glucose, malignant brain tumors are strongly dependent on glycolysis for energy. The transition from glucose to ketone bodies as a major energy source is an evolutionary conserved adaptation to food deprivation that permits the survival of normal cells during extreme shifts in nutritional environment. Only those cells with a flexible genome and normal mitochondria can effectively transition from one energy state to another. Mutations restrict genomic and metabolic flexibility thus making tumor cells more vulnerable to energy stress than normal cells. We propose an alternative approach to brain cancer management that exploits the metabolic flexibility of normal cells at the expense of the genetically defective and metabolically challenged tumor cells. This approach to brain cancer management is supported from recent studies in mice and humans treated with calorie restriction and the ketogenic diet. Issues of implementation and use protocols are presented for the metabolic management of brain cancer.

  17. Metabolic regulation of insulin secretion.

    Science.gov (United States)

    Keane, Kevin; Newsholme, Philip

    2014-01-01

    Regulation of metabolic fuel homeostasis is a critical function of β-cells, which are located in the islets of Langerhans of the animal pancreas. Impairment of this β-cell function is a hallmark of pancreatic β-cell failure and may lead to development of type 2 diabetes mellitus. β-Cells are essentially "fuel sensors" that monitor and react to elevated nutrient load by releasing insulin. This response involves metabolic activation and generation of metabolic coupling factors (MCFs) that relay the nutrient signal throughout the cell and induce insulin biosynthesis and secretion. Glucose is the most important insulin secretagogue as it is the primary fuel source in food. Glucose metabolism is central to generation of MCFs that lead to insulin release, most notably ATP. In addition, other classes of nutrients are able to augment insulin secretion and these include members of the lipid and amino acid family of nutrients. Therefore, it is important to investigate the interplay between glucose, lipid, and amino acid metabolism, as it is this mixed nutrient sensing that generate the MCFs required for insulin exocytosis. The mechanisms by which these nutrients are metabolized to generate MCFs, and how they impact on β-cell insulin release and function, are discussed in detail in this article.

  18. Sleep apnoea and metabolic dysfunction

    Directory of Open Access Journals (Sweden)

    Maria R. Bonsignore

    2013-09-01

    Full Text Available Obstructive sleep apnoea (OSA is a highly prevalent condition often associated with central obesity. In the past few years, several studies have analysed the potential independent contribution of OSA to the pathogenesis of metabolic abnormalities, including type 2 diabetes, the metabolic syndrome and non-alcoholic fatty liver disease. New perspectives in OSA patient care have been opened by the promotion of lifestyle interventions, such as diet and exercise programmes that could improve both OSA and the metabolic profile. The rich clinical literature on this subject, together with the growing amount of data on pathophysiological mechanisms provided by animal studies using the chronic intermittent hypoxia model, urged the organising Committee of the Sleep and Breathing meeting to organise a session on sleep apnoea and metabolic dysfunction, in collaboration with the European Association for the Study of Diabetes. This review summarises the state-of-the-art lectures presented in the session, more specifically the relationship between OSA and diabetes, the role of OSA in the metabolic consequences of obesity, and the effects of lifestyle interventions on nocturnal respiratory disturbances and the metabolic profile in OSA patients.

  19. Comparative study of depressive disorder with somatic symptoms treated by duloxetine combined with aripiprazole%度洛西汀联合阿立哌唑治疗伴躯体化症状抑郁症的对照研究

    Institute of Scientific and Technical Information of China (English)

    魏宏强; 康瑞; 霍军; 曹雍华; 李淑英

    2013-01-01

    目的 探讨度洛西汀联合阿立哌唑治疗伴躯体化症状抑郁症患者的临床疗效及安全性.方法 将60例伴躯体化症状中度抑郁症患者随机分为两组,每组30例:度洛西汀(40~60 mg/d)联合阿立哌唑(2.5~7.5 mg/d)组(研究组)、度洛西汀(40~60 mg/d)组(对照组),治疗观察期均为8周.两组患者于基线及治疗后1、2、4、8周末分别评定24项汉密尔顿抑郁量表(HAMD-24)及躯体化症状自评量表(SSS)的部分单项分,并采用副反应量表(TESS)评定治疗期间的不良反应.结果 研究组、对照组分别脱落3、2例;1周末与基线比较,研究组的抑郁症状评分差异有统计学意义(P<0.05),而该组四类躯体化症状及对照组的抑郁症状评分差异均无统计学意义(P均>0.05);研究组的抑郁症状及四类躯体化症状评分差异在1、2、4、8周末时点间均有统计学意义(P均<0.05);8周末时两组间抑郁症状有效率及四类躯体化症状评分差异均有统计学意义(P均<0.05),而不良反应发生率差异均无统计学意义(P均>0.05).结论 度洛西汀联合阿立哌唑治疗伴躯体化症状中度抑郁症患者可有效、持续改善其抑郁及躯体化症状,且不良反应发生率与单一度洛西汀治疗相当.%Objective To investigate the efficacy and safety of duloxetine combined with aripiprazole in the treatment of depressive patients with somatic symptoms.Methods Total 60 moderate depressive patients with somatic symptoms were randomly divided into two groups:duloxetine(40-60 mg/d) combined with aripiprazole (2.5-7.5 mg/d) group (study group) and duloxetine (40-60 mg/d) group(control group),30 cases for each group.Each group had a 8-week treatment.The efficacy were assessed and analyzed by 24-item Hamilton Depression Scale(HAMD-24) and parts of the individual scores of Self-rating Somatization symptom Scale (SSS) at baseline and at week 1,2,4 and 8.The side effects were assessed by Treatment

  20. 阿立哌唑联合奥氮平治疗老年阿尔茨海默病伴精神障碍的临床疗效及安全性评价%Clinical efficacy and safety of aripiprazole combined with olanzapine in the treatment of elderly Alzheimer’ s disease with mental disorders

    Institute of Scientific and Technical Information of China (English)

    付旭; 秦晓霞

    2016-01-01

    目的:观察阿立哌唑联合奥氮平治疗老年阿尔茨海默病伴精神障碍的临床疗效及安全性。方法将80例老年阿尔茨海默病伴精神障碍患者随机分为对照组40例和试验组40例。对照组予以口服奥氮平2.5 mg,每晚一次;试验组予以口服奥氮平2.5 mg,每晚一次联合阿立哌唑2.5 mg,每晚一次。2组患者一个疗程均为2周,共治疗4个疗程。比较2组患者的临床疗效、简易智能精神状态表(MMSE)评分、临床失智表(CDR)评分、日常生活能力表(ADL)评分、阿尔茨海默病评价表-认知分量表(ADAS-cog)评分、精神神经科问卷(NPI)评分、激动性问卷( CMAI)评分,以及不良反应发生率。结果治疗后,试验组的总有效率97.50%显著高于对照组47.50%( P<0.05)。治疗后,试验组的MMSE评分显著高于对照组( P<0.05),试验组的CDR、ADL、ADAS-cog、NPI、CMAI的评分显著低于对照组(P<0.05)。试验组的不良反应发生率7.50%显著低于对照组40.00%( P<0.05)。结论阿立哌唑联合奥氮平治疗老年阿尔茨海默病伴精神障碍的临床疗效确切,有利于患者神经功能的恢复,且不良反应较小。%Objective To evaluate the clinical efficacy and safety of aripiprazole combined with olanzapine in the treatment of elderly Alzhei-mer’s disease with mental disorders.Methods Eighty patients of elder-ly Alzheimer’ s disease with mental disorders were randomly divided into treatment group ( n=40) and control group ( n=40).Patients in control group were received olanzapine 2.5 mg, oral, qn.Patients in treatment group were given olanzapine 2.5 mg, oral, qn and aripiprazole 2.5 mg, oral, qn.The course of treatment was 2 weeks in two groups.A total of treatment was 4 courses.They were compared with clinical efficacy, easy-mental state table ( MMSE) score, clinical dementia table ( CDR) score, table of daily living ( ADL

  1. Treatment of Antipsychotic Drug-induced Phlegm Dampness Type Amenorrhea by Wuji Powder and a Small Dose Aripiprazole: a Clinical Study%五积散与小剂量阿立哌唑治疗抗精神病药物所致痰湿型闭经的临床研究

    Institute of Scientific and Technical Information of China (English)

    夏时炎; 张颖然; 虞洪; 孟旭; 张鹏; 刘军

    2014-01-01

    Objective To assess the efficacy and safety of Wuji Powder (WP) and a small dose aripiprazole in treatment of antipsychotic drug-induced phlegm dampness type amenorrhea.Methods Seventy female schizophrenic patients with antipsychotic drug-induced galactorrhea-amenorrhea syndrome (GAS) were recruited and randomly assigned to the treatment group and the control group,35 in each group.All patients received antipsychotic drug therapy.Patients in the treatment group additionally took WP,while those in the control group took aripiprazole (at the daily dose of 5 mg,once daily).The therapeutic course for all was 4 weeks.Prolactin levels and obesity indices [body weight、waist aircumstance、body mass index(BMI) and waist-hit ratio (WHR)] were determined before and after treatment.The efficacy was evaluated.Results The treatment course was completed in 95.71% of patients.The total effective rate of the 33 patients of the treatment group was 93.94% (31/33),while it was 91.18%(31/34) in the 34 patients of the control group.There was no difference in the total effective rate between the two groups (P >0.05).Prolactin levels in both group after treatment were significantly lower than those of the baseline (P <0.01).There was no significant difference in prolactin levels between the two groups after treatment (P >0.05).Compared with before treatment,body weight,BMI,waist circumstance,and waist-hip ratio obviously decreased after treatment,showing significant difference when compared with the control group (P <0.05).There was no significant difference in body weight,BMI,waist circumstance,and waist-hip ratio in the control group between before and after treatment (P >0.05).Conclusions Both WP and aripiprazole could lower high prolactin levels of schizophrenics with phlegm dampness type amenorrhea.They showed equivalent efficacy.But WP showed more obvious effect in reducing obesity indices.%目的 探讨五积散与小剂量阿立哌唑治疗抗精神病药物所

  2. Inborn Errors of Metabolism

    Institute of Scientific and Technical Information of China (English)

    2007-01-01

    2007164 Diagnosis, treatment and long-term following up of 223 patients with hyperphenylalaninemia detected by neonatal screening programs. YE Jun(叶军), et al. Xinhua Hosp, Shanghai Jiaotong Univ Med Sch, Shanghai Instit Pediatr Res, Shanghai 200092. Chin J Prev Med 2007;41(3);189-192. Objective To investigate the incidence of hyperphenylalaninemia (HPA) caused by different etiologic factors in China and the relationship between the phenylalanine and mental development of patients with HPAs who were diagnosed by neonatal screening and early treated. Methods Two hundred and twenty-three patients with HPA detected by neonatal screening programs were refered to us at the age of (41±27) days after birth. The differential diagnosis was performed by BH4 (20 mg/kg) loading test, urinary pterin analysis and dihydropteridine reductase (DHPR) activity determination respectively. The control of phenylalanine (Phe) metabolism, growth and mental development were evaluated in all treated patients. Related gene mutation analysis was performed in some patients. Results One hundred and twenty nine of 223 patients (57.8%) were diagnosed as phenylalanine hydroxylase deficiency (PAHD), 64 patients (28.7%) as BH4 responsive PAHD, 30 patients (13.5%) as 6-pyruvoyl tetrahydropterin synthase deficiency (PTSD). One hundred and forty-nine patients were followed at age of 4 m-22 y in our clinic. The 136 of 149 patients were treated according to different etiology at the age of 1.6 m(0.5~3.5 m) after birth. Thirteen patients were followed up without the need for treatment. All patients had normal growth development. One hundred and eight (79.4%) of 136 treated patients had normal mental development. The negative correlation(r=-0.439, P<0.01) between IQ and average Phe levels were observed in 58 patients. Twenty-eight patients were able to go to primary school or even university. Nine kinds of PTS gene mutations were found in 9 cases with PTSD, among which 286G→A and 259C→T were most

  3. Analysis of metabolic flux using dynamic labelling and metabolic modelling.

    Science.gov (United States)

    Fernie, A R; Morgan, J A

    2013-09-01

    Metabolic fluxes and the capacity to modulate them are a crucial component of the ability of the plant cell to react to environmental perturbations. Our ability to quantify them and to attain information concerning the regulatory mechanisms that control them is therefore essential to understand and influence metabolic networks. For all but the simplest of flux measurements labelling methods have proven to be the most informative. Both steady-state and dynamic labelling approaches have been adopted in the study of plant metabolism. Here the conceptual basis of these complementary approaches, as well as their historical application in microbial, mammalian and plant sciences, is reviewed, and an update on technical developments in label distribution analyses is provided. This is supported by illustrative cases studies involving the kinetic modelling of secondary metabolism. One issue that is particularly complex in the analysis of plant fluxes is the extensive compartmentation of the plant cell. This problem is discussed from both theoretical and experimental perspectives, and the current approaches used to address it are assessed. Finally, current limitations and future perspectives of kinetic modelling of plant metabolism are discussed.

  4. Analog regulation of metabolic demand

    Directory of Open Access Journals (Sweden)

    Muskhelishvili Georgi

    2011-03-01

    Full Text Available Abstract Background The 3D structure of the chromosome of the model organism Escherichia coli is one key component of its gene regulatory machinery. This type of regulation mediated by topological transitions of the chromosomal DNA can be thought of as an analog control, complementing the digital control, i.e. the network of regulation mediated by dedicated transcription factors. It is known that alterations in the superhelical density of chromosomal DNA lead to a rich pattern of differential expressed genes. Using a network approach, we analyze these expression changes for wild type E. coli and mutants lacking nucleoid associated proteins (NAPs from a metabolic and transcriptional regulatory network perspective. Results We find a significantly higher correspondence between gene expression and metabolism for the wild type expression changes compared to mutants in NAPs, indicating that supercoiling induces meaningful metabolic adjustments. As soon as the underlying regulatory machinery is impeded (as for the NAP mutants, this coherence between expression changes and the metabolic network is substantially reduced. This effect is even more pronounced, when we compute a wild type metabolic flux distribution using flux balance analysis and restrict our analysis to active reactions. Furthermore, we are able to show that the regulatory control exhibited by DNA supercoiling is not mediated by the transcriptional regulatory network (TRN, as the consistency of the expression changes with the TRN logic of activation and suppression is strongly reduced in the wild type in comparison to the mutants. Conclusions So far, the rich patterns of gene expression changes induced by alterations of the superhelical density of chromosomal DNA have been difficult to interpret. Here we characterize the effective networks formed by supercoiling-induced gene expression changes mapped onto reconstructions of E. coli's metabolic and transcriptional regulatory network. Our

  5. [Lead compound optimization strategy (1)--changing metabolic pathways and optimizing metabolism stability].

    Science.gov (United States)

    Wang, Jiang; Liu, Hong

    2013-10-01

    Lead compound optimization plays an important role in new drug discovery and development. The strategies for changing metabolic pathways can modulate pharmacokinetic properties, prolong the half life, improve metabolism stability and bioavailability of lead compounds. The strategies for changing metabolic pathways and improving metabolism stability are reviewed. These methods include blocking metabolic site, reduing lipophilicity, changing ring size, bioisosterism, and prodrug.

  6. Response to trauma and metabolic changes: posttraumatic metabolism.

    Science.gov (United States)

    Şimşek, Turgay; Şimşek, Hayal Uzelli; Cantürk, Nuh Zafer

    2014-01-01

    Stress response caused by events such as surgical trauma includes endocrine, metabolic and immunological changes. Stress hormones and cytokines play a role in these reactions. More reactions are induced by greater stress, ultimately leading to greater catabolic effects. Cuthbertson reported the characteristic response that occurs in trauma patients: protein and fat consumption and protection of body fluids and electrolytes because of hypermetabolism in the early period. The oxygen and energy requirement increases in proportion to the severity of trauma. The awareness of alterations in amino acid, lipid, and carbohydrate metabolism changes in surgical patients is important in determining metabolic and nutritional support. The main metabolic change in response to injury that leads to a series of reactions is the reduction of the normal anabolic effect of insulin, i.e. the development of insulin resistance. Free fatty acids are primary sources of energy after trauma. Triglycerides meet 50 to 80 % of the consumed energy after trauma and in critical illness. Surgical stress and trauma result in a reduction in protein synthesis and moderate protein degradation. Severe trauma, burns and sepsis result in increased protein degradation. The aim of glucose administration to surgical patients during fasting is to reduce proteolysis and to prevent loss of muscle mass. In major stress such as sepsis and trauma, it is important both to reduce the catabolic response that is the key to faster healing after surgery and to obtain a balanced metabolism in the shortest possible time with minimum loss. For these reasons, the details of metabolic response to trauma should be known in managing these situations and patients should be treated accordingly.

  7. Gut microbiota and metabolic syndrome.

    Science.gov (United States)

    Festi, Davide; Schiumerini, Ramona; Eusebi, Leonardo Henry; Marasco, Giovanni; Taddia, Martina; Colecchia, Antonio

    2014-11-21

    Gut microbiota exerts a significant role in the pathogenesis of the metabolic syndrome, as confirmed by studies conducted both on humans and animal models. Gut microbial composition and functions are strongly influenced by diet. This complex intestinal "superorganism" seems to affect host metabolic balance modulating energy absorption, gut motility, appetite, glucose and lipid metabolism, as well as hepatic fatty storage. An impairment of the fine balance between gut microbes and host's immune system could culminate in the intestinal translocation of bacterial fragments and the development of "metabolic endotoxemia", leading to systemic inflammation and insulin resistance. Diet induced weight-loss and bariatric surgery promote significant changes of gut microbial composition, that seem to affect the success, or the inefficacy, of treatment strategies. Manipulation of gut microbiota through the administration of prebiotics or probiotics could reduce intestinal low grade inflammation and improve gut barrier integrity, thus, ameliorating metabolic balance and promoting weight loss. However, further evidence is needed to better understand their clinical impact and therapeutic use.

  8. Nucleotide Metabolism and DNA Replication.

    Science.gov (United States)

    Warner, Digby F; Evans, Joanna C; Mizrahi, Valerie

    2014-10-01

    The development and application of a highly versatile suite of tools for mycobacterial genetics, coupled with widespread use of "omics" approaches to elucidate the structure, function, and regulation of mycobacterial proteins, has led to spectacular advances in our understanding of the metabolism and physiology of mycobacteria. In this article, we provide an update on nucleotide metabolism and DNA replication in mycobacteria, highlighting key findings from the past 10 to 15 years. In the first section, we focus on nucleotide metabolism, ranging from the biosynthesis, salvage, and interconversion of purine and pyrimidine ribonucleotides to the formation of deoxyribonucleotides. The second part of the article is devoted to DNA replication, with a focus on replication initiation and elongation, as well as DNA unwinding. We provide an overview of replication fidelity and mutation rates in mycobacteria and summarize evidence suggesting that DNA replication occurs during states of low metabolic activity, and conclude by suggesting directions for future research to address key outstanding questions. Although this article focuses primarily on observations from Mycobacterium tuberculosis, it is interspersed, where appropriate, with insights from, and comparisons with, other mycobacterial species as well as better characterized bacterial models such as Escherichia coli. Finally, a common theme underlying almost all studies of mycobacterial metabolism is the potential to identify and validate functions or pathways that can be exploited for tuberculosis drug discovery. In this context, we have specifically highlighted those processes in mycobacterial DNA replication that might satisfy this critical requirement.

  9. Metabolic Cost of Experimental Exercises

    Science.gov (United States)

    Webb, James T.; Gernhardt, Michael L.

    2009-01-01

    Although the type and duration of activity during decompression was well documented, the metabolic cost of 1665 subject-exposures with 8 activity profiles from 17 altitude decompression sickness (DCS) protocols at Brooks City-Base, TX from 1983-2005 was not determined. Female and male human volunteers (30 planned, 4 completed) performed activity profiles matching those 8 activity profiles at ground level with continuous monitoring of metabolic cost. A Cosmed K4b2 Cardio Pulmonary Exercise Testing device was used to measure oxygen uptake (VO2) during the profiles. The results show levels of metabolic cost to the females for the profiles tested varied from 4.3 to 25.5 ml/kg/min and from 3.0 to 12.0 ml/kg/min to the males. The increase in VO2 from seated rest to the most strenuous of the 8 activity profiles was 3.6-fold for the females and 2.8-fold for the males. These preliminary data on 4 subjects indicate close agreement of oxygen uptake for activity performed during many subject-exposures as published earlier. The relatively low average oxygen uptake required to perform the most strenuous activity may imply the need for adjustment of modeling efforts using metabolic cost as a risk factor. Better definition of metabolic cost during exposure to altitude, a critical factor in DCS risk, may allow refinement of DCS prediction models.

  10. Mathematical Modeling of Cellular Metabolism.

    Science.gov (United States)

    Berndt, Nikolaus; Holzhütter, Hermann-Georg

    2016-01-01

    Cellular metabolism basically consists of the conversion of chemical compounds taken up from the extracellular environment into energy (conserved in energy-rich bonds of organic phosphates) and a wide array of organic molecules serving as catalysts (enzymes), information carriers (nucleic acids), and building blocks for cellular structures such as membranes or ribosomes. Metabolic modeling aims at the construction of mathematical representations of the cellular metabolism that can be used to calculate the concentration of cellular molecules and the rates of their mutual chemical interconversion in response to varying external conditions as, for example, hormonal stimuli or supply of essential nutrients. Based on such calculations, it is possible to quantify complex cellular functions as cellular growth, detoxification of drugs and xenobiotic compounds or synthesis of exported molecules. Depending on the specific questions to metabolism addressed, the methodological expertise of the researcher, and available experimental information, different conceptual frameworks have been established, allowing the usage of computational methods to condense experimental information from various layers of organization into (self-) consistent models. Here, we briefly outline the main conceptual frameworks that are currently exploited in metabolism research.

  11. Energy metabolism during human pregnancy.

    Science.gov (United States)

    Forsum, Elisabet; Löf, Marie

    2007-01-01

    This review summarizes information regarding how human energy metabolism is affected by pregnancy, and current estimates of energy requirements during pregnancy are presented. Such estimates can be calculated using either increases in basal metabolic rate (BMR) or increases in total energy expenditure (TEE). The two modes of calculation give similar results for a complete pregnancy but different distributions of energy requirements in the three trimesters. Recent information is presented regarding the effect of pregnancy on BMR, TEE, diet-induced thermogenesis, and physical activity. The validity of energy intake (EI) data recently assessed in well-nourished pregnant women was evaluated using information regarding energy metabolism during pregnancy. The results show that underreporting of EI is common during pregnancy and indicate that additional longitudinal studies, taking the total energy budget during pregnancy into account, are needed to satisfactorily define energy requirements during the three trimesters of gestation.

  12. DNA methylation in metabolic disorders

    DEFF Research Database (Denmark)

    Barres, Romain; Zierath, Juleen R

    2011-01-01

    DNA methylation is a major epigenetic modification that controls gene expression in physiologic and pathologic states. Metabolic diseases such as diabetes and obesity are associated with profound alterations in gene expression that are caused by genetic and environmental factors. Recent reports...... have provided evidence that environmental factors at all ages could modify DNA methylation in somatic tissues, which suggests that DNA methylation is a more dynamic process than previously appreciated. Because of the importance of lifestyle factors in metabolic disorders, DNA methylation provides...... a mechanism by which environmental factors, including diet and exercise, can modify genetic predisposition to disease. This article considers the current evidence that defines a role for DNA methylation in metabolic disorders....

  13. Exercise in the Metabolic Syndrome

    Directory of Open Access Journals (Sweden)

    Saeid Golbidi

    2012-01-01

    Full Text Available The metabolic syndrome is a clustering of obesity, diabetes, hyperlipidemia, and hypertension that is occurring in increasing frequency across the global population. Although there is some controversy about its diagnostic criteria, oxidative stress, which is defined as imbalance between the production and inactivation of reactive oxygen species, has a major pathophysiological role in all the components of this disease. Oxidative stress and consequent inflammation induce insulin resistance, which likely links the various components of this disease. We briefly review the role of oxidative stress as a major component of the metabolic syndrome and then discuss the impact of exercise on these pathophysiological pathways. Included in this paper is the effect of exercise in reducing fat-induced inflammation, blood pressure, and improving muscular metabolism.

  14. Cellular compartmentalization of secondary metabolism

    Directory of Open Access Journals (Sweden)

    H. Corby eKistler

    2015-02-01

    Full Text Available Fungal secondary metabolism is often considered apart from the essential housekeeping functions of the cell. However, there are clear links between fundamental cellular metabolism and the biochemical pathways leading to secondary metabolite synthesis. Besides utilizing key biochemical precursors shared with the most essential processes of the cell (e.g. amino acids, acetyl CoA, NADPH, enzymes for secondary metabolite synthesis are compartmentalized at conserved subcellular sites that position pathway enzymes to use these common biochemical precursors. Co-compartmentalization of secondary metabolism pathway enzymes also may function to channel precursors, promote pathway efficiency and sequester pathway intermediates and products from the rest of the cell. In this review we discuss the compartmentalization of three well-studied fungal secondary metabolite biosynthetic pathways for penicillin G, aflatoxin and deoxynivalenol, and summarize evidence used to infer subcellular localization. We also discuss how these metabolites potentially are trafficked within the cell and may be exported.

  15. Cancer Metabolism: A Modeling Perspective

    DEFF Research Database (Denmark)

    Ghaffari, Pouyan; Mardinoglu, Adil; Nielsen, Jens

    2015-01-01

    requires both the advancement of experimental technologies for more comprehensive measurement of omics as well as the advancement of robust computational methods for accurate analysis of the generated data. Here, we review cancer-associated reprogramming of metabolism and highlight the capability of genome...... suggest that utilization of amino acids and lipids contributes significantly to cancer cell metabolism. Also recent progresses in our understanding of carcinogenesis have revealed that cancer is a complex disease and cannot be understood through simple investigation of genetic mutations of cancerous cells....... Cancer cells present in complex tumor tissues communicate with the surrounding microenvironment and develop traits which promote their growth, survival, and metastasis. Decoding the full scope and targeting dysregulated metabolic pathways that support neoplastic transformations and their preservation...

  16. Dynamic Metabolism in Immune Response

    Science.gov (United States)

    Al-Hommrani, Mazen; Chakraborty, Paramita; Chatterjee, Shilpak; Mehrotra, Shikhar

    2016-01-01

    Cell, the basic unit of life depends for its survival on nutrients and thereby energy to perform its physiological function. Cells of lymphoid and myeloid origin are key in evoking an immune response against “self” or “non-self” antigens. The thymus derived lymphoid cells called T cells are a heterogenous group with distinct phenotypic and molecular signatures that have been shown to respond against an infection (bacterial, viral, protozoan) or cancer. Recent studies have unearthed the key differences in energy metabolism between the various T cell subsets, natural killer cells, dendritic cells, macrophages and myeloid derived suppressor cells. While a number of groups are dwelling into the nuances of the metabolism and its role in immune response at various strata, this review focuses on dynamic state of metabolism that is operational within various cellular compartments that interact to mount an effective immune response to alleviate disease state.

  17. Public goods and metabolic strategies.

    Science.gov (United States)

    Bachmann, Herwig; Bruggeman, Frank J; Molenaar, Douwe; Branco Dos Santos, Filipe; Teusink, Bas

    2016-06-01

    Microbial growth can be characterized by a limited set of macroscopic parameters such as growth rate, biomass yield and substrate affinity. Different culturing protocols for laboratory evolution have been developed to select mutant strains that have one specific macroscopic growth parameter improved. Some of those mutant strains display tradeoffs between growth parameters and changed metabolic strategies, for example, a shift from respiration to fermentation. Here we discuss recent studies suggesting that metabolic strategies and growth parameter tradeoffs originate from a common set of physicochemical and cellular constraints, associated with the allocation of intracellular resources over biosynthetic processes, mostly protein synthesis. This knowledge will give insight in ecological and biological concepts and can be used for metabolic and evolutionary engineering strategies.

  18. Complexity of vitamin E metabolism

    Institute of Scientific and Technical Information of China (English)

    Lisa Schm?lz; Marc Birringer; Stefan Lorkowski; Maria Wallert

    2016-01-01

    Bioavailability of vitamin E is influenced by several factors, most are highlighted in this review. While gender, age and genetic constitution influence vitamin E bioavailability but cannot be modified, life-style and intake of vitamin E can be. Numerous factors must be taken into account however, i.e., when vitamin E is orally administrated, the food matrix may contain competing nutrients. The complex metabolic processes comprise intestinal absorption, vascular transport, hepatic sorting by intracellular binding proteins, such as the significant α-tocopherol-transfer protein, and hepatic metabolism. The coordinated changes involved in the hepatic metabolism of vitamin E provide an effective physiological pathway to protect tissues against the excessive accumulation of, in particular, non-α-tocopherol forms. Metabolism of vitamin E begins with one cycle of CYP4F2/CYP3A4-dependent ω-hydroxylation followed by five cycles of subsequent β-oxidation, and forms the water-soluble end-product carboxyethylhydroxychroman. All known hepatic metabolites can be conjugated and are excreted, depending on the length of their sidechain, either via urine or feces. The physiological handling of vitamin E underlies kinetics which vary between the different vitamin E forms. Here, saturation of the side-chain and also substitution of the chromanol ring system are important. Most of the metabolic reactions and processes that are involved with vitamin E are also shared by other fat soluble vitamins. Influencing interactions with other nutrients such as vitamin K or pharmaceuticals are also covered by this review. All these processes modulate the formation of vitamin E metabolites and their concentrations in tissues and body fluids. Differences in metabolism might be responsible for the discrepancies that have been observed in studies performed in vivo and in vitro using vitamin E as a supplement or nutrient. To evaluate individual vitamin E status, the analytical procedures used for

  19. Genome scale metabolic modeling of cancer

    DEFF Research Database (Denmark)

    Nilsson, Avlant; Nielsen, Jens

    2016-01-01

    been used as scaffolds for analysis of high throughput data to allow mechanistic interpretation of changes in expression. Finally, GEMs allow quantitative flux predictions using flux balance analysis (FBA). Here we critically review the requirements for successful FBA simulations of cancer cells......Cancer cells reprogram metabolism to support rapid proliferation and survival. Energy metabolism is particularly important for growth and genes encoding enzymes involved in energy metabolism are frequently altered in cancer cells. A genome scale metabolic model (GEM) is a mathematical formalization...... of metabolism which allows simulation and hypotheses testing of metabolic strategies. It has successfully been applied to many microorganisms and is now used to study cancer metabolism. Generic models of human metabolism have been reconstructed based on the existence of metabolic genes in the human genome...

  20. Metabolism of phthalates in humans

    DEFF Research Database (Denmark)

    Frederiksen, Hanne; Skakkebaek, Niels E; Andersson, Anna-Maria

    2007-01-01

    on the foetal testis and they are similar to those seen in humans with testicular dysgenesis syndrome. Therefore, exposure of the human foetus and infants to phthalates via maternal exposure is a matter of concern. The metabolic pathways of phthalate metabolites excreted in human urine are partly known for some...... phthalates, but our knowledge about metabolic distribution in the body and other biological fluids, including breast milk, is limited. Compared to urine, human breast milk contains relatively more of the hydrophobic phthalates, such as di-n-butyl phthalate and the longer-branched, di(2-ethylhexyl) phthalate...

  1. Metabolic phenotype of bladder cancer.

    Science.gov (United States)

    Massari, Francesco; Ciccarese, Chiara; Santoni, Matteo; Iacovelli, Roberto; Mazzucchelli, Roberta; Piva, Francesco; Scarpelli, Marina; Berardi, Rossana; Tortora, Giampaolo; Lopez-Beltran, Antonio; Cheng, Liang; Montironi, Rodolfo

    2016-04-01

    Metabolism of bladder cancer represents a key issue for cancer research. Several metabolic altered pathways are involved in bladder tumorigenesis, representing therefore interesting targets for therapy. Tumor cells, including urothelial cancer cells, rely on a peculiar shift to aerobic glycolysis-dependent metabolism (the Warburg-effect) as the main energy source to sustain their uncontrolled growth and proliferation. Therefore, the high glycolytic flux depends on the overexpression of glycolysis-related genes (SRC-3, glucose transporter type 1 [GLUT1], GLUT3, lactic dehydrogenase A [LDHA], LDHB, hexokinase 1 [HK1], HK2, pyruvate kinase type M [PKM], and hypoxia-inducible factor 1-alpha [HIF-1α]), resulting in an overproduction of pyruvate, alanine and lactate. Concurrently, bladder cancer metabolism displays an increased expression of genes favoring the pentose phosphate pathway (glucose-6-phosphate dehydrogenase [G6PD]) and the fatty-acid synthesis (fatty acid synthase [FASN]), along with a decrease of AMP-activated protein kinase (AMPK) and Krebs cycle activities. Moreover, the PTEN/PI3K/AKT/mTOR pathway, hyper-activated in bladder cancer, acts as central regulator of aerobic glycolysis, hence contributing to cancer metabolic switch and tumor cell proliferation. Besides glycolysis, glycogen metabolism pathway plays a robust role in bladder cancer development. In particular, the overexpression of GLUT-1, the loss of the tumor suppressor glycogen debranching enzyme amylo-α-1,6-glucosidase, 4-α-glucanotransferase (AGL), and the increased activity of the tumor promoter enzyme glycogen phosphorylase impair glycogen metabolism. An increase in glucose uptake, decrease in normal cellular glycogen storage, and overproduction of lactate are consequences of decreased oxidative phosphorylation and inability to reuse glucose into the pentose phosphate and de novo fatty acid synthesis pathways. Moreover, AGL loss determines augmented levels of the serine-to-glycine enzyme

  2. Artificial Promoters for Metabolic Optimization

    DEFF Research Database (Denmark)

    Jensen, Peter Ruhdal; Hammer, Karin

    1998-01-01

    In this article, we review some of the expression systems that are available for Metabolic Control Analysis and Metabolic Engineering, and examine their advantages and disadvantages in different contexts. In a recent approach, artificial promoters for modulating gene expression in micro-organisms......In this article, we review some of the expression systems that are available for Metabolic Control Analysis and Metabolic Engineering, and examine their advantages and disadvantages in different contexts. In a recent approach, artificial promoters for modulating gene expression in micro......-organisms were constructed using synthetic degenerated oligonucleotides. From this work, a promoter library was obtained for Lactococcus lactis, containing numerous individual promoters and covering a wide range of promoter activities. Importantly, the range of promoter activities was covered in small steps...... of activity change. Promoter libraries generated by this approach allow for optimization of gene expression and for experimental control analysis in a wide range of biological systems by choosing from the promoter library promoters giving, e.g., 25%, 50%, 200%, and 400% of the normal expression level...

  3. Does Metabolically Healthy Obesity Exist?

    Science.gov (United States)

    Muñoz-Garach, Araceli; Cornejo-Pareja, Isabel; Tinahones, Francisco J.

    2016-01-01

    The relationship between obesity and other metabolic diseases have been deeply studied. However, there are clinical inconsistencies, exceptions to the paradigm of “more fat means more metabolic disease”, and the subjects in this condition are referred to as metabolically healthy obese (MHO).They have long-standing obesity and morbid obesity but can be considered healthy despite their high degree of obesity. We describe the variable definitions of MHO, the underlying mechanisms that can explain the existence of this phenotype caused by greater adipose tissue inflammation or the different capacity for adipose tissue expansion and functionality apart from other unknown mechanisms. We analyze whether these subjects improve after an intervention (traditional lifestyle recommendations or bariatric surgery) or if they stay healthy as the years pass. MHO is common among the obese population and constitutes a unique subset of characteristics that reduce metabolic and cardiovascular risk factors despite the presence of excessive fat mass. The protective factors that grant a healthier profile to individuals with MHO are being elucidated. PMID:27258304

  4. Vitamin D metabolism and function

    Energy Technology Data Exchange (ETDEWEB)

    DeLuca, H.F.

    1978-05-15

    A general review of the biological functions of vitamin D and the metabolism of vitamin D are given in order to elucidate the biochemical possibilities of calcipdiol. The biochemical mechanisms of calcipdiol use in the treatment of skeletal system diseases are discussed. (DS)

  5. SIRT1 and metabolic syndrome

    Directory of Open Access Journals (Sweden)

    Katarzyna Mac-Marcjanek

    2011-04-01

    Full Text Available Both obesity and type 2 diabetes mellitus, two major components of metabolic syndrome, become healthepidemics in the world. Over the past decade, advances in understanding the role of some regulators participatingin lipid and carbohydrate homeostasis have been made.Of them, SIRT1, the mammalian orthologue of the yeast Sir2 protein has been identified. SIRT1 is a nuclearNAD+-dependent deacetylase that targets many transcriptional modulators, including PPAR-α and -γ (peroxisomeproliferator-activated receptors α and γ, PGC-1α (PPAR-γ coactivator-1α, FOXO (forkhead box O proteins,and nuclear factor κB (NF-κB, thereby this enzyme mediates a wide range of physiological processes like apoptosis,fat metabolism, glucose homeostasis, and neurodegeneration.In this article, we discuss how SIRT1 regulates lipid and carbohydrate metabolism, and insulin secretion indifferent metabolic organs/tissue, including liver, muscle, pancreas, and fat. Additionally, the role of this enzymein reduction of inflammatory signalling is highlighted.

  6. Metabolic networks: beyond the graph.

    Science.gov (United States)

    Bernal, Andrés; Daza, Edgar

    2011-06-01

    Drugs are devised to enter into the metabolism of an organism in order to produce a desired effect. From the chemical point of view, cellular metabolism is constituted by a complex network of reactions transforming metabolites one in each other. Knowledge on the structure of this network could help to develop novel methods for drug design, and to comprehend the root of known unexpected side effects. Many large-scale studies on the structure of metabolic networks have been developed following models based on different kinds of graphs as the fundamental image of the reaction network. Graphs models, however, comport wrong assumptions regarding the structure of reaction networks that may lead into wrong conclusions if they are not taken into account. In this article we critically review some graph-theoretical approaches to the analysis of centrality, vulnerability and modularity of metabolic networks, analyzing their limitations in estimating these key network properties, consider some proposals explicit or implicitly based on directed hypergraphs regarding their ability to overcome these issues, and review some recent implementation improvements that make the application of these models in increasingly large networks a viable option.

  7. Histone variants and lipid metabolism

    NARCIS (Netherlands)

    Borghesan, Michela; Mazzoccoli, Gianluigi; Sheedfar, Fareeba; Oben, Jude; Pazienza, Valerio; Vinciguerra, Manlio

    2014-01-01

    Within nucleosomes, canonical histones package the genome, but they can be opportunely replaced with histone variants. The incorporation of histone variants into the nucleosome is a chief cellular strategy to regulate transcription and cellular metabolism. In pathological terms, cellular steatosis i

  8. MicroRNAs in Metabolism

    DEFF Research Database (Denmark)

    Vienberg, Sara; Geiger, Julian; Madsen, Søren

    2016-01-01

    MicroRNAs (miRNAs) have within the past decade emerged as key regulators of metabolic homeostasis. Major tissues in intermediary metabolism important during development of the metabolic syndrome, such as β-cells, liver, skeletal and heart muscle as well as adipose tissue have all been shown...... to be affected by miRNAs. In the pancreatic β-cell a number of miRNAs are important in maintaining the balance between differentiation and proliferation (miR-200 and miR-29 families) and insulin exocytosis in the differentiated state is controlled by miR-7, miR-375 and miR-335. MiR-33a and -33b play crucial...... roles in cholesterol and lipid metabolism, whereas miR-103 and -107 regulates hepatic insulin sensitivity. In muscle tissue a defined number of miRNAs (miR-1, miR-133, mir-206) control myofiber type switch and induce myogenic differentiation programs. Similarly, in adipose tissue a defined number of miRNAs...

  9. Bone scintigraphy and metabolic disorders

    Energy Technology Data Exchange (ETDEWEB)

    Mari' , C.; Catafau, A.; Carrio' , I. [Hospital de Sant Pau, Barcelone (Spain). Serv. of Nuclear Medicine

    1999-09-01

    The paper discusses the main clinical value of bone scan in metabolic bone disease: its detection of focal conditions or focal complications of such generalized disease, its most common use of being the detection of fractures in osteoporosis, pseudo fractures in osteomalacia and the evaluation of Paget's disease.

  10. Genetic determinants for metabolic abnormalities

    NARCIS (Netherlands)

    Risselada, A.J.

    2012-01-01

    Psychiatric patients often use psychotropic drugs. Apart from frequent problems regarding lack of efficacy, use of these drugs also often results in (severe) adverse effects. The use of (atypical) antipsychotic drugs in particular can give rise to weight gain and metabolic deregulation regarding glu

  11. Metabolic engineering in methanotrophic bacteria

    Energy Technology Data Exchange (ETDEWEB)

    Kalyuzhnaya, MG; Puri, AW; Lidstrom, ME

    2015-05-01

    Methane, as natural gas or biogas, is the least expensive source of carbon for (bio)chemical synthesis. Scalable biological upgrading of this simple alkane to chemicals and fuels can bring new sustainable solutions to a number of industries with large environmental footprints, such as natural gas/petroleum production, landfills, wastewater treatment, and livestock. Microbial biocatalysis with methane as a feedstock has been pursued off and on for almost a half century, with little enduring success. Today, biological engineering and systems biology provide new opportunities for metabolic system modulation and give new optimism to the concept of a methane-based bio-industry. Here we present an overview of the most recent advances pertaining to metabolic engineering of microbial methane utilization. Some ideas concerning metabolic improvements for production of acetyl-CoA and pyruvate, two main precursors for bioconversion, are presented. We also discuss main gaps in the current knowledge of aerobic methane utilization, which must be solved in order to release the full potential of methane-based biosystems. (C) 2015 International Metabolic Engineering Society. Published by Elsevier Inc. All rights reserved.

  12. Synthetic biology and metabolic engineering.

    Science.gov (United States)

    Stephanopoulos, Gregory

    2012-11-16

    Metabolic engineering emerged 20 years ago as the discipline occupied with the directed modification of metabolic pathways for the microbial synthesis of various products. As such, it deals with the engineering (design, construction, and optimization) of native as well as non-natural routes of product synthesis, aided in this task by the availability of synthetic DNA, the core enabling technology of synthetic biology. The two fields, however, only partially overlap in their interest in pathway engineering. While fabrication of biobricks, synthetic cells, genetic circuits, and nonlinear cell dynamics, along with pathway engineering, have occupied researchers in the field of synthetic biology, the sum total of these areas does not constitute a coherent definition of synthetic biology with a distinct intellectual foundation and well-defined areas of application. This paper reviews the origins of the two fields and advances two distinct paradigms for each of them: that of unit operations for metabolic engineering and electronic circuits for synthetic biology. In this context, metabolic engineering is about engineering cell factories for the biological manufacturing of chemical and pharmaceutical products, whereas the main focus of synthetic biology is fundamental biological research facilitated by the use of synthetic DNA and genetic circuits.

  13. Metabolic diversity in apple germplasm

    NARCIS (Netherlands)

    Khan, S.A.; Tikunov, Y.M.; Chibon, P.Y.F.R.P.; Maliepaard, C.A.; Beekwilder, M.J.; Jacobsen, E.; Schouten, H.J.

    2014-01-01

    We analysed metabolic diversity in apples from wild species, elite material and a F1 population, using liquid chromatography–mass spectrometry (LC-QTOF-MS). The evaluated elite material appeared to have strongly reduced levels of phenolic compounds, down to 1% of the concentrations in the investigat

  14. Antihypertensive drugs and glucose metabolism

    Institute of Scientific and Technical Information of China (English)

    Christos; V; Rizos; Moses; S; Elisaf

    2014-01-01

    Hypertension plays a major role in the development and progression of micro-and macrovascular disease.Moreover,increased blood pressure often coexists with additional cardiovascular risk factors such as insulin resistance.As a result the need for a comprehensive management of hypertensive patients is critical.However,the various antihypertensive drug categories have different effects on glucose metabolism.Indeed,angiotensin receptor blockers as well as angiotensin converting enzyme inhibitors have been associated with beneficial effects on glucose homeostasis.Calcium channel blockers(CCBs)have an overall neutral effect on glucose metabolism.However,some members of the CCBs class such as azelnidipine and manidipine have been shown to have advantageous effects on glucose homeostasis.On the other hand,diuretics andβ-blockers have an overall disadvantageous effect on glucose metabolism.Of note,carvedilol as well as nebivolol seem to differentiate themselves from the rest of theβ-blockers class,being more attractive options regarding their effect on glucose homeostasis.The adverse effects of some blood pressure lowering drugs on glucose metabolism may,to an extent,compromise their cardiovascular protective role.As a result the effects on glucose homeostasis of the various blood pressure lowering drugs should be taken into account when selecting an antihypertensive treatment,especially in patients which are at high risk for developing diabetes.

  15. Alcohol abuse and glycoconjugate metabolism

    Directory of Open Access Journals (Sweden)

    Sylwia Chojnowska

    2012-04-01

    Full Text Available The relationship between alcohol consumption and glycoconjugate metabolism is complex and multidimensional. This review summarizes the advances in basic and clinical research on the molecular and cellular events involved in the metabolic effects of alcohol on glycoconjugates (glycoproteins, glycolipids, and proteoglycans. We summarize the action of ethanol, acetaldehyde, reactive oxygen species (ROS, nonoxidative metabolite of alcohol — fatty acid ethyl esters (FAEEs, and the ethanol-water competition mechanism, on glycoconjugate biosynthesis, modification, transport and secretion, as well as on elimination and catabolism processes. As the majority of changes in the cellular metabolism of glycoconjugates are generally ascribed to alterations in synthesis, transport, glycosylation and secretion, the degradation and elimination processes, of which the former occurs also in extracellular matrix, seem to be underappreciated. The pathomechanisms are additionally complicated by the fact that the effect of alcohol intoxication on the glycoconjugate metabolism depends not only on the duration of ethanol exposure, but also demonstrates dose- and regional-sensitivity. Further research is needed to bridge the gap in transdisciplinary research and enhance our understanding of alcohol- and glycoconjugate-related diseases.

  16. Alcohol Metabolism and Epigenetics Changes

    Science.gov (United States)

    Zakhari, Samir

    2013-01-01

    Metabolites, including those generated during ethanol metabolism, can impact disease states by binding to transcription factors and/or modifying chromatin structure, thereby altering gene expression patterns. For example, the activities of enzymes involved in epigenetic modifications such as DNA and histone methylation and histone acetylation, are influenced by the levels of metabolites such as nicotinamide adenine dinucleotide (NAD), adenosine triphosphate (ATP), and S-adenosylmethionine (SAM). Chronic alcohol consumption leads to significant reductions in SAM levels, thereby contributing to DNA hypomethylation. Similarly, ethanol metabolism alters the ratio of NAD+ to reduced NAD (NADH) and promotes the formation of reactive oxygen species and acetate, all of which impact epigenetic regulatory mechanisms. In addition to altered carbohydrate metabolism, induction of cell death, and changes in mitochondrial permeability transition, these metabolism-related changes can lead to modulation of epigenetic regulation of gene expression. Understanding the nature of these epigenetic changes will help researchers design novel medications to treat or at least ameliorate alcohol-induced organ damage. PMID:24313160

  17. Metabolic polymorphisms and cancer susceptibility.

    Science.gov (United States)

    Smith, G; Stanley, L A; Sim, E; Strange, R C; Wolf, C R

    1995-01-01

    The vast majority of cancers arise as a consequence of exposure to environmental agents that are toxic or mutagenic. In response to this, all higher organisms have evolved complex mechanisms by which they can protect themselves from environmental challenge. In many cases, this involves an adaptive response in which the levels of expression of enzymes active in the metabolism and detoxification of the foreign chemical are induced. The best characterized of these enzyme systems are the cytochrome P450s, the GSTs and the NATs. An unfortunate consequence of many of these reactions, however, is the creation of a toxic or mutagenic reaction product from chemicals that require metabolic activation before realizing their full carcinogenic potential. Altered expression of one or more of these drug metabolizing enzymes can therefore be predicted to have profound toxicological consequences. Genetic polymorphisms with well defined associated phenotypes have now been characterized in P450, GST and NAT genes. Indeed, many of these polymorphisms have been associated with decreased or increased metabolism of many tumour promoters and chemical carcinogens and hence offer protection against or increased susceptibility to many distinct tumour types.

  18. Clinical effect and influence in cognitive function of aripiprazole and risperidone in patients with schizophrenia%阿立哌唑与利培酮对精神分裂症患者的临床疗效及认知功能的影响

    Institute of Scientific and Technical Information of China (English)

    刘旭; 程哲; 杨芳; 程传宝

    2013-01-01

    [Objective]To explore the clinical effect and safety of aripiprazole and risperidone in patients with schizophrenia, and the influence in cognitive function of patients. [ Methods] 156 schizophrenia patients were randomly divided into two groups, 78 cases in each group. The research group was treated with aripiprazole orally, and the control group was given risperidone, for 8 weeks. Before treatment and at the end of the 4th and 8th week of treatment, the clinical effect was assessed with the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression ( CGIS) , and the adverse reactions were evaluated with the Treatment Emergent Symptom Scale (TESS). Before treatment and at the end of the 8th week of treatment, the cognitive functions of patients was assessed with the Wechsler Adult Intelligence Scale (WAIS) , the Wechsler memory scale (WMS) and the Wisconsin Card Sorting Test (WCST). The evaluation results of two groups were analyzed and compared. [ Results] At the end of 4th week of treatment, the total and each factors scores of PANSS, as well as CGIS score decreased significantly as compared with those before treatment (P 0.05). At the end of 8th week of treatment, the obvious effective rate and effective rate in the research group was 73.08% and 96.15% respectively, and that in the control group was 71. 79% and 92. 31% respectively, which showed no significantly difference (X2 = 0. 032, 0. 806,P >0.05). At the end of 8th week, the error answers and non-persistent error of WCST of two groups decreased significantly than those before treatment, while factor scores of WMS in the recognition, regeneration, comprehension, memory quotient were significantly higher than those before treatment (P 0.05). Adverse reactions of both groups were mild, and appeared at the beginning of treatment. The incidence rates of extrapyramidal reactions, menstrual disorders, lactation and weight gain in the research group were significantly lower than those in the

  19. Neck Circumference and Cardio- Metabolic Syndrome

    OpenAIRE

    Kumar, Nagendran Vijaya; Ismail, Mohammed H.; P, Mahesha; M, Girish; Tripathy, Monica

    2014-01-01

    Background: Only few studies about neck circumference (NC) as a measure of cardio metabolic syndrome available from India. Study was conducted to establish an association between neck circumference and cardio metabolic syndrome.

  20. Urban metabolism: a review of research methodologies.

    Science.gov (United States)

    Zhang, Yan

    2013-07-01

    Urban metabolism analysis has become an important tool for the study of urban ecosystems. The problems of large metabolic throughput, low metabolic efficiency, and disordered metabolic processes are a major cause of unhealthy urban systems. In this paper, I summarize the international research on urban metabolism, and describe the progress that has been made in terms of research methodologies. I also review the methods used in accounting for and evaluating material and energy flows in urban metabolic processes, simulation of these flows using a network model, and practical applications of these methods. Based on this review of the literature, I propose directions for future research, and particularly the need to study the urban carbon metabolism because of the modern context of global climate change. Moreover, I recommend more research on the optimal regulation of urban metabolic systems.

  1. 乌鸡白凤丸与阿立哌唑治疗利培酮所致闭经临床对比研究%Comparative clinical study on effect of Wuji Baifeng pills and aripiprazole in the treatment of risperidone induced amenorrhea

    Institute of Scientific and Technical Information of China (English)

    许勤伟; 刘向来; 黄胜; 黄兹高

    2013-01-01

    Objective:To explore clinical therapeutic effect and adverse reaction of Wuji Baifeng pills on risperidone induced amenorrhea.Methods:85 female schizophrenia patients with amenorrhea induced by risperidone were randomly divided into the treatment group of Wuji Baifeng pills (43 cases) and risperidone for aripiprazole contrast group (42 cases),90 days was a course.Results:Wuji Baifeng pills in the treatment of risperidone induced amenorrhea total clinical curative effect was obviously superior to risperidone,there was significant difference in effective rate between two groups (P < 0.05).Common adverse reactions were mild in two groups,and there was no significant difference in the score of TESS scale between the two groups (P > 0.05).Conclusion:Wuji Baifeng pills in the treatment of amenorrhea induced by risperidone has good clinical curative effect and adverse reaction is mild.%目的:探讨乌鸡白风丸治疗利培酮所致闭经的临床疗效及不良反应.方法:对85例利培酮治疗出现闭经的女性精神分裂症患者随机分为乌鸡白凤丸治疗组(43例)及停利培酮换用阿立哌唑的对比组(42例),以90天为一疗程.结果:乌鸡白凤丸治疗利培酮所致闭经的临床总疗效明显优于利培酮换用阿立哌唑的治疗,两治疗组有效率比较差异有统计学意义(P<0.05);两治疗组常见不良反应均较轻微,两组治疗不良反应采用TESS量表定期跟踪测评比较差异无统计学意义(P>0.05).结论:乌鸡白凤丸治疗利培酮所致闭经的临床疗效好,不良反应轻.

  2. Aripiprazole Open Controlled Study of Refractory Depression Combined with Fluoxetine and Olanzapine Fluoxetine in the Treatment of Women%阿立哌唑联合氟西汀与奥氮平联合氟西汀治疗女性难治性抑郁的开放式对照研究

    Institute of Scientific and Technical Information of China (English)

    刘希平; 吴彬; 陈湘清

    2012-01-01

      目的 探讨氟西汀联合阿立哌唑与氟西汀联合奥氮平治疗难治性抑郁的疗效与安全性.方法 将48例难治性抑郁患者随机分为1组(氟西汀+阿立哌唑)24例和2组(氟西汀+奥氮平)24例,观察8周.于治疗前和治疗1周、2周、4周及6周末采用汉密尔顿抑郁量表(Hamilton depressive,HAMD-17)评定疗效,用不良反应量表(TESS)评定不良反应.结果 阿立哌唑组显效率为55.0%,奥氮平组为52.3%.奥氮平组第4周HAMD评分低于阿立哌唑组,差异无显著性.阿立哌唑组不良反应较少.结论 阿立哌唑联合氟西汀治疗难治性抑郁的疗效好,起效快,且不良反应少.%  Objective To investigate the efficacy of fluoxetine combined with aripiprazole and combination of fluoxetine and olanzapine in the treatment of refractory depression curative effect and safety. Methods 48 patients with refractory depression patients were randomly divided into 1 groups (fluoxetine plus aripiprazole) in 24 patients and 2 groups (fluoxetine and olanzapine) in 24 cases, observation of 8 weeks.Before treatment and 1 weeks of treatment, 2 weeks, 4 weeks and 6 weeks with the Hamilton Depression Rating Scale (Hamilton depressive, HAMD-17) assessment of efficacy, with adverse effect scale (TESS) assessment of adverse reactions. Results The effective rate was 55.0% in aripiprazole group, the olanzapine group 52.3%.Olanzapine group fourth weeks HAMD score lower than in aripiprazole group, no significant difference.Aripiprazole group and less adverse reaction. Conclusion Aripiprazole combined with fluoxetine in the treatment of refractory depression has good curative effect, quick effect, and less adverse reaction.

  3. Insulin signaling meets mitochondria in metabolism

    OpenAIRE

    Cheng, Zhiyong; Tseng, Yolanda; White, Morris F.

    2010-01-01

    Insulin controls nutrient and metabolic homeostasis via the IRS–PI3K–AKT signaling cascade that targets FOXO1 and mTOR. Mitochondria, as the prime metabolic platform, malfunction during insulin resistance in metabolic diseases. However, the molecular link between insulin resistance and mitochondrial dysfunction remains undefined. Here we review recent studies on insulin action and the mechanistic association with mitochondrial metabolism. These studies suggest that insulin signaling underpins...

  4. Flux-P: Automating Metabolic Flux Analysis

    OpenAIRE

    Ebert, Birgitta E.; Anna-Lena Lamprecht; Bernhard Steffen; Blank, Lars M.

    2012-01-01

    Quantitative knowledge of intracellular fluxes in metabolic networks is invaluable for inferring metabolic system behavior and the design principles of biological systems. However, intracellular reaction rates can not often be calculated directly but have to be estimated; for instance, via 13C-based metabolic flux analysis, a model-based interpretation of stable carbon isotope patterns in intermediates of metabolism. Existing software such as FiatFlux, OpenFLUX or 13CFLUX supports experts in ...

  5. Hypothyroidism and possible association with Metabolic Syndrome

    OpenAIRE

    Iqbal, Shahid; Sharma, Anil Kumar; Ahmad, Mushir; Nagtilak, Suryakant; Ahmad, Naved

    2016-01-01

    Background: Thyroid dysfunctions are the most common forms of endocrine disorder in our country, Thyroid hormones perform a wide array of metabolic functions including regulation of lipids, carbohydrates, protein and electrolytes and mineral metabolism, Thyroid hormones are major regulatory hormones that controls the rate of metabolic function and alteration in the levels of thyroid hormones may be associated with metabolic syndromeAim: The study was performed to investigate the association b...

  6. Parma consensus statement on metabolic disruptors

    OpenAIRE

    Heindel, Jerrold J.; Frederick S Vom Saal; Blumberg, Bruce; Bovolin, Patrizia; Calamandrei, Gemma; Ceresini, Graziano; Cohn, Barbara A.; Fabbri, Elena; Gioiosa, Laura; Kassotis, Christopher; Legler, Juliette; La Merrill, Michele; Rizzir, Laura; Machtinger, Ronit; Mantovani, Alberto

    2015-01-01

    © 2015 Heindel et al. A multidisciplinary group of experts gathered in Parma Italy for a workshop hosted by the University of Parma, May 16-18, 2014 to address concerns about the potential relationship between environmental metabolic disrupting chemicals, obesity and related metabolic disorders. The objectives of the workshop were to: 1. Review findings related to the role of environmental chemicals, referred to as "metabolic disruptors", in obesity and metabolic syndrome with special attenti...

  7. It must be my metabolism: Metabolic control of mind

    Directory of Open Access Journals (Sweden)

    Dana M Small

    2014-07-01

    relationship between the reinforcing potency of sugared solutions and the metabolic effects that follow their consumption (16, also see the abstract of I. de Araujo. We therefore hypothesized that metabolic response provides the critical signal necessary to condition preference. To test this prediction in humans we designed a flavor nutrient conditioning study in which participants first rated their liking for novel flavored beverages and then, over a three week-long conditioning protocol, alternately ingested one of the flavored beverages with 112.5 kcal from maltodextrin, a tasteless and odorless polysaccharide that breaks down into glucose, and another flavored beverage with no calories added. Plasma glucose was measured before and after each of the drinks’ consumption as a proxy measure of metabolic response, assuming that glucose oxidation depends upon the level of circulating glucose. For each participant flavor-calorie pairings were held constant but the identity of the conditioned flavors were counterbalanced across participants. Following the exposure phase, participants’ liking of, and brain responses to, non-caloric versions of the flavors were assessed. We predicted that change in plasma glucose produced by beverage consumption during the exposure sessions would be associated with neural responses in dopamine source and target regions to the calorie predictive flavor. As predicted, response in the ventral striatum and hypothalamus to the calorie-predictive flavor (CS+ vs. non the noncaloric-predictive flavor (CS- was strongly associated with the changes in plasma glucose levels produced by ingestion of these same beverages when consumed previously either with (CS+ or without (CS- calories (17. Specifically, the greater the increase in circulating glucose occurring post ingestion of the beverage containing 112.5 kcal from maltodextrin versus the noncaloric drink, the stronger was the brain response to the CS+ compared to the CS- flavor. Importantly, because each

  8. Can resveratrol help to maintain metabolic health?

    NARCIS (Netherlands)

    Schrauwen, P.; Timmers, S.

    2014-01-01

    The number of people suffering from metabolic diseases is dramatically increasing worldwide. This stresses the need for new therapeutic strategies to combat this growing epidemic of metabolic diseases. A reduced mitochondrial function is one of the characteristics of metabolic diseases and therefore

  9. Intestinal Microbiota and Metabolic Diseases: Pharmacological Implications.

    Science.gov (United States)

    Shen, Liang; Ji, Hong-Fang

    2016-03-01

    An increasing number of studies show that alterations in intestinal microbiota are linked with metabolic diseases. Here, we propose that intestinal microbiota regulation by polyphenols may be an important mechanism underlying their therapeutic benefits for metabolic diseases. This helps elucidate the intriguing pharmacology of polyphenols and optimize the treatment of metabolic diseases.

  10. Cholesterol metabolism and colon cancer.

    Science.gov (United States)

    Broitman, S A; Cerda, S; Wilkinson, J

    1993-01-01

    While epidemiologic and concordant experimental data indicate a direct relationship between dietary fat (and presumably caloric) intake and the development of colon cancer, the effect of dietary cholesterol on this disease is still not clear. However, there appears to be a developing literature concerning an inverse relationship between serum and plasma cholesterol levels, and the risk for colon cancer. Findings that low serum cholesterol levels are apparent as early as ten years prior to the detection of colon cancer implies that sub clinical disease is probably not involved initially in this process. The possibility of low serum cholesterol as a bio-marker was considered in epidemiologic studies which focused upon obese men with lower than normal serum cholesterol levels who were found to be at increased risk to colon cancer. While the relationship between low serum cholesterol and colonic or intestinal cholesterol metabolism is presently not understood, current genetic studies provide a promising though as yet unexplored potential association. Alterations which occur during the developmental progression of colonic cancer include changes in chromosome 5, which also carries two genes vital to the biosynthesis and regulation of systemic and cellular cholesterol metabolism, 3-hydroxy-3-methylglutaryl coenzyme A synthase, and 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCoA R). Regulation of cholesterol metabolism in intestinal cells in vivo and in vitro varies from that seen in normal fibroblasts or hepatocytes in terms of exogenous sources of cholesterol and how these sources regulate internal synthesis. Colonic cancer cells have been used to assess small bowel enterocyte cholesterol metabolism, which has been possible because of their ability to differentiate in culture, however information regarding true colonic enterocyte cholesterol metabolism is relatively scarce. Colonic cancer cells have been shown to possess a diminished or nonexistent ability to use

  11. Metabolic markers in sports medicine.

    Science.gov (United States)

    Banfi, Giuseppe; Colombini, Alessandra; Lombardi, Giovanni; Lubkowska, Anna

    2012-01-01

    Physical exercise induces adaptations in metabolism considered beneficial for health. Athletic performance is linked to adaptations, training, and correct nutrition in individuals with genetic traits that can facilitate such adaptations. Intense and continuous exercise, training, and competitions, however, can induce changes in the serum concentrations of numerous laboratory parameters. When these modifications, especially elevated laboratory levels, result outside the reference range, further examinations are ordered or participation in training and competition is discontinued or sports practice loses its appeal. In order to correctly interpret commonly used laboratory data, laboratory professionals and sport physicians need to know the behavior of laboratory parameters during and after practice and competition. We reviewed the literature on liver, kidney, muscle, heart, energy, and bone parameters in athletes with a view to increase the knowledge about clinical chemistry applied to sport and to stimulate studies in this field. In liver metabolism, the interpretation of serum aminotransferases concentration in athletes should consider the release of aspartate aminotransferase (AST) from muscle and of alanine aminotransferase (ALT) mainly from the liver, when bilirubin can be elevated because of continuous hemolysis, which is typical of exercise. Muscle metabolism parameters such as creatine kinase (CK) are typically increased after exercise. This parameter can be used to interpret the physiological release of CK from muscle, its altered release due to rhabdomyolysis, or incomplete recovery due to overreaching or trauma. Cardiac markers are released during exercise, and especially endurance training. Increases in these markers should not simply be interpreted as a signal of cardiac damage or wall stress but rather as a sign of regulation of myocardial adaptation. Renal function can be followed in athletes by measuring serum creatinine concentration, but it should

  12. Metabolic encephalopathy in Egyptian children.

    Science.gov (United States)

    Hindawy, A; Gouda, A; El-Ayyadi, A; Megahed, H; Bazaraa, H

    2007-01-01

    Fatty Acid Oxidation disorders represent an expanding group of inborn errors of metabolism. Clinical manifestations include episodic encephalopathy, hypoketotic hypoglycemia, Reye like episodes, hepatic, muscular, cardiac affection and sudden death. Analysis of urinary organic acids and plasma fatty acids of 44 clinically suspected patients by Gas Chromatography Mass spectrometry revealed 4 cases of Medium chain acyl-CoA dehydrogenase deficiency (MCADD), 3 cases of Very long chain acyl-CoA dehydrogenase deficiency, 9 cases of multiple defects of acyl-CoA dehydrogenation in addition to 3 patients with other metabolic disorders. Timely detection of these disorders including screening for MCADD can have a favorable impact on the outcome of these patients (Tab. 11, Fig. 3, Ref. 24) Full Text (Free, PDF).

  13. Metabolism of phthalates in humans

    DEFF Research Database (Denmark)

    Frederiksen, Hanne; Skakkebaek, Niels E; Andersson, Anna-Maria

    2007-01-01

    on the foetal testis and they are similar to those seen in humans with testicular dysgenesis syndrome. Therefore, exposure of the human foetus and infants to phthalates via maternal exposure is a matter of concern. The metabolic pathways of phthalate metabolites excreted in human urine are partly known for some......Phthalates are synthetic compounds widely used as plasticisers, solvents and additives in many consumer products. Several animal studies have shown that some phthalates possess endocrine disrupting effects. Some of the effects of phthalates seen in rats are due to testosterone lowering effects...... phthalates, but our knowledge about metabolic distribution in the body and other biological fluids, including breast milk, is limited. Compared to urine, human breast milk contains relatively more of the hydrophobic phthalates, such as di-n-butyl phthalate and the longer-branched, di(2-ethylhexyl) phthalate...

  14. Metabolic responses during postprandial exercise.

    Science.gov (United States)

    Kang, Jie; Raines, Emily; Rosenberg, Joseph; Ratamess, Nicholas; Naclerio, Fernando; Faigenbaum, Avery

    2013-01-01

    To examine metabolic interaction between meal and exercise, 10 men and 10 women completed three trials: (1) exercise (E), (2) consumption of a meal (M), and (3) consumption of a meal followed by exercise (M+E). All trials commenced after an overnight fast and were preceded by a rest period in which resting metabolic rate (RMR) was determined. The meal contained 721 kilocalories composed of 41%, 36%, and 23% of carbohydrate, lipids, and protein, respectively. Exercise protocol consisted of three continuous 10-minute cycling at 50%, 60%, and 70% VO2peak. Measurement began 60 min after the start of the meal and included VO2 that was used to determine meal-induced thermogenesis (MIT). VO2 was greater (p exercise at 50% VO2peak than at rest. It appears that postprandial exercise of mild intensities can potentiate MIT, thereby provoking a greater increase in energy expenditure.

  15. [Copper metabolism and genetic disorders].

    Science.gov (United States)

    Shimizu, Norikazu

    2016-07-01

    Copper is one of essential trace elements. Copper deficiency lead to growth and developmental failure and/or neurological dysfunction. However, excess copper is also problems for human life. There are two disorders of inborn error of copper metabolism, Menkes disease and Wilson disease. Menkes disease is an X linked recessive disorder with copper deficiency and Wilson disease is an autosomal recessive disorder with copper accumulation. These both disorders result from the defective functioning of copper transport P-type ATPase, ATP7A of Menkes disease and ATP7B of Wilson disease. In this paper, the author describes about copper metabolism of human, and clinical feature, diagnosis and treatment of Menkes disease and Wilson disease.

  16. Spontaneous emergence of a metabolism

    Energy Technology Data Exchange (ETDEWEB)

    Bagley, R.J.; Farmer, J.D. (Los Alamos National Lab., NM (USA) Santa Fe Inst., NM (USA))

    1990-01-01

    Networks of catalyzed reactions with nonlinear feedback have been proposed to play an important role in the origin of life. We investigate this possibility in a polymer chemistry with catalyzed cleavage and condensation reactions. We study the properties of a well-stirred reactor driven away from equilibrium by the flow of mass. Under appropriate non-equilibrium conditions. The nonlinear feedback of the reaction network focuses the material of the system into a few specific polymer species. The network of catalytic reactions digests'' the material of its environment, incorporating it into its own form. We call the result an autocatalytic metabolism. Under some variations it persists almost unchanged, while in other cases it dies. We argue that the dynamical stability of autocatalytic metabolisms gives them regenerative properties that allow them to repair themselves and to propagate through time. 43 refs., 16 figs., 3 tabs.

  17. Cholesterol metabolism in Huntington disease.

    Science.gov (United States)

    Karasinska, Joanna M; Hayden, Michael R

    2011-09-06

    The CNS is rich in cholesterol, which is essential for neuronal development and survival, synapse maturation, and optimal synaptic activity. Alterations in brain cholesterol homeostasis are linked to neurodegeneration. Studies have demonstrated that Huntington disease (HD), a progressive and fatal neurodegenerative disorder resulting from polyglutamine expansion in the huntingtin protein, is associated with changes in cellular cholesterol metabolism. Emerging evidence from human and animal studies indicates that attenuated brain sterol synthesis and accumulation of cholesterol in neuronal membranes represent two distinct mechanisms occurring in the presence of mutant huntingtin that influence neuronal survival. Increased knowledge of how changes in intraneuronal cholesterol metabolism influence the pathogenesis of HD will provide insights into the potential application of brain cholesterol regulation as a therapeutic strategy for this devastating disease.

  18. Metabolic syndrome in children (Review)

    OpenAIRE

    Wu, Yue-E; Zhang, Chong-Lin; Zhen, Qing

    2016-01-01

    Metabolic syndrome (MetS) is a cluster of cardiometabolic risk factors, including central obesity, insulin resistance, glucose intolerance, dyslipidemia and increased blood pressure. The prevalence of MetS is on the increase worldwide owing to the epidemic of overweight and obesity. The risk of prevalence of MetS greatly increases during adulthood for those children exposed to cardiometabolic risk factors in their early lives. MetS has also been associated with liver fat accumulation in child...

  19. Phytoestrogens and the metabolic syndrome.

    Science.gov (United States)

    Jungbauer, Alois; Medjakovic, Svjetlana

    2014-01-01

    Phytoestrogens are a diverse class of non-steroidal compounds that have an affinity for estrogen receptors α and β, for the peroxisome proliferator-activated receptor (PPAR) family and for the aryl hydrocarbon receptor. Examples of phytoestrogens include prenylated flavonoids, isoflavones, coumestans and lignans. Many phytoestrogens counteract the cellular derailments that are responsible for the development of metabolic syndrome. Here we propose a mechanism of action which is based on five pillars/principles. First, phytoestrogens are involved in the downregulation of pro-inflammatory cytokines, such as COX-2 and iNOS, by activating PPAR and by inhibiting IκB activation. Second, they increase reverse cholesterol transport, which is mediated by PPARγ. Third, phytoestrogens increase insulin sensitivity, which is mediated via PPARα. Fourth, they exert antioxidant effects by activating antioxidant genes through KEAP. Fifth, phytoestrogens increase energy expenditure by affecting AMP-activated kinase signaling cascades, which are responsible for the inhibition of adipogenesis. In addition to these effects, which have been demonstrated in vivo and in clinical trials, other effects, such as eNOS activation, may also be important. Some plant extracts from soy, red clover or licorice can be described as panPPAR activators. Fetal programming for metabolic syndrome has been hypothesized; thus, the consumption of dietary phytoestrogens during pregnancy may be relevant. Extracts from soy, red clover or licorice oil have potential as plant-derived medicines that could be used to treat polycystic ovary syndrome, a disease linked to hyperandrogenism and obesity, although clinical trials have not yet been conducted. Phytoestrogens may help prevent metabolic syndrome, although intervention studies will be always be ambiguous, because physical activity and reduced calorie consumption also have a significant impact. Nevertheless, extracts rich in phytoestrogens may be an

  20. Organizational Actions of Metabolic Hormones

    OpenAIRE

    Bouret, Sebastien G.

    2013-01-01

    Brain development is a complex and dynamic process, and many environmental factors have been found to influence the normal development of neural pathways. Cumulative evidence suggests that metabolic hormones that regulate the hypothalamic circuits that control energy homeostasis function in much the same way that sex steroids act on sexually dimorphic circuits. For example, although the effects of the adipocyte-derived hormone leptin were originally thought to be limited to the neural control...

  1. Industry as a metabolic activity.

    OpenAIRE

    Smart, B.(SUPA - School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom)

    1992-01-01

    The concept of "industrial economic metabolism" can provide a bridge to better understanding between environmentalists and industry. In nature each individual or species reacts to natural stimuli, competing with others for resources, extending its domain until it loses comparative advantage and comes to equilibrium with an adjacent competitor. Those species that succeed over time flourish; those that do not, diminish or disappear. Nature's rule book has no moral or ethical ingredient beyond s...

  2. Identification of Metabolic Pathway Systems

    Directory of Open Access Journals (Sweden)

    Sepideh eDolatshahi

    2016-02-01

    Full Text Available The estimation of parameters in even moderately large biological systems is a significant challenge. This challenge is greatly exacerbated if the mathematical formats of appropriate process descriptions are unknown. To address this challenge, the method of dynamic flux estimation (DFE was proposed for the analysis of metabolic time series data. Under ideal conditions, the first phase of DFE yields numerical representations of all fluxes within a metabolic pathway system, either as values at each time point or as plots against their substrates and modulators. However, this numerical result does not reveal the mathematical format of each flux. Thus, the second phase of DFE selects functional formats that are consistent with the numerical trends obtained from the first phase. While greatly facilitating metabolic data analysis, DFE is only directly applicable if the pathway system contains as many dependent variables as fluxes. Because most actual systems contain more fluxes than metabolite pools, this requirement is seldom satisfied. Auxiliary methods have been proposed to alleviate this issue, but they are not general. Here we propose strategies that extend DFE toward general, slightly underdetermined pathway systems.

  3. Metabolic alkalosis: pathogenesis and physiopathology

    Directory of Open Access Journals (Sweden)

    Mario Tarantino

    2008-12-01

    Full Text Available Metabolic alkalosis is an acid-base disorder frequently encountered in hospitalised patients, particularly those in critical conditions and is not infrequently complicated by mixed acid-base disorders. This disorder can have serious clinical consequences, especially on the cardiovascular and central nervous systems. The disorder’s gravity is partly due to the precarious nature of the defence and compensation processes the body is able to provide to combat the alteration in the blood’s pH. Metabolic alkalosis is just one, secondary component of a complex water and electrolyte balance disorder, on which the maintenance of the acid-base disorder depends. Metabolic alkalosis can be a complication of various somewhat diverse conditions and is often common in hospital settings. A multitude of pathophysiological factors contribute to maintaining the acid-base disorder: these factors influence and feed one another. As the resolution of the acid-base disorder depends on the correction of these factors, it is essential to know their exact mechanisms in order to undertake the most appropriate therapeutic action.

  4. Sirtuins Link Inflammation and Metabolism

    Directory of Open Access Journals (Sweden)

    Vidula T. Vachharajani

    2016-01-01

    Full Text Available Sirtuins (SIRT, first discovered in yeast as NAD+ dependent epigenetic and metabolic regulators, have comparable activities in human physiology and disease. Mounting evidence supports that the seven-member mammalian sirtuin family (SIRT1–7 guard homeostasis by sensing bioenergy needs and responding by making alterations in the cell nutrients. Sirtuins play a critical role in restoring homeostasis during stress responses. Inflammation is designed to “defend and mend” against the invading organisms. Emerging evidence supports that metabolism and bioenergy reprogramming direct the sequential course of inflammation; failure of homeostasis retrieval results in many chronic and acute inflammatory diseases. Anabolic glycolysis quickly induced (compared to oxidative phosphorylation for ROS and ATP generation is needed for immune activation to “defend” against invading microorganisms. Lipolysis/fatty acid oxidation, essential for cellular protection/hibernation and cell survival in order to “mend,” leads to immune repression. Acute/chronic inflammations are linked to altered glycolysis and fatty acid oxidation, at least in part, by NAD+ dependent function of sirtuins. Therapeutically targeting sirtuins may provide a new class of inflammation and immune regulators. This review discusses how sirtuins integrate metabolism, bioenergetics, and immunity during inflammation and how sirtuin-directed treatment improves outcome in chronic inflammatory diseases and in the extreme stress response of sepsis.

  5. Intestinal Microbiota Metabolism and Atherosclerosis

    Institute of Scientific and Technical Information of China (English)

    Tian-Xing Liu; Hai-Tao Niu; Shu-Yang Zhang

    2015-01-01

    Objective:This review aimed to summarize the relationship between intestinal microbiota metabolism and cardiovascular disease (CVD) and to propose a novel CVD therapeutic target.Data Sources:This study was based on data obtained from PubMed and EMBASE up to June 30,2015.Articles were selected using the following search temps:"Intestinal microbiota","trimethylamine N-oxide (TMAO)","trimethylamine (TMA)","cardiovascular",and "atherosclerosis".Study Selection:Studies were eligible if they present information on intestinal microbiota metabolism and atherosclerosis.Studies on TMA-containing nutrients were also included.Results:A new CVD risk factor,TMAO,was recently identified.It has been observed that several TMA-containing compounds may be catabolized by specific intestinal microbiota,resulting in TMA release.TMA is subsequently converted to TMAO in the liver.Several preliminary studies have linked TMAO to CVD,particularly atherosclerosis;however,the details of this relationship remain unclear.Conclusions:Intestinal microbiota metabolism is associated with atherosclerosis and may represent a promising therapeutic target with respect to CVD management.

  6. Prisoner's dilemma in cancer metabolism.

    Directory of Open Access Journals (Sweden)

    Irina Kareva

    Full Text Available As tumors outgrow their blood supply and become oxygen deprived, they switch to less energetically efficient but oxygen-independent anaerobic glucose metabolism. However, cancer cells maintain glycolytic phenotype even in the areas of ample oxygen supply (Warburg effect. It has been hypothesized that the competitive advantage that glycolytic cells get over aerobic cells is achieved through secretion of lactic acid, which is a by-product of glycolysis. It creates acidic microenvironment around the tumor that can be toxic to normal somatic cells. This interaction can be seen as a prisoner's dilemma: from the point of view of metabolic payoffs, it is better for cells to cooperate and become better competitors but neither cell has an incentive to unilaterally change its metabolic strategy. In this paper a novel mathematical technique, which allows reducing an otherwise infinitely dimensional system to low dimensionality, is used to demonstrate that changing the environment can take the cells out of this equilibrium and that it is cooperation that can in fact lead to the cell population committing evolutionary suicide.

  7. Identification of Metabolic Pathway Systems.

    Science.gov (United States)

    Dolatshahi, Sepideh; Voit, Eberhard O

    2016-01-01

    The estimation of parameters in even moderately large biological systems is a significant challenge. This challenge is greatly exacerbated if the mathematical formats of appropriate process descriptions are unknown. To address this challenge, the method of dynamic flux estimation (DFE) was proposed for the analysis of metabolic time series data. Under ideal conditions, the first phase of DFE yields numerical representations of all fluxes within a metabolic pathway system, either as values at each time point or as plots against their substrates and modulators. However, this numerical result does not reveal the mathematical format of each flux. Thus, the second phase of DFE selects functional formats that are consistent with the numerical trends obtained from the first phase. While greatly facilitating metabolic data analysis, DFE is only directly applicable if the pathway system contains as many dependent variables as fluxes. Because most actual systems contain more fluxes than metabolite pools, this requirement is seldom satisfied. Auxiliary methods have been proposed to alleviate this issue, but they are not general. Here we propose strategies that extend DFE toward general, slightly underdetermined pathway systems.

  8. Metabolic aspects of bacterial persisters

    Directory of Open Access Journals (Sweden)

    Marcel ePrax

    2014-10-01

    Full Text Available Persister cells form a multi-drug tolerant subpopulation within an isogenic culture of bacteria that are genetically susceptible to antibiotics. Studies with different Gram negative and Gram positive bacteria have identified a large number of genes associated with the persister state. In contrast, the revelation of persister metabolism has only been addressed recently. We here summarize metabolic aspects of persisters, which includes an overview about the bifunctional role of selected carbohydrates as both triggers for the exit from the drug tolerant state and metabolites which persisters feed on. Also alarmones as indicators for starvation have been shown to influence persister levels via different signaling cascades involving the activation of toxin-antitoxin systems and other regulatory factors. Finally, recent data obtained by 13C-isotopologue profiling demonstrated an active amino acid anabolism in Staphylococcus aureus cultures challenged with high drug concentrations. Understanding the metabolism of persister cells poses challenges but also paves the way for the development of anti-persister compounds.

  9. Metabolic regulation by p53 family members.

    Science.gov (United States)

    Berkers, Celia R; Maddocks, Oliver D K; Cheung, Eric C; Mor, Inbal; Vousden, Karen H

    2013-11-05

    The function of p53 is best understood in response to genotoxic stress, but increasing evidence suggests that p53 also plays a key role in the regulation of metabolic homeostasis. p53 and its family members directly influence various metabolic pathways, enabling cells to respond to metabolic stress. These functions are likely to be important for restraining the development of cancer but could also have a profound effect on the development of metabolic diseases, including diabetes. A better understanding of the metabolic functions of p53 family members may aid in the identification of therapeutic targets and reveal novel uses for p53-modulating drugs.

  10. Current perspectives between metabolic syndrome and cancer.

    Science.gov (United States)

    Micucci, Carla; Valli, Debora; Matacchione, Giulia; Catalano, Alfonso

    2016-06-21

    Metabolic syndrome is a cluster of risk factors that lead to cardiovascular morbidity and mortality. Recent studies linked metabolic syndrome and several types of cancer. Although metabolic syndrome may not necessarily cause cancer, it is linked to poorer cancer outcomes including increased risk of recurrence and overall mortality. This review tends to discuss the major biological and physiological alterations involved in the increase of incidence and mortality of cancer patients affected by metabolic syndrome. We focus on metabolic syndrome-associated visceral adiposity, hyperinsulinemia, hyperglycemia, insulin-like growth factor (IGF-I) pathway as well as estrogen signaling and inflammation. Several of these factors are also involved in carcinogenesis and cancer progression. A better understanding of the link between metabolic syndrome and cancer may provide new insight about oncogenesis. Moreover, prevention of metabolic syndrome - related alterations may be an important aspect in the management of cancer patients during simultaneous palliative care.

  11. Genome-scale modeling for metabolic engineering

    Energy Technology Data Exchange (ETDEWEB)

    Simeonidis, E; Price, ND

    2015-01-13

    We focus on the application of constraint-based methodologies and, more specifically, flux balance analysis in the field of metabolic engineering, and enumerate recent developments and successes of the field. We also review computational frameworks that have been developed with the express purpose of automatically selecting optimal gene deletions for achieving improved production of a chemical of interest. The application of flux balance analysis methods in rational metabolic engineering requires a metabolic network reconstruction and a corresponding in silico metabolic model for the microorganism in question. For this reason, we additionally present a brief overview of automated reconstruction techniques. Finally, we emphasize the importance of integrating metabolic networks with regulatory information-an area which we expect will become increasingly important for metabolic engineering-and present recent developments in the field of metabolic and regulatory integration.

  12. ER stress and hepatic lipid metabolism

    Directory of Open Access Journals (Sweden)

    Huiping eZhou

    2014-05-01

    Full Text Available The endoplasmic reticulum (ER is an important player in regulating protein synthesis and lipid metabolism. Perturbation of ER homeostasis, referred as ER stress, has been linked to numerous pathological conditions, such as inflammation, cardiovascular diseases and metabolic disorders. The liver plays a central role in regulating nutrient and lipid metabolism. Accumulating evidence implicates that ER stress disrupts lipid metabolism and induces hepatic lipotoxicity. Here, we review the major ER stress signaling pathways, how ER stress contributes to the dysregulation of hepatic lipid metabolism, and the potential causative mechanisms of ER stress in hepatic lipotoxicity. Understanding the role of ER stress in hepatic metabolism may lead to the identification of new therapeutic targets for metabolic diseases.

  13. Genome-scale modeling for metabolic engineering.

    Science.gov (United States)

    Simeonidis, Evangelos; Price, Nathan D

    2015-03-01

    We focus on the application of constraint-based methodologies and, more specifically, flux balance analysis in the field of metabolic engineering, and enumerate recent developments and successes of the field. We also review computational frameworks that have been developed with the express purpose of automatically selecting optimal gene deletions for achieving improved production of a chemical of interest. The application of flux balance analysis methods in rational metabolic engineering requires a metabolic network reconstruction and a corresponding in silico metabolic model for the microorganism in question. For this reason, we additionally present a brief overview of automated reconstruction techniques. Finally, we emphasize the importance of integrating metabolic networks with regulatory information-an area which we expect will become increasingly important for metabolic engineering-and present recent developments in the field of metabolic and regulatory integration.

  14. Metabolism pathways in chronic lymphocytic leukemia.

    Science.gov (United States)

    Rozovski, Uri; Hazan-Halevy, Inbal; Barzilai, Merav; Keating, Michael J; Estrov, Zeev

    2016-01-01

    Alterations in chronic lymphocytic leukemia (CLL) cell metabolism have been studied by several investigators. Unlike normal B lymphocytes or other leukemia cells, CLL cells, like adipocytes, store lipids and utilize free fatty acids (FFA) to produce chemical energy. None of the recently identified mutations in CLL directly affects metabolic pathways, suggesting that genetic alterations do not directly contribute to CLL cells' metabolic reprogramming. Conversely, recent data suggest that activation of STAT3 or downregulation of microRNA-125 levels plays a crucial role in the utilization of FFA to meet the CLL cells' metabolic needs. STAT3, known to be constitutively activated in CLL, increases the levels of lipoprotein lipase (LPL) that mediates lipoprotein uptake and shifts the CLL cells' metabolism towards utilization of FFA. Herein, we review the evidence for altered lipid metabolism, increased mitochondrial activity and formation of reactive oxygen species (ROS) in CLL cells, and discuss the possible therapeutic strategies to inhibit lipid metabolism pathways in patient with CLL.

  15. Lipid metabolism in experimental animals

    Directory of Open Access Journals (Sweden)

    Sánchez-Muñiz, Francisco J.

    1998-08-01

    Full Text Available Publications are scarce in the way in chich metabolic processes are affected by the ingestion of heated fats used to prepare food. Similarly studies measuring metabolic effects of the consumption on fried food are poorly known. The purpose of this presentation is to summarize information on frying fats and frying foods upon lipid metabolism in experimental animals. Food consumption is equivalent or even higher when oils or the fat content of frying foods are poorly alterated decreasing their acceptability when their alteration degree increase. After 4hr. experiment the digestibility and absorption coefficients of a single dosis of thermooxidized oils were significantly decreased in rats, however the digestive utilization of frying thermooxidized oils included in diets showed very little change in comparison with unused oils by feeding trials on rats. Feeding rats different frying fats induced a slight hypercholesterolemic effect being the magnitude of this effect related to the linoleic decrease in diet produced by frying. However HDL, the main rat-cholesterol carrier, also increased, thus the serum cholesterol/HDL-cholesterol ratio did not change. Results suggest that rats fed frying fats adapt their lipoprotein metabolism increasing the number of HDL particles. Deep fat frying deeply changed the fatty acid composition of foods, being possible to increase their n-9 or n-6 fatty acid and to decrease the saturated fatty acid contents by frying. When olive oil-and sunflower oil-fried sardines were used as the only protein and fat sources of rats-diets in order to prevent the dietary hypercholesterolemia it was provided that both fried-sardine diets showed a powerful check effect on the cholesterol raising effect induced by dietary cholesterol. The negative effect of feeding rats cholesterol plus bovine bile to induce hypercholesterolemia on some cell-damage markers such as lactate dehydrogenase, transaminases, alkaline phosphatase, was

  16. METABOLISM

    Institute of Scientific and Technical Information of China (English)

    2003-01-01

    4.1 Nutritional disorder2003271 Iron status and effect of early iron supplementation of sub-clinical iron deficiency in rural school-age children from mountainous areas of Beijing.LIN Xiaoming(林晓明),et al.Dept Nutr & Food Hyg, Public Health Sch Peking Univ, Beijing 100083. Chin J Prev Med 2003;37(2): 115-118.

  17. METABOLISM

    Institute of Scientific and Technical Information of China (English)

    2003-01-01

    7.1 Nutritional disorder2003038 An epidemiological study on vitamin K deficiency bleeding in infants under six months. ZHOU Fengrong(周凤荣), et al.Dept Child Health, Shandong Prov Matern Childed Health Instit, Jinan 250014. Chin J Prev Med 2002;36(5):305 - 307.Objective: To understand the incidence and relevant affecting factors of infant vitamin K deficiency bleeding

  18. Metabolism

    Institute of Scientific and Technical Information of China (English)

    2006-01-01

    4.1 Nutrition imbalance 2006024 Effect of multiple micronutrients supplementation on anti - oxidative activity and oxidized DNA damage of lymphocytes in children ZHANG Ming ( 张明), Nutrit Dept, Weifang People Hosp, Weifang 261041. Chin J Epidemiol 2005 ;26(4) :268 -272. Objective:To examine the effect of multiple micronutrients supplementation on anti - oxidative activity and decreasing oxidized DNA damage of lymphocytes in Chinese children. Methods:82 healthy children in rural areas, aged 9-11 years, were selected and randomized into group receiving supplements and control group with 41 in

  19. Metabolic fingerprint of dimethyl sulfone (DMSO2) in microbial-mammalian co-metabolism.

    Science.gov (United States)

    He, Xuan; Slupsky, Carolyn M

    2014-12-01

    There is growing awareness that intestinal microbiota alters the energy harvesting capacity of the host and regulates metabolism. It has been postulated that intestinal microbiota are able to degrade unabsorbed dietary components and transform xenobiotic compounds. The resulting microbial metabolites derived from the gastrointestinal tract can potentially enter the circulation system, which, in turn, affects host metabolism. Yet, the metabolic capacity of intestinal microbiota and its interaction with mammalian metabolism remains largely unexplored. Here, we review a metabolic pathway that integrates the microbial catabolism of methionine with mammalian metabolism of methanethiol (MT), dimethyl sulfide (DMS), and dimethyl sulfoxide (DMSO), which together provide evidence that supports the microbial origin of dimethyl sulfone (DMSO2) in the human metabolome. Understanding the pathway of DMSO2 co-metabolism expends our knowledge of microbial-derived metabolites and motivates future metabolomics-based studies on ascertaining the metabolic consequences of intestinal microbiota on human health, including detoxification processes and sulfur xenobiotic metabolism.

  20. Metabolic cartography: experimental quantification of metabolic fluxes from isotopic labelling studies.

    Science.gov (United States)

    O'Grady, John; Schwender, Jörg; Shachar-Hill, Yair; Morgan, John A

    2012-03-01

    For the past decade, flux maps have provided researchers with an in-depth perspective on plant metabolism. As a rapidly developing field, significant headway has been made recently in computation, experimentation, and overall understanding of metabolic flux analysis. These advances are particularly applicable to the study of plant metabolism. New dynamic computational methods such as non-stationary metabolic flux analysis are finding their place in the toolbox of metabolic engineering, allowing more organisms to be studied and decreasing the time necessary for experimentation, thereby opening new avenues by which to explore the vast diversity of plant metabolism. Also, improved methods of metabolite detection and measurement have been developed, enabling increasingly greater resolution of flux measurements and the analysis of a greater number of the multitude of plant metabolic pathways. Methods to deconvolute organelle-specific metabolism are employed with increasing effectiveness, elucidating the compartmental specificity inherent in plant metabolism. Advances in metabolite measurements have also enabled new types of experiments, such as the calculation of metabolic fluxes based on (13)CO(2) dynamic labelling data, and will continue to direct plant metabolic engineering. Newly calculated metabolic flux maps reveal surprising and useful information about plant metabolism, guiding future genetic engineering of crops to higher yields. Due to the significant level of complexity in plants, these methods in combination with other systems biology measurements are necessary to guide plant metabolic engineering in the future.

  1. Ensemble Kinetic Modeling of Metabolic Networks from Dynamic Metabolic Profiles

    Directory of Open Access Journals (Sweden)

    Gengjie Jia

    2012-11-01

    Full Text Available Kinetic modeling of metabolic pathways has important applications in metabolic engineering, but significant challenges still remain. The difficulties faced vary from finding best-fit parameters in a highly multidimensional search space to incomplete parameter identifiability. To meet some of these challenges, an ensemble modeling method is developed for characterizing a subset of kinetic parameters that give statistically equivalent goodness-of-fit to time series concentration data. The method is based on the incremental identification approach, where the parameter estimation is done in a step-wise manner. Numerical efficacy is achieved by reducing the dimensionality of parameter space and using efficient random parameter exploration algorithms. The shift toward using model ensembles, instead of the traditional “best-fit” models, is necessary to directly account for model uncertainty during the application of such models. The performance of the ensemble modeling approach has been demonstrated in the modeling of a generic branched pathway and the trehalose pathway in Saccharomyces cerevisiae using generalized mass action (GMA kinetics.

  2. Dyslipidemic drugs in metabolic syndrome

    Directory of Open Access Journals (Sweden)

    Sheelu S Siddiqi

    2013-01-01

    Full Text Available Introduction: Metabolic syndrome predisposes to diabetes and atherosclerotic vascular disease. Statins reduce cardiovascular events, so all metabolic syndrome patients should be evaluated for dyslipidemia. Many patients fail to achieve lipid goals with statin monotherapy. Co-administration of ezetimibe (EZE and atorvastatin (ATV may enable more patients to achievelow-density lipoproteincholesterol (LDL-C goal while avoiding risks of high-dose statin monotherapy. Materials and Methods: The present study compares rosuvastatin (Rsv with a combination of (Atv and (Eze. Metabolic syndrome patients, 30-70 years with LDL-C ≥130 mg/dl and a 10-year CHD risk score of 10% were randomized to double-blind treatment with (Rsv 5 mg (n = 67 or (Atv 10 mg+(Eze 10 mg (n = 68 for 12 weeks. Results: LDL-C reduced significantly; (32.3% and 30.3%, P < 0.001 in (Atv+(Eze and (Rsv, respectively, but there was no significant difference between two arms. More patients achieved LDL-C goal of ≤100 mg/dl with (Atv+(Eze compared to (Rsv (65% vs. 58%, P < 0.05. Triglycerides (TG were reduced more with (Atv+(Eze compared to (Rsv (28.1% and 21.4%, P < 0.001. Greater increase in high-density lipoprotein cholesterol (HDL-C was observed with (Atv+(Eze. Both treatments were well tolerated. Conclusion: This study shows that the combination of (Atv+(Eze has more efficacy and comparable safety to that of (Rsv.

  3. Engineering triterpene metabolism in tobacco.

    Science.gov (United States)

    Wu, Shuiqin; Jiang, Zuodong; Kempinski, Chase; Eric Nybo, S; Husodo, Satrio; Williams, Robert; Chappell, Joe

    2012-09-01

    Terpenes comprise a distinct class of natural products that serve a diverse range of physiological functions, provide for interactions between plants and their environment and represent a resource for many kinds of practical applications. To better appreciate the importance of terpenes to overall growth and development, and to create a production capacity for specific terpenes of industrial interest, we have pioneered the development of strategies for diverting carbon flow from the native terpene biosynthetic pathways operating in the cytosol and plastid compartments of tobacco for the generation of specific classes of terpenes. In the current work, we demonstrate how difficult it is to divert the 5-carbon intermediates DMAPP and IPP from the mevalonate pathway operating in the cytoplasm for triterpene biosynthesis, yet diversion of the same intermediates from the methylerythritol phosphate pathway operating in the plastid compartment leads to the accumulation of very high levels of the triterpene squalene. This was assessed by the co-expression of an avian farnesyl diphosphate synthase and yeast squalene synthase genes targeting metabolism in the cytoplasm or chloroplast. We also evaluated the possibility of directing this metabolism to the secretory trichomes of tobacco by comparing the effects of trichome-specific gene promoters to strong, constitutive viral promoters. Surprisingly, when transgene expression was directed to trichomes, high-level squalene accumulation was observed, but overall plant growth and physiology were reduced up to 80 % of the non-transgenic controls. Our results support the notion that the biosynthesis of a desired terpene can be dramatically improved by directing that metabolism to a non-native cellular compartment, thus avoiding regulatory mechanisms that might attenuate carbon flux within an engineered pathway.

  4. Metabolic fate of hallucinogenic NBOMes

    DEFF Research Database (Denmark)

    Leth-Petersen, Sebastian; Gabel-Jensen, Charlotte; Gillings, Nic

    2016-01-01

    as a PET-ligand for clinical investigations of the 5HT2AR ([11C]Cimbi-36). Herein, we have identified the phase I and phase II metabolites of 25B-NBOMe in pigs as well as in humans. We find that the primary route of metabolism is 5'-demethylation, followed by conjugation to glucuronic acid. [11C......]-labelling of 25B-NBOMe in three different positions followed by in vivo evaluation in pigs and in humans corroborated these findings....

  5. Novel Adipokines and Bone Metabolism

    Directory of Open Access Journals (Sweden)

    Yuan Liu

    2013-01-01

    Full Text Available Osteoporosis is a serious social issue nowadays. Both the high morbidity and its common complication osteoporotic fracture load a heavy burden on the whole society. The adipose tissue is the biggest endocrinology organ that has a different function on the bone. The adipocytes are differentiated from the same cell lineage with osteoblast, and they can secrete multiple adipokines with various functions on bone remolding. Recently, several novel adipokines have been identified and investigated thoroughly. In this paper, we would like to highlight the complicated relation between the bone metabolism and the novel adipokines, and it may provide us with a new target for prediction and treatment of osteoporosis.

  6. Thiophene metabolism by E. coli

    Energy Technology Data Exchange (ETDEWEB)

    Clark, D.P.

    1990-01-01

    The objective of this project is to investigate the mechanism of degradation of sulfur containing heterocyclic molecules such as those found in coal, by mutants of Escherichia coli K-12. We previously isolated multiple mutants of E. coli which were selected for improved oxidation of furan and thiophene derivatives. We have focused on the thdA mutation in our subsequent research as it appears to be of central importance in thiophene oxidation. We hope that analysis of the thd genes of E. coli will lead to improvement of our thiophene metabolizing bacterial strains. 1 tab.

  7. Adenosine, Energy Metabolism, and Sleep

    Directory of Open Access Journals (Sweden)

    Tarja Porkka-Heiskanen

    2003-01-01

    Full Text Available While the exact function of sleep remains unknown, it is evident that sleep was developed early in phylogenesis and represents an ancient and vital strategy for survival. Several pieces of evidence suggest that the function of sleep is associated with energy metabolism, saving of energy, and replenishment of energy stores. Prolonged wakefulness induces signs of energy depletion in the brain, while experimentally induced, local energy depletion induces increase in sleep, similarly as would a period of prolonged wakefulness. The key molecule in the induction of sleep appears to be adenosine, which induces sleep locally in the basal forebrain.

  8. ER Stress and Lipid Metabolism in Adipocytes

    Directory of Open Access Journals (Sweden)

    Beth S. Zha

    2012-01-01

    Full Text Available The role of endoplasmic reticulum (ER stress is a rapidly emerging field of interest in the pathogenesis of metabolic diseases. Recent studies have shown that chronic activation of ER stress is closely linked to dysregulation of lipid metabolism in several metabolically important cells including hepatocytes, macrophages, β-cells, and adipocytes. Adipocytes are one of the major cell types involved in the pathogenesis of the metabolic syndrome. Recent advances in dissecting the cellular and molecular mechanisms involved in the regulation of adipogenesis and lipid metabolism indicate that activation of ER stress plays a central role in regulating adipocyte function. In this paper, we discuss the current understanding of the potential role of ER stress in lipid metabolism in adipocytes. In addition, we touch upon the interaction of ER stress and autophagy as well as inflammation. Inhibition of ER stress has the potential of decreasing the pathology in adipose tissue that is seen with energy overbalance.

  9. Some metabolic effects of overeating in man.

    Science.gov (United States)

    Welle, S L; Seaton, T B; Campbell, R G

    1986-12-01

    Metabolic responses to 20 days of overeating were examined in five healthy volunteers. Overfeeding caused a variable increase (1-18%) in basal metabolic rate but no change in metabolic rate during light exercise. Postprandial resting metabolic rate was 8-40% higher (mean 18%) during overeating. The increase in oxygen consumption during a norepinephrine infusion was the same before (20 +/- 2%) and after (17 +/- 3%) overfeeding. Overfeeding elevated basal insulin concentrations in all subjects and increased the insulin response to intravenous glucose in four of five subjects. Overfeeding did not significantly alter mean serum T3 concentrations or erythrocyte 86Rb uptake (an index of Na+,K+-ATPase activity). These data do not confirm reports that overfeeding increases metabolic rate more during exercise than during rest. They also suggest that the increase in resting metabolic rate during overfeeding is not caused by increased responsiveness to norepinephrine or increased serum T3 concentrations.

  10. Metabolic remodeling in chronic heart failure

    Institute of Scientific and Technical Information of China (English)

    Jing WANG; Tao GUO

    2013-01-01

    Although the management of chronic heart failure (CHF) has made enormous progress over the past decades,CHF is still a tremendous medical and societal burden.Metabolic remodeling might play a crucial role in the pathophysiology of CHF.The characteristics and mechanisms of metabolic remodeling remained unclear,and the main hypothesis might include the changes in the availability of metabolic substrate and the decline of metabolic capability.In the early phases of the disease,metabolism shifts toward carbohydrate utilization from fatty acids (FAs) oxidation.Along with the progress of the disease,the increasing level of the hyperadrenergic state and insulin resistance cause the changes that shift back to a greater FA uptake and oxidation.In addition,a growing body of experimental and clinical evidence suggests that the improvement in the metabolic capability is likely to be more significant than the selection of the substrate.

  11. Deciphering transcriptional and metabolic networks associated with lysine metabolism during Arabidopsis seed development.

    Science.gov (United States)

    Angelovici, Ruthie; Fait, Aaron; Zhu, Xiaohong; Szymanski, Jedrzej; Feldmesser, Ester; Fernie, Alisdair R; Galili, Gad

    2009-12-01

    In order to elucidate transcriptional and metabolic networks associated with lysine (Lys) metabolism, we utilized developing Arabidopsis (Arabidopsis thaliana) seeds as a system in which Lys synthesis could be stimulated developmentally without application of chemicals and coupled this to a T-DNA insertion knockout mutation impaired in Lys catabolism. This seed-specific metabolic perturbation stimulated Lys accumulation starting from the initiation of storage reserve accumulation. Our results revealed that the response of seed metabolism to the inducible alteration of Lys metabolism was relatively minor; however, that which was observable operated in a modular manner. They also demonstrated that Lys metabolism is strongly associated with the operation of the tricarboxylic acid cycle while largely disconnected from other metabolic networks. In contrast, the inducible alteration of Lys metabolism was strongly associated with gene networks, stimulating the expression of hundreds of genes controlling anabolic processes that are associated with plant performance and vigor while suppressing a small number of genes associated with plant stress interactions. The most pronounced effect of the developmentally inducible alteration of Lys metabolism was an induction of expression of a large set of genes encoding ribosomal proteins as well as genes encoding translation initiation and elongation factors, all of which are associated with protein synthesis. With respect to metabolic regulation, the inducible alteration of Lys metabolism was primarily associated with altered expression of genes belonging to networks of amino acids and sugar metabolism. The combined data are discussed within the context of network interactions both between and within metabolic and transcriptional control systems.

  12. Simulating metabolism with statistical thermodynamics.

    Directory of Open Access Journals (Sweden)

    William R Cannon

    Full Text Available New methods are needed for large scale modeling of metabolism that predict metabolite levels and characterize the thermodynamics of individual reactions and pathways. Current approaches use either kinetic simulations, which are difficult to extend to large networks of reactions because of the need for rate constants, or flux-based methods, which have a large number of feasible solutions because they are unconstrained by the law of mass action. This report presents an alternative modeling approach based on statistical thermodynamics. The principles of this approach are demonstrated using a simple set of coupled reactions, and then the system is characterized with respect to the changes in energy, entropy, free energy, and entropy production. Finally, the physical and biochemical insights that this approach can provide for metabolism are demonstrated by application to the tricarboxylic acid (TCA cycle of Escherichia coli. The reaction and pathway thermodynamics are evaluated and predictions are made regarding changes in concentration of TCA cycle intermediates due to 10- and 100-fold changes in the ratio of NAD+:NADH concentrations. Finally, the assumptions and caveats regarding the use of statistical thermodynamics to model non-equilibrium reactions are discussed.

  13. Chronic Metabolic Acidosis Destroys Pancreas

    Directory of Open Access Journals (Sweden)

    Peter Melamed

    2014-11-01

    Full Text Available One primary reason for the current epidemic of digestive disorders might be chronic metabolic acidosis, which is extremely common in the modern population. Chronic metabolic acidosis primarily affects two alkaline digestive glands, the liver, and the pancreas, which produce alkaline bile and pancreatic juice with a large amount of bicarbonate. Even small acidic alterations in the bile and pancreatic juice pH can lead to serious biochemical/biomechanical changes. The pancreatic digestive enzymes require an alkaline milieu for proper function, and lowering the pH disables their activity. It can be the primary cause of indigestion. Acidification of the pancreatic juice decreases its antimicrobial activity, which can lead to intestinal dysbiosis. Lowering the pH of the pancreatic juice can cause premature activation of the proteases inside the pancreas with the potential development of pancreatitis.The acidification of bile causes precipitation of the bile acids, which irritate the entire biliary system and create bile stone formation. Aggressive mixture of the acidic bile and the pancreatic juice can cause erratic contractions of the duodenum’s walls and subsequent bile reflux into the stomach and the esophagus. Normal exocrine pancreatic function is the core of proper digestion. Currently, there is no effective and safe treatment for enhancing the exocrine pancreatic function. Restoring normal acid-base homeostasis can be a useful toolfor pathophysiological therapeutic approaches for various gastrointestinal disorders. There is strong research and practical evidence that restoring the HCO3 - capacity in the blood can improve digestion.

  14. Metabolic Syndrome: Polycystic Ovary Syndrome.

    Science.gov (United States)

    Mortada, Rami; Williams, Tracy

    2015-08-01

    Polycystic ovary syndrome (PCOS) is a heterogeneous condition characterized by androgen excess, ovulatory dysfunction, and polycystic ovaries. It is the most common endocrinopathy among women of reproductive age, affecting between 6.5% and 8% of women, and is the most common cause of infertility. Insulin resistance is almost always present in women with PCOS, regardless of weight, and they often develop diabetes and metabolic syndrome. The Rotterdam criteria are widely used for diagnosis. These criteria require that patients have at least two of the following conditions: hyperandrogenism, ovulatory dysfunction, and polycystic ovaries. The diagnosis of PCOS also requires exclusion of other potential etiologies of hyperandrogenism and ovulatory dysfunction. The approach to PCOS management differs according to the presenting symptoms and treatment goals, particularly the patient's desire for pregnancy. Weight loss through dietary modifications and exercise is recommended for patients with PCOS who are overweight. Oral contraceptives are the first-line treatment for regulating menstrual cycles and reducing manifestations of hyperandrogenism, such as acne and hirsutism. Clomiphene is the first-line drug for management of anovulatory infertility. Metformin is recommended for metabolic abnormalities such as prediabetes, and a statin should be prescribed for cardioprotection if the patient meets standard criteria for statin therapy.

  15. Metabolism of phthalates in humans.

    Science.gov (United States)

    Frederiksen, Hanne; Skakkebaek, Niels E; Andersson, Anna-Maria

    2007-07-01

    Phthalates are synthetic compounds widely used as plasticisers, solvents and additives in many consumer products. Several animal studies have shown that some phthalates possess endocrine disrupting effects. Some of the effects of phthalates seen in rats are due to testosterone lowering effects on the foetal testis and they are similar to those seen in humans with testicular dysgenesis syndrome. Therefore, exposure of the human foetus and infants to phthalates via maternal exposure is a matter of concern. The metabolic pathways of phthalate metabolites excreted in human urine are partly known for some phthalates, but our knowledge about metabolic distribution in the body and other biological fluids, including breast milk, is limited. Compared to urine, human breast milk contains relatively more of the hydrophobic phthalates, such as di-n-butyl phthalate and the longer-branched, di(2-ethylhexyl) phthalate (DEHP) and di-iso-nonyl phthalate (DiNP); and their monoester metabolites. Urine, however, contains relatively more of the secondary metabolites of DEHP and DiNP, as well as the monoester phthalates of the more short-branched phthalates. This differential distribution is of special concern as, in particular, the hydrophobic phthalates and their metabolites are shown to have adverse effects following in utero and lactational exposures in animal studies.

  16. Sex steroids and glucose metabolism

    Directory of Open Access Journals (Sweden)

    Carolyn A Allan

    2014-04-01

    Full Text Available Testosterone levels are lower in men with metabolic syndrome and type 2 diabetes mellitus (T2DM and also predict the onset of these adverse metabolic states. Body composition (body mass index, waist circumference is an important mediator of this relationship. Sex hormone binding globulin is also inversely associated with insulin resistance and T2DM but the data regarding estrogen are inconsistent. Clinical models of androgen deficiency including Klinefelter's syndrome and androgen deprivation therapy in the treatment of advanced prostate cancer confirm the association between androgens and glucose status. Experimental manipulation of the insulin/glucose milieu and suppression of endogenous testicular function suggests the relationship between androgens and insulin sensitivity is bidirectional. Androgen therapy in men without diabetes is not able to differentiate the effect on insulin resistance from that on fat mass, in particular visceral adiposity. Similarly, several small clinical studies have examined the efficacy of exogenous testosterone in men with T2DM, however, the role of androgens, independent of body composition, in modifying insulin resistance is uncertain.

  17. Metabolic syndrome in bipolar disorders

    Directory of Open Access Journals (Sweden)

    Sandeep Grover

    2012-01-01

    Full Text Available To review the data with respect to prevalence and risk factors of metabolic syndrome (MetS in bipolar disorder patients. Electronic searches were done in PUBMED, Google Scholar and Science direct. From 2004 to June 2011, 34 articles were found which reported on the prevalence of MetS. The sample size of these studies varied from 15 to 822 patients, and the rates of MetS vary widely from 16.7% to 67% across different studies. None of the sociodemographic variable has emerged as a consistent risk factor for MetS. Among the clinical variables longer duration of illness, bipolar disorder- I, with greater number of lifetime depressive and manic episodes, and with more severe and difficult-to-treat